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Abstract 
 
The regulation of cellular genes by the Epstein-Barr virus. 
Susan Phelan 
 
The Epstein-Barr virus (EBV) is a common herpesvirus that establishes a 
lifelong silent infection in the majority of all human beings. EBV has 
oncogenic potential, and is linked with the genesis of some cancers including 
Burkitt’s Lymphoma (BL), Hodgkin’s lymphoma (HL), Post-Transplant 
Lymphoproliferative Disease (PTLD), and nasopharyngeal and gastric 
carcinomas. EBV infection of primary B cells induces cell activation and 
proliferation, an efficient process that leads to the outgrowth of permanently 
growing lymphoblastoid cell lines (LCLs). Central to B-cell immortalisation by 
EBV is the modulation of host cellular gene expression by viral gene 
products. The characterisation of these host-virus interactions will shed light 
on the mechanisms that drive cell transformation, the establishment of life-
long latency and potentially the development of EBV-associated B cell 
malignancies.  A better understanding of the EBV B cell immortalisation 
process may present therapeutic targets of relevance to EBV associated and 
non-associated B cell diseases. 
 
Different cell signaling pathways are activated by EBV during infection of B 
cells, this project initially involved an exploration of the molecular basis for 
the up-regulation of the cellular anti-apoptotic bfl-1 gene by the EBV products 
LMP1 and EBNA. LMP1 mimics the NF-κB signaling pathway, while EBNA2 
is a constitutively active functional homologue of Notch. It was determined in 
this study that EBV can regulate bfl-1 in either an NF-κB or Notch dependent 
manner. Furthermore, mutation of both the putative NF-κB and Notch binding 
sites in the bfl-1 promoter is required to prevent EBV mediated regulation of 
bfl-1. 
 
Novel host cellular genes, the expression of which is modulated by EBV, 
were identified in this study by infecting untouched naϊve B-cells, derived 
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from Peripheral Blood Mononuclear Cells, with recombinant green 
fluorescent protein (GFP)-tagged EBV.  The transcription profiles of genes 
associated with selected cell signaling pathways were then determined by 
Reverse Transcription Quantitative Real-Time Polymerase Chain Reaction 
(RT-qPCR) using gene panel PCR arrays, and a comparison of relative 
transcript levels pre- and post-infection with virus was made. The 
transcriptional modulation of selected novel genes was then confirmed using 
an established conditional LCL in which the EBV growth programme can be 
controlled with β-estradiol.  
 
Several candidate genes were identified using this approach. In particular, 
the cellular gene Transducin-Like Enhancer of Split 1 (TLE1) was identified 
as a novel negative target of EBV. TLE1 is a nuclear co-repressor 
component from the cellular Notch signaling pathway. Notch signaling is a 
major determinant of B cell fate, and the manipulation of this pathway by 
EBV features prominently on the route to virus-induced cell ‘immortalisation’. 
The role of TLE1 was investigated by establishing lymphoblastoid cell line 
(LCL) transfected cell pools either expressing ectopic TLE1 or in which 
endogenous TLE1 was knocked down using RNAi. It was shown that the 
level of TLE1 expression affected the proliferative capacity of an LCL. In 
addition, other genes were found to be modulated due to the presence of 
ectopic TLE1. This was corroborated by knockdown of TLE1 in the same 
LCL. It is concluded that this host-virus interaction between EBV and TLE1 
may positively contribute to the survival of EBV-infected B-lymphocytes 
proliferating on the EB viral growth programme. 
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Chapter 1: Introduction 
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1.1 The Discovery of the Epstein Barr Virus (EBV) 
 
The Epstein Barr Virus (EBV) is a ubiquitous human gamma herpes virus 
that infects approximately 95% of the world’s adult population. EBV was 
discovered in 1958, in Uganda by an Irish surgeon, Denis Burkitt, who 
observed what he described as a lymphosarcoma primarily affecting children 
in equatorial Africa. This malignancy would later be re-designated and 
named Burkitt’s Lymphoma (BL) (Burkitt 1958, Burkitt 1962a). Due to onset 
of BL at a young age and the climatic and geographical distribution of the 
patients affected, Burkitt began to suspect that an external pathogen, such 
as a virus, may play a role in the development of this form of cancer. These 
suspicions led Burkitt to map the ‘lymphoma belt’ in Africa, which identified 
the regions where significant numbers of BL malignancies were observed 
(Burkitt 1962b). Further to this geographical analysis Burkitt and colleague 
also tried to analyse Burkitt’s lymphoma samples for the presence of a 
causative entity, but without success (Burkitt 1962b).  
 
In 1964, research was carried out on cultured biopsies from Burkitt’s patients 
by Anthony Epstein and his colleagues Yvonne Barr and Bert Achong. This 
study revealed, via electron microscopy, the presence of herpes viral 
particles in the lymphoma samples (Epstein and Barr 1964, Epstein, Achong 
and Barr 1964). Sera from BL patients were examined and subsequently 
found to have higher titres of anti-EBV antibody when compared to control 
patients (Henle, et al. 1969). Indeed, high antibody titres were also observed 
in a lymphoepithelial malignancy with a high incidence in south China, called 
nasopharyngeal carcinoma (NPC) (Henle, et al. 1970). These observations 
and further subsequent investigations led to the implication of EBV as an 
oncogenic virus, not only in Burkitt’s lymphoma but also in a number of other 
malignancies, including undifferentiated nasopharyngeal carcinoma 
(Reviewed in Bornkamm 2009b). Remarkably, however, it became evident 
that EBV infection was widespread, indicating that EBV infection alone was 
not a causative agent for malignancy, and that other genetic and 
environmental factors were required for tumour development (Bornkamm 
2009b). EBV is now well known as the causative agent of infectious 
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mononucleosis (IM; also known as glandular fever) and for its capacity to 
potently growth-transform its principal target cell, the B lymphocyte. In 
culture, these ‘immortalised’ cells are referred to as lymphoblastoid cell lines 
(LCLs). 
 
In later life Burkitt noted that his ‘lymphoma belt’ study carried out on BL was 
also a map of malaria-infested regions in Africa. The link between endemic 
BL occurrence and malarial transmission areas has been established, but to 
date no defined functional role for malaria in EBV-led BL has been elucidated 
(Reviewed in Griffin and Rochford 2005).  
 
1.2 Classification of EBV 
 
Herpesviridae consist of a family of herpes viruses that infect birds, reptiles 
and mammals (Lacoste, et al. 2010). The herpes family of viruses can be 
divided into three sub-types according to their genome organisation, growth 
characteristics and cell tropism, namely α-herpesviruses, β-herpesviruses 
and γ-herpesviruses (Hardie 2010). The γ-herpesviruses are further divided 
into lymphocryptoviruses (LCV; also known as gamma1-herpes virus) and 
rhadinovirus (RV; also known as gamma2-herpes virus) (Lacoste, et al. 
2010). It is generally accepted that the LCV evolved from the RV due to the 
more divergent genomes found in RVs. EBV [also known as human herpes 
virus 4 (HHV4)], is a γ-herpesviruses of the genus lymphocryptovirus that 
targets B lymphocytes (Lacoste, et al. 2010, Hardie 2010, Barozzi, et al. 
2007). EBV was the first herpesviral genome to be completely sequenced 
(Baer, et al. 1984). Typical γ-herpesviruses replicate in epithelial cells and 
then establish a lifelong latent infection in the host lymphocytes (Hardie 
2010, Kieff and Rickinson 2007). The EBV genome, like all herpesviruses 
has a signature structure of conserved genes divided by defined regions of 
genetic variation (Lacoste, et al. 2010). EBV, like all herpes viruses, has 
extensively co-evolved with its host, adapting its genetic code and 
incorporating genes of host origin to enable the latent virus to go undetected 
by the immune system (Hardie 2010).  
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1.3 Structure of EBV 
 
Herpesviruses, including EBV, possess a toroid shaped DNA/protein 
associated core enclosed in a 162 capsomere nucleocapsid (Figure 1.1). 
The icosahedral nucleocapsid is surrounded by a protein tegument that is 
itself confined by an outer envelope. This outer envelope is coated by 
glycoprotein spikes (Kieff and Rickinson 2007, Thompson and Kurzrock 
2004). 
 
 
Figure 1.1:  Schematic representation of herpes virus structure.  
The EBV associated toriod protein core is illustrated within the icosahedral 
nucleocapsid. This capsid is itself covered by a protein tegument and enclosed in a 
glycoprotein covered envelope.  
 
The double stranded EBV genome is 172 kbp long with a guanine/cytosine 
content of ~60% and encodes ~85 genes (Thompson and Kurzrock 2004, 
Kieff 1996). However, due to the splicing potential of the RNA transcripts the 
number of possible proteins far exceeds the number of genes present on the 
episome. The ends of the EBV genome contain a 500 bp motif of variable 
number terminal repeats; this genome variation is further compounded by the 
presence of four internal tandem repeats that divide the genome into unique 
long and short fragments (Lacoste, et al. 2010). The internal repeats include 
one 3 kbp tandem internal direct repeat (IR1) that differentiates the unique 
short region (US) from the unique long region (UL) which contains another 
three short tandem internal direct repeats (IR2-4) (Figure 1.2) (Lacoste, et al. 
2010, Kieff and Rickinson 2007). Upon entry into the host cell, the linear 
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genome becomes circularised by the fusion of the two termini (Lindahl, et al. 
1976). 
 
 
 
Figure 1.2: EBV Genome Schematic.  
A schematic of the 172 kbp EBV genome including the internal repeats (IR) 1-4. The 
unique long arm (UL) and the unique short arm (US) are indicated. Figure taken from 
Lacoste et al 2010. 
 
 
1.4 Serotypes of EBV 
 
Limited genetic variation has been found among the EBV isolates studied to 
date. Indeed, there are only two designated subtypes, designated type A and 
type B (also known as type 1 and type 2). EBV A and B were classified 
originally through the analysis of two EBV isolates that presented significant 
differences in their EBV nuclear antigen 2 (EBNA2)-coding regions (Chang, 
et al. 2009) (EBNA2 functions as a transcription factor; see section 1.13.3). 
EBV type A was characterised from an EBV genome isolated from an 
infectious mononucleosis (IM) patient in North America, designated B95-8. 
AG987, a strain derived from an African BL case, was found to have a 
shorter EBNA2 sequence and was designated EBV type B. Remarkably, the 
EBNA2s of the two strains have only 55% homology at the protein level (Kieff 
and Rickinson 2001, Lucchesi, et al. 2008). Type A has been proven to be 
more competent at transforming human B cells into proliferating 
lymphoblastoid cell lines (LCLs) than type B (Rickinson, et al. 1987). The two 
strains show differing geographical distributions. In Africa, both strains are 
present at approximately the same frequency, however, the type A strain 
predominates in Europe and the United States (Reviewed in Lucchesi, et al. 
2008). Although the two serotypes show significant variation [including the 
presence of three additional open reading frames (ORFs) in type B 
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(BFRF1A, BGLF3.5 and BDLF3.5) (Lacoste, et al. 2010, Dolan, et al. 2006) 
and sequence variation in other EBV genes such as the EBNA3 genes and 
EBNA-LP (Sample, et al. 1990)], the differences in the EBNA2 region have 
been proven to be the key behind the altered transformation efficiencies and 
capabilities of the two strains. In 1989, Cohen et al proved that the distinction 
between the immortalising capabilities of the two strains was EBNA2-
dependent. A recombinant type B EBV strain was developed in which the 
type B EBNA2 coding region was substituted by the coding sequence for 
type A EBNA2. This resulted in an increased transforming efficiency in the 
type B strain on a par with the type A variant (Lucchesi, et al. 2008, Cohen, 
et al. 1989).  
 
The diminished transformation proficiency of the type B EBNA2 compared to 
the type A variant, has not yet been fully elucidated. However, a number of 
recent findings may clarify the differing effects of the two EBNA2s on B cell 
immortalisation. In 1989 Cohen et al found that the EBV Latent Membrane 
Protein 1 gene (LMP1), an EBV EBNA2 target, showed similar expression 
levels in LCLs proliferating due to either EBV type A or B. It was recently 
discovered however, that there is a transient difference in LMP1 levels 
immediately following B cell infection by the two types of EBV (Lucchesi, et 
al. 2008, Cohen, et al. 1989). The initial induction of LMP1 by EBNA2 type A 
is a significantly earlier and more intense response than the induction 
initiated by EBNA2 type B. LMP1 is a key player in B cell immortalisation, 
and delayed expression caused by inefficient LMP1 induction by EBV type B 
may be one reason why the type B variant is less proficient at B cell 
immortalisation than type A EBV (Lucchesi, et al. 2008). A small number of 
cellular genes were also highlighted as differentially regulated by the two 
forms of EBV. EBV type A has been found to trans-activate the cellular target 
genes listed in Table 1.1 more potently that EBV type B: 
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Table 1.1: EBNA2 target genes that are differentially regulated by EBV 
type A and type B 
 
Gene Function 
Runx3 Positively affects B cell proliferation 
(Spender, et al. 2005) 
MARCKS Regulates membrane ruffling and cell 
spreading (Myat, et al. 1997) 
IL-1β Role in lymphocyte proliferation (Krauer, 
et al. 1998) 
ADAMDEC1 A metalloprotease expressed in 
lymphocytes. Function unknown (Bates, 
et al. 2002) 
CXCR7 Required for LCL proliferation or survival 
(Lucchesi, et al. 2008) 
 
1.5 EBV Epidemiology  
 
Epidemiological evidence points to a key role for EBV in some malignancies 
such as African endemic BL. Indeed, EBV is present in approximately 95% of 
African BL tumours, in comparison to a 10-20% EBV-positivity in sporadic 
cases of BL found worldwide (Bornkamm 2009a). Epidemiological studies 
have also further pointed to an aetiological role for EBV in the western world 
in the development of IM, and for its 100% association with undifferentiated 
nasopharyngeal carcinoma tumours in southern Asia, especially the Canton 
region (de Thé 2005, Klein 2005). However, to date no definitive link has 
been established between EBV genotype and disease distribution. 
 
1.6 Primary EBV Infection 
 
Upon initial infection via exposure to EBV-positive saliva, EBV infects the 
stratified epithelium of the oropharnyx where it replicates, then migrates and 
establishes latent infection in the B lymphocyte constituency (Sixbey, et al. 
1984, Murray and Young 2002). Through its viral proteins, the actions of 
which mimic several growth factors, transcription factors, and anti-apoptotic 
factors, EBV subverts control of the cellular pathways that regulate diverse 
homeostatic cellular functions (Thompson and Kurzrock 2004). Humans are 
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the only natural host of EBV. Infection usually occurs at a young age and is 
asymptomatic; however, due to the hygienic conditions in more developed 
countries, EBV infection is often postponed until adolescence or adulthood. 
When infection occurs after childhood, the primary infection can lead to IM. 
This lymphoproliferative symptomatic infection is self limiting, and 
characterised by a sore throat, fever, malaise, lymphadenopathy and mild 
hepatitis (Thompson and Kurzrock 2004, Baumforth, et al. 1999). However, 
once active infection is complete, EBV establishes a lifelong latent infection 
of the memory B cell compartment. During latent infection only a limited 
number of viral genes are expressed. The panel of eleven characterised EBV 
latently expressed genes are, six EBV Nuclear Antigens EBNA1, EBNA2, 
EBNA3A, EBNA3B, EBNA3C and EBNA-LP, three integral latent membrane 
proteins LMP1, LMP2A and LMP2B and two small non-polyadenylated EBV 
encoded RNAs known as EBER1 and EBER2. There is also a further set of 
poorly understood transcripts known as BARTs (Murray and Young 2002). 
Throughout the life of the host, intermittent and silent activation of latently 
infected cells will allow sporadic shedding of EBV virions into the saliva 
(Hardie 2010). Throughout the host’s life the viral load is maintained at a 
fixed level with, on average, approximately one EBV positive cell detected in 
every million peripheral blood lymphocytes. However, although each host 
maintains a fixed level of infection throughout their lifespan, the load level 
among individuals has been found to vary (Miyashita, et al. 1995).  
 
The EBV infection process begins by exposure of the host to the virus via 
salivary contact. Once in the host’s system, EBV infects the epithelial cells of 
the oropharnyx. This, however, is a poorly defined process (Young and 
Rickinson 2004). EBV establishes a transient lytic growth programme in this 
target site to produce more EBV virons. These pass into the lymphatic 
system where the viral surface glycoprotein (gp) gp350 binds to the B 
lymphocyte surface marker CD21, the receptor required to bind the C3d 
component of complement (Fingeroth, et al. 1984, Nemerow, et al. 1985). A 
second viral glycoprotein, gp42, binds to the human leukocyte antigen (HLA) 
class II molecule of both naive and memory B cells (Nemerow, et al. 1987, 
Borza and Hutt-Fletcher 2002). After antigen binding, EBV is endocytosed 
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into the cell via CD21-derived cytoplasmic vesicles and the capsids are 
released into the cytoplasm (Carel, et al. 1990, Nemerow and Cooper 1984). 
This instigates mRNA synthesis, B cell blast formation, homotypic cell 
adhesion, surface CD23 expression and interleukin (IL)-6 production 
(Thompson and Kurzrock 2004). Within 12 hours the linear viral genome 
moves into the nucleus and becomes a circular episome (Reviewed in Kieff 
and Rickinson 2007) with a variable number of terminal repeats (TR) which 
gives rise to a fingerprint for the original infected cell and any arising 
daughter cells. This is a valuable feature that can be exploited to determine 
the clonality of EBV-associated tumours (Kutok and Wang 2006, Raab-Traub 
and Flynn 1986). EBV does not encode its own RNA polymerase for 
transcription, it utilises the cellular RNA polymerase II (Kieff 1996). The first 
detectable EBV proteins are EBNA-LP and EBNA2 (Thompson and Kurzrock 
2004). An EBNA2- induced shift from the EBV latent Wp promoter to the 
alternative viral Cp promoter occurs at approximately 24-48 hours post-
infection, and leads to an increase in EBNA mRNA expression (Kieff 1996, 
Takacs, et al. 2010). By 32 hours post-infection, all of the EBV latent proteins 
(six EBNAs and three LMPs) are expressed; however, significant EBV-
encoded non-coding RNA (EBERs 1 and 2) expression is not detected until 
70 hours post-infection (Kieff 1996, Murray and Young 2002). These EBV 
proteins quickly begin to subvert normal cell function instigating B cell 
activation and proliferation. This occurs due to EBV-led manipulation of 
normal B cell activation pathways such as (i) CD40 signaling, (ii) B cell 
receptor (BCR) signaling and (iii) Toll like receptor (TLR) signaling. LMP1, 
the only EBV latent membrane protein essential for B cell immortalisation, 
functions as a ligand-independent constitutively active tumour necrosis factor 
(TNF)-receptor. LMP1 mimics activated CD40 and therefore confers the 
survival signals to the EBV-infected cell that can be provided by CD40. 
LMP2A, while not an essential protein for immortalisation, provides an 
important survival signal in vivo by mimicking BCR activation. EBV also 
commandeers the Toll signaling pathway to enhance the chances of a 
successful infection. EBV activates Toll signaling through TLR7, taking 
advantage of the proliferative effects of stimulated TLR7. Together these 
three events are required for optimal B cell activation. The success of EBV 
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as a B cell transforming agent is therefore due to its adept nature, by which it 
utilises advantageous cell pathways such as CD40, BCR and Toll signaling 
and suppresses limiting factors associated with these pathways. An example 
of this is the EBV-led modification of downstream TLR7 signaling. TLR7 up-
regulates interferon regulatory factor 5 (IRF5) which possess both anti-viral 
and tumour-suppressive properties. EBV stimulates TLR7, benefitting from 
the proliferative effects but then limits the negative effect of the TLR7 target 
IRF5, by inducing the expression of a dominant negative IRF5 splice variant 
(Martin, et al. 2007). Cytotoxic T cells (CTL) detect many of these freshly 
infected B lymphocytes by identifying and eradicating cells expressing EBV 
latency proteins (Hislop, et al. 2007). Enough infected cells evade detection, 
however, to allow EBV to establish a latent infection in the memory B cell 
population. These B cells elude the vigorous CTL response by a poorly-
understood mechanism which leads to the repression of many or all of the 
EBV latency-associated genes (Uchida, et al. 1999).  
 
1.7 EBV Latency Programmes 
 
Due to differing combinations of EBV latency gene expression in various 
EBV associated malignancies and EBV derived cell lines, a set of distinct 
EBV latency programmes have been defined (Shah and Young 2009). These 
have been established from LCLs and tumour biopies, and have been 
characterised as latency Type 0, I, II and III, and the locations of their 
transcripts on the EBV genome are depicted in Fig 1.3. The distinguishing 
EBV latent gene expression pattern between each form of latent infection is 
defined in Table 1.2. Some controversy surrounds the designation of latency 
Type 0. In this ‘persistence’ latency, no EBV latent proteins are detected 
(Shah and Young 2009). Type I latency is characterised by Burkitt’s 
lymphoma; the only latent genes expressed are EBNA1 from a third latent 
EBNA promoter, the Qp promoter, along with the non-coding groups of 
transcripts known as EBERs and BARTs. In Type II latency, EBNA1 and 
three latent membrane proteins (LMP1, LMP2A and LMP2B) are expressed, 
along with the non-coding EBERs and BART trancripts. EBNA1 expression 
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again originates from the Qp promoter. Nasopharyngeal carcinoma is 
characterised by type II latent gene expression. All known latent viral genes 
are expressed in Type III latency -EBNA1, -2, -3A, -3B, -3C and EBNA-LP 
along with LMP1, -2A and -2B and the non-coding EBERs and BARTs. 
However, unlike in Type I and II latency, EBNA1 expression is initiated from 
the Wp/Cp promoter. Initially the Wp promoter drives EBNA expression; 
however, as EBNA-LP and EBNA2 expression increases, transcription 
switches predominantly to the Cp promoter. Type III latency is characterised 
by the EBV expression profile found in LCLs; also, some forms of Burkitt’s 
lymphoma can be classified as Type III latency (Reviewed in Kieff and 
Rickinson 2007, Thompson and Kurzrock 2004, Shah and Young 2009, 
Lopes, Young and Murray 2003). These latent expression programmes are 
not a definitive profile of EBV activity within a cell, as recent evidence has 
highlighted significant variations in the level of EBV encoded microRNA 
expression. The function and effect of these microRNAs is still under scrutiny 
(Reviewed in Shah and Young 2009). 
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Figure 1.3: Pattern of EBV latency transcripts.  
The transcriptional profile of EBV in each type of latency. The direction of 
transcription relative to each gene is indicated. White illustrations indicate non-
coding RNA, black illustrations indicate mRNA (Adapted from (Kieff and Rickinson 
2007)). 
 
The EBV latency programme found in a given cell can be influenced by the 
immune status of the environment. In non-malignant EBV associated 
diseases such as IM, the cells have a Type III latency programme. However, 
in these non-malignant cases the infection is not silent; there is a self limiting 
and symptomatic response observed in the host as the immune system 
detects and targets the EBV assault. In EBV associated malignancies, Type 
III latency is generally found only in immunosuppressed patients, such as in 
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tumours from transplant and AIDS patients. In immunocompetent hosts, the 
EBV latency programme Type I or Type II is usually observed. These latency 
types express less EBV viral proteins reducing the likelihood of detection by 
the immunosurveillance system of a healthy host, allowing EBV to be 
sustained as an asymptomatic infection (Dolcetti and Masucci 2003). 
 
Table 1.2: EBV gene expression in EBV-associated malignancies 
 
Type of 
Latency 
Viral Genes 
Expressed 
Associated 
Malignancies 
Type 0 None Detectable Sustained 
asymptomatic 
infection 
Type I EBNA1, EBERs, 
BARTs 
Burkitts Lymphoma, 
Gastric Carcinoma 
Type II EBNA1, EBERs, 
BARTs, BARF0 
Hodgkins Disease, 
Nasopharyngeal 
Carcinoma, Peripheral 
T/NK lymphoma 
LMP1,LMP2A, 
LMP2B 
 
Type III All EBV Latent 
Genes 
AIDS-associated 
lymphomas 
PTLD,  
IM 
Other EBNA1, 2, LMP1 T cell Lymphomas 
Other EBERs, EBNA1,2 Smooth Muscle 
tumors 
Other EBNA1, 2, LP, 
LMP1 
Oral Hairy leucoplakia 
(OHL) 
 
1.8 EBV Associated Diseases 
 
EBV infection has been linked to a number of B, T and NK lymphocyte 
malignancies such as Burkitt ’s lymphoma, Hodgkin’s lymphoma, peripheral 
T cell lymphoma and nasal T/NK lymphomas, that arise in both 
immunosuppressed and immunocompetent hosts. EBV has also been 
associated with a host of non-lymphoid malignancies including 
nasopharyngeal carcinoma, smooth muscle tumours in immunocompromised 
patients (Jenson, et al. 1999) and a selection of gastric carcinomas 
(Reviewed in Dolcetti and Masucci 2003). It has been observed from a 
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diverse panel of tumours that high grade tumours are three times more likely 
to be EBV positive than low grade tumours (Hummel, et al. 1995). A list of 
EBV associated diseases and their features are given in Table 1.2. 
 
Table 1.3: EBV Associated Diseases 
Non-Malignant EBV Associated Diseases 
Disease Infection Site 
Immunity 
Status Latency 
Infectious mononucleosis 
(IM) 
B cell Competent III 
Chronic active EBV B cell Competent III 
Oral hairy leukoplakia 
(OHL) 
Epithelium Suppressed N/A 
Malignant EBV Associated Diseases 
Burkitt's Lymphoma (BL) B cell Competent I 
Hodgkin’s Disease (HD) B cell Competent II 
Nasopharangeal 
Carcinoma (NPC) 
Epithelium Competent II 
T/NK Lymphoma T Cell Competent II 
Peripheral T Cell 
Lymphoma 
T Cell Competent II 
Gastric Carcinoma Epithelium Competent II 
    
AIDS-Burkitt's Lymphoma B cell Suppressed I/II 
AIDS-immunoblastic or 
large cell lymphoma 
B cell Suppressed II/III 
X-linked 
lymphoproliferative 
disease 
B cell Suppressed III 
Post transplant 
lymphoproliferative 
disease (PTLD) 
B cell Suppressed III 
AIDS-CNS lymphoma  Suppressed III 
Lymphatoid 
granulomatosis 
B cell Suppressed III 
Smooth muscle tumours 
(e.g. Leiomyosarcomas) 
Mesenchymal Suppressed Various 
 
To date it is generally accepted that immunocompromised patients frequently 
succumb to EBV related diseases due to the absence of cytotoxic T cells that 
would normally eradicate a large population of the EBV-infected B cells. 
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Indeed, the immunosurveillance of the cytotoxic T cells pressurises the EBV 
infected cells into sustaining a latent state (Maeda, et al. 2009). There are 
many ways in which a person can become immunocompromised and is 
therefore more likely to develop an EBV-associated disease. 
Immunodeficiency can arise from a number of sources including anti-
rejection drugs administered to transplant patients, patients with Wiskott-
Aldrich syndrome or X-linked lymphoproliferative syndrome, Ataxia 
telangiectasia, acute lymphoblastic leukemia or AIDS (Cohen 2005).  
 
It is not yet clear how EBV-associated diseases become established in 
immunocompetent hosts, although a number of plausible theories have been 
presented. Tumourgenesis of epithelial cells is thought to arise when latently 
infected memory B cells migrate to peripheral tissues and progress into 
plasma cells. These EBV infected plasma cells enter the lytic cycle exposing 
the epithelial cells to EBV virions. The events leading to lymphoid 
malignancies depend on the incorrect passage of EBV-infected B cells 
through the germinal centre (GC). It has been considered that EBV-
associated BL arises due to a combination of a chromosomal translocation 
leading to the activation of the oncogenic c-myc and the passage of the 
infected cells into the GC where EBV drives proliferation of the B cell. C-myc 
subverts natural anti-proliferative cell signals thus enabling continuous 
proliferation of the EBV-stimulated cells. EBV-related Hodgkin’s lymphoma is 
thought to occur in a similar manner. EBV- infected B cells move into the GC, 
but cellular mutations prevent their exit, causing the cells to be blocked at the 
GC. EBV continues to drive the proliferation of these cells resulting in a 
neoplasm of B cells that enlarges the lymph node in a manner that is 
characteristic of classical Hodgkin’s lymphoma (Reviewed in Maeda, et al. 
2009; Pattle and Farrell 2006; Tao, et al. 2006). 
 
In vivo, EBV-infected BL cells usually exhibit type I latency, expressing only 
EBNA1, EBER and BARTs. However, some do exist as type III latency BLs. 
When brought to cell culture type I BLs can maintain type I latency but also 
have the potential to drift to express the type III latency pattern. Interestingly, 
in vivo type III BLs explanted to culture always maintain their EBV episome, 
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sustaining type III latency in culture. Indicating that in vivo type III BLs have 
evolved with EBV and require the virus for survival (Reviewed in Kieff and 
Rickinson 2007) (see Figure 1.4). 
  
1.9 Established EBV Infection in vivo 
 
In its normal life cycle, a naϊve B cell that comes into contact with a 
recognisable antigen will migrate to the GC, there to be transformed into a 
memory B or plasma cell. The naive cell does this by undergoing somatic 
hypermutation (SHM) to increase B cell receptor recognition for the antigen. 
Within the GC, the cell also undergoes class-switch recombination (CSR) to 
alter the class of antibody expressed (Cader, et al. 2010). EBV-infected 
naϊve B cells undergo the same processes as their naturally-stimulated 
counterparts, migrating into the GC and undergoing SHM and the CSR 
immunoglobulin rearrangements, and then passing out of the GC as latently 
EBV infected memory B cells which persist silently in the host. 
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Figure 1.4: Schematic of EBV primary and persistent infection events.  
(A) Primary infection involves the passage of EBV into the epithelial cells of the 
oropharnyx; from here it passes into the lymphatic system infecting naive and 
memory B cells, driving them into a proliferative state. The majority of these are 
eliminated by CTLs. Within the GC, the infected cell mimics natural physiological 
processes such as SHM and CSR to emerge as a long-lived, undetected EBV 
infected cell that establishes the reservoir of EBV infected cells (Type 1 or Type 0 
viral gene expression) for persistent lifelong host infection in the memory B cell 
compartment;  (B) Once EBV infection has been established within the host, 
sporadic shedding of virus occurs following the submission of the EBV positive 
memory B cells to the host’s physiological control. The immune system can cause 
migration of the memory B cells back into the GC, which can lead to further 
differentiation of the memory cell into a plasma cell. These terminally differentiated 
cells will leave the GC and may move into the mucosal sites initiating the lytic cycle, 
producing viral progeny that can be shed into the oropharnyx (Adpated from Young 
and Rickinson 2004). (C) An illustration of EBV persistence in vivo. EBV utilises the 
normal B cell development pathway to establish long-term persistence. After naϊve 
B cell infection, EBV expresses all latent genes (latency III); however, to emulate an 
activated naϊve B cell and to evade immune detection, the infected cell moves into 
the GC and a switch to latency II occurs. This facilitates minor proliferation of the 
cells in the GC where the cell is concealed from immunosurveillance. Once expelled 
from the GC the infected cells switch to either latency I or latency 0 to maintain 
infection without instigating an immune response (Figure adapted from Allday 
2009).  
A 
C 
B 
18 
 
Evidence is building which indicates that EBV infection of resting B cells 
mimics the mechanisms behind physiological B lymphocyte activation via 
antigen stimulation and T cell association. Once EBV-transformed, human B 
cells gain cellular characteristics common to naturally activated B 
lymphocytes, such as blast morphology, expression of B cell activation 
markers and production of IgM (Dolcetti and Masucci 2003). One way in 
which EBV can pass by host immune detection is to present itself as a 
functioning memory B cell. Antigen presenting B cells present the CD40 
protein on their cell surface. CD40 interacts with the CD40 ligand on an 
activated T cell to create a cell survival signal to the immune system (Kooten 
and Banchereau 1997). EBV infected cells mimic this survival mechanism by 
expressing both CD40 antigen and the CD40 ligand on the B cell surface. 
This method of EBV stimulated cell survival signaling has been shown to be 
a cell survival mechanism for B cell transformation (Imadome, et al. 2003), 
NK/T lymphoma (Imadome, et al. 2005) and gastric carcinoma-derived 
epithelial cells (Imadome, et al. 2009). 
 
The mechanism of EBV internalisation into B lymphocytes has been 
elucidated; however, the ability of EBV to infect T/NK and epithelial cells is 
less apparent. T/NK cells show variable CD21expression, leading to the 
possibility of another potential mode of entry for the virus (Dolcetti and 
Masucci 2003, Tsoukas and Lambris 1993). Many studies have shown that 
CD21 is not expressed by epithelial cells (Speck, et al. 2000, Burgos and 
Vera-Sempere 2000), and this is corroborated by the inability of EBV to infect 
epithelial cells unaided in vitro. However co-cultivation of epithelial cells with 
EBV infected B lymphocytes can effectively enable EBV infection of epithelial 
cells (Imai, et al. 1998), suggesting that the mechanism for epithelial EBV 
infection requires infected B cell contact. When a global picture is 
considered, EBV is responsible for causing a surprisingly small amount of 
pathology. Taking into account that approximately 95% of the world’s 
population are EBV carriers, only a small portion of these hosts will actually 
develop an EBV-related malignancy (Middeldorp and Pegtel 2008). 
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Figure 1.5: Schematic of the EBV Latent Genes.  
(A). Diagram of the double stranded EBV episome with the EBV latent gene 
transcription sites marked. The episomal origin of replication (OriP) is shown in 
orange. EBNA1 binds to the OriP in a sequence specific manner to activate 
replication of the EBV genome. The large green arrows depict the coding regions for 
the six nuclear antigens (EBNA1, 2, 3A, 3B, 3C and EBNA-LP) and the three latent 
membrane proteins (LMP1, 2A and 2B). The highly transcribed non-coding RNAs 
EBER1 and EBER2 are represented at the top of the genome by the blue arrows. 
The BamHIA region contains the BARF0 and BARF1 transcript codes. The thin 
green arrow indicates the direction and transcript region utilised from the Cp/Wp 
promoter during type III latency. The EBNA latency III primary transcript is 
alternatively spliced to give rise to the EBV nuclear antigen-coing mRNAs. The Qp 
promoter is active during latency I and II and gives rise to the expression of EBNA1, 
as highlighted by the red arrow. (B). Diagram illustrating the locations of the ORFs 
of EBV latent genes ( EBNA1, 2, 3A, 3B, 3C, EBNA-LP, LMP1, LMP2A and LMP2B) 
and the EBV encoded RNA’s EBER1 and EBER2. The location of the ORF 
encoding the key immediate early gene BZLF1 is also indicated (Figure adapted 
from Chang, et al. 2009). 
  
A 
B 
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1.10 The Lytic and Latent Cycles of EBV 
 
EBV has two replicative phases, a virus production phase and a latent 
persistence phase. Infection with EBV involves both programmes, as the lytic 
cycle permits assembly of EBV virions whilst the latent cycle guarantees 
maintenance of a constant reservoir of virus within the host to ensure 
continuity of the infection. The viral lytic cycle is an explosion of viral 
replication that harms the host and in turn reduces the sustainability of the 
virus. This method of replication is not “in the best interests of the virus” as it 
will either itself be eliminated by the host immune system or it shall eliminate 
the host, which is vital for the existence of the virus (Shen and Shenk 1995). 
The two life cycles use two different origins of DNA replication, the lytic cycle 
uses OriLyt (Hammerschmidt and Sugden 1988), whilst the latent cycle uses 
OriP (Yates, et al. 1984, Yates, et al. 1985) (Reviewed in Takacs, et al. 
2010). 
 
EBV has co-evolved with its host by modifying its existence so as not to 
threaten the host and activate the immune system, sustaining this symbiotic 
relationship (Middeldorp and Pegtel 2008). EBV lytic infection is a significant 
disturbance within the host that presents many markers leading to 
recognition and elimination of EBV lytic activity by the body’s immune system 
and this cycle can be used as a target for drug treatment. Survival of EBV is 
dependent on the virus persisting long enough to infect new hosts. Cell death 
caused by the lytic cycle alerts the immune system to the presence of EBV 
virions; however, by establishing a latent infection EBV can hide from the 
host’s surveillance and maintain an equilibrium whereby EBV can persist in 
memory B cells and sporadically infect new hosts following intermittent 
activation of EBV replication in cells that become terminally differentiated. 
EBV lytic infection can be controlled by administration of the anti-viral drug 
acyclovir. This inhibits viral DNA polymerase-led replication. Acyclovir, 
however, has no effect on latent infection due to the absence of this viral 
enzyme. During latent infection, replication of the genome takes place by 
subversion of cellular processes, and utilisation of the cell’s own DNA 
polymerase to replicate the genome (Reviewed in Kutok and Wang 2006).  
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LMP2 inhibits viral reactivation in an attempt to protect latently infected B 
lymphocytes from immune detection (Longnecker 2000).  
 
1.11 EBV Lytic Gene Expression  
 
The EBV lytic cycle involves the expression of approximately 80 viral 
proteins including transcription activators, DNA replication factors and 
structural proteins such as viral capsid components (Kutok and Wang 2006). 
During the EBV lytic cycle, genes are expressed that delay cell death long 
enough to allow viral replication to be completed (de Oliveira, et al. 2010). 
Lytic gene expression follows a sequential order (Amon and Farrell 2005). 
The immediate early genes include BZLF1, BRLF1 and BILF4 and the 
products of these genes trans-activate the early lytic genes (Reviewed in 
Young and Rickinson 2004). The lytic cycle begins directly after infection and 
the immediate early gene BZLF1 is expressed just 1.5 hours after infection 
(Reviewed in Chang, et al. 2009). BZLF1 alone can activate the lytic cycle; it 
is a master regulator of lytic genes required for replication (Amon and Farrell 
2005). BRLF1 is the second immediate early gene and is a key mediator of 
viral lytic replication and along with BZLF1 is the earliest indicator of lytic 
infection. BZLF1 and BRLF1 together can activate the lytic cascade in the 
infected cell. The early lytic viral genes are expressed soon after the 
immediate early genes and approximately 30 different EBV RNA transcripts 
have been classified as early lytic products (Hummel and Kieff 1982). Of 
these early gene products the most abundant are BALF2 and BHRF1. 
BALF2 is important for DNA replication, while BHRF1 is a partial homologue 
of the human bcl-2 gene and contributes apoptotic resistance to the cell 
(Young and Rickinson 2004). The late lytic genes encode structural proteins 
or glycoproteins that permit enveloping of the viral package. The late genes 
BCLF1, BNRF1 and BXRF1 encode the major nucleocapsid protein, the 
major external non-glycoprotein of the viron and the basic core protein 
respectively. EBV also encodes a glycoprotein, BCRF1, which shows 84% 
sequence homology to human IL-10 (Vieira, et al. 1991). IL-10 is an anti-
inflammatory cytokine and thus BCRF1 serves to aid evasion of the infected 
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cell from the immune response. After replication the linear EBV genomes are 
cleaved at their terminal repeats (TR) and packaged into their viral envelopes 
before being released from the sacrificed cell (Reviewed in Kutok and Wang 
2006).  
 
1.12 EBV Latent Gene Expression 
 
No infectious virus particles are generated during the EBV latent infection 
programme. The panel of latently expressed EBV genes is highly restricted 
and, as mentioned already, is confined EBNA1, EBNA2, EBNA3A, EBNA3B, 
EBNA3C, EBNA-LP, LMP1, LMP2A, LMP2B, EBER1 and EBER2. Of these 
eleven latently expressed proteins, only six are required for B cell 
immortalisation -EBNA1, EBNA2, EBNA3A, EBNA3C and EBNA-LP along 
with LMP1. These genes subvert normal B cell mechanisms to establish a 
long term sustained silent infection. EBV maintains its circular viral genome 
by usurping the natural cell division processes, utilising cellular DNA 
polymerase when the cell divides and distributing its episomal copies equally 
among the daughter cells (Kutok and Wang 2006). 
 
1.13 The EBV Latent Gene Products 
 
1.13.1 Epstein-Barr Virus Nuclear Antigen 1 (EBNA 1)  
 
EBV nuclear antigen 1 (EBNA1) is a sequence-specific DNA binding 
phosphoprotein that has a number of critical roles in the EBV infected cell 
including activating replication of the episome, maintenance of the genome 
and maintaining the latent EBV Infection (Reviewed in Thompson and 
Kurzrock 2004). EBNA1 is a 73 kDa protein comprising 641 amino acids (aa) 
and is the only EBV protein detectably expressed in all EBV-associated 
tumours and EBV-proliferating cells in healthy carriers. EBNA1 has also 
been found to be a stable protein with a long half life, which has been 
attributed to its Glycine-Glycine-Alanine repeat sequence shown in Fig. 1.6 
(Kirchmaier and Sugden 1997). 
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The EBNA1 protein consists of a short amino terminal region, a stabilising 
20-40 kDa Glycine-Glycine-Alanine (Gly-Gly-Ala) repetitive sequence flanked 
by Arginine rich regions and a highly charged acidic carboxy terminal 
sequence (Hennessy and Kieff 1985). The gly-gly-ala repeat sequence has 
been implicated in down-regulating the host’s EBV-induced immune 
response by preventing antigen presentation by the host cell (Levitskaya, et 
al. 1995); however, it is now accepted that the main role for this repeat 
sequence is the stabilisation of the active protein through prevention of 
proteasomal degradation.  
 
 
Figure 1.6: Functional domains of the 641 aa EBV nuclear antigen 1 
(EBNA1).  
The GlyAla box highlighted in blue is a repetitive region of a 20-40 kDa glycine-
alanine repetitive sequence; the length of this region varies between viral strains. 
The Nuclear localization sequence (NLS), DNA binding domain and a protein 
dimerisation domain have also been highlighted on the above protein schematic 
(Figure adapted from Avolio-Hunter and Frappier 1998). 
 
1.13.2 EBNA1 Mechanism and Function 
 
EBNA1 plays a crucial role in EBV persistence as the protein responsible for 
both maintenance of the infection and promoter-dependant activation of the 
other EBNAs. The EBV genome does not usually integrate into the host 
genome but persists as a circularised episome (Humme, et al. 2003). EBNA1 
plays a critical role in maintaining EBV persistence by ensuring minimal loss 
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1 40 32790 376 607459 641
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of EBV latently infected cells during cellular replication. It achieves this by 
binding in a sequence specific manner to the OriP of the plasmid, activating 
replication of the genome and dictating equal partitioning of the EBV genome 
to the daughter cells once during every cellular S phase (Aiyar, et al. 1998). 
EBNA1 has been shown to possess anti-apoptotic function by directly 
antagonising p53 function. This is thought to occur due to sequestering of the 
de-ubiquitination enzyme, HAUSP/USP7, which leads to p53 destabilisation 
(Reviewed in Bornkamm 2009a). 
 
EBNA1 also regulates the transcription of its own gene. EBNA1 homo-
dimerises and binds to the specific consensus site 5’ G(A/G)TATCAT-
ATGCTA(C/T) 3’. This motif has been identified in two regions on the EBV 
genome: in the EBNA Q promoter and also at two sites in the OriP, upstream 
of the EBNA Cp. These sites have been designated the dyad symmetry (DS) 
and the family of repeats (FR). Activation of the Cp promoter requires the 
binding of EBNA1 to the FR-responsive element upstream of the Cp. The FR 
is composed of 20 repeat sequences, and binding by EBNA1 leads to the 
activation of the Cp and expression of the EBNA proteins (Almqvist 2005; 
Sugden and Warren 1989). EBNA1 expression is regulated in a latency-
dependent manner by the Cp and Qp (Altiok, et al. 1992). During latency III, 
EBNA1 is expressed through the Cp and positively self-regulates its 
expression through the FR binding site of the Cp. Conversely, during latency 
I and II, EBNA1 is expressed through the Qp and this binding results in 
negative self-regulation (Reviewed in Almqvist, et al. 2005). A consequence 
of this is lower EBNA1 levels expressed in type I and II latency than those in 
type III latency cells. 
 
1.13.3 Epstein-Barr Virus Nuclear Antigen 2 (EBNA 2)  
 
EBNA2 is an 83 kDa transcription factor that plays a critical role in B cell 
immortalisation. It is a transcriptional co-activator that modulates the 
expression of viral and cellular genes, driving the cell cycle progression from 
G0 to G1. Together with EBNA-LP, EBNA2 is the first EBV latent gene 
expressed upon infection of a B cell (Reviewed in Middeldorp, et al. 2003). 
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EBNA2 can be nucleoplasm-, chromatin- and nuclear-matrix associated and 
localises to large nuclear granules (Hennessy and Kieff 1985; Petti, et al. 
1990). A crucial role for EBNA2 in B cell immortalisation was discovered 
when a mutant strain of EBV, called P3HR1 was isolated and found to lack 
the ability to transform B cells in vitro. Further investigation found a deletion 
encompassing the EBNA2 open reading frame (ORF) and that of EBNA-LP. 
It was soon discovered that the ability of P3HR1 to transform B cells could be 
restored by the re-introduction of EBNA2 to the genome. This implicated 
EBNA2 as a vital EBV latent protein in the process of EBV-led B cell 
immortalisation (Reviewed in Thompson and Kurzrock 2004, Young, et al. 
2000).  Further studies have shown that EBNA2 is also essential for 
maintaining immortalised B cells (Kempkes, et al. 1995b). As described 
previously in section 1.4, EBNA2 has two known variants, EBNA2A and 
EBNA2B, that share only approximately 55% protein homology and are 
found in the two isoforms of EBV (type A/1 and type B/2 respectively) 
(Aitken, et al. 1994, Adldinger, et al. 1985).  
  
1.13.4 Structure of EBNA2 
 
EBNA2A is 483 aa long whilst EBNA2B is composed of 455 aa. Both contain 
a negatively charged highly homologous amino terminal region that facilitates 
homo-dimerisation (Figure 1.7). This is followed by a proline-rich domain 
which can contain from 10-40 successive prolines. The homology between 
the two types of EBNA2 differs most significantly in the “diversity” region 
which then leads into the domain responsible for binding the CBF1/RBP-Jκ 
DNA-binding protein. This region is followed by an arginine-glycine rich 
domain that spans approximately 18 aa, and is followed by a negatively 
charged trans-activation domain that has been found to interact with a 
number of general transcription factors and co-activators in the cell. Finally 
the carboxy terminus is responsible for nuclear localisation (Palermo, et al. 
2008; Zimber-Strobl and Strobl 2001). Three fundamentally required aa 
regions of the EBNA2 protein have been identified through extensive 
mutational analysis: residues 94-110, encompassing the proline rich region; 
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280-337, containing the region required for interaction with CBF1; and 425-
462, a region that harbours the acidic trans-activation domain (Zimber-Strobl 
and Strobl 2001; Cohen and Kieff 1991; Ling, et al. 1993).  
 
Figure 1.7: Illustration of the Structural domains of Epstein-Barr virus 
nuclear antigen 2.   
EBNA2 consists of a negatively charged region at the amino-terminus, which is 
likely to play a role in homo-dimerisation (Dim), a polyproline region (Pro) consisting 
of 10-40 consecutive prolines depending on the virus strain, a diversity region with 
low homology between EBNA2A and EBNA2B, a domain responsible for interaction 
with RBP-Jk/CBF1 (RBP-Jκ), an arginine-glycine rich stretch (ArgGly) and a 
negatively charged carboxy terminus region, which harbors a trans-activation 
domain (TAD) and nuclear localization signal (NLS) (adapted from Zimber-Strobl 
and Strobl 2001). 
 
1.13.5 EBNA2 transcriptional regulation by EBNA2 
 
EBNA2 does not directly bind DNA; rather, it utilises a number of cellular 
transcription factors to achieve specific promoter activation including (i) 
CBF1/RBP-Jκ, (ii) the ETS family protein Spi-1/Pu.1, (iii) ATF/CRE, (iv) the 
CREB-binding protein CBP and (v) the chromatin remodelling complex 
SWI/SNF (Henkel, et al. 1994; Ling, et al. 1994; Johannsen, et al. 1995; 
Pegman, et al. 2006; Zimber-Strobl, et al. 1993; Laux, et al. 1994; Waltzer, et 
al. 1994; Wu, et al. 1996; Sjoblom, et al. 1998; Wang, et al. 2000; Wu, et al. 
2000). EBNA2 has two principal mechanisms by which it activates EBNA2-
responsive genes: (i) it associates with its target genes to alleviate the 
repressive effect elicited by bound CBF1/RBP-Jκ (detailed in Fig. 1.8) and 
this is followed by (ii) strong transcriptional promotion of the target gene, 
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depicted in Fig 1.8 (Palermo, et al. 2008). EBNA2 can also interact with 
members of the basal transcription machinery (BTM) through its acidic trans-
activation domain, including TFIIH, TFIIE, TFIIB, TAF40 and RPA70 
(Palermo, et al. 2008; Tong, et al. 1995a; Tong, et al. 1995b; Tong, et al. 
1995c). Further to these interactions, EBNA2 has been shown to associate 
with the DEAD-box protein DP103 (Grundhoff, et al. 1999) which has an 
established role in transcriptional repression (Yan, et al. 2003). Of the BTM 
utilised by EBNA2 for specific promoter regulation, of particular interest is the 
cellular DNA binding protein, Cp binding factor 1 (CBF-1) which binds to the 
cognate DNA sequence 5’CGT GGG AA 3’ (Zimber-Strobl, et al. 1993). CBF-
1 is also known as recombination signal-binding protein 1 for Jκ (RBP-Jκ). 
CBF1/RBP-Jκ is a ubiquitously expressed transcription factor that has been 
highly conserved during evolution (Zimber-Strobl and Strobl 2001). CBF-1 
directs EBNA2 to its target genes, allowing regulation of the genes by 
EBNA2. EBNA2 drives the EBV Cp promoter via an upstream EBNA2 
responsive element (called the EBNA2-responsive enhancer (E2RE) by 
alleviating CBF1/ RBP-Jκ mediated repression (Jin and Speck 1992; Sung, 
et al. 1991). In the absence of EBNA2, CBF1/ RBP-Jκ acts as a co-repressor 
in the cell bound by a large multi-protein complex of cellular proteins 
comprising SMRT/NcoR, Sin3-associated protein 30 (SAP30), SIN3A, the 
CBF1-interacting co-repressor (CIR), histone deacetylase (HDAC) 1 and 
HDAC2. Another protein that can bind to this complex is Ski interacting 
protein, SKIP.  EBNA2 mediates trans-activation of genes by competing with 
the SMRT-HDAC co-repressor complex, thus relieving the target promoter of 
this repressor complex (Figure 1.8).  
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Figure 1.8: Schematic for EBNA2-mediated promoter activation.  
 (A) EBNA2 acts as a transcriptional activator by interacting with the DNA-binding 
Jκ-recombination-binding protein (RBP-Jκ/CBF1) and relieving transcriptional 
repression that is mediated by a large cellular multi-protein complex consisting of 
SMRT/NcoR, SAP30, SIN3A, CIR, SKIP, HDAC1 and HDAC2.  The binding of SKIP 
to SMRT facilitates nuclear entry of CBF1. (B) EBNA2 abolishes CBF1-mediated 
repression by competing with the SMRT-HDAC co-repressor for binding to both 
CBF1 and SKIP. The EBNA2 acidic domain recruits the BTM, TFIIB, TFIIH and 
p300 to drive transcriptional activation. (Figure adapted from Young and Rickinson 
2004). 
 
Once repression is relieved, EBNA2 brings strong transcriptional activation to 
the promoter (Hsieh and Hayward 1995). To instigate this, EBNA2 binds 
histone acetyltransferases (HATs) and chromatin remodelers such as 
SWI/SNF to alter chromatin structure, rendering the gene accessible for 
transcription. EBV utilises cellular RNA polymerase II (RNA pol II) for 
transcription of target genes. The activity of RNA pol II is tightly controlled 
and requires phosphorylation of the RNA pol II c-terminal domain (CTD) 
subunit (Palancade and Bensaude 2003), shown in Figure 1.9. EBNA2 
interacts with general transcription factors such as TFIIH and TFIIE along 
A
B
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with the cyclin dependent kinase (CDK) 9 to initiate and maintain 
phosphorylation of RNA pol II. The main phosphorylation sites of the CTD 
are Ser-2 and Ser-5. Bark-Jones et al, have shown, by CDK9 inhibition 
studies, that EBNA2 requires CDK9 recruitment for efficient transcriptional 
activation (Bark-Jones, et al. 2005). The CTD Ser-5 phosphorylation has also 
been shown to fluctuate relative to EBNA2 expression levels, demonstrating 
that Ser-5 phosphorylation may be an EBNA2-dependent process (Reviewed 
in Palermo, et al. 2008). In peptide studies, CDK9 has been shown to 
preferentially phosphorylate Ser-5 (Ramanathan, et al. 2001), implicating a 
transcriptional initiation model that involves recruitment of CDK9 by EBNA2 
for the phosphorylation of Ser-5, thus activating the CTD and RNA pol II 
activity (Palermo, et al. 2008; Ramanathan, et al. 2001). EBNA2 interaction 
with TFIIH aids phosphorylation of the CTD, leading to strong sustained 
transcriptional up-regulation of the target gene (Palermo, et al. 2008). 
 
 
 
Figure 1.9: Mechanism for EBNA2 led transcriptional activation. 
Association with the target promoter leads to binding of EBNA2 and the chromatin 
remodelers SWI/SNF along with HATs, to make the gene accessible for 
transcription. EBNA2 then promotes assembly of the transcription complex by 
interacting with the general transcription factors TFIIH and TFIIE. Transcription 
initiation is activated by CDK9 stimulated phosphorylation of the Ser-5 and possibly 
the Ser-2 on the C-terminal domain (CTD). TFIIH also plays a role in Ser-5 
phosphorylation through its bound subunit, CDK7. However, there is no evidence to 
suggest that EBNA2 has a task in this process (Figure adapted from Palermo, et al. 
2008). 
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EBNA2 functions in two ways, (i) to alleviate repression to allow up-
regulation of its target genes: it binds to the repressor domain, as described 
in figure 1.9, alleviating the repression complex; (ii) EBNA2 also brings a 
strong transcriptional activation domain to the promoter which plays an 
important role in the trans-activation of the target gene (Palermo, et al. 2008; 
Hsieh and Hayward 1995). EBNA2 directly up-regulates the expression of a 
range of viral and cellular genes; some of the most significant among these 
targets are those encoding the activated B cell surface marker CD23, the 
cellular proto-oncogene c-myc, the B cell differentiation marker CD21, the 
anti-apoptotic Bcl-2 family member bfl-1, the B cell specific transcription 
factors Runx3 and BATF, the chemokine receptor CCR7 that navigates the B 
cell to lymphoid organs, along with the EBV latent membrane proteins LMP1, 
LMP2A and LMP2B and the EBNA Cp promoter (Ling, et al. 1994; 
Johannsen, et al. 1995; Pegman, et al. 2006; Burgstahler, et al. 1995; 
Spender, et al. 2002) (Reviewed in Kieff and Rickinson 2007). EBNA2 has 
also been shown to elicit negative transcriptional regulation. Evidence from 
LCL studies has exposed EBNA2 as a repressive influence on Nurr77-
mediated apoptosis. This inhibition mechanism involves the interaction of the 
EBNA2 transcriptional complex with Nurr77 protein, sequestering Nurr77 
within the nucleus and preventing signaling to the mitochondria that would 
lead to cytochrome c release and stimulation of apoptosis (Lee, et al. 2002, 
Li, et al. 2000). To date EBNA2 is known to transcriptionally repress two 
cellular genes, the immunoglobulin heavy chain locus (IgM) (Jochner, et al. 
1996) and the pro-apoptotic bik gene (Campion, 2008).  
 
1.13.6 EBV latent promoter switching by EBNA2  
 
It is accepted that transcription through the EBV W promoter is an inefficient 
process that leads only to the amplification of the promoter proximal genes, 
EBNA-LP and EBNA2 (Palermo, et al. 2008; Bell, et al. 1998), (see Figure 
1.5 for Wp coordinates relative to the EBNAs). The Wp is located in the 
internal repeat region 1 (IR1) and thus there are multiple copies of the Wp 
present on the genome, see Figure 1.5. This is thought to facilitate the 
production of abundant EBNA2 transcripts which are required to switch 
31 
 
transcription from the Wp to the Cp (Palermo, et al. 2008). As discussed 
previously, phosphorylation of the CTD subunit of RNA pol II is required for 
transcriptional initiation and is also critical for efficient elongation and RNA 
processing of transcripts (Palancade and Bensaude 2003). The Wp itself 
does not appear to competently maintain transcription to allow the remaining 
EBNAs to become fully transcribed. The Wp, however, produces sufficient 
EBNA2 mRNA such that the EBNA2 protein made stimulates CDK9 
dependent phosphorylation and recruits general transcription factors that 
activate and maintain the RNA pol II function from the Cp. The C promoter 
contains an E2RE, allowing successful transcriptional initiation, promoter 
clearance, elongation and RNA processing of the product of interest. This 
yields an approximately 120 kb primary transcript encoding the full range of 
EBNAs. Due to the inefficiency of the Wp activity, the switch to EBNA2-led 
Cp transcription does not occur until approximately 48 hours after infection 
(Reviewed in Palermo, et al. 2008).  
 
1.13.7 EBNA2 Hijacks the cellular Notch Signaling pathway 
 
In recent years, the discovery of the ability of EBNA2 to exert its function 
using overlapping effector proteins involved in the Notch signaling cascade 
has led to the hypothesis that EBNA2 may be a viral functional analogue of 
the activated Notch signaling protein (Reviewed in Kempkes, et al. 2005). 
EBNA2 hijacks and manipulates B cell function, by usurping the mechanisms 
and diverse role of Notch signaling in normal B cell physiology as well as B 
lymphocyte malignancy. 
 
1.13.7.1 The Notch Pathway  
 
The Notch signaling pathway is a highly conserved, fundamental multitasking 
cell signaling pathway that plays a critical role in diverse systems such as the 
nervous system, somitogenesis, cardiovascular and endocrine development. 
Notch regulates these systems by modulating cell mechanisms such as cell 
fate specification, differentiation, proliferation, apoptosis and adhesion 
(Bolos, et al. 2007).  
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The Notch signaling pathway is one of the key cellular pathways that is 
regulated by EBV. This regulation is elicited by EBNA2 which may be 
considered as a functional homologue of the activated Notch1 receptor (NIC). 
Notch belongs to a conserved family of trans-membrane receptors that 
regulate cell fate. All of the members of this family are single-pass trans-
membrane proteins that respond to the ligands of the Delta-Serrate-Lag2 
(DSL) family (Struhl and Adachi 1998; Miele 2006). The Notch signaling 
pathway was originally discovered through genetic studies in the fruit fly 
Drosophila melanogaster, and the name derives from the effect of some 
Notch alleles to lead to notched wings upon mutation (Hansson, et al. 2004). 
To date, there have been four mammalian Notch genes identified: Notch 1, 
Notch 2, Notch 3 and Notch 4. These are trans-membrane spanning proteins 
and possess three major domains, a large external ligand binding region and 
an internal signal transducing region along with a trans-membrane domain 
(see Figure 1.10 below). It is understood that the extracellular ligands (Delta-
like-1, Delta-like-3 and Delta-like-4, also Jagged-1 and Jagged-2) interact 
with Notch receptors of adjacent cells activating the Notch cell signaling 
pathway. Notch signaling is regulated post-translationally by events such as 
glycosylation of the receptor or ligand (Reviewed by Bolos, et al. 2007).  
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Figure 1.10. Notch Signaling.  
Notch proteins are synthesised in the golgi prior to transportation to the cell surface. 
Interaction of the Notch extracellular domain with Delta-like or Jagged ligands leads 
to a cascade of cleavage events described in the text. The CBF1 transcription factor 
is represented by CSL in the illustration. Evidence also points to a CBF-1 
independent pathway; however, to date this pathway is poorly characterised (Figure 
adapted from Radtke and Raj 2003). 
Once the Notch ligand binds to its receptor the notch signaling cascade is 
initiated. This leads to the dissociation of the notch receptor extracellular 
region (NEC) from the notch receptor trans-membrane unit (NTM) by 
metalloprotease-led cleavage via TNF-α-converting enzyme (TACE) (Brou, 
et al. 2000; Hartmann, et al. 2002). Further cleavage is then activated on the 
intracellular portion on the notch receptor by γ-secretase (Edbauer, et al. 
2003). This liberates NIC allowing translocation to the nucleus directed by the 
notch nuclear localisation signal (NLS) (Pinnix and Herlyn 2007). Within the 
nucleus the CBF1 transcription factor can be recruited by the activated NIC to 
form a multi-protein transcriptional activator complex (Reviewed in Miele 
2006). CBF1 is usually part of a repressor complex composed of SMRT, 
SKIP, CIR and histone deacetylases (Kao, et al. 1998; Taniguchi, et al. 1998; 
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Hsieh, et al. 1999; Zhou, et al. 2000; Oswald, et al. 2002). Cellular CBF1 
binds to the recognition sequence 5’ CGTGGGAA ’3, repressing the 
associated Notch target gene. The introduction of activated Notch into the 
nucleus displaces CBF1 co-repressors and chromatin remodelling proteins, 
relieving this repression and  allowing modulation of the Notch target genes 
via activated CBF1 (Fortini and Artavanis-Tsakonas 1994; Tamura, et al. 
1995; Kato, et al. 1997; Tani, et al. 2001). 
 
Notch signaling constitutes a cell-contact driven network of communication 
between cells. Notch signals regulate cellular events such as development, 
angiogenesis, differentiation and cell lineage commitment. Notch activates a 
diverse range of genes, for example the hairy enhancer of split complex 
related genes Hes-1, Hes-5, Hey-1, Hey-2 and Hey-L (Maier and Gessler 
2000; Jarriault, et al. 1995; Nishimura, et al. 1998). These transcription 
factors act as repressor proteins in the absence of Notch. ERBB-2 (Chen, et 
al. 1997), also called HER2, encodes an epidermal growth factor (EGF) that, 
once activated, modulates cellular gene expression to increase cellular 
proliferation and promote resistance to apoptosis (Rusnak, et al. 2001). NF-
κB2 forms a subunit of the NF-κB transcription factor (p52) which plays a 
role in apoptosis and inflammatory responses (Oswald, et al. 1998). The 
hairy-related transcription factor (Hey/HRT) (Nakagawa, et al. 2000) 
negatively regulates genes in the absence of Notch signaling and plays a 
particularly important role in the development of the cardiovascular system 
(Fischer, et al. 2005). Furthermore, evidence has shown that Notch 
regulation is context dependent. Notch signaling has dual functions within the 
body, regulating cell fate in either a positive or negative manner. This 
implicates Notch, in a framework-dependent manner, as both a tumour 
suppressor gene and as an oncogene. Notch plays an oncogenic role in 
some T cell and B cell malignancies, while the tumour suppressor activity of 
Notch has been shown in Keratinocyte-derived carcinoma and late stage 
cervical cancer (Bolos, et al. 2007; Radtke and Raj 2003).  
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1.13.7.2 Functional overlap of EBNA2 and Notch 
 
As stated previously, EBNA2 function is elicited through the recruitment of 
cellular transcription factors such as CBF-1 which is a key effector of the 
activated Notch signaling pathway. This CBF-1-led gene regulation usually 
relies upon activation of the Notch signaling cascade, however, EBNA2 
appears to act as a functional homologue of activated Notch, usurping the 
cellular Notch function and acting as a constitutively activated NIC (Hsieh, et 
al. 1996, Hayward 2004). The mechanism by which EBNA2 and NIC 
dismantle the CBF-1 repressor complex appears to be one and the same: 
each protein interacts with CBF-1 and SKIP, subsequently displacing 
SMRT/NcoR from the complex. Both EBNA2 and NIC proceed to enlist 
chromatin modifying molecules, some of which overlap. EBNA2 binds p300, 
PCAF and CBP (Wang, et al. 2000) and p100, a co-activator that stimulates 
TFIIE (Tong, et al. 1995b), while NIC recruits GCN4, PCAF and p300. Indeed, 
unsurprisingly, EBNA2 and NIC overlap in functional activities and target 
genes. Both EBNA2 and NIC can inhibit Nur77-induced apoptosis by binding 
and sequestering this pro-apoptotic transcription factor (Lee, et al. 2002; 
Jehn, et al. 1999). Both have also been implicated in modulating the activity 
of a number of overlapping genes in B cells such as Hes1, LMP2A (EBV), 
BATF, CD21 and IgH. Contrastingly, Notch cannot regulate the EBNA2 
targets LMP1, CD23 and c-myc (Reviewed in Zimber-Strobl and Strobl 
2001).  
 
1.13.8 Epstein-Barr Virus Nuclear Antigen -3A, -3B and -3C (EBNA -3A, -
3B and -3C)  
 
The EBNA3 family comprises three nuclear proteins, EBNA -3A, -3B and -
3C, encoded by three genes that lie adjacent to one another on the viral 
genome (Wensing and Farrell 2000). This family is expressed exclusively in 
B lymphocytes and all three interact with the CBF-1 isoform, RBP-2N 
(Krauer, et al. 1996). The NH2-terminal regions of the three family members 
are conserved; however, the remaining two thirds of the proteins show 
diversity (Rowe 1999). Although their functions may overlap, the EBNA3s 
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have distinct roles and a contrasting spectrum of potential binding factors 
(Yenamandra, et al. 2009). This family produces strikingly stable hydrophilic 
proteins, a feature that may aid nuclear localisation (Kieff and Rickinson 
2007). Their CBF-1 interaction implies a role in transcriptional regulation and 
associations with both the cellular Notch pathway and the activities of 
EBNA2. Also in parallel with EBNA2, the EBNA3 family shows sequence 
variation between type 1 and type 2 EBV strains. Type 1 EBNA3A, 3B and 
3C are proteins of 944, 938 and 992 aa respectively. In contrast to this, the 
type 2 variants are 925, 946 and 1069 aa respectively. The EBNA3A variants 
share only 84% homology, which decreases to 80% homology for EBNA3B, 
and 72% for EBNA3C (Sample, et al. 1990). Despite the significant diversity 
between EBV types, there is as yet no evidence of a discernible effect of 
either variant in the role of B cell transformation in vitro (Kieff and Rickinson 
2007; Tomkinson and Kieff 1992a). EBNA 3A and 3C are crucial for in vitro B 
cell immortalisation (Murray and Young 2002, Tomkinson and Kieff 1992a). 
In vitro EBNA3B appears to have a redundant function (Tomkinson and Kieff 
1992b); however, it most likely does play a key role in vivo as EBNA3B is 
consistently present and induces a strong host recognition by cytotoxic T 
cells. If EBNA3B had no positive role in vivo, the immune pressure would 
have led to the negative selection and loss of the gene (Reviewed in Kieff 
and Rickinson 2007).  
 
EBNA3A is vital for B cell immortalisation (Kempkes, et al. 1995) and has a 
range of cellular binding targets. The effect elicited by EBNA3A is 
concentration-dependent: at low concentrations it acts as a transcriptional 
repressor, however at higher expression levels it has a positive effect on 
transcriptional regulation (Cludts and Farrell 1998). When over expressed in 
an LCL EBNA3A binds CBF-1 to down-regulate c-myc, CD21 and CD23, and 
leads to G0/G1 growth arrest. These studies indicated that EBNA3A is also 
crucial for LCL proliferation. Indeed, removal of EBNA3A expression from an 
LCL leads to cell death (Yenamandra, et al. 2009; Cooper, et al. 2003; 
Maruo, et al. 2003). 
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EBNA3C is to date the best studied of the EBNA3 family. It has been found 
to regulate both cellular CD21 expression and that of the viral LMP1 gene 
(Allday and Farrell 1994). In vitro, both EBNA3A and 3B have also been 
shown to activate LMP1 transcription from its promoter in the presence of 
EBNA2 (Zhao, et al. 1996; Le Roux, et al. 1994). In fact, it has been shown 
that EBNA3C can activate or repress transcription in the presence or 
absence of EBNA2. This is perhaps due to the ability of EBNA3C to 
associate with transcription factors such as CtBP (binding protein to the C-
terminal half of E1A) and NcoR (a nuclear receptor co-repressor) (Reviewed 
in Yenamandra, et al. 2009). Recent evidence by Kashuba et al. (2008) has 
also uncovered a new mechanism for EBNA3C that involves inhibiting the 
association of pRb with E2F1 via EBNA3C interactions with the pRb binding 
protein MRPS18-2, to facilitate entry of EBV-infected cells into S phase 
(Kashuba, et al. 2008). 
 
1.13.9 Epstein-Barr Virus Nuclear Antigen – Leader Protein (EBNA-LP)  
 
EBNA-LP, also known as EBNA5, is one of the first EBV proteins expressed 
in infected B lymphocytes (Kieff 1996). It is composed of amino-terminal 
repetitive segments, as it is encoded by a repeating sequence, followed by a 
unique carboxy-terminal sequence. This gives an EBNA-LP protein that 
varies in size from 20-130 kDa depending on the number of repetitive 
segments in the splice variant. EBNA-LP is not essential for B cell 
immortalisation; however, it potentiates the efficiency of the process 
(Hammerschmidt and Sugden 1989). In addition, loss of EBNA-LP has no 
diverse effect on immortalised cell lines (Allan, et al. 1992). EBNA-LP’s 
functions within the EBV infected cell include associating with EBNA2 to 
drive the resting B lymphocytes into the G1 phase of the cell cycle by 
inducing Cyclin D2 and co-operating with EBNA2 to drive LMP1 expression. 
In addition, recent studies have identified an independent role for EBNA-LP 
in the induction and repression of cellular genes (Reviewed in Peng, et al. 
2005). EBNA-LP is mostly localised to the nucleus; mutants that cannot 
localise to the nucleus are incapable of co-activating EBNA2 targets (Ling, et 
al. 2009). Within the nucleus, EBNA-LP can associate with promyelocytic 
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leukemia nuclear bodies (PML NBs). Furthermore, the PML NB-associated 
protein Sp100A has been implicated as an important mediator for the co-
activator function of EBNA-LP. Sp100A plays a role in chromatin remodelling 
(Reviewed in Ling, et al. 2009), and a recent study has suggested that 
histone deacetylase 4 (HDAC4) is sequestered in the cytoplasm by EBNA-
LP; this is possibly a contributing factor in EBNA-LP co-activation (Portal, et 
al. 2006). 
 
1.13.10 Latent Membrane Protein 1 (LMP1) 
 
LMP1 is a 63 kDa integral membrane phosphoprotein that is a member of 
the tumour necrosis factor receptor (TNFR)/CD40 super-family (Figure 1.11). 
It functions as a constitutively active CD40 receptor (Gires, et al. 1997) and 
modulates immune responses within infected B cells (Middeldorp and Pegtel 
2008). Reminiscent of an activated CD40 response, LMP1 induces adhesion 
molecule expression leading to the cell clumping typically observed in EBV-
infected B cells with latency III (Soni, et al. 2007). LMP1 is also the only 
latent membrane protein required for B lymphocyte immortalisation. LMP1 
expression has also been shown in NPC, EBV-positive HL and NK/T cell 
lymphoma, but no expression has been detected in BL (Tao, et al. 2006).  
 
The LMP1 protein can be divided into three domains: (i) the first is a 
hydrophilic amino-terminal cytoplasmic tail (amino acids 1-23), which tethers 
LMP1 to the plasma membrane and orientates the protein;  (ii) secondly, a 
trans-membrane region, consisting of six hydrophobic trans-membrane loops 
creating three membrane spanning domains, which are involved in self-
aggregation and oligomerisation (amino acids 24-186);  (iii) third, a long 
cytoplasmic carboxy terminus (amino acids 187-386), which possesses most 
of the signaling activity of the molecule (Young and Rickinson 2004, 
Middeldorp and Pegtel 2008). The carboxy terminal region contains two 
domains that interact with cellular proteins: these are the C-terminal 
Activation Region 1 (CTAR1) and Region 2 (CTAR2). These elicit LMP1-
mediated regulation by activating up to four cell signaling pathways that lead 
to the activation of nuclear factor κB (NF-κB), the c-Jun NH2 terminal kinase 
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(JNK), the p38/mitogen activated protein kinase (p38/MAPK) and the janus 
kinase/signal transducers and activators of transcription (JAK/STAT) (Murray 
and Young 2002).   
 
 
 
Figure 1.11: Schematic of the Structure of LMP1.   
LMP1 elicits signals by association with a family of tumour necrosis factor receptor 
(TNFR)-associated factors (TRAFs) directly with CTAR1 or indirectly via TNF-
receptor associated death domain (TRADD), with CTAR2. These factors then recruit 
a catalytic complex containing NF-κB-inducing kinase (NIK) and IκB kinases (IKKs) 
activating NF-κB signaling. The canonical NF-κB pathway involves an IκBα-
dependent recruitment of the p50-p65 heterodimer while the alternative NF-κB 
pathway involves processing by p100 resulting in a p52-RelB heterodimer. The 
TRAFs can also recruit proteins to activate other signaling pathways such as the 
MAPK and Pl3K pathways (Figure adapted from Young and Rickinson 2004).   
 
LMP1 shares functional homology with cellular CD40, and both proteins can 
signal to activate NF-κB (Gires, et al. 1997; Lalmanach-Girard, et al. 1993). 
In turn, this up-regulation of NF-κB drives LMP1 expression in a positive 
feedback loop that sustains elevated NF-κB expression throughout some 
types of EBV latency (Johansson, et al. 2009). Normally, CD40 signaling 
involves a deactivated CD40 receptor on the cell surface that requires 
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interaction with a specific ligand presented by T cells, the CD40 ligand 
(CD40L), for activation. Once stimulated, CD40 activates NF-κB which has a 
positive effect on cell survival. This signaling is a tightly controlled process 
and dys-regulation can lead to malignancy. Studies have shown that when 
CD40 is rendered constitutively active, it drives lymphomagenesis (Hömig-
Hölzel, et al. 2008). LMP1 acts as a constitutively active CD40 receptor; 
thus, regulation of LMP1 expression must be limited by some alternative 
mechanism to the receptor/ligand control seen in CD40 signaling, as 
otherwise LMP1 would instigate all EBV carriers to succumb to EBV-derived 
carcinogenesis (Kulwichit, et al. 1998; Shair, et al. 2007). Indeed, although 
CD40 and LMP1 signaling elicit similar eventual responses, divergent 
regulatory methods must be employed within the cell (Middeldorp and Pegtel 
2008). 
 
1.13.10.1 NF-κB activation 
 
NF-κB activation has been found to be essential in the EBV life cycle and 
this transcription factor complex has also been shown to be constitutively 
active in certain EBV-associated malignancies. NF-κB is activated by a wide 
spectrum of stimuli and in turn, regulates a large number of diverse genes. 
This allows NF-κB to modulate a range of cellular processes such as 
inflammation, cell survival, proliferation and differentiation. NF-κB activation 
involves stimulation of certain cell surface receptors such as CD40, TNFSF 
and TLR, leading to IκB kinase complex (IKK) activation via signal 
transduction adaptor proteins such as TRAFs. IKK is composed of the sub-
units IKKα, IKKβ and the regulatory sub-unit, IKKγ (also called NEMO). In the 
canonical NF-κB pathway, signaling to the IKK is elicited through (TGFβ)-
activated kinase I (TAK-1); while, in an alternative pathway, NF-κB-inducing 
kinase (NIK) is employed (Figure 1.12). In the canonical pathway, this 
activated IKK complex is activated through the IKKβ subunit and leads to the 
phosphorylation and degradation of IκB from the IκB inhibitory complex, 
allowing the liberation of the NF-κB subunits, usually p65 and p50. In the 
non-canonical pathway, the p52 precursor protein, p100 is processed to yield 
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active p52. The two pathways converge in the dimerisation of NF-κB 
subunits followed by translocation to the nucleus to regulate NF-κB 
responsive genes in a sequence specific manner (Reviewed in de Oliveira, et 
al. 2010) (Hayden and Ghosh 2008). 
 
 
Figure 1.12: Schematic representation of NF-κB transduction.  
This illustration describes a simplified version of the canonical and alternative NF-
κB activation pathways. Binding of the internal domain, by factors such as the TRAF 
family members, results in activation and nuclear translocation of the heterodimers 
p65-p50 and p52-RelB respectively. IKKβ is essential for the canonical pathway, as 
it is responsible for the phosphorylation and eventual degradation of IκBα, a step 
which is required to liberate the NF-κB sub-unit, p65-p50. However, in the 
alternative pathway, the effector unit IKKα is required to phosphorylate p100, which 
initiates cleavage of the factor to generate p52. This dimerises with RelB and is 
translocated to the nucleus. This figure was taken from (de Oliveira, et al. 2010). 
 
The NF-κB pathway involves activation of a cascade that leads to post-
transcriptional modification and nuclear localisation of NF-κB and Rel family 
members. These, in turn, modify the expression of a diverse range of genes 
including those involved in: (i) cell survival (e.g. Cyclin D1 and Cyclin E); (ii) 
cell survival (e.g. cFLIP and IAPs); (iii) inflammation and angiogenesis (e.g. 
IL-1, IL-6, VEGF and ICAM-1); and (iv) invasion and metastasis (e.g. MMP2, 
MMP9 and ICAM-1) (Reviewed in de Oliveira, et al. 2010). The life cycle of 
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EBV involves characteristic steps such as: (i) cell binding and entry by the 
virus; (ii) the expression of latent viral genes; (iii) modulation of cellular genes 
to stimulate growth and suppress immune responses and (iv) transient lytic 
expression. NF-κB has been shown to play a role in each of these stages 
(Reviewed in de Oliveira, et al. 2010). During virus binding and 
internalisation, NF-κB is up-regulated by gp350/220 binding of the cell 
surface receptor, CD21. This activation of NF-κB facilitates binding to the 
NF-κB responsive elements in the EBV Wp and thus the expression of viral 
genes (Sugano, et al. 1997). In addition, NF-κB up-regulation drives the 
expression of CD21. As EBV infected cells can promote NF-κB activation in 
neighbouring cells via EBV dUTPase stimulation of TLR2, this may also 
serve to enhance the susceptibility of neighbouring cells to infection (Ariza, et 
al. 2009). During EBV latency, NF-κB activation is required to prevent a 
switch to the lytic cycle. NF-κB represses the lytic gene, BZLF1, preventing 
lytic re-activation (Morrison and Kenney 2004). However, unexpectedly, once 
viral lytic cycle is activated, NF-κB levels are once again elevated. This is 
believed to function as a survival mechanism to preserve the cell until viral 
replication is complete (de Oliveira, et al. 2010).  
 
1.13.11 Role of LMP1 
 
LMP1 displays a number of functions that are key to maintaining a sufficient 
reservoir of EBV-infected cells within the host. (i) EBV positive cells typically 
maintain the type I or type 0 latency programme in vivo. LMP1 has been 
shown to be transiently activated, reminiscent of type II latency, whilst the 
EBV infected cell intermittently passes through the GC. This drives 
proliferation of the B cell. Due to the occurrence of this propagation in the 
GC, LMP1-mediated proliferation is hidden from the immunesurveillance. 
Thus, LMP1 facilitates silent expansion of the EBV infected cell pool 
(Reviewed in Middeldorp and Pegtel 2008). (ii) LMP1, like EBNA1, can 
increase cellular resistance to p53 induced cell death in genetically damaged 
cells. This supports survival of the infected cell and could indicate one 
possible mechanism for EBV associated oncogenesis (Saridakis, et al. 2005; 
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Holowaty and Frappier 2004). The link between LMP1 expression and 
malignancy is one of the most robust associations with an EBV latent protein. 
The detectable expression of LMP1 in EBV-infected cells in vivo is relatively 
rare and the only cells exhibiting any LMP1 expression appear to be tonsilar 
cells, calculated at a LMP1-positive rate of 1:500,000 (Hudnall, et al. 2005). 
In contrast, immunocompromised patients who progress to develop 
lymphoproliferative disease display abundant LMP1 expression in tonsillar B 
cells. This not only relates LMP1 to oncogenesis but further reveals that the 
tonsils act as an in vivo reservoir for EBV infected B cells (Mowry, et al. 
2008). LMP1 has been found to be highly expressed in a number of EBV-
associated tumours including Post-Transplant Lymphoproliferative Disease 
(PTLD) (Liebowitz 1998), Hodgkins disease (Dukers, et al. 2000), and 
undifferentiated NPC (Khabir, et al. 2005). The expression of LMP1 has been 
associated with metastasis in NPC (Horikawa, et al. 2007). The oncogenic 
potential of LMP1 can be further substantiated by studies demonstrating 
morphological changes, altered adhesion, cell motility and exo-proteolytic 
activity in epithelial cells exposed to LMP1 expression (Dawson, et al. 2008). 
 
LMP1 levels are regulated by diverse cellular mechanisms including 
ubiquitination (Aviel, et al. 2000), autophagy (Lee and Sugden 2008) and by 
micoRNA (miRNA) activity which blocks LMP1 activity (Lo, et al. 2007). In 
addition, LMP1 is regulated by viral EBNA2-dependent and independent 
mechanisms. When taken together, these indicate a possible area for 
targeted therapy to reduce oncogenesis in individuals with increased LMP1 
expression (Middeldorp and Pegtel 2008).  
 
1.13.12 Latent Membrane Protein 2A and 2B (LMP2A and LMP2B) 
 
The latently expressed LMP2 gene encodes two proteins known as LMP2A 
and LMP2B. Their transcripts consist of 9 exons which differ only in their first 
exon (Laux, et al. 1989; Sample, et al. 1989). Due to this, the structures of 
the two proteins have a high degree of similarity. Both proteins contain 12 
trans-membrane domains and a 27 aa cytoplasmic C-Terminus. However, 
the first exon of the LMP2B sequence is non-coding (Kieff 1996). For this 
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reason investigations have been focused on the LMP2A transcript (Ikeda, et 
al. 2005). Structurally, LMP2A and LMP2B resemble signal modulators 
(Chen, et al. 2002). LMP2A is localised to the plasma membrane and cytosol 
(Longnecker 2000). The evidence indicates a role for LMP2A in modifying 
the normal programme of B cell development to favour the maintenance of 
EBV latency and to prevent inappropriate activation of the EBV lytic cycle.  A 
modulatory role for LMP2B in regulating LMP2A function has been 
suggested (Ikeda, et al. 2005; Scholle, et al. 2000).  
 
LMP2A plays a major role in subverting normal B cell function. One of the 
best studied modulation capacities of LMP2A is thought to occur through 
hijacking B cell receptor (BCR) signals (Chen, et al. 2002). BCR signaling is 
a complex cellular communication system facilitating a variety of outcomes 
such as cell differentiation, survival, apoptosis and proliferation (Dal Porto, et 
al. 2004). LMP2A acts as a constitutively active receptor in the BCR 
pathway, activating inappropriate cell survival signals (Longnecker 2000, 
Caldwell, et al. 1998) and preventing BCR-mediated terminal differentiation 
(Chen, et al. 2002). When co-expressed with LMP1, LMP2A can inhibit 
plasma cell differentiation by impeding downstream BCR signaling factors 
required to complete B cell activation. These required factors include Lyn 
and consequently Syk, both adaptor molecules required for plasma B cell 
establishment. LMP2A-mediates proteosomal degradation of these factors, 
thus preventing plasma cell differentiation (Matskova, et al. 2007). B cell 
activation (plasma cell formation) induces the EBV lytic cycle in infected cells 
(Kieff and Rickinson 2001, Miller, et al. 1995), a vastly immunogenic process 
that exposes EBV existence (Rickinson and Kieff 2001). LMP2A modulation 
of the BCR cascade may serve to maintain EBV latency (Chen, et al. 2002) 
and therefore this protein may have a key role in sustaining EBV survival 
within the host. In addition to this function, in vivo studies have revealed that 
LMP2A promotes cell proliferation and survival; however, these mechanisms 
remain ill-defined (Longnecker 2000, Caldwell, et al. 1998). LMP2A function 
appears to be regulated by ubiquitination which leads to negative modulation 
of LMP2A signaling. LMP2A contains two repeat motifs (PPXY) that 
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associate with Nedd 4-family ubiquitin-protein ligases (E3s) to down-regulate 
LMP2A led activity (Reviewed in Ikeda and Longnecker 2009).  
 
1.13.13 Epstein-Barr virus-encoded RNA’s 1 and 2 (EBER1 and EBER2) 
 
EBERs 1 and 2 are non-polyadenylated, uncapped, non-coding RNAs of 167 
and 172 nucleotides respectively (Thompson and Kurzrock 2004). The 
EBERs are expressed in abundance in nearly all EBV-infected cells with the 
exception of oral hairy leukoplakia lesions from AIDS patients and some 
hepatocellular carcinomas (Sugawara, et al. 1999). EBERs have been 
identified as having a possible role in oncogenesis due to studies indicating a 
function for EBERs in maintenance of the BL cell malignant phenotype 
(Takada and Nanbo 2001). Upon reintroduction of EBER genes into the EBV 
negative BL-derived Akata cell line (Akata cells that were once EBV positive 
but lost their EBV genome) the cells regained the oncogenic potential 
possessed when Akata was EBV positive. However, recombinant EBV with 
EBER deletions can still transform B lymphocytes, leaving unclear the role of 
EBERs in B cell immortalisation. Conflicting interpretations for the role of 
EBERs with respect to interferon resistance exist. It appears that EBERs can 
protect the EBV-infected cell from interferon activity, but are not essential for 
EBV-led interferon resistance in infected cells. Furthermore, it has been 
reported that EBV-led B cell immortalisation efficiency is enhanced 
approximately 100-fold by EBER2 activity. Studies have identified a c-MYC 
binding site in the EBER1 promoter and it has been speculated that c-MYC 
may drive EBER expression (Reviewed in Bornkamm 2009a).  
 
1.14 Wnt Signaling  
 
Wnt is a key signaling pathway for cell maintenance and oncogenic control in 
adult differentiated cells. Wnt activity has been linked to cellular functions 
such as apoptosis, survival, proliferation and cell motility (Reviewed in Willert 
and Jones 2006). It has been determined that defects in the wnt canonical 
pathway contribute to the pathogenesis of a variety of malignant states 
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(Gelebart, et al. 2008). Wnts are secreted glycoproteins that interact with a 
dimeric cell surface receptor complex containing the proteins Frizzled and 
low-density-lipoprotein receptor 5 or 6 (Mikels and Nusse 2006).  
 
In the canonical Wnt signaling pathway (Figure 1.13), Wnt receptor activation 
stimulates the stabilisation of the protein β-catenin within the cell by 
preventing phosphorylation. This allows nuclear translocation of β-catenin, 
facilitating binding to the T cell factor (Tcf) and lymphoid enhancer-binding 
proteins (LEFs) (He, et al. 2004). This β-catenin and Tcf/LEF nuclear 
complex drives Tcf/LEF transcription factors as transcriptional co-activators 
for Wnt target genes. In addition, the transcriptional repressor, transducin like 
enhancer of split 1 (TLE1; see chapters 4 and 5), appears to play a role in 
the Wnt pathway. This role involves the binding of the Wnt-associated 
proteins Tcf/LEF, by TLE1, negatively regulating Wnt targets (Daniels and 
Weis 2005; Logan and Nusse 2004). This β-catenin–Tcf/Lef mediated 
regulation modifies the expression of a number of genes pertinent to the 
study of tumourgenesis and EBV cell control including c-myc (He, et al. 
1998), Cyclin D1 (Shtutman, et al. 1999; Tetsu and McCormick 1999) MMP7 
(Crawford, et al. 1999) and WISP proteins (Pennica, et al. 1998). The Wnt 
effector protein, β-catenin, is a multi-functional protein found in the cell 
membrane, cytoplasm, and nucleus. Due to this wide distribution of β-
catenin, the cell has developed several methods of regulating β-catenin 
levels, such as forming mutually exclusive repressor complexes with 
adenomatous polyposis coli (APC) (Figure 1.13) and E-Cadherin (Orsulic, et 
al. 1999). Increasing evidence suggests that EBV modulates the Wnt 
signalling pathway. However, conflicting studies have been published, some 
proposing that this effect is mediated by LMP1, while others have indicated 
that LMP1 expression has a minimal effect on the E-cadherin/β-catenin 
interaction (Reviewed in Webb, et al. 2008). In epithelial cells it has been 
observed that LMP2A can modulate Wnt signaling by inducting β-catenin 
(Morrison, et al. 2003). 
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Figure 1.13: The Wnt signalling pathway. (A) In the absence of Wnt, Axin, 
the scaffolding protein assembles a β-catenin repressor complex containing 
Apc, Gsk3, Ck1 and β-catenin. Ck1 and Gsk3 sequentially phosphorylate β-
catenin. Trcp, a component of an ubiquitin-ligase complex, recognises the 
phosphorylated β-catenin. Trcp conjugates β-catenin with Ubiquitin  flagging 
β-catenin for proteosomal degradation. (B) Wnt signals are thought to be 
received through frizzle (Fz)-Lrp5/Lrp6 co-receptor complex. The Lrp5/Lrp6 
complex recruits Axin to the plasma membrane, causing dissociation of the 
β-catenin repressor complex. This prevents phosphorylation and thus 
degradation of β-catenin, allowing accumulation of β-catenin in the cytoplasm 
from which it is translocated to the nucleus. Once in the nucleus it forms a 
complex with the DNA bound TCF/LEF transcription factor. This results in 
activation of Wnt-responsive genes (He, et al. 2004). 
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1.15 Cell cycle progression and EBV 
 
Cells have a defined division cycle that progresses through a number of 
phases to create two daughter cells. Quiescent cells are non-dividing or 
resting cells designated G0. The cell cycle is regulated in four discrete 
phases: G1, S-phase, G2 and M-phase.  The G1 phase of the cell cycle is 
the longest and occurs prior to DNA synthesis, which occurs during S-phase.  
Cell Division occurs during M-phase.  The progression through the cell cycle 
is regulated by many different proteins, some of which are illustrated.  The 
first biochemical event observed, in early G1 phase, is the induction of the D-
type cyclins and their partners, cyclin dependent kinases (cdks), cdk4 and 
cdk6.  In the absence of cyclin dependent kinase inhibitors (CDKIs), D-type 
cyclins are catalytically activated by either cdk4 or cdk6.  Loss of CDKIs 
correlates with the induction of D-type cyclins.  The most important substrate 
of the cyclin D/cd4/6 complex is the family of pocket proteins, typified by 
pRb, the retinoblastoma susceptibility gene product.  Other members of the 
pocket protein family include p130 and p107.  These pocket proteins repress 
a family of transcription factors called E2F, and the E2F-pocket protein 
complexes also act as gene suppressors.  Phosphorylation of pRb by the 
cyclin D/cdk4/6 complex results in the release of E2F transcription factors 
and transcription of E2F-responsive genes.  E2F binding sites have been 
identified in the promoters of many genes important for cell cycle regulation 
and the promoters of proteins involved in DNA synthesis.  In many systems, 
the induction of E2F transcriptional activity results in entry into the cell cycle 
(Figure 1.13) (Brennan 2001). 
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Figure 1.14: Phases of lymphocyte cell cycle.  
Quiescent cells are in resting or G0 phase, the stimulated cells move into the growth 
phase (G0/G1) in which the cell enlarges. Once G1 checkpoints are met, the cell 
passes into a DNA synthesis phase (S) before returning to a second growth phase 
(G2) prior to mitotic phase (M), in which the cell is divided into two daughter cells in 
an orderly fashion. Once this cycle is completed the resulting cells return to the 
resting state (G0) (Flaitz and Hicks, 1998). (Figure adapted from Brennan 2001). 
 
B lymphocytes are found generally in a quiescent state in the peripheral 
blood circulation. B cell activation due to a normal immune response results 
in rapid stimulation of many genes but of particular note are the four key 
genes Cdc-2, Cyclin E, CD23 and Cyclin D2 (Hollyoake, et al. 1995). EBV-
led stimulation of quiescent B cells results in the activation of the same 
genes, thus indicating that EBV exploits the normal B cell programme to 
activate B cell cycle progression. Following EBV infection, the first cell cycle 
protein to be activated is Cyclin D2 (Spender, et al. 1999) and this is 
regulated by EBNA2 and EBNA-LP (Sinclair, et al. 1994). This Cyclin D2 
induction is accompanied by a loss of the cyclin-dependent kinase inhibitor 
(CDKI), p27kip1. Approximately 6 hours later, the pocket protein, pRB is 
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phosphorylated and thus inactivated, facilitating progression of the cell into 
G1 phase. EBNA3C has been found to be capable of negatively regulating 
the activity of pRB (Knight, et al. 2005). EBNA3C is a vital EBV latent protein 
required for B cell immortalisation (Kieff and Rickinson 2001), and it has 
been demonstrated that loss of EBNA3C results in a reduction of S and G2/M 
phase cells. This is thought to be due to the EBNA3C-associated loss of pRb 
activity (Maruo, et al. 2006). This EBV-elicited response mimics exactly the 
events that occur during normal B cell stimulated proliferation. This implies 
that EBV exploits the normal cell pathway to subvert normal cellular 
progression regulatory factors such as pRb. 
 
The EBV proteins EBNA2 and LMP1 have also been implicated in the 
regulation of another key cell cycle transcription factor, p53 (Chen and 
Cooper 1996; Li, et al. 2008). LMP1 has been shown to regulate p53 at both 
a transcriptional and translational level (Li, et al. 2008, Li, et al. 2007). p53 is 
a tumour suppressor gene that induces cell cycle arrest, apoptosis, DNA 
repair or senescence in response to genotoxic stimuli (Li, et al. 2008, 
Cannell, et al. 1998). Mutations in p53 are one of the most frequently 
detected molecular events in carcinogenesis (Hollstein, et al. 1991). p53 
expression has been found to increase after EBV infection. This is surprising 
as EBV drives the infected cell to divide, causing indefinite cell proliferation 
(Cannell, et al. 1998, Rickinson and Kieff 1996). Evidence suggests that EBV 
appears to keep p53 at basal expression levels that are below the cell cycle 
arrest or apoptotic threshold but can still easily respond to genotoxic stimuli. 
Alternatively, the p53 transcription factor may have an unknown function that 
somehow supports EBV infection (Li, et al. 2008; Cannell, et al. 1998). 
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1.16 Apoptosis and EBV  
 
In mammals, homeostasis is controlled by a fine balance between cell 
proliferation and cell death. Cell death can be divided according to three 
morphologies: apoptosis, necrosis and cell death associated with autophagy 
(Krysko, et al. 2008). During the establishment of latent infection, EBV 
targets the molecular machinery in the host B cell to promote long term 
survival of the cell by inhibiting apoptotic pathways. The EBV strategy of 
apoptotic resistance may be instrumental as a contributing factor in the 
development of EBV-associated malignant disease. 
 
Apoptosis is a genetically pre-programmed form of cell suicide that functions 
to eliminate redundant or superfluous cells, thereby maintaining homeostasis 
(Figure 1.14). Apoptotic cells exhibit dramatic morphological changes 
including cell shrinkage, nuclear re-organisation, blebbing and eventual 
fragmentation of the cell into membrane bound apoptotic bodies (Kuroda and 
Taniwaki 2009). This is a multistage process dependent upon a tightly 
regulated and well defined programme for its initiation and execution (Fink 
and Cookson 2005).  
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Figure 1.15: The process and outcome of the apoptotic and necrotic 
cell death pathways.  
Apoptotic cells send signals to the immune system to alert phagocytes. If apoptotic 
bodies are not recovered, and thus neutralised by the immunesurveillance, they will 
in time result in the slow release of inflammatory materials. In addition, both necrotic 
cascades conclude in a sizeable release of pro-inflammatory substances. 
Consequently, the death inducing pathway chosen greatly influences other cells in 
the environment (Fink and Cookson 2005). 
 
Apoptosis has numerous crucial roles: during embryogenesis, apoptosis 
eliminates excess cells to shape organs; it maintains tissue homeostasis 
within the developed organism, and it also functions as a safety mechanism 
within the body by eradicating cells that show aberrant growth due to the de-
regulation of oncogenes as a response to radiation damage or due to viral 
infection. In the case of virus-infected cells, the induction of early cell death 
would severely limit virus production and reduce or eliminate spread of virus 
progeny in the host. In order to maximize their replicative capacity many 
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viruses, including EBV, have evolved mechanisms that suppress the 
apoptotic programme (Shen and Shenk 1995; Lin, et al. 2000). A failure in 
the ability to elicit apoptosis in a redundant or aberrant cell can lead to the 
cell gaining an extended life span in which it can survive genetic mutations 
and continue to proliferate inappropriately. The increased resistance to 
apoptosis is a feature of cancer cells that allows them to function outside the 
normal control parameters of cellular regulation and contributes to their 
resistance to chemotherapeutic drugs and treatments. The ability to induce 
apoptosis is a critical attributing factor in the success or failure of 
chemotherapy. Indeed, identifying apoptotic targets could reduce the 
chemotherapeutic load, diminishing the short and long term side effects of 
treatment. Thus, extending the knowledge of apoptosis and the mechanisms 
of apoptotic regulators (such Bcl-2 family proteins) could aid in the 
development of more targeted cancer therapies (Reviewed in Kuroda and 
Taniwaki 2009). 
 
The defining morphology and biochemical markers of apoptosis distinguish 
this form of cell death from the others (Krysko, et al. 2008). These 
morphological features include blebbing of the plasma membrane, chromatin 
condensation, nuclear fragmentation and formation of apoptotic bodies. The 
defining biochemical markers of apoptosis are externalisation of 
phosphatidylserine, a change in the permeability of the mitochondrial 
membrane, release of signature mitochondrial proteins, caspase dependent 
activation and DNA cleavage due to nuclear localisation of a caspase 
activated DNase (Reviewed in Krysko, et al. 2008) (Sprick and Walczak 
2004). The characteristic events of apoptosis are regulated by a family of 
related caspases. Caspase induction is initiated by one of two pathways, the 
extrinsic or ‘death receptor’ pathway and intrinsic or ‘mitochondrial’ pathway 
(See Figure 1.16). The extrinsic pathway involves the stimulation of the TNF 
receptor super family, by their corresponding ligands (TNF, Fas or TRAIL), 
leading to the activation of caspase-8. The intrinsic pathway is known to be 
controlled by Bcl-2 family proteins (described below); if the pro-apoptotic 
family members tip the balance, the mitochondrial membrane becomes 
permeable, releasing pro-apoptotic factors such as cytochrome c, AIF or 
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Diablo/Smac, triggering the activation of caspase dependent or independent 
cell dismantling (Reviewed in Kuroda and Taniwaki 2009, Sprick and 
Walczak 2004).  
 
 
Figure 1.16: The Intrinsic and extrinsic apoptotic pathways.  
Extrinsic apoptosis instigation requires activation of factors such as FAS and TNF to 
stimulate Caspase-8 activity. Intrinsic stimuli include cellular stress such as growth 
factor deprivation or toxic agents such as viruses. The intrinsic pathway involves 
either the alleviation of anti-apoptotic Bcl-2 family member led Bax and Bak 
inhibition, due to BH3-only protein expression or post-translational activation, or via 
direct activation of Bax and/or Bak (as shown by the dotted line) by pro-apoptotic 
members such as Bim, Bid or Puma (Kuroda and Taniwaki 2009). Once activated, 
Bax and Bak promote cytochrome c release and mitochondrial fission, leading to 
activation of Apaf-1 into an apoptosome and activation of caspase-9. The caspases 
in turn cleave a series of substrates, activating DNases resulting in the destruction 
of the cell. The extrinsic pathway can bypass the mitochondrial step and activate 
caspase-8 directly, ultimately leading to cell dismantling (Adapted from Youle and 
Strasser 2008). 
 
The fate of a cell is a fine balance dictated by the interactions between the 
anti-apoptotic and pro-apoptotic members of the Bcl-2 family. The Bcl-2 
family regulates the integrity of the mitochondrial membrane; disruption of 
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this membrane by some of the Bcl-2 proteins can lead to cellular dismantling 
(Kuroda and Taniwaki 2009). The Bcl-2 family consists of about 20 
homologues of pro- and anti-apoptotic regulators (Kirkin, et al. 2004). These 
share between one and four conserved Bcl-2 homology (BH) domains (BH1, 
BH2, BH3 and BH4). The anti-apoptotic members of this family include Bcl2, 
Bcl-XL, Boo and Bfl-1. The pro-apoptotic members are further divided into the 
BH3-only proteins (Bik, Bim, Bad, Bid, Hrk, PUMA, Noxa and Bmf) and the 
pro-apoptotic members (Bax, Bak, Bok and Bcl-Xs) (Kuroda and Taniwaki 
2009, Sprick and Walczak 2004). Pro-apoptotic members can neutralise the 
anti-apoptotic members to stimulate apoptosis within the cell (Kuroda and 
Taniwaki 2009). The Bcl-2 family respond to cues from within the cell and its 
environment e.g. cellular stress, DNA damage, deprivation of necessary 
factors, to determine whether or not a cell will undergo programmed cell 
death.  
 
In a healthy cell, the pro-apoptotic Bcl-2 proteins Bax and Bak are bound and 
inactivated by the anti-apoptotic Bcl-2 family members. Bax is located in the 
cytosol or loosely associated with membranes, while Bak is localised to the 
outer membrane of the mitochondria and endoplasmic reticulum (ER). The 
generally accepted model for the Bcl-2-led apoptotic mechanism indicates 
that anti-apoptotic Bcl-2 family members bind Bax and Bak to prevent 
oligomerisation of the two on the mitochondrial outer membrane (Huang and 
Strasser 2000; Czabotar, et al. 2007; Puthalakath and Strasser 2002). Upon 
the presentation of death signals to the cell, BH3-only proteins are activated 
transcriptionally or post-transcriptionally. BH3-only proteins have a stronger 
affinity to the anti-apoptotic Bcl-2 proteins than either Bax or Bak. The BH3-
only proteins displace Bax and Bak, liberating them and allowing them to 
form oligomers on the mitochondrial membrane, stimulating mitochondrial 
outer membrane permeabilisation, resulting in the release of the apoptotic 
factors into the cell (Kuroda and Taniwaki 2009) (Figure 1.17). Importantly, 
EBV can modulate both the pro and anti-apoptotic Bcl-2 family members 
during infection to prolong the life of the host cell. 
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Figure 1.17: Bcl-2 family mediated apoptosis pathway.  
(1)The intrinsic apoptotic pathway is mediated by the Bcl-2 family. This pathway is 
activated by extracellular stress factors such as cytotoxic drugs, hypoxia, growth 
factor withdrawal and DNA damage. (2) The extrinsic pathway is Bcl-2 family 
independent and involves activation of caspase 8 via death receptors such as Fas 
and TRAIL. (3) In the intrinsic pathway, anti-apoptotic family members such as Bcl-
2, Bcl-Xl and Mcl-1 bind the pro-apoptotic factors, Bax and Bak within the cell, 
sequestering these proteins and preventing apoptosis activation. The pro-apoptotic 
BH3-only family members, Bim, Bid, Bad, Noxa and Puma directly interact with the 
anti-apoptotic family members liberating Bax and Bak. (4) The activated Bax and 
Bak proteins can homo-oligomerise in the mitochondrial outer membrane, inducing 
permeability of the membrane. (5) Permeabilisation facilitates the release of 
cytochrome c and/or Smac/DIABLO from the mitochondria. Once in the cytoplasm, 
cytochrome c associates with apoptosis protease-activating factor 1 (APAF-1) and 
pro-caspase 9, allowing the activation of caspase 9 which in turn stimulates 
caspase 3, which initiates a caspase cascade resulting in cellular dismantling. 
Smac/DIABLO antagonises inhibitors of apoptosis (IAPs) aiding apoptotic 
progression (Figure taken from Kang and Reynolds 2009). 
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1.17 EBV regulation of apoptosis 
 
The ability of EBV to establish and maintain life-long in vivo latency is due in 
part to its ability to regulate apoptosis within the cell. The EBV LMP1 has 
been implicated in a multitude of apoptotic regulatory functions, such as the 
up-regulation of A20, which encodes an anti-apoptotic protein that inhibits 
p53-mediated apoptosis (Fries, et al. 1996). LMP1 has a particularly strong 
role in Bcl-2 family modulation. LMP1 induces the expression of anti-
apoptotic Bcl-2 family members which sequester Bax and Bak, thus 
preventing heterodimerisation of the two at the mitochondrial membrane and 
inhibiting the activation of apoptosis (Mei, et al. 2007). The interactions 
between pro and anti-apoptotic Bcl-2 family members are selective. Noxa, 
the pro-apoptotic BH-3 only protein binds to Mcl-1 but not to the other anti-
apoptotic multi-domain proteins such as Bcl-2 and Bcl-xL (Mei, et al. 2007). 
LMP1 interferes with this balance by up-regulating Mcl-1, thus hindering 
Noxa-induced apoptosis (Reviewed in Le Clorennec, et al. 2008). The pro-
apoptotic protein, Bad, interacts only with Bcl-2 and Bcl-xL (Mei, et al. 2007). 
The EBV latent protein LMP2A has been associated with increased Bcl-xL 
levels, and the inhibition of this up-regulation in LMP2A transgenic mice 
resulted in increased apoptosis (Portis and Longnecker 2004). In addition, 
LMP1 has been shown to induce Bcl-2 (Reviewed in Le Clorennec, et al. 
2008). Both Puma and Bim can interact with all known anti-apoptotic Bcl-2 
family members, and the co-operation of two EBV latent proteins, EBNA3A 
and EBNA3C, results in the transcriptional down-regulation of Bim (Anderton, 
et al. 2007). EBV also modulates the pro-apoptotic Bcl-2 gene, bfl-1. Bfl-1 
(also known as A1) can inhibit the pro-apoptotic Bid protein (both full length 
and truncated) preventing activation of Bax and Bak. Bfl-1 also plays a 
negative role in p53-mediated apoptosis. It has been demonstrated that bfl-1 
is a direct transcriptional target of both LMP1 (D'Souza, et al. 2004) and 
EBNA2 (Pegman, et al. 2006). EBNA2 has also been shown to bind to and 
repress the activity of the pro-apoptotic factor Nurr77, an orphan receptor 
that responds to apoptotic stimuli by trans-locating from the nucleus to the 
mitochondria and inducing cytochrome c release (Lee, et al. 2002). 
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1.18 Aims of this study 
 
Previous work in our laboratory has shown that EBV regulates cellular 
genes, including bfl-1. Bfl-1 plays a crucial role in regulating the survival of 
EBV-infected B cells (D'Souza, et al. 2000). Furthermore, it has been 
demonstrated that this regulation is elicited by two different EBV latent 
proteins utilising two different pathways: LMP1 regulates bfl-1 via NF-κB 
(D'Souza, et al. 2004) while EBNA2 modulates bfl-1 by recruiting a Notch 
transcription factor, CBF1 (Pegman, et al. 2006). In this study (Chapter 3), 
aspects of the mechanism of bfl-1 regulation in EBV-infected cells are 
elucidated.  
 
The primary focus of this study was to identify novel cellular genes that are 
targetted, following B cell infection, by EBV. Untouched Naive B cells were 
first infected with a recombinant Green Fluorescent Protein (GFP)-
expressing strain of EBV. The expression of selected cellular genes was 
then compared before and after infection by real-time semi-quantitative PCR 
(RT-qPCR) using an RT Profiler PCR SuperArray. This experiment led to the 
identification of several novel cellular genes that are candidate targets of 
EBV. Several genes showing the most promise in that regard were further 
investigated using a cell culture model of EBV infection, known as ER/EB2.5, 
in which EBV latent gene expression could be activated/inactivated using 
estrogen. One interesting cellular gene, namely TLE1, was determined to be 
a negative target of EBV, and the role and regulation of TLE1 was 
investigated in more detail (Chapters 4 and 5). The study also led to the 
identification of a small number of other genes showing potential as EBV 
targets following infection (Chapter 6 and 7). 
 
EBV subverts a wide variety of responses within the cell to alter the 
phenotype, survival and proliferation status of infected cells, but the 
mechanisms by which these modifications are achieved have not all been 
defined. Identifying cellular genes that are deregulated by EBV may lead to 
the identification of novel host-virus interactions that present promise as 
therapeutic targets for EBV-associated diseases. The main objectives of this 
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study were, therefore, to identify and determine the role of cellular genes that 
are regulated by EBV.  
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2.1 Materials 
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2.1.1 Biological Materials 
2.1.1.1 Cell lines 
 
Table 2.1 Cell lines used in this study 
Cell Line EBV 
Status 
Classification Description 
AG876 + Type III BL Type III BL cell line expressing all of the 
EBV latent genes. 
    Akata 4E3 - EBV Negative BL During cultivation of the Epstein-Barr 
virus (EBV)-positive Burkitt's lymphoma 
(BL) line Akata, EBV DNA was lost from 
some of the cells and EBV-negative 
clones were isolated (Shimizu, et al. 
1994). 
    Akata BX1 + EBV Positive BL EBV negative BL (Akata 4E3) infected 
with a recombinant GFP tagged strain of 
EBV. In this EBV strain, the non-
essential thymidine kinase encoded by 
the BXLF1 ORF was disrupted by a 
cassette expressing neomycin resistance 
and a modified green fluorescence 
protein (GFP) (Molesworth, et al. 2000).  
    BJAB - Burkitt-like lymphoma 
cell line 
BJAB is a B cell derived from a patient 
with EBV-negative African Burkitt's 
lymphoma. The cells do not contain 
detectable amounts of EBV DNA, nor do 
they express the EBV-determined 
nuclear antigen EBNA. However, the 
cells have the characteristics of B-type 
lymphocytes and carry receptors for EBV 
(Menezes, et al. 1975).  
    BL41P3HR1-
ER/EBNA2 
(9A) 
+ EBV Positive BL 
(Stable transfectant) 
EBV negative BL infected with the 
P3HR1 strain of EBV and subsequently 
transfected with an EBNA2 fusion protein 
where EBNA2 activation is dependent on 
the presence of estrogen as above 
(Kempkes, et al. 1996). 
    BL41-
ER/EBNA2 
(K3) 
+ BL (stable 
Transfectant) 
EBV negative BL cell line stably 
transfected with an EBNA2 expression 
plasmid in which the EBNA2 activation 
domain is fused to the estrogen binding 
domain, rendering the activation of 
EBNA2 dependent on the presence of 
estrogen (Kempkes, et al. 1996). 
    DG75 - EBV Negative BL Lymphoid B cell line derived from an 
Israeli Burkitt’s-like lymphoma case 
(Ben-bassats, et al. 1977). 
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DG75 tTA 
EBNA2 
- Stable transfectant Tetracycline regulated system whereby 
the expression of EBNA2 can be induced 
by the removal of tetracycline from the 
growth media (Floettmann, et al. 1996). 
    EREB2.5 + LCL An LCL established by co-infecting B-
cells with a 28kb mini-EBV plasmid that 
only expresses estrogen-responsive 
EBNA2, together with the EBV P3HR1 
strain in which its own EBNA2 gene is 
deleted (Kempkes, et al. 1995). 
    
IB4 + LCL An LCL established by infection of fetal 
cord blood lymphocytes with the EBV 
strain B95.8 (King, et al. 1980). 
    P493-6 + LCL An EREB 2-5-derived cell line, P493-6, in 
which c-Myc is expressed under the 
control of a tetracycline-regulated 
promoter (Pajic et al, 2000).  
    Ramos - Type I BL EBV negative B Lymphocyte cell line 
derived from an American Burkitt's 
Lymphoma patient (DSMZ). 
 
All BL cell lines and LCLs were obtained from Professor Martin Rowe, 
University of Wales, Cardiff, Wales.  The estrogen-responsive cell line EREB 
2.5 was a gift from Dr. Ursula Zimber-Strobl, GSF-National Research Centre 
for Environment and Health, Munich, Germany.  The EREB 2.5-derived cell 
line, P493-6 was a gift from Prof. Dr. med. Georg W. Bornkamm, Institute of 
Clinical Molecular Biology and Tumor Genetics Munich, Germany.  The 
estrogen responsive cell lines BL41K3 and BL419A were gifts from Dr. 
Bettina Kempkes GSF-National Research Centre for Environment and 
Health, Munich, Germany. Akata-4E3 was received from Professor Diane 
Hayward, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, 
USA. 
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2.1.1.2 Antibodies used in this study 
 
Table 2.2 Antibodies used in this study 
Antibody Name Description Supplier 
Mouse Anti-
EBNA2 
PE2 A monoclonal antibody that 
reacts with the latent gene 
product EBNA2. 
Professor 
Martin Rowe, 
University of 
Cardiff, 
Wales, and 
Dako. 
    Goat anti-mouse 
IgG, Alkaline 
Phosphatase (AP) 
Conjugate 
Anti-
mouse 
IgG, AP 
conjugate 
A goat anti-mouse antibody that 
reacts with mouse IgG, and is 
conjugated to AP. 
Promega 
    Rabbit Anti-TLE1 TLE1 
Antibody 
Rabbit polyclonal reactive to 
synthetic peptide conjugated to 
KLH derived from within residues 
200 - 300 of Human Tle1. 
Abcam 
    Goat Anti-rabbit 
IgG, Horse 
Radish 
Peroxidase (HRP) 
Conjugate 
Anti-
Rabbit 
IgG, HRP 
Conjugate 
A goat anti-rabbit antibody that 
reacts with rabbit IgG, and is 
conjugated to HRP. 
Santa Cruz 
    
    Mouse Anti- β - 
Actin Clone AC-
15 
Anti- β – 
Actin 
A1978 
Monoclonal IgG Raised against 
β-cytoplasmic actin N-terminal 
peptide. 
Sigma 
 
 
2.1.1.3 Bacterial Strains used in this study 
 
Table 2.3 Bacterial Strains used in this study 
Bacterial Strain Genotype 
E. coli JM109 
endA1, recA1, gyrA96, thi, hsdR17 (rk-, mk+), relA1, 
supE44, λ-, ∆(lac-proAB), [F´, traD36, proA + B + , lacl q 
Z∆M15] 
E. coli XL1-Blue endA1, recA1, gyrA96, thi-1, hsdR17, relA1, supE44, lac [F´, proAB, lacl q Z∆M15, Tn10 (Tetr)] 
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2.1.1.4 Bioinformatics Software 
 
Table 2.4 Web based bioinformatics tools used in this study 
Tool Source Use 
BLAST http://www.ncbi.nlm.nih.gov/BLAST Comparison of nucleotide or 
protein sequences to 
GenBank sequence 
database. Statistical 
significance of matches 
calculated. 
   BioSeq File 
Format converter 
http://bioinformatics.org/JaMBW/1/2/ind
ex.html 
Conversion of nucleotide 
sequences to other formats 
including FASTA and 
GenBank.   
   MatInspector http://www.genomatix.de/products/MatI
nspector/MatInspector1.html 
Nucleic Acid Sequence 
Searches, to identify putative 
transcription factor binding 
sites. 
   Multialin http://multalin.toulouse.inra.fr/multalin/m
ultalin.html 
Comparison and alignment of 
nucleotide sequences. 
   NEBcutter V2.0 http://tools.neb.com/NEBcutter2/index.p
hp 
Identification of restriction 
enzymes sites along a DNA 
sequence, and prediction of 
fragment sizes. 
   NetPrimerLaunch http://www.premierbiosoft.com/netprime
r/netprlaunch/netprlaunch.html 
Primer analysis software for 
prediction of primer 
properties including, Tm, GC 
content, probability of primer-
dimers/hairpins formation. 
   RTB Primer http://medgen.ugent.be/rtprimerd
b 
Real time primer database 
   Translate tool http://www.expasy.org/tools/dna.html Translation of a nucleotide 
(DNA/RNA) sequence to a 
protein sequence. 
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2.1.1.5 Plasmids 
 
Table 2.5 Expression and reporter constructs used in this study 
Plasmid Name Source 
 pSG5  Lindsey Spender, Ludwig Institute 
for Cancer Research, Imperial 
College School of Medicine, 
London. 
pSG5-EBNA2 expresses the wild type 
B95.8 EBNA2 gene that has been 
cloned into pSG5 (Stratagene). 
 pSG5-EBNA2 
 
SV-EB2NA2 Baltimore. SV-EB2NA2 expresses the B variant  
EBNA2 gene that has been cloned into 
pSG5 (Stratagene).  
pSG5 hHey1 Dr. Borja Belandia, Institute of 
Reproductive and Developmental 
Biology1 and Department of 
Histopathology, Imperial College 
London, London, United Kingdom. 
The complete open reading frames of 
full-length human Hey1 were amplified 
by PCR and sub-cloned into pSG5. 
 
pRTS-1  Professor Dr. Georg W. Bornkamm, 
GSF-Research Centre for 
Environment and Health, Institute of 
Clinical Molecular Biology and 
Tumour Genetics, Munich, 
Germany. 
Novel tetracycline-inducible vector 
carrying all the elements for conditional 
gene expression including the gene of 
interest on one EBV-derived episomally 
replicating plasmid (Bornkamm et al., 
2005).  
 
pRTS-1 Hey1 This Study. Generated by insertion of, Hey1 ORF 
from pcDNA3-FLAG-Hey1 into pRTS-1, 
generating a tetracycline regulatable 
vector capable of conditional 
expression of Hey1 protein. 
 
 
3x enh κB luc Professor Martin Rowe, University 
of Wales College of Medicine, 
Cardiff, U.K. 
This reporter construct contains 3 κB 
elements upstream of a minimal 
conalbumin promoter linked to the 
firefly luciferase gene (Floettmann and 
Rowe, 1997). 
 
 
pGA981-6 Dr. Bettina Kempkes, Institute of 
Clinical Molecular Biology and 
Tumour Genetics, GSF, Munich, 
Germany. 
The pGa981-6 reporter construct 
(Minoguchi et al., 1997) was generated 
using a 50 bp oligonucleotide 
harbouring both CBF1 binding sites of 
the EBV TP1 promoter, which was then 
ligated as a hexamer into plasmid 
pGa50-7 (Laux et al., 1994). 
 
 
pCMV-LacZ Clontech. pCMV-LacZ contains E.coli β-
galactosidase gene under the control of 
the CMV promoter-enhancer.  
-1374/+81-Luc Dr. Brendan D'Souza, School of 
Biotechnology, Dublin City 
University. 
-1374/+81-Luc was generated by sub-
cloning the bfl-1 promoter sequence 
from a corresponding CAT reporter 
construct (Zong et al., 1999) into pGL2-  
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-1374/+81 mκB 
(-52) 
Basic. -1374/+81 mκB (-52) contains a 
mutation at the NF-κB-like binding site 
at position -52 to -43 (D’Souza et al., 
2004). -1374/+81 mκB (-833) contains a 
mutation at the NF-κB-like binding site 
at position –833. (D’Souza et al., 2004). 
 
 
-1374/+81 mκB 
(-52) mCBF1    
(-249) 
This Study. -1374/+81 mkB (-52) mCBF1 (-249) 
was generated by mutation to 
incorporate an Xba I restriction site at 
the CBF1 like binding site at position -
251 to -259 of the -1374/+81 mkB (-52) 
single mutant vector.  
 
 
pGL3-Basic Promega. The pGL3-Basic is a reporter construct 
containing the backbone of the pGL2-
Basic with increased expression, and 
contains a modified coding region for 
firefly luciferase that has been 
optimised for monitoring transcriptional 
activity in transfected eukaryotic cells. 
pGL3-Basic lacks eukaryotic promoter 
and enhancer sequences. 
pGL3 GATA4 Professor Manfred Gessler, 
Theodor Boveri Institute, 
Physiological Chemistry I, 
University of Wuerzburg, 
Wuerzburg, Germany. 
A 5kb fragment of the 5' upstream 
GATA4 region was ligated into the 
SmaI site of the pGL3-basic vector 
(Promega).   
pGL3 Hey1 Professor Manfred Gessler, 
Theodor Boveri Institute, 
Physiological Chemistry I, 
University of Wuerzburg, 
Wuerzburg, Germany. 
Full length Human Hey1 promoter 
fragment (3.9 kb) isolated from human 
BAC clone RP11-27N21, subcloned 
into pGL3 luciferase construct.  
pcDNA3 Invitrogen. The pcDNA3 Vector is a eukaryotic 
expression vector, harbouring the CMV 
promoter and the ampicillin and G418 
resistance gene. 
 
 
pcDNA3-TLE1 Professor Stefano Stifani, Center 
for Neuronal Survival, Montreal 
Neurological Institute, McGill 
University, Montreal, Quebec H3A 
2B4, Canada. 
The complete open reading frame of 
full-length human TLE1, amplified by 
PCR and sub-cloned into pcDNA3. 
 
 
 
 
sh205  
sh206  
sh207 
sh208 
Origene. Sequence-verified TLE1 expression 
plasmids with gene-specific shRNA 
cassettes. 
 
 
 
 
 
 
 sh20003 Origene. A sequence-verified plasmid without 
shRNA cassette insert. 
 
 
sh30003 Origene. A sequence-verified plasmid containing 
non-effective 29-mer scrambled shRNA 
cassette.  
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2.1.1.6 Oligonucleotides 
 
Table 2.6 Oligonucleotides used in this study 
Target  Primer Sequence Annealing Temperature 
AES 5' CCA CCT CTA GCT TTC TTC CTA 3' 53ºC 
5' G ACT GTC GGT TAC ACA TGT TC 3' 
   
Bfl-1 Promoter              
(Site Directed 
Mutagenesis) 
5' GGG TTG TAC CAT TTC ACT CTA GAA CCA 
GCA ATC T 3' 62ºC 5' AGA TTG CTG GTT CTA GAG TGA AAT GGT 
ACA ACC C 3' 
   
Bfl-1                               
(Real Time) 
5' TTC ATA TTT TGT TGC GGA GTT 3'  53ºC 
5' AGC ATT TCA CAG ATC TTT CCT 3' 
   
CD23 5' GGA ATT GAA CGA GAG GAA CGA AG 3' 53ºC 
5' AAA GCC GCT GGA CAC CTG 3' 
   
CIDEB 5' AGG ATG GAA CTG CAG TGG AC 3'  53ºC 
5' AGG TCT CGA GGG TTT TGC TT 3' 
  
Cyclin D1 5’ TAT TGC GCT GCT ACC GTT GA 3’ 53ºC 
5’ CCA ATA GCA GCA AAC AAT GTG AAA 3’ 
  
Cyclin E 
5' CTT CAC AGG GAG ACC TTT TAC  3'  53ºC 
5' CAT TCA GCC AGG ACA CAA TAG 3' 
   
E2A 5' TAGACACGCAGCCCAAGAA 3' 55ºC 
5' GGTACACCGAGGATGGAAGA 3' 
   
EBNA1 
5' GAGCGGGGAGATAATGTACA 3' 
55ºC 
5' TAAAAGATGGCCGGACAAGG 3' 
   
EBNA2 5’ AGA GGA GGT GGT AAG CGG TTC 3’ 60ºC 
5’ TGA CGG GTT TCC AAG ACT ATC C 3’ 
   
FAS 
5' GGG GTG GCT TTG TCT TCT TCT TTT 3' 
58ºC 
5' ACC TTG GTT TTC CTT TCT GTG CTT TCT 3' 
   
Fos 5' AAA AGG AGA ATC CGA AGG GAA A 3'  60ºC 
5' GTC TGT CTC CGC TTG GAG TGT AT 3'  
   Hes-1 5' ACG TGC GAG GGC GTT AAT AC 3' 58ºC 
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5' ATT GAT CTG GGT CAT GCA GTT G 3' 
   
hHey1 (pRTS-1 
Cloning)  
5' TCT ATG GGC CTC ACT GGC C AT GAA GCG 
AGC TCA CCC C 3'  
5' AAT TCG CGG GCC TCA CTG GC C TTA AAA 
AGC TCC GAT CTC 3'  
   
Hey1  5' AGC CGA GAT CCT GCA GAT GA 3'  60ºC 5' GCC GTA TGC AGC ATT TTC AG 3' 
   
Jun 5' ATG ACT GCA AAG ATG GAA ACG 3'  58ºC 5' GCT CTC GGA CGG GAG GAA 3' 
   
LRP5 5' ACC TGG ACT TCG TGA TGG AC 3' 55ºC 5' TGA ACA GCA AGA AGG TGG TG 3' 
   
MMP7 5' GGA TGG TAG CAG TCT AGG GAT TAA CT 3' 60ºC 
5' GGA ATG TCC CAT ACC CAA AGA A 3' 
  
NR4A2 (Nurr1) 5' CAA GGA ACC CAA GAG AGT GG 3' 53ºC 
5' TGT GTG CAA AGG GTA CGA AG 3' 
  
Pax5 5' TGGAGGATCCAAACCAAAGG 3' 55ºC 5' GGCAAACATGGTGGGATTTT 3' 
  
Runx1 5' GATGGCACTCTGGTCACTGTGA 3' 55ºC 5' CTTCATGGCTGCGGTAGCAT 3' 
  
Runx3 
5' AGC GTG GGA GGC ACC TTT 3' 
53ºC 
5' CAG GAT CAG GAA GGG TTA GTA ATC T 3' 
   
STIL 5' CCT TGC TTC ATC AAC CAT CA 3' 60ºC 5' GTT TTG GGT TCT GGT GCA TT 3' 
  
TBP 5' CAC GAA CCA CGG CAC TGA TT 3' 50-60ºC 5' TTT TCT TGC TGC CAG TCT GGA 3' 
  
TLE1 Stage 1 5' ACG GAG CCA GCT GTA TTG AC 3' 53ºC 
5' ACC TCC ACA TTG CTG CTC TC 3' 
  
TLE1 Stage 2 5' TC TTT CTC ATG GCC ACG GA 3' 53ºC 
5' T GCG TTT ATC TGT GCC TCT T 3' 
  
TLE2 5' C GAA GAC AAG AGT GAT TAC 3' 53ºC 
5' CAA GGA GGC TGG ACT GTC 3' 
  
TLE3 5' GAT ACG ACA GTG ATG GAG ACA 3' 53ºC 
5' ATT TTC AGG AGG GGA GTG T 3' 
  
TLE4 5' CCG TGG ACG ACA AAT ACA 3' 53ºC 
5' AAG GAT GAC AGA GCA AAG TG 3' 
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TNFSF7 5' TAC GTA TCC ATC GTG ATG 3' 53ºC 5' GTT GGT GCA GAG TGT GTC 3' 
  
TRAF4 
5' ATC TCC TTG AGT GGC CCT TT 3' 
53ºC 
5' CTG GTG GGA GAT GAA CTT GG 3' 
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2.1.2 Chemical Materials 
 
Table 2.7 Suppliers of chemical and biological materials used in this 
study 
Supplier Product/Code 
Abcam TLE1 antibody (ab15587). 
Amersham Rainbow Molecular Weight Markers (RPN800). 
Amaxa GmBH Cell Line Nucleofector Kit T (VCA-1002), Kit V (VCA-1003). 
Applied Biosystems AmpliTaq Gold DNA Polymerase (N8080240). 
ASP Presept Disinfectant Tablets (SPR25). 
BD Biosciences Annexin V-PE kit code 559763, FACS flow (342003). 
BDH Bromophenol blue (44385), EDTA (280254D), Glycine (444495D), 
Hydrochloric acid (28507BF), Isopropanol (296946H), Magnesium sulphate 
(29117), Methanol (29192BL), Nitrocellulose membrane (436107E), 
Potassium acetate (295814P), Sodium dihydrogen orthophosphate (30716), 
Sucrose (102745C), Tris(hydroxymethyl)methylamine (271195Y). 
Biosciences HiYield Gel/PCR DNA Fragment Extraction Kit (YDF100).  
Digital Bio Solution T/N Accustain, AccuChip2x Kit (AD2k-200).  
Eppendorf Perfectprep Gel Cleanup (955152000). 
Fermentas GeneRuler 100bp DNA Ladder Plus (SM0323), GeneRuler 1kb DNA Ladder 
Plus (SM1333), PageRuler Plus Prestained Protein Ladder (SM1811), 
ProteoJET mammalian cell lysis reagent (K0301), ProteoJET cytoplasmic 
and nuclear protein extraction kit (K0311), Restriction enzymes. 
Finnzymes Phusion (F-530S). 
Invitrogen 1 Kb DNA ladder (15615-016),100 bp DNA ladder (15628-019), Foetal calf 
serum (10270-106),  HEPES (15630-056), Glutamax 1640 (61870-010), 
RPMI 1640 (31870-025), Trypan blue (15250-061), Trypsin (25090-028), 
Sodium Pyruvate (11360-039), SYBR Gold Nucleic Acid Gel Stain (S11494), 
SYBR Safe DNA Gel Stain (S33102).    
Kodak X-ray film (FS388). 
Labkem  Nitrocellulose Membrane (436107E). 
Labscan Chloroform (A3505E).  
Lennox Chemicals IMS (B0982). 
Merck Calcium chloride (23821000), Glacial acetic acid (100632511), Magnesium 
chloride (1058321000), Potassium Hydroxide (50321000), Sodium 
carbonate (A654792), di-Sodium hydrogen phosphate (1065860500). 
National diagnostics Acrylagel (EC810), Bis-acrylagel (EC820). 
Millipore Amicon Ultrafilter (UFC8 00508), Immobilon Western Chemiluminescent 
HRP Substrate (WBKLSOO50), Snap I.d. Antibody collection trays 
(WBAVDABTR), Snap I.d. Double well blot holders (WBAVDBH02).  
New England Biolabs Alkaline Phosphatase (CIP) & 10X dephosphorylation buffer (M0290S). T4 
DNA Ligase & 10X ligation buffer (M0202L), Restriction enzymes. 
Oxoid Agar (L13), PBS tablets (BR14), Tryptone (L42), Yeast extract (L21), PBS 
(Br14A). 
Pierce SuperSignal® West Pico Chemiluminescent Substrate (34080). 
Promega dNTPs (U1330), Dual-Luciferase Reporter Assay System (E1910), 
Luciferase Assay System (E1501), Magnesium chloride 25mM (A3511), M-
MLV reverse transcriptase & RT buffer (M1701), 5X Reporter lysis buffer 
(E3971), RNasin (N2111), Wizard® PCR Preps DNA purification system 
(A7170), Donkey Anti-Goat HRP V8051, Goat Anti-mouse Alkaline 
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phosphatase conjugate S3721.  
Roche Taq polymerase & 10 X enzyme buffer (1146173), Hygromycin B (843555), 
Leupeptin (1017128).  
Qiagen Qiagen® Plasmid Purification Kit (12143), Quantitect TM SYBR® Green PCR 
Kit (204143), UNG (1054568). 
Santa Cruz 
Biotechnology 
Anti-Rabbit IgG, HRP Conjugate (sc-2030). 
Sigma-Aldrich 
Chemical Co.  
3M sodium acetate, pH5.2 (S7899), Agarose (A5093), Ampicillin (A9518), 
Aprotinin (A4529), Ammonium Persulfate (215589), BCIP-NBT (B1911), 
Bovine serum albumin (A9647), Chlorofrom:isoamyl alcohol (24:1) (C0549), 
Colorburst electrophoresis markers (C4105), Con A (C7275), Coomassie 
Brilliant Blue R (B0149), Copper (II) Sulphate pentahydrate (31293), DEAE-
dextran (D9855), DEPC (D5758), DMSO (D8779), Dnase I kit (D5307-
1000UN), EDAC (E7750) β-estradiol (E8875), Ethidium bromide (E4391), 
Geneticin (G418) (A1720), Glucose (G7528), Glycerol (G5516), Hydrogen 
peroxide (H1009), Hydroquinone (H9003), L-glutamine (G7513), Manganese 
Chloride (M3634), MOPS (M3183), ONPG (N1127), Penicillin/streptomycin 
(P0781), Phenol:chloroform:isoamyl alcohol (25:24:1) (P3803), PMSF 
(P7626), Ponceau S (P7170), Potassium chloride (P4504), Puromycin 
(P8833), RedTaq (D4309), RNase A (R6513), Rubidium chloride (R2252), 
Lauryl Sulfate (L6026), Sodium Butyrate (B5887), Sodium chloride (S3014), 
Sodium hydroxide (S5881), α-Thioglycerol (M1753 ),Tetracycline (T7660), 
TEMED (T7024), Tri reagent (T9424),3,3’,5,5’-Tetramethylbenzidine (TMB) 
(T0565), Triton® X-100(T8787), Trizma® Base (T1503), Tween 20 (P1379), 
Water (Molecular Grade) (W4502), Mouse Anti-β-Actin A1978, Sodium 
Citrate (S1804). 
Stratagene QuikChange Site Directed Mutagenesis Kit (200518). 
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2.2 Methods 
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2.2.1 DNA Manipulation 
 
2.2.1.1 DNA Storage 
 
DNA samples were stored in Tris-EDTA (TE) buffer (pH 8.0) at 4ºC.  EDTA 
was used to chelate heavy metal ions that are needed for DNase activity 
while storage at pH 8.0 minimises deamidation.  DNA was also stored in 
sterile distilled H2O (dH2O) at 4ºC and -20ºC.  
 
2.2.1.2 Phenol/chloroform extraction and ethanol precipitation 
 
Phenol/chloroform extraction followed by ethanol precipitation was performed 
to concentrate nucleic acid samples, remove proteins or change the buffers 
in which a sample was dissolved. DNA partitions into the aqueous phase, 
denatured proteins collect at the interface, and lipids partition into the organic 
phase. Nucleic acids are routinely recovered from aqueous solutions using 
ethanol precipitation in the presence of sodium acetate.  
An equal volume of phenol/chloroform/isoamyl alcohol (25:24:1) was added 
to the DNA solution, mixed by vortexing and centrifuged for 5 mins at 13,000 
x g at room temperature.  The upper aqueous phase was removed, avoiding 
any material at the interphase, and placed in a sterile microfuge tube.  An 
equal volume of chloroform/isoamyl alcohol (24:1) was added to the aqueous 
phase (to remove any residual phenol), vortexed as before, and centrifuged 
for 5 mins at 13,000 x g at room temperature.  Again the upper aqueous 
phase was removed to a fresh tube.  One-tenth volume of 3M sodium 
acetate (pH 5.2) was added to the solution of DNA to aid precipitation, mixed 
and followed by 2 and a half volumes of 100 % (v/v) ethanol.  This mixture 
was vortexed and incubated at -20ºC for a minimum of 20 mins. When 
dealing with very small quantities of DNA, samples were precipitated in 
ethanol at -20ºC overnight. The DNA samples were then centrifuged for 20 
mins at 12,000 x g at 4ºC, the supernatant was removed and pellets were 
washed with 300µl 70% (v/v) ethanol to remove excess salts.  The tube was 
centrifuged for 5 mins at 10,000 x g, the supernatant was removed and 
pellets were air dried for approximately 10 mins.  Pellets were re-suspended 
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in an appropriate volume of sterile TE (pH 8.0) or dH2O and were stored at 
4ºC or -20ºC respectively. 
 
2.2.1.3 Restriction digestion of DNA 
 
Restriction analysis was used as a means of DNA identification, for vector 
linearization or to excise specific DNA fragments from a plasmid. Restriction 
enzymes specifically bind and cleave double-stranded DNA at specific sites 
within or adjacent to a particular sequence, which is known as the 
recognition site. Restriction digestion patterns were predicted for DNA 
sequences using the NEBCutter or the WebCutter 2.0 bioinformatics tool 
(Table 2.4). All restriction enzymes used were supplied with incubation 
buffers at a concentration of 10X (working concentration 1X).  The addition of 
Bovine Serum Albumin (BSA) was required for certain enzymes to stabilize 
the enzyme during digestion, (working concentration 1X). DNA digestion 
reactions were performed according to manufacturer’s instructions (New 
England Biolabs) and incubated for 3 hours at the optimum enzyme 
temperature (between 37ºC and 50ºC, usually 37ºC). 
 
2.2.1.4 Dephosphorylation of linearised plasmid DNA 
 
To minimize the occurrence of a linearised plasmid re-annealing to itself the 
vector is treated with Calf intestinal Phosphatase (CIP). Re-circularisation 
occurs when T4 DNA ligase catalyses the formation of a phosphodiester 
bond between juxtaposed 5' phosphate and 3' hydroxyl termini in duplex 
DNA during a ligation reaction. The CIP enzyme catalyses the removal of 
5´ phosphate groups from DNA.  Since CIP-treated fragments lack the 5´ 
phosphoryl termini required by ligases, they cannot self-ligate, decreasing 
the vector background in cloning strategies.  
Digested DNA (<100 ng/µl) was de-phosphorylated using CIP in a 100 µl 
volume (CIP was added 1 unit/100 pmoles for cohesive termini).  The 
solution was mixed by pipetting, centrifuged briefly and incubated for 1 hour 
at 37ºC. This was followed by an enzyme denaturation step achieved by 
heating to 75ºC for 10 mins.  The DNA was then purified by 
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phenol/chloroform extraction and ethanol precipitation, or gel purification. 
The purified linearised, CIP-treated DNA was stored at 4ºC until required for 
ligation. 
 
2.2.1.5 Polymerase chain reaction (PCR) 
 
PCR was used to amplify specific DNA through multiple cycles of 
denaturation, annealing and elongation. This involved the use of short 
synthetic oligonucleotides to bind to the sequences flanking the region of 
interest, one primer lies on the forward strand of DNA whilst the second 
primer anneals to the reverse strand. This allows the polymerization of both 
strands by the action of the thermostable enzyme Taq DNA polymerase. This 
method of exponential amplification can be used to generate target 
sequences of DNA for sub-cloning into linearised vectors, or as a method of 
identification. PCR reactions were set up by the addition of reagents in the 
following order: 
Component Volume 
10x Reaction Buffer (+MgCl2) 5µl 
Template DNA (~500ng) 1µl 
Forward primer (40pmole) 2.5µl 
Reverse primer (40pmole) 2.5µl 
dNTP mix  (each at 10mM) 1µl 
dH2O to 50µl 37µl 
Taq polymerase (5 U/µl) 1µl 
 
 
2.2.1.6 Purification of PCR products 
 
PCR products were purified from reaction contaminants such as primer 
dimers and amplification primers by one of two purification systems, the 
Promega Wizard® PCR Preps DNA Purification System or Bioscience 
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HiYieldTM Gel/PCR DNA Extraction Kit according to the respective 
manufacturer’s protocol.  The purified DNA was stored at 4ºC until required 
for further use.   
 
2.2.1.7 Ligation of DNA molecules 
 
To join blunt or cohesive ended double-stranded DNA, the enzyme T4 DNA 
ligase was employed to catalyse the formation of a phosphodiester bond 
between juxtaposed 5' phosphate and 3' hydroxyl termini of the two. 
Cohesive end ligations were carried out in a 3:1 molar ratio of insert DNA to 
vector DNA. This was performed overnight at 16ºC or alternatively for 3 
hours at 20-25ºC in a commercial ligation buffer (containing 5 mM ATP) with 
10 units of T4 DNA ligase/ml in a total volume of 10 µl.  After ligation, the 
samples were heated at 70ºC for 10 mins to inactivate the ligase and were 
transformed immediately or stored at –20ºC until required for transformation. 
 
2.2.1.8 Preparation of competent cells 
 
Competence is the ability of a cell to take up extracellular DNA from its 
environment. E. coli cells are more likely to incorporate foreign DNA if the 
cultures are treated to make them transiently permeable to DNA. In this 
regard, a modified Rubidium chloride (RbCl2) method was employed to 
prepare competent cells.  A JM109 E.coli strain was streaked from a glycerol 
stock on to a Luria-Bertani (LB) (Appendix) agar plate and incubated at 37ºC 
overnight.  An isolated colony was then picked using a sterile inoculating 
loop and used to inoculate 5 ml of LB broth, which was incubated at 37ºC in 
a shaking incubator at 200 rpm overnight.  Following this, 2.5 ml of this 
culture was then used to inoculate 250 ml of sterile LB broth supplemented 
with 20 mM MgSO4.  The 250 ml culture was incubated in a 1L flask at 37ºC 
until the optical density (O.D.) of the culture was between 0.4 and 0.8, at 640 
nm (approximately 4-5 hours).  The cells were then transferred to two sterile 
250 ml centrifuge tubes and collected by centrifugation at 4,500 x g, 4ºC for 
5 mins.  The cells were then gently re-suspended in 0.4 of their original 
volume in ice cold TFB1 (Appendix) (100 ml for 250 ml culture). Cells were 
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kept on ice for all subsequent steps and pipettes, tubes and flasks were 
chilled. The re-suspended cells were then incubated on ice at 4ºC for 5 mins 
followed by centrifugation at 4,500 x g at 4ºC for 5 mins. Cells were then 
gently re-suspended in 1/25 of the original volume of ice-cold TFB2 
(Appendix) (10 ml for a 250 ml culture). These cells were then dispensed into 
100 µl aliquots and incubated on ice for 1 hour.  Prior to storage the 
aliquoted cells were snap frozen in a dry ice/isopropanol bath. JM109 
competent cells prepared by this method and stored at -80ºC are stable for 1 
year.  
 
  
79 
 
2.2.1.9 Transformations 
 
A 95 µl aliquot of competent cells was placed in a pre-chilled microfuge tube 
containing 5 µl DNA (~100 ng/10µl).  The contents of the tube were mixed 
gently by flicking, and incubated on ice for 30 mins, during which time an 
aliquot of SOC medium (Appendix) was pre-heated to 37ºC.  After 30 mins 
on ice the cells were heat-shocked in a water bath at 42ºC for 55-65 
seconds, and were then removed immediately for incubation on ice for a 
further 2 mins.  A 900 µl aliquot of preheated SOC medium was added to the 
cells which were then incubated at 37ºC in a shaking incubator for 1 hour.  
The cells were then pelleted by centrifugation for 3 minutes at 6,000 x g.  
Following centrifugation, 900 µl of supernatant was removed and discarded.  
The cells were re-suspended in the remaining supernatant and plated out, 
along with the controls, on LB plates containing antibiotic at the appropriate 
concentration, and incubated overnight at 37ºC.  Plasmids carrying the 
antibiotic resistance gene confer this resistance to the transformed cells and 
thus only transformed cells will yield colonies.  These colonies were 
subsequently used to prepare broth cultures for DNA mini-preparations. 
 
2.2.1.10 Small scale preparation of plasmid DNA (Miniprep) 
 
A single bacterial colony was used to inoculate 5 ml of LB medium containing 
the appropriate antibiotic and incubated overnight on a shaker (200 rpm) at 
37ºC.  A 1.5 ml aliquot of this culture was transferred to a sterile microfuge 
tube and centrifuged for 30 seconds at room temperature; the remainder was 
stored at 4ºC.  The supernatant was removed carefully from the tube using a 
pipette, leaving the pellet as dry as possible.  The pellet was re-suspended 
thoroughly using a pipette in 100 µl of buffer P1 (Appendix).  200 µl of fresh 
buffer P2 (Appendix) was added, and the tube contents were mixed by 
inverting the tube rapidly a number of times.  150 µl of ice-cold buffer P3 
(Appendix) was added and the tubes were again mixed by inversion. 
The lysate was centrifuged for 5 mins at 12,000 x g; the supernatant was 
transferred to a fresh tube, taking care not to carry over any of the white 
precipitate.  An equal volume of phenol/chloroform/isoamyl alcohol (25:24:1) 
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was added, mixed by vortexing and centrifuged for 5 mins at 12,000 x g.  
The upper aqueous phase was removed to a fresh tube, to which 2 volumes 
of 100% (v/v) ethanol were added; the solution was vortexed and centrifuged 
for 5 mins at 12,000 x g.  The supernatant was discarded, the pellet was 
washed with 1 ml 70% (v/v) ethanol, centrifuged as before and the 
supernatant was removed.  The pellet was air-dried, then re-suspended in 50 
µl of TE (pH 8.0).  1 µl of DNase-free RNase A (20 µg/ml) was also added, 
and the mixture was vortexed, incubated at 37ºC for 1 hour and then stored 
at 4ºC.  Glycerol stocks of all bacterial cultures were prepared at this stage 
by the adding 0.5 ml of a 50% (v/v) glycerol solution to 0.5 ml of the 
overnight bacterial culture of interest and storing at -80ºC. 
 
2.2.1.11 Glycerol Stocks 
 
Glycerol stocks enable long term storage of bacteria since glycerol prevents 
water in the broth from forming ice crystals that can puncture and kill the 
bacterial cells. Glycerol stocks of bacterial cultures were prepared by adding 
0.5 ml of a 50% (v/v) glycerol solution to 0.5 ml of the overnight bacterial 
culture of interest, mixing and storing at -80ºC for future use. 
 
2.2.1.12 Qiagen® plasmid DNA purification protocol (Midiprep) 
 
Plasmid DNA was isolated and purified using the Qiagen® Plasmid Midi Kit.  
This process of plasmid amplification and isolation involves the lysis of the 
cells, by a treatment with lysozyme, followed by an SDS solution which 
denatures proteins after the lysis of the membranes. The precipitation of the 
SDS-protein complex with high-molarity salt specifically removes the 
chromosomal DNA from the supernatant, as it remains attached to the 
mesosome. 
 
A glycerol stock of the bacteria of interest was streaked on an LB agar plate 
(containing the appropriate antibiotic) and incubated overnight at 37ºC.  An 
isolated colony from this plate was used to inoculate a 5 ml starter culture 
(with the appropriate antibiotic) and incubated in a shaking incubator at 225 
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rpm 37ºC for 7-8 hours.  100 µl of the starter culture was used to inoculate 
50 ml of LB (containing the appropriate antibiotic) in a 250 ml sterile flask 
and incubated overnight in a shaking incubator at 37ºC.  It was important that 
the O.D. of the culture was between 1 and 1.5 at 600 nm.  The bacterial 
culture was transferred to a centrifuge tube and the bacterial cells were 
harvested by centrifugation at 6,000 x g for 15 mins at 4ºC using a JA-20 
rotor in a Beckman centrifuge.  The supernatant was decanted and the cells 
were re-suspended completely in 4 ml of Buffer P1 containing RNase A (100 
µg/ml).  The bacterial cells were then lysed by addition of 4 ml Buffer P2 and 
incubation at room temperature for 5 mins.  Following incubation, 4 ml of pre-
chilled Buffer P3 was added (to precipitate genomic DNA, protein, cell debris 
and SDS), mixed gently by inverting the tube 5-6 times and incubated on ice 
for 15 mins.  The mixture was then centrifuged for 1 hour 30 mins at 16,000 x 
g at 4ºC and the supernatant saved. 
 
The Qiagen-tip 100 column was equilibrated by applying 4 ml of QBT buffer 
and allowing the column to empty by gravity.  The column does not dry out at 
this stage, as the flow of buffer will stop when the buffer reaches the upper 
filter.  Following equilibration, the supernatant from the previous 
centrifugation step was applied to the column and allowed to flow through the 
filter.  The Qiagen-tip was washed with 2 x 10 ml of Buffer QC.  DNA was 
then eluted with 5 ml of Buffer QF.  DNA was precipitated by adding 3.5 ml of 
room-temperature isopropanol. The DNA/isopropanol mixture was then 
aliquoted and centrifuged immediately at 13,000 x g for 45 mins at 4ºC and 
the supernatant was carefully removed using pipettes.  The resulting pellet 
was washed with 70 % (v/v) ethanol (13,000 x g for 15 mins at 4ºC), allowed 
to air dry for 5 mins and re-dissolved in 30 µl of TE or dH2O.  DNA was then 
quantified by spectrophotometric analysis, and quality of the DNA was 
checked by Agarose gel electrophoresis (Adapted from the manufactures 
protocol Qiagen® Plasmid Purification Handbook, 2005). 
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2.2.1.13 Qiagen®  EndoFree plasmid purification protocol (Maxiprep) 
 
Endotoxins are frequent contaminants in plasmid DNA prepared from 
bacteria. These endotoxins may reduce the efficiency of transfection or 
induce non-specific effects within certain cell types that can inhibit 
reproducibility. In order to improve transfection efficiency, endotoxin free 
plasmid DNA was isolated and purified using the Qiagen® EndoFree Plasmid 
Midi Kit from Promega according to the manufacturer’s protocol (EndoFree® 
Plasmid Purification Handbook, 2005). Endotoxin free DNA was then 
quantified by spectrophotometric analysis, and quality of the DNA was 
checked by Agarose gel electrophoresis. 
 
2.2.1.14 Determination of Nucleic Acid Sample Concentration. 
 
The concentration of isolated nucleic acids can be determined 
spectrophotometrically. Nucleic acids absorbs UV light maximally at a 
wavelength of 260 nm; thus, optical absorbance can be used as an accurate 
measurement of its concentration. Pure DNA at 50 µg/ml in aqueous solution 
has an A260 of 1, while 40 µg/ml of pure RNA also has an absorbance 
reading of 1 at this wavelength.    
 
Absorbance is also useful as a measure of the purity of DNA. The ratio of 
A260/A280 of a pure dsDNA preparation should be between 1.65 and 1.85. 
Higher values are often due to RNA contamination and lower values to 
protein and phenol contamination.  Pure DNA and RNA have A260/A280 ratios 
of 1.8 and 2.0 respectively.   
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Shimadzu UV-160A Spectrophotometer 
 
Absorbances were read on the Shimadzu UV-160A spectrophotometer using 
a quartz cuvette and nucleic acid concentrations were determined according 
to the following equations: 
 
Concentration of DNA (µg/µl) = Absorbance (260 nm) x 50 x dilution 
factor 
            1000 
 
Concentration of RNA (µg/µl) = Absorbance (260 nm) x 40 x dilution 
factor             1000 
 
2.2.1.15 The NanoDrop® ND-1000 Spectrophotometer 
 
The NanoDrop® ND-1000 Spectrophotometer was also used to determine 
nucleic acid sample concentrations. An undiluted 1 µl sample was pipetted 
onto the end of a fibre optic cable (the receiving fibre). A second fibre optic 
cable (the source fibre) was then brought into contact with the liquid sample 
causing the liquid to bridge the gap between the fibre optic ends. (The gap is 
controlled to both 1 mm and 0.2 mm paths by the computer). A pulsed xenon 
flash lamp provided the light source and a spectrometer was used to analyse 
the light after passing through the sample. The instrument is controlled by 
special software run from a PC, and the data was logged in an archive file on 
the PC. 
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2.2.1.16 Agarose gel electrophoresis of DNA 
 
DNA has a negative charge in solution, and the magnitude of this charge is 
relative to the DNA fragment length. DNA will migrate to the positive pole in 
an electric field and thus linear DNA fragments can be separated based on 
size by passing through a porous agarose matrix under an electrical current. 
This is the basis for agarose gel electrophoresis and it is the standard 
method used to separate, identify, and purify DNA fragments.  
 
The appropriate quantity of agarose was added to 100 ml 1X TAE buffer 
based on the percentage agarose gel required.  Increasing the percentage 
agarose (1.8-2.0%) in the gel was generally used to improve resolution of 
smaller DNA fragments while separation of larger DNA molecules was best 
achieved by using lower percentage gels (0.7-1.0%).  The agarose was 
completely dissolved by boiling with intermittent mixing and after sufficient 
cooling (~60ºC) the gel was cast into the Hybaid horizontal gel 
electrophoresis system.  A comb was inserted for formation of the wells.  The 
gel was left to polymerise before filling the chamber with 1X TAE and 
removing the comb.  Sample buffer, containing bromophenol blue as a 
tracking marker (Appendix), was added to each sample before loading up to 
20 µl of the sample containing the nucleic acid per well.  DNA sample buffer 
was also added to 500 ng of a 1Kb or 100bp ladder, which was loaded as a 
size marker.  The gel was run at constant voltage (5 V/cm, usually 100V), for 
1 to 2 hours.  After completion, the gel was stained in ethidium bromide (0.5 
mg/ml) for 30 mins, destained in dH2O for 15 mins and viewed under UV 
illumination. 
 
2.2.1.17 Isolation of DNA from Agarose Gels. 
 
Agarose gels were prepared in 1X TAE buffer as described previously in 
2.2.1.16. Ethidium Bromide was added to the samples before electrophoresis 
so as to minimize manipulation with the gel. After electrophoresis, the gel 
was viewed in a dark-room under 70% UV illumination. The time of exposure 
to UV light was kept to a minimum, as overexposure to UV leads to DNA 
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damage. The DNA band of interest was excised from the gel using a clean 
scalpel blade, excess agarose was cut away (without disrupting the 
fragment) to minimise the size of the gel slice, which was then placed in a 
pre-weighed sterile microfuge tube. 
 
2.2.1.18 Eppendorf Perfectprep® Gel Cleanup 
 
Extraction and Purification of dsDNA fragments from TAE agarose gels was 
achieved using the eppendorf Perfectprep® Gel Cleanup kit following the 
manufacturers’ protocol (Perfectprep® Gel Cleanup Manual, 2002). The 
purified DNA was eluted in 30 µl of molecular biology grade water and stored 
at 4ºC or -20ºC. 
 
2.2.1.19 Site Directed Mutagenesis 
 
QuikChange site directed mutagenesis allows single or multiple specific base 
changes in a double stranded parental template vector. High fidelity Pfu 
turbo DNA polymerase replicates both strands of the plasmid utilising 
oligonucleotides, containing the desired mutations, complementary to each 
target strand. Successfully amplified mutant plasmid strands produced during 
the PCR will be nicked and un-methylated. This allows digestion of the un-
mutated methylated parental vector by the enzyme Dpn I, an endonuclease 
specific for methylated or hemi-methylated DNA, permitting recovery of the 
successful mutant amplicons.  
 
The plasmid DNA of interest was purified using a dam+ E. coli host strain 
(JM109) and the midi prep DNA purification method described previously 
section 2.2.1.12. Oligonucleotides containing the desired mutations were 
designed ensuring the desired mutation anneals to the same sequence on 
the opposite strands of the plasmid and the base pair mismatch was flanked 
by ~10-15 bp of correct sequence on either side. Control and mutagenesis 
PCR reactions were set up by the addition of the reagents in the order listed 
in Table 2.8 
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 Table 2.8 Components of PCR reactions 
Control PCR 
 
Sample  PCR 
Component Volume 
 
Component Volume 
10x Reaction Buffer 5µl 
 
10x Reaction Buffer 5µl 
pWhitescript control 
(5ng/µl) 2µl  dsDNA template (50ng) Xµl 
Forward control primer 
(100ng/µl) 1.25µl  Forward primer (125ng) Xµl 
Reverse control primer 
(100ng/µl) 1.25µl  Reverse primer (125ng) Xµl 
dNTP mix  1µl 
 
dNTP mix  1µl 
dH2O to 50µl 39.5µl 
 
dH2O to 50µl Xµl 
Pfu Turbo DNA polymerase 1µl Pfu Turbo DNA polymerase 1µl 
 
Control and Sample PCR reactions were carried out using the following 
cycling conditions listed in Table 2.9 below. Reduced cycle number 
decreases potential for random mutation generation. 
 
Table 2.9 PCR Cycling Programme 
 
Stage Cycles Temperature Time 
1 1 95ºC 30 Seconds 
2 16 
95ºC 31 Seconds 
XºC 1 minute 
68ºC 7 minutes 
 
The PCR reactions were then placed on ice for 2 mins. The reactions were 
incubated to 37ºC before addition of 1 µl of Dpn I restriction enzyme. These 
were incubated at 37ºC for 1 hour to allow digestion of the methylated 
parental dsDNA.  
 
The mutated products were transformed into XL1-Blue supercompetent cells. 
The XL1-Blue cells were thawed gently on ice and aliquoted into 14 ml BD 
falcon polypropylene round bottom tubes. 1 µl of digested plasmid was 
added to each aliquot; pUC18 was used as a transformation control. The 
transformations were mixed gently and incubated on ice for 30 mins. Heat 
shock was then performed at 42ºC for 45 seconds. The reactions were then 
returned to ice for 2 mins. Following this, 0.5 ml of preheated NZY+ broth 
(Appendix) was added to each reaction and incubated at 37ºC for 1 hour with 
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agitation on a shaker at 225-250 rpm. Then 250 µl of each sample was 
plated onto the appropriate agar plates. Mutagenesis and Transformation 
controls were spread onto LBamp plates containing 80 µg/ml X-gal and 20 mM 
IPTG. Plates were incubated at 37ºC overnight.  
 
2.2.1.20 DNA Sequencing 
 
Sequencing of plasmid DNA was performed to ensure the nucleic acid fidelity 
and ‘in-frame’ insertion of DNA fragments following cloning. Plasmid DNA as 
prepared in section 2.2.1.12 was quantified (Section 2.2.1.14-15) and 15 µl 
of plasmid DNA at a concentration of 50-100 ng/µl was transferred to a 
sterile 1.5 ml eppendorf. Alternatively, for sequencing of PCR products, the 
DNA was purified as per section 2.2.1.6, quantified and 15 µl of product at a 
concentration of between 2-5 ng/µl was transferred to a sterile 1.5 ml 
eppendorf. The DNA was sent to MWG-Biotech, Ebersberg, Germany for 
sequencing. Sequencing forward and reverse primers were supplied by 
MWG-Biotech for most commercially available vectors. In the absence of 
existing sequencing primers (as in the case of the pRTS-1 vector or PCR 
products), a forward and/or reverse primer was designed and 15 µl at a 
concentration 2 pmol/µl (30 pmol total) of each primer was transferred to a 
sterile eppendorf and sent with each sequencing reaction to MWG-Biotech. 
Sequencing results were obtained electronically as linear nucleotide 
sequences. 
 
2.2.3 Cell Culture Methods 
 
All cell culture techniques were performed in a sterile environment using a 
Holten laminar flow cabinet.  Cells were visualised with an Olympus CK2 
inverted phase contrast microscope. All media compositions and media 
supplements are given in the Appendix. 
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2.2.3.1 Culture of cells in suspension 
 
The cell lines AG876, Akata4E3, BJAB, BL41K3, BL419A, DG75, DG75-tTA-
EBNA2, DG75-tTA-LMP1, EREB 2.5, IARC 290B, IB4, LCL327, Ramos were 
maintained in RPMI 1640 supplemented with 10% (v/v) foetal bovine serum 
(FBS), 2 mM L-glutamine, 100 µg/ml streptomycin and 100 U/ml penicillin. 
Cultures were seeded at a density of 2 X 105 to 5 X 105 cells per ml in 25cm2 
flasks and expanded in 75cm2 flasks.  P493-6 was maintained in RPMI 1640 
supplemented with 10% (v/v) FBS, 2% (v/v) L-glutamine, and 1% (v/v) 
Sodium Pyruvate. These cells were seeded at a density of 2 X 105 to 5 X 105 
cells per ml in 25cm2 flasks. Additional supplements were added to some 
culture media as described in Section 2.2.3.2.  Cells were sub-cultured two 
or three times per week by harvesting the cells into a sterile centrifuge tube 
and centrifuging at 1000 rpm for 5 mins at room temperature.  The cells were 
gently re-suspended in an appropriate volume of fresh supplemented 
medium and replaced into the tissue culture flask.  All cell lines were 
incubated in a humid 5% CO2 atmosphere at 37ºC in a Heraeus cell culture 
incubator. 
 
2.2.3.2 Medium supplements 
 
Certain cell lines require specific supplements to promote cellular 
maintenance and proliferation, activate/de-activate the function or expression 
of a gene of interest or to select cells containing transfected plasmids. 
The DG75-tTA-EBNA2 and DG75-tTA-LMP1 cell lines were maintained in 
supplemented RPMI containing 1 µg/ml of tetracycline.  Every three weeks 
the transfected cells were reselected by the addition of 500 µg/ml of 
hygromycin and 1,000 µg/ml of geneticin (G418) to DG75-tTA-EBNA 2 and 
800 µg/ml of hygromycin and 2,000 µg/ml of G418 to DG75-tTA-LMPI. The 
stably transfected cell lines BL41K3 and BL419A were maintained under 
permanent selection, with the addition of 800 ug/ml or 1200 ug/ml of 
geneticin to BL41K3 and BL419A respectively. In experiments where EBNA2 
activation was required, cells were washed twice in PBS and placed in fresh 
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supplemented RPMI with the appropriate antibiotics for selection. Estrogen 
was then added to a final concentration of 1 µM.   
 
The estrogen responsive ER/EB2.5 cell line was maintained in supplemented 
medium containing 1 µM estrogen. To abolish functional EBNA2 activity, 
ER/EB2.5 cells were washed 4 times in PBS and re-suspended in estrogen-
free supplemented medium. A further 2 washes were carried out 24 hours 
later and the cells were once again replaced in estrogen-free supplemented 
medium.    
 
In the P493-6, functional EBNA2 activity was induced by culturing cells in 
supplemented medium containing 1 µM estrogen. To abolish functional 
EBNA2 activity, cells were washed 4 times in PBS, with a further 2 washes 
60 hours later and replaced in estrogen-free medium.   Expression of c-myc, 
was repressed by treatment with 0.1 µg/ml tetracycline was added to culture 
medium. For myc re-introduction, cells were washed 3 times with 
tetracycline-free culture medium and reseeded in tetracycline-free medium. 
 
2.2.3.3 Trypan blue cell counts 
 
Cell counts were carried out using an improved Neubauer haemocytometer 
slide.  Cell viability was determined using trypan blue exclusion dye. A 
volume of 10 µl of trypan blue was added to 90 µl of a cell suspension and 
mixed.   A sample 10 µl of this mixture was added to the counting chamber of 
the haemocytometer and cells were visualised by light microscopy.  Viable 
cells excluded the dye and remained clear while dead cells stained blue.  
Cell numbers were determined by multiplying the average cell count (of 3-5 
individual counts) by the dilution factor (usually 1.1) and again by the volume 
of the haemocytometer chamber (1 X 104 cells/ml).  Thus, cell counts were 
expressed as the number of cells per ml. 
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2.2.3.4 ADAMTM cell counter 
 
Cell counts can also be made using an Advanced Detection and Accurate 
Measurement (ADAMTM) cell counter which utilizes fluorescent cell staining 
to determine total and viable cell count in a give sample. Cells are mixed with 
two solutions one contains Propidium Iodide (PI), a fluorescent dye that will 
intercalate with DNA; however, PI cannot enter cells with intact membranes. 
Only non-viable cells will fluoresce with PI alone. The second solution 
contains PI and a detergent that will disrupt viable cell membranes allowing 
PI to stain both viable and non-viable cells. ADAM contains both laser optics 
and image analysis software that allows determination of both total and 
viable cell numbers in a sample from these two staining methods. 
 
Two 14 µl aliquots of cells were taken, one aliquot was mixed with 14 µl of 
Solution T accustain (Digital Bio) the second with 14 µl solution N accustain 
(Digital bio). Following this, 20 µl of each cell mixture was then loaded into 
the appropriate labelled chamber in an AccuChip (Digital bio). Then 40-60 
images are taken of the cell chambers. Average cell number and viability are 
calculated using the integrated image analysis software. 
 
2.2.3.5 Cell storage and recovery 
 
Mammalian cells can be stored indefinitely in liquid nitrogen; however, the 
correct protective medium is vital as the effects of freezing can be lethal. 
Formation of ice crystals or shifts in electrolyte concentrations can cause the 
loss of cell membrane integrity, leading to cell death. To reduce these effects 
significantly, DMSO, a cryoprotectant chemical which lowers the freezing 
point of the storage medium, must be added. FBS is a rich source of proteins 
and other growth factors. FBS is added to the freezing medium as a 
cryoprotective additive. The precise function of FBS is unclear; however, it 
has long been proven to enhance long term cryostability.  
 
In order to prepare stocks of suspension cells for long-term storage, 1 X 107 
cells in exponential phase were centrifuged, the excess medium was 
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discarded and the cells were re-suspended in 1 ml of freezing medium 
composed of 750 µl of supplemented RPMI, 150 µl of FBS and 10% (v/v) 
DMSO, mixed gently and transferred to a sterile cryotube. The cryotubes 
were slowly lowered into the gas phase of liquid nitrogen and then immersed 
in liquid nitrogen in a cryofreezer (Cooper Cryoservices).   
 
Cells were recovered from liquid nitrogen by thawing rapidly at 37ºC and 
transferring to a sterile centrifuge tube containing 10 ml of pre-warmed 
supplemented medium. The cells were centrifuged at 100 x g for 5 mins, the 
cells were re-suspended in 5-10 ml of fresh supplemented medium, 
transferred to a culture flask and incubated at 37ºC in 5% CO2. 
 
2.2.3.6 Isolation of Naïve B cells 
 
Naϊve B cells were isolated from human peripheral blood mononuclear cells 
(PBMCs) using MACS naϊve B-cell isolation kit II. This is an indirect magnetic 
labelling system for the isolation of untouched naϊve B cells from human 
PBMCs. Non-B cells, i.e., T cells, NK cells, dendritic cells, monocytes, 
granulocytes, platelets, and erythroid cells, and non-naϊve B cells, such as 
memory B cells, activated B cells, and plasma cells, are indirectly 
magnetically labelled using a cocktail of biotinylated CD2, CD14, CD16, 
CD27, CD36, CD43, and CD235a (glycophorin A) antibodies. These cells are 
subsequently magnetically labelled with Anti-Biotin MicroBeads for depletion. 
Highly pure naϊve B cells are obtained by depletion of magnetically labelled 
cells. The purity of the sample was confirmed by FACS analyses of PBMC 
and the naive B-cell fraction stained with PE-labelled anti-CD27 (memory B-
cell marker) and FITC-labelled anti-CD19 (pan-B-cell marker) antibodies. 
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2.2.3.7 EBV Infection  
 
Recombinant GFP-tagged EBV was obtained from Akata BX-1 cells that had 
been re-suspended at a concentration of 4 x 106 cells/ml, and induced with 
50 mg/ml of anti-human immunoglobulin G for 5 days (Molesworth, et al. 
2000). The Virus was harvested and sterilised by passing through a 0.45-mm 
(pore-size) filter. Approximately 5 x 105 naïve B cells were incubated at 37ºC 
with 150 µl of dilutions of filtered recombinant GFP-tagged BX1 EBV virus. 
After 2 hours, the volume was brought to 3 ml with medium containing serum 
and the cells were re-incubated. Three days later the cells were harvested 
and analysed for expression of EBNA-2 by Western blotting.  
 
2.2.3.8 Transient transfections 
 
Transient transfection of cells was performed by electroporation, 
nucleofection or using the DEAE-dextran method. In all cases, cells were 
seeded at a density of 2-5 X 105 per ml of medium 24 hours prior to 
transfection. After this time in culture, cells were counted again. It was 
essential for cell numbers to have almost doubled before beginning the 
transfection, thus ensuring that cell growth was in logarithmic phase, allowing 
for optimal DNA uptake during transfection. The same quantity of total DNA 
was used per transfection.  
 
2.2.3.9 Electroporation of B lymphocytes 
 
Transfection of AG876, IB4, BJAB and ER/EB 2.5 cell lines (Table 2.1) was 
carried out by electroporation. During the electroporation method of 
transfection, the application of brief high voltage electric pulses to the cells 
leads to the formation of nanometer-sized pores in the plasma membrane. 
DNA is taken directly into the cell cytoplasm either through these pores or as 
a consequence of redistribution of membrane components that accompanies 
the closure of the pores.   
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Total DNA (10-20 µg per transfection) dissolved in 30 µl TE buffer (pH 8.0) 
was transferred into a sterile electroporation cuvette. A total of 1 X 107 cells 
were used per transfection. Cells were centrifuged at 100 x g for 5 mins and 
the supernatant discarded. The cells were then washed in PBS, centrifuged 
at 100 x g for 5 mins and the supernatant again discarded. For each 1 X 107 
cells, 220 µl of serum-free medium was used for re-suspension and the cells 
transferred to the DNA-containing electroporation cuvettes. The cell/DNA mix 
was incubated at room temperature for 5 mins. Each cell/DNA mix was then 
pulsed at 220-250 V (BJAB, 250 V; AG876, IB4 and EREB 2.5 220 V) with a 
capacitance of 960 µF (using a capacitance extender) and resistance set to 
infinity using a Bio-rad Gene Pulser. Immediately after electroporation the 
cuvettes were placed on ice until the cell/DNA mix was transferred into 5 ml 
supplemented media in a 6 well dish, and the contents were mixed by gently 
rocking back and forth.  Care was taken to ensure cells were stored no 
longer than 10 mins after electroporation to avoid reduction in cell 
viability/gene transfer efficiency.  Transfected cells were harvested 48 hours 
later.  
 
2.2.3.10 Nucleofection of B lymphocytes 
 
The Nucleofector technology is based on electroporation. It consists of the 
Nucleofector device II (Amaxa), which delivers a cell-specific combination of 
electrical parameters, and Nucleofector Solutions, in which the cells are 
contained while the unique electrical program is executed. Optimised 
conditions for nucleofection of BJAB and IB4 cells yielded higher percentage 
transfection efficiency, when compared to cells transfected using the 
electroporation technique.  
 
The appropriate nucleofector solution to the particular cell line being 
transfected (Solution T/V for BJAB/IB4) was pre-warmed to room 
temperature and 50 ml of supplemented medium was pre-warmed to 37ºC. 
Supplemented medium (2 ml) was aliquoted into the appropriate number of 
wells of a 6 well plate and pre-incubated at 37ºC/5% CO2/humidified 
atmosphere. A total of ~7 µg DNA was prepared in sterile 1.5 ml eppendorfs 
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for each sample. For each transfection, 2.5 X 106 (IB4)/ 5 X 106 (BJAB) cells 
were collected by centrifugation at 90 x g for 10 mins and the supernatant 
was discarded completely so that no residual medium remained. The cells 
were resuspended in room-temperature solution in question to a final 
concentration of 2.5 x 106 cells/100µl (IB4) or 5 X 106 /100µl (BJAB). Care 
was taken to ensure cells were stored in nucleofector solution no longer than 
15 mins to avoid reduction in cell viability/gene transfer efficiency. A volume 
of 100 µl of cell suspension was mixed with the DNA and the nucleofection 
sample was transferred to an Amaxa-certified cuvette, taking care to avoid 
bubbles. The cuvette was placed in the nucleofection chamber and pulsed 
on program T-016 (IB4 and BJAB). Immediately after this, 500 µl of pre-
warmed medium was added to the cuvette. The contents were then gently 
transferred to the prepared 6-well plates, mixed gently and incubated at 
37ºC/5% CO2/humidified atmosphere until cells were harvested. 
 
2.2.3.11 DEAE-Dextran-mediated transfection 
 
Transfection of DG75 cells was performed using this method of transfection. 
During transfection, positively charged DEAE-dextran binds to the negatively 
charged phosphate groups of the DNA, forming aggregates. These 
complexes, when applied to cells, subsequently bind to the negatively 
charged plasma membrane. It is believed that cellular uptake of DNA is 
mediated by endocytosis, and further assisted by osmotic shock.   
 
A maximum of 25 µg of DNA dissolved in TE buffer (pH 8.0) was used per 
transfection. Total DNA was prepared in a sterile microfuge tube and brought 
to a volume of 600 µl with TBS (Appendix). Following this, 600 µl of 1 mg/ml 
DEAE-dextran solution (Appendix) was mixed with the DNA solution. 
Meanwhile, 1 X 107 cells/transfection were centrifuged at 100 x g for 5 mins 
and the supernatant was discarded. The cells were then washed in PBS, 
centrifuged at 100 x g for 5 mins and the supernatant again discarded. The 
cells were then gently re-suspended in the DNA/DEAE-dextran mix. The 
transfection cocktails were incubated at 37ºC for 30 mins with gentle swirling 
every 5-10 mins to promote homogenisation. Transfections were terminated 
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by the addition of 10 ml supplemented medium to the tube and the cells were 
collected by centrifugation at 100 x g for 5 mins, washed in PBS as before 
and transferred to 6 well plates containing 10 ml supplemented medium for 
incubation. Cells were harvested at 48 hours post-transfection.   
 
2.2.3.12 Microscopic analysis following gene transfer 
 
Following selected transfections, gene transfer efficiency was monitored by 
fluorescence microscopy. Green fluorescent protein (GFP) expressing 
vectors were co-transfected, cells were harvested 4-72 hours post-
transfection and positively transfected cells expressed this fluorescent 
protein. A volume of 500 µl of suspension cells was removed to a 1.5 ml 
sterile eppendorf and centrifuged at 100 x g for 5 mins. The supernatant was 
discarded and the cells were re-suspended in 20 µl of PBS/0.5 % (w/v) BSA 
and applied to a glass microscope slide. A coverslip was applied with care 
taken to avoid air bubbles and the slide was examined under bright field and 
fluorescent field microscopy using an Olympus DP-50 fluorescent 
microscope [excitation 450–500 nm, emission 515–565 nm] with a camera 
and StudioLife software (Olympus Optical Company).  
 
2.2.3.13 Harvesting cells post-transfection for luciferase/β-gal assays 
 
Cells were collected by centrifugation at 100 x g for 5 mins at room 
temperature. The cells were washed once in sterile PBS and centrifuged 
again at 100 x g for 5 mins.  The supernatant was discarded, ensuring all 
traces of PBS were removed using pipettes. The cells were re-suspended in 
50 µl of 1X reporter lysis buffer (diluted with dH2O from a 5X stock, Promega) 
and the cell suspension transferred to a microfuge tube. The tubes were 
vortexed for 10-15 seconds.  The lysates were clarified by centrifugation at 
13,000 x g for 5 mins and the supernatant saved in a fresh tube.  Samples 
were stored at –80ºC until luciferase/β-galactosidase assays were 
performed.  
96 
 
2.2.3.14 Luciferase assay 
  
Following transfection, promoter activity was determined by means of the 
luciferase assay. Firefly luciferase from the firefly Photinus pyralis, a 
monomeric 61 kDa protein, catalyses luciferin oxidation using ATP-Mg++ as a 
co-substrate. In this luminescent reaction, light is produced by converting the 
chemical energy of luciferin oxidation through an electron transition, forming 
the product molecule oxyluciferin.  In the conventional assay for luciferase, a 
flash of light is generated that decays rapidly after the enzyme and 
substrates are combined.   
 
Luciferase assay reagent was prepared by reconstituting luciferase assay 
substrate with luciferase assay buffer (Promega) and stored in aliquots 
protected from light at –70ºC. Sufficient time was allocated to allow the 
luciferase detection reagent to equilibrate to room temperature. A volume of 
20 µl of cell lysate was dispensed into individual wells in a white 96 well 
plate, along with 20 µl of 1X lysis buffer to act as a blank. Subsequently, in 
order to initiate enzyme activity, 100 µl of detection reagent was added to the 
lysate immediately prior to measuring, mixed by repetitive pipetting (3 times) 
ensuring no bubbles are produced. Then, light emission integrated over a 
period of 60 seconds, after a lag period of 10 seconds, was measured on a 
luminometer (Labsystems Luminoskan 391A). Luciferase activity levels were 
adjusted for transfection efficiencies, estimated using β-galactosidase assay.    
 
2.2.3.15 β-Galactosidase assay  
 
When measuring the effect of promoters or enhancers on gene expression, it 
is essential to include an internal control that will distinguish differences in 
the level of transcription from differences in the efficiency of transfection or in 
the preparation of extracts. This is best achieved by co-transfecting the cells 
with two plasmids: one that carries the construct under investigation, and 
another that constitutively expresses an activity that can be assayed in a 
separate experiment. An enzyme frequently used for this is E. coli β-
galactosidase (β-gal). This assay is a convenient method for assaying β-gal 
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activity in lysates prepared from cells transfected with β-gal reporter vectors, 
in this case pCMV-LacZ.  
 
The β-gal assay was performed using a sample from the same lysates 
assayed for luciferase activity. Cell extract (30 µl) was added to 3 µl 100X 
Mg solution, 66 µl 1X o-nitrophenyl-β-D-galactopuranoside (ONPG) and 201 
µl 0.1M sodium phosphate (all described in Appendix) and incubated at 37ºC 
for >30 mins or until a faint yellow colour developed. This yellow colour 
development is the result of hydrolysis of ONPG by β-gal to form o-
nitrophenyl. A reaction tube was included containing 1X lysis buffer instead 
of cell lysate in order to obtain a background reading. Reactions were 
terminated by addition of 500 µl 1M Na2CO3 (Appendix). Optical densities 
were read at 420 nm using a Shimadzu spectrophotometer over a linear 
range of 0.2-0.8. 
 
2.2.3.16 Flow cytometric analysis  
 
Flow cytometry may be defined as a technology to measure properties of 
cells as they move, or flow, in liquid suspension. Most flow cytometers can 
measure two kinds of light from cells, light scatter and fluorescence. Light 
scatter is the interaction of light and matter. All materials, including cells, will 
scatter light. In the flow cytometer, light scatter detectors are located 
opposite the laser (relative to the cell), and to one side of the laser, in-line 
with the fluid-flow/laser beam intersection. The measurements made by 
these detectors are called forward light scatter and side light scatter, 
respectively. Forward light scatter provides information on the relative size of 
individual cells, whereas side light scatter provides information on the relative 
granularity of individual cells. Fluorescence is the property of a molecule to 
absorb light of a particular wavelength and re-emit light of a longer 
wavelength. The wavelength change relates to an energy loss that takes 
place during the process.  
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The term apoptosis was originally coined to describe a controlled type of cell 
suicide that involved a series of systematic characteristic cellular events 
(Kerr, et al. 1972). Within a healthy cell the phospholipid, phosphatidylserine 
(PS), can be found bound to the inner-leaflet of the cell membrane. However 
apoptotic caspase activity leads to the externalisation of PS, flagging the cell 
for phagocytic engulfment (Fadok, et al. 1992). The human anticoagulant, 
annexin V, is a Ca2+-dependent phospholipid-binding protein that has a high 
affinity for PS and can be used to identify apoptotic cells by binding to PS. A 
fluorescent dye that binds to nucleotides and penetrates only damaged 
cellular membranes was used (vital dye). Intercalation complexes are formed 
by 7-Amino-actinomycin (7-AAD) with double-stranded DNA, which effect an 
amplification of the fluorescence.  
 
The Annexin-PE Apoptosis Detection Kit (Becton Dickinson) contains 
recombinant annexin V conjugated to the fluorochrome, phycoerythrin (PE) 
and the vital dye 7-AAD. Viable cells with intact membranes exclude 7-AAD, 
whereas the membranes of dead and damaged cells are permeable to 7-
AAD. Cells that stain positive for Annexin V-PE and negative for 7-AAD are 
undergoing apoptosis. Cells that stain positive for both Annexin V-PE and 7-
AAD are either in the end stage of apoptosis, are undergoing necrosis, or are 
already dead. Cells that stain negative for both Annexin V-PE and 7-AAD are 
alive and not undergoing measurable apoptosis. 
 
To perform the assay, cells were harvested and washed twice in ice-cold 
PBS. The cells were resuspended in 1X annexin-binding buffer at a 
concentration of ~1 X 106 cells/ml. A volume of 5µl of Annexin V-PE solution 
and 5 µl of 7-AAD solution were added to 100µl of cell suspension. The cells 
were incubated at room temperature for 15 mins in the dark and 400 µl of 1X 
annexin-binding buffer was then added. The samples were analysed within 
one hour by flow cytometry. 
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2.2.3.17 Stable Transfections 
 
Stable cells lines were established by transfection (as in Sections 2.2.3.8-
2.2.3.11) followed by selection with the appropriate drug 48 hours later. 
Within 2-4 weeks drug resistant cells grew out. In some cases, specific drug 
concentrations for selection in individual cell lines were known from previous 
publications/projects; otherwise, drug curves were prepared in advance of 
transfection to determine the minimum drug concentration to cause cell 
death. The pcDNA3 IB4 and pcDNA3 TLE1 IB4 stable cell pools were 
selected in 800 µg/ml G418. 
 
2.2.3.18 Establishment of mammalian cell line sensitivity for cell 
selection 
 
IB4 cells in exponential growth phase were seeded at a density of 1 x 105 
cells/ml, in media containing a range of puromycin concentrations ranging 
from 0, 0.25, 0.5 and 1 µg/ml. These cells were cultured for 10 days under 
standard conditions. Medium was changed every 3 days and cell viability 
was measured every day by trypan blue exclusion. The minimum 
concentration of puromycin which killed >95% of the cell pool after 10 days 
was determined, and this concentration was used for subsequent selection 
procedures for the selection of puromycin resistant cells 
 
2.2.3.19 Enrichment of live cell population using Ficoll 
 
The process of electroporation damages a cell line dependent portion of the 
cell population beyond repair. Ficoll gradient separation discriminates 
between live cells and dead cells based on a cell density gradient (Boyum 
1968), allowing enrichment for the live cell population post-transfection. Ficoll 
is a neutral, water soluble synthetic polymer of sucrose and epichlorohydrin 
possessing a high molecular weight. Ficoll has a density of 1.077 ± 0.001 
g/ml, this can be overlaid with media containing lymphocytes, and after rapid 
centrifugation at room temperature, with no aided acceleration or 
100 
 
deceleration, the sample becomes segregated according to density. Healthy 
lymphocytes are not dense enough to penetrate the Ficoll layer. The viable 
lymphocytes concentrate at the interface of the growth medium and 
separation fluid; but dead cells, which are more dense, pass through the 
medium and gather below the Ficoll layer. Ficoll is commercially available as 
a ready to use separation medium called LymphoprepTM. 
 
For each Ficoll purification, the transfected cells were collected by 
centrifugation at 100 x g for 5 mins and the supernatant was discarded 
completely. The cells were re-suspended in room-temperature supplemented 
RPMI to a final concentration of 1 x 107 cells/ 3 ml, before being transferred 
to a 12 ml centrifuge tube. The LymphoprepTM was then carefully under-laid 
below the cell suspension, and the sample was centrifuged at 800 x g for 15 
min at room temperature, ensuring that the brake and accelerator in the 
centrifuge have been disabled (use of a brake or accelerator can cause 
mixing at the interface). The culture medium remains above the Ficoll 
medium, the live lymphocytes gather at the interface and the non-viable cells 
and cellular debris are found either within the Ficoll medium or as a pellet at 
the bottom of the tube. The culture medium and lymphocyte layer above the 
Ficoll were gently transferred into a fresh container, using a pipette. The 
purified cells were collected by centrifugation at 100 x g for 5 mins and the 
supernatant was discarded completely. The cells were re-suspended in pre-
warmed supplemented RPMI, transferred to a culture flask and incubated at 
37ºC in 5% CO2. 
 
2.2.3.20 Enrichment of live cell population using Con A selection 
 
Concanavalin A (Con A) is a plant derived lectin that binds specifically to the 
α-mannosyl glycoprotein present on the membrane of healthy B lymphocytes 
(Thøger-Andersen and Junker 1994). Panning a cell population with fixed 
Con A allows discriminative selection between live and dead lymphocytes. 
Equal volumes of 100 µg/ml Con A (Appendix) and the activating agent 
EDAC (75 mg/ml appendix) were combined and added to a cell culture grade 
dish to allow coating of the lectin to the surface. This was incubated for 2 
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hours at room temperature followed by 1.5 hours incubation with constant 
gentle agitation (30 rpm). The dish was then washed gently three times in 
PBS, and left under PBS to maintain hydration of the lectin. To sterilise the 
surface the dish was then subjected to UV irradiation for 20 mins. At this 
stage the dish can be stored under PBS for 3 days at 4ºC.  
 
To begin panning, the Con A coated dish was blocked by washing with room 
temperature supplemented RPMI medium. The cells were then pipetted onto 
the dish, ensuring even distribution of the sample on the coated surface, and 
incubated for 20 mins at 37ºC in 5% CO2, followed by 10 mins incubation at 
room temperature. The supernatant was then carefully removed and the dish 
was washed twice with PBS. To acquire the bound cells, pre-warmed 
medium was flushed gently against the Con A coated surface using a 
pipette. The purified cells were collected by centrifugation at 100 x g for 5 
mins and the supernatant was discarded. The cells were re-suspended in 
pre-warmed supplemented RPMI, transferred to a culture flask and 
incubated at 37ºC in 5% CO2. 
 
2.2.3.21 Measurement of Cell Proliferation 
 
The CellTiter 96 Aqueous One Solution cell proliferation assay is a 
colorimetric method for determining the activity of the mitochondria in active 
cells; this can be compared to control cells to determine relative cell 
proliferation. The assay is based on the addition of a reagent containing a 
novel tetrazolium compound, 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl) -2-(4-sulfophenyl)-2H-tetrazolium (MTS) and an 
electron-coupling reagent, phenazine ethosulphate (PES) to cells in culture. 
The MTS tetrazolium compound is bio-reduced by cells into a coloured 
formazon product that is soluble in cell culture media. This conversion is 
thought to be facilitated by NADPH or NADH produced by dehydrogenase 
enzymes in metabolically active cells (Berridge and Tan 1993). The quantity 
of formazon product, as measured by the amount of absorbance at a 
wavelength of 490 nm, is directly proportional to the number of living cells in 
culture. 
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To perform the assay, the CellTiter 96 Aqueous One Solution was thawed 
from frozen in a 37ºC water bath. Subsequently, 20 µl of reagent was added 
directly to 100 µl of cells in culture media (in triplicate) in 96-well plates. The 
plates were incubated at 37ºC/5 % CO2 for 4 hour and absorbance at 495 
nm was measured using a Tecan Saffire II 96-well plate reader. Triplicate 
control wells containing media alone were prepared to correct for 
background absorbance. 
 
2.2.3.22 Immunostaining 
 
This technique allows visualisation of the target protein of interest in situ 
using specific antibody/antigen interactions by either direct or indirect 
labelling. In this study, an un-labelled antibody specific for the target was 
used in co-ordination with a HRP-labelled secondary antibody against the 
primary. Immunostaining involves the fixation and permeabilsation of cells to 
a non-interfering solid support surface. Fixation is a key step ensuring the 
cells are stabilized on the support against further staining procedures, whilst 
preserving the cells in their native state. Fixation can be performed by using 
either aldehydes such as formalin to cause cross linkage of proteins or an 
alcohol solvent such as isopropanol to fix the mammalian cells by 
coagulating surface proteins. Each method binds the cells to the support 
surface. 
 
The cells were pelleted by centrifugation at 100 x g for 5 mins, washed with 5 
ml of PBS (Appendix) and centrifuged at 100 x g for 5 mins. The cell pellet 
was re-suspended in 20 µl of PBS and applied to a glass microscope slide, 
then fixed in ice-cold 100% (v/v) isopropanol for 5 mins, allowed to air dry, 
and subsequently rehydrated in PBS for 10 mins. The cells were incubated in 
5% blocking buffer (Appendix) with constant gentle agitation for 1 hour at 
room temperature. The cells were then incubated in primary antibody again 
with gentle agitation for 2 hours at room temperature followed by overnight 
incubation at 4ºC. The slide was washed three times at 5 mins intervals with 
1 ml PBS. The secondary HRP conjugated antibody was then incubated on 
the slide for 1 hour with gentle agitation at room temperature. The cells were 
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washed again as above before adding 3,3’,5,5’-tetramethylbenzidine (TMB, 
Sigma), a substrate cleaved by HRP resulting in a coloured product. This 
allowed the probed slide to be examined under brightfield microscopy using 
an Olympus DP-50 with a camera and StudioLife software (Olympus Optical 
Company). 
 
2.2.4 RNA Analysis 
 
2.2.4.1 RNase-free environment 
 
Because RNA is easily degraded by ubiquitous RNases, standard 
procedures were employed to avoid this potential hazard (Sambrook, et al. 
1989). Prior to working with RNA, any apparatus or surfaces to be used were 
treated to remove RNase. The apparatus/surface was washed in detergent 
and rinsed well in DEPC-treated H2O, then in 100% (v/v) ethanol and finally 
allowed to air dry. Any apparatus to be used were also immersed in a 3% 
(v/v) solution of hydrogen peroxide (Sigma-Aldrich) for 15 mins, and were 
then rinsed thoroughly in DEPC treated upH2O and allowed to dry.  As hands 
are a major source of RNase contamination, gloves were used at all times 
and changed frequently. 
 
2.2.4.2 RNA analysis by gel electrophoresis 
 
In order to examine the quality of RNA, isolated samples were run on 1.5% 
(w/v) agarose gels. The appropriate amount of agarose was dissolved in 
DEPC-treated H2O and prepared according to Appendix. The RNA samples 
(1 µl of 1 ug/ul RNA) were prepared for electrophoresis by adding 3 µl of 
RNA sample buffer (Appendix) and made up to 15 µl in DEPC-treated H2O. 
The samples were heated to 65ºC for 10 mins prior to loading on the gel.  
The gel was run in 1X TAE as described in section 2.2.1.16.  As ethidium 
bromide is included in the RNA sample buffer, the gels did not require further 
staining and could be visualised directly on a UV trans-illuminator.   
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2.2.4.3 RNA extraction from cultured cells 
 
Prior to RNA isolation the condition of cells was reviewed by phase contrast 
microscopy.  A cell count was performed as described in Section 2.2.3.4.  
 
2.2.4.4 RNA extraction using Tri-reagent   
 
Cells grown in suspension were centrifuged at 100 x g for 5 mins, washed 
once in PBS and the cells were lysed by repeat pipetting in Tri Reagent 
(Sigma-Aldrich). A volume of 1 ml of Tri-reagent was used per 1 X 107 
cultured cells.  The lysate was left at room temperature for 5 mins after which 
time the procedure could be halted by storing samples at –80ºC.  
Phase separation was achieved by adding 200 µl of chloroform per 1 ml of 
lysate.  The samples were covered and shaken gently but thoroughly for 15 
seconds until completely emulsified.  Samples were incubated at room 
temperature for 15 mins.  The resulting mixture was centrifuged at 13,000 x g 
for 20 mins at 4ºC.  During centrifugation the mixture separated according to 
the density gradient into a lower red, phenol-chloroform phase, an interphase 
and a colourless upper aqueous phase. The aqueous phase, which 
contained the RNA, was removed to a fresh tube and RNA was precipitated 
by addition of 500 µl of ice-cold isopropanol per ml of Tri-reagent used 
initially. The samples were incubated overnight at -20ºC, then centrifuged at 
13,000 x g for 15 mins at 4ºC. The resulting RNA pellet was washed using 1 
ml of 75% (v/v) ethanol by inverting the tube 5 times.  The pellets were then 
centrifuged at 13,000 x g for 5 mins at 4ºC, and the 75% (v/v) ethanol was 
aspirated.  Pellets were air dried and dissolved in DEPC treated upH2O.  The 
resulting RNA preparation was heated at 60ºC and mixed gently to ensure a 
homogeneous solution prior to aliquoting. An aliquot was removed for 
spectrophotometric (Section 2.2.1.15) and gel electrophoretic analysis 
(Section 2.2.1.16) and the remainder of the purified RNA was stored at – 
80ºC.  
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2.2.4.5 Total RNA isolation from cells using QIAgen RNeasy™ kit  
 
RNA was extracted from small numbers of cultured cells (<5 X 105) using an 
RNeasy kit (QIAgen) according to the manufacturer’s protocol (RNeasy Mini 
Handbook, 2006). An aliquot of purified RNA was removed for 
spectrophotometric (Section 2.2.1.15) and gel electrophoretic analysis 
(Section 2.2.1.16) prior to reverse transcription PCR (RT-PCR). 
 
2.2.4.6 Quantification of mRNA from cultured cells by RT-qPCR 
 
The quantification of mRNA purified from cultured cells was performed in a 
three-step procedure.  In the first step, RNA was treated with DNase to 
remove any possible residual genomic or vector DNA, this process was 
stopped by heat inactivation of the DNase enzyme. The cDNA was then 
prepared from DNase treated RNA by RT-PCR with random hexamers 
serving as primers.  During the third step, cDNA was amplified by real time 
quantitative PCR (qPCR). RT-qPCR is increasingly being adopted for RNA 
quantification based on its ability to monitor with a high degree of sensitivity, 
the amount of PCR product present at every cycle (i.e. in real time). This 
method shows accuracy over a wide linear range, as opposed to the 
endpoint detection by conventional PCR methods, thus allowing the real-time 
progress of the reaction to be viewed. Data is measured at the exponential 
phase of the PCR reaction, the real-time analysis method is based on the 
detection and quantification of a fluorescent reporter dye present in the 
reaction that gives a proportional response to the amount of product 
accumulated in a reaction. 
 
2.2.4.7 Dnase treatment of mRNA 
 
The RNA sample for analysis was digested with 1 µl 10x DNase Buffer and 1 
µl RNase-free DNase I (Sigma-Aldrich) and incubated for 15 mins at 37ºC. 1 
µl DNase stop solution (Sigma-Aldrich) was added to the reaction mixture 
and was incubated for a further 10 mins at 70ºC to denature the DNase 
enzyme. The RNA could then be synthesized to cDNA. 
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2.2.4.8 Moloney Murine Leukemia Virus (M-MLV) reverse transcriptase 
 
In this process mRNA was transcribed into cDNA using Moloney Murine 
Leukemia Virus (M-MLV) reverse transcriptase.  Initially, 2 µl of random 
hexamers was added to 2 µg DNase treated RNA and the volume brought up 
to 10 µl with DEPC H2O. The mixture was heated to 70ºC for 5 mins, to de-
stabilise secondary mRNA structures, and then placed on ice for 5 mins. 
Then, the RT reactants were added in the order listed in Table  2.10.  
 
Table 2.10 MMLV RT reactants  
Component Volume 
Reverse Transcriptase buffer (5X) 
dNTP mix (20mM) 
MgCl2 (25mM) 
BSA (4µg/µl) 
DEPC H2O  
RNasin ribonuclease inhibitor 
M-MLV reverse transcriptase (200U/µl) 
8µl 
1µl 
4µl 
1µl 
      13µl 
2µl 
  1µl 
    
The reactions were placed in a thermocycler at 37ºC for 1 hour and 95ºC for 
2 mins followed by storage at 4ºC. 
 
2.2.4.9 Real time relative PCR (RT-qPCR) 
 
cDNA generated by RT was quantified by real time PCR using QuantiTect® 
SYBR® Green PCR kit. In this study SYBR green was utilised as the method 
of choice as it is the most straightforward and least expensive method, 
making it the first choice for high throughput samples. SYBR green binds 
only to double stranded DNA by intercalating between two base pairs and 
only actively fluoresces upon binding to DNA. As SYBR green is not gene- or 
product-specific the assay must be optimised to ensure that only one product 
is being generated (dissociation analysis) and that it is the correct target 
amplicon. To normalise the optical system involved in real time analysis, 
ROX, a passive dye, is incorporated into the SYBR mastermix.  
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The QuantiTect® kit provided a SYBR® Green master mix that contained Taq 
polymerase, dNTPs, reaction buffer and ROX dye. Real time PCR reactions 
were set up as follows: 
 
Table 2.11 Real Time PCR Reactants  
 
Component Volume 
cDNA 2µl 
Forward primer  1µl 
Reverse  primer  1µl 
UNG 0.25µl 
nuclease free H2O 8.25µl 
SYBR master mix 12.5µl 
Total  25μl 
  
 
Quantification of cDNA target was normalised for differences across 
experiments/samples using an endogenous control as an active reference 
(TBP). The PCR reaction mix was prepared for each sample (in triplicate) by 
addition of the reagents listed in Table 2.11 to the individual wells of a 96-
well reaction plate (Applied Biosystems) followed by the addition of 2 µl of 
cDNA to give a total reaction volume of 25 µl. Samples were quantified using 
the ABI 7500 Prism detector (Applied Biosystems) under the following 
thermo-cycling conditions: 
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Table 2.12 Real Time PCR Cycling Parameters 
 
Stage Cycles Temperature Time 
1 1 50ºC 2 mins 
2 1 95ºC 15 mins 
3 35 
95ºC 20 Seconds 
XºC 30 Seconds 
72ºC 37 seconds 
4 Dissociation 60ºC - 95ºC temperature rises 1ºC each 
step. Each step held for 5 seconds. 
 
During amplification, the ABI Prism sequence detector monitored real-time 
PCR amplification by quantitatively analysing fluorescence emissions. The 
reporter dye (SYBR) signal was measured against the passive reference dye 
(ROX) signal to normalise for non-PCR-related fluorescence fluctuations 
occurring from well to well. The threshold cycle represented the refraction 
cycle number at which a positive amplification reaction was measured and 
was set at 10 times the standard deviation of the mean baseline emission 
calculated for PCR cycles 3 to 15. The results were analysed according to 
the Comparative CT method (∆∆CT) as described by Livak and Schmittgen 
(2001). 
 
2.2.5 Protein Analysis 
 
2.2.5.1 Preparation of cellular protein 
 
Proteins were isolated from suspension cells for analysis by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) and by western blotting. 
Prior to isolation, cells were washed once in PBS. Suspension cells were 
centrifuged at 100 x g for 5 mins and the supernatant removed. Following 
this, 10 ml Ice-cold PBS was added; the cells were centrifuged again at 100 
x g and all of the supernatant removed. The cells were re-suspended in ice-
cold suspension buffer (Appendix) using 200 µl of suspension buffer for 
every 1 X 107 cells and the cell suspension transferred to a microfuge tube. 
An equal volume of 2 X SDS gel loading buffer (Appendix) was immediately 
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added to the cell suspension, after which the sample became extremely 
viscous. The sample was then subjected to sonication for 30 seconds at 6 
second 40% Amp pulses (using a Vibra Cell or Branson Sonicator) to shear 
the DNA.  The lysate was clarified by centrifugation at 13,000 x g for 10 mins 
at room temperature. The supernatant was aliquoted and stored at –20ºC 
until required for analysis.   
 
2.2.5.2 SDS-polyacrylamide gel electrophoresis of proteins 
 
SDS-polyacrylamide gel electrophoresis resolves cellular proteins based 
solely on their electrophoretic mobility. During polyacrylamide gel 
electrophoresis (PAGE), proteins are driven by an applied current through a 
mesh of cross-linked polyacrylamide gel. PAGE is carried out in the 
presence of the negatively charged detergent sodium dodecylsulphate 
(SDS), which binds to all types of protein molecules, denaturing the protein 
to its primary structure. Electrostatic repulsion between the bound SDS 
molecules causes the proteins to unfold into a similar rod-like shape, 
removing secondary and tertiary structure as a factor in separation. As the 
amount of SDS bound is proportional to the molecular weight of the 
polypeptide and is sequence independent, SDS-polypeptide complexes 
migrate through polyacrylamide gels in accordance with the size of the 
polypeptide. 
 
2.2.5.3 Preparation of SDS-polyacrylamide gels 
 
SDS-PAGE was performed using resolving gels between 7.5 - 10% (v/v) and 
5% (v/v) stacking polyacrylamide gels prepared (Appendix). An ATTO protein 
gel electrophoresis system was used in this study. Glass plates were washed 
with detergent, rinsed first with tap water, then with dH2O and finally wiped in 
one direction with tissue soaked in 100% (v/v) ethanol. The gasket was 
placed around the ridged plate; the plates were assembled and secured with 
clamps. The resolving gel was then poured to within 2 cm of the top of the 
larger plate and overlaid with 100% (v/v) ethanol. When set, the ethanol was 
removed and the stacking gel was poured. A clean comb that had been 
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wiped in 100% (v/v) ethanol was inserted and the gel was allowed to 
polymerise for at least 20 mins. The electrophoresis tank was filled with 1X 
Tris-glycine running buffer (Appendix) to a level of about 5 cm deep. After 
polymerisation, the gaskets and clamps were removed and the pre-poured 
gels were lowered into the buffer at an angle to exclude air bubbles from the 
gel-buffer interface.  The tank was completely filled with 1X running buffer 
and the comb removed from the gel. Un-polymerised gel was removed by 
gently rinsing the wells with 1X running buffer and the wells were then 
straightened using a loading tip. The gel plates were fixed firmly in place with 
the pressure plates. The chamber formed by the inner plates (notched plate 
facing inwards) was filled with 1X running Buffer, the samples were loaded 
and the electrodes attached. The gels were electrophoresed at a constant 
current of 30 mA per gel until the blue dye front had cleared the bottom of the 
gel. When complete the plates were removed, separated and the gel was 
placed in transfer buffer (Appendix) prior to Western blotting.  
 
2.2.5.4 Western Blotting 
 
During western blotting, electrophoretically separated proteins were 
transferred from the polyacrylamide gel to a solid support, usually a 
nitrocellulose membrane, and probed with antibodies that reacted specifically 
with antigenic epitopes displayed by the target protein attached to the solid 
support. The bound antibody, unless conjugated, was detected by a 
secondary immunological reagent, conjugated to either the alkaline 
phosphatase (AP) or HRP enzyme for detection. 
 
2.2.5.5 Transfer of resolved proteins to nitrocellulose membrane 
 
Following gel electrophoresis, gels were equilibrated in transfer buffer 
(Appendix) for at least 15 mins. Equilibration facilitated the removal of 
electrophoresis salts and detergents. Salts, if not removed, increase the 
conductivity of the transfer and the amount of heat generated during transfer. 
Nitrocellulose membrane was cut to the dimensions of the gel, along with 6 
pieces of 3 MM filter paper that were required for the gel/membrane 
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sandwich. Protein transfer was carried out on the Bio-Rad Trans-Blot® SD 
semi-dry electrophoretic transfer cell. A pre-soaked sheet of filter paper was 
placed onto the platinum anode. A pipette was rolled over the surface of the 
filter paper to exclude all air bubbles. This step was repeated with two more 
sheets of filter paper.  Then, the pre-wetted blotting membrane was placed 
on top of the filter paper and all bubbles rolled out. The equilibrated gel was 
carefully placed on top of the nitrocellulose membrane, aligning the gel on 
the centre of the membrane. Any air bubbles were again rolled out. Another 
3 sheets of pre-wetted filter were placed on top of the gel, with care taken to 
remove air bubbles. The cathode was placed on top of the stack and the 
safety cover replaced on the transfer unit. Gels were transferred for 20 mins 
at 17 V.    
 
2.2.5.6 Staining of proteins immobilized on nitrocellulose membranes 
 
To visually confirm uniform transfer of protein to the nitrocellulose membrane 
Ponceau S stain was applied. Ponceau S is a negative stain, which binds to 
positively charged amino acid groups of proteins. It also binds non-covalently 
to non-polar regions of proteins. Transferred protein was detected as red 
bands on a white background. This staining technique is reversible to allow 
further immunological analysis. Following electrophoretic transfer, the 
nitrocellulose membrane was immersed in 20 ml Ponceau S solution (Sigma-
Aldrich) and stained for 5 mins with constant agitation. After proteins were 
visualised, the membrane was washed in several changes of dH2O until all 
the stain had been washed away. The membrane was then used for 
immunological probing.   
 
2.2.5.7 Immunological probing method 1 – manual probing 
 
Following Ponceau S staining, the membrane was incubated in 5% blocking 
buffer (Appendix) for 2.5 hours at room temperature followed by incubation 
with the appropriate primary antibody (diluted in blocking buffer, see Table 
2.13) at 4ºC overnight.   
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Table 2.13 Incubation Conditions for Antibodies Used in Western 
Blotting (Manual Probing Method) 
 
Primary 
Antibody Name 
Dilution 
Secondary 
Antibody 
Dilution 
In Blocking 
Buffer 
In Blocking 
Buffer 
Anti-β-actin Anti-actin AC-15 1/15,000 AP-conjugated Anti-mouse IgG 1/20,000 
Anti-EBNA2 PE2 1/200 AP-Conjugated Anti-Mouse IgG  1/5,000 
     
Anti-TLE1 Rbt. Poly. to TLE1: 
ab15587 1/200     
 
After overnight incubation, the membrane was washed three times in TBS-T 
(0.1% (v/v) Tween-20 in TBS [Appendix]) for 15 mins. The filter was then 
incubated with the appropriate secondary antibody (Table 2.13 for 1 hour 30 
mins at room temperature, followed by three 15 min washes in TBS-T. All of 
the above incubations were carried out with constant agitation.  The 
membrane was then placed in a clean container and colorimetric detection of 
the conjugated antibodies was performed by immersing the membrane in 
either 5-Bromo-4-chloro-3-indolyl phosphate/Nitro Blue Tetrazolium 
(BCIP/NBT, Sigma) for AP conjugated antibodies or 3,3’,5,5’-
tetramethylbenzidine (TMB, Sigma) for HRP antibody conjugates. When 
incubated with AP or HRP substrates, bound enzyme catalysed the 
production of a coloured product from the substrate that was easily 
observable.  The membrane was then rinsed in distilled water to stop the 
reaction and photographed.  
 
2.2.5.8 Immunological probing method 2 – SNAP i.d. TM 
 
Following Ponceau S staining, the membrane was applied to an incubation 
chamber according to manufacturer’s guidelines. The SNAP incubation 
chambers were hydrated with dH2O, and the nitrocellulose membrane was 
placed face down into the chamber, any air bubbles were removed by 
running a roller over the blot. A support was placed at the reverse of the 
membrane and the chamber was sealed; again, air bubbles were expelled 
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using the roller. This device was then placed within the SNAP i.d.TM system. 
The nitrocellulose support was then evenly covered with 0.2% blocking buffer 
(Appendix) ensuring the liquid was applied in an ‘s’ shaped manner to 
prevent pressure against any one area of the blot, which may cause 
displacement of bound antibody. After blocking a vacuum was applied to the 
well pulling the blocking buffer through the membrane. The primary antibody 
was then added to the chamber and incubated for 10-15 mins at room 
temperature. The antibody concentrations used are as laid out below in 
Table 2.14. 
 
Table 2.14 Incubation Conditions for Antibodies Used in Western 
Blotting SNAP i.d. Method 
 
Primary 
Antibody 
Incubation Dilution 
In 
Blocking 
Buffer 
Secondary 
Antibody 
Incubation Dilution 
In 
Blocking 
Buffer 
Time Repeats Time Repeats 
Anti-β-
actin 10mins 1 1/15,000 
AP-conjugated 
Anti-mouse IgG 10mins 1 1/20,000 
Anti-
TLE1 15mins 2 1/500 
Goat anti-rabbit            
IgG-HRP: sc-
2004 
10mins 1 1/500 
 
After the indicated incubation period in Table 2.14, a vacuum was once again 
applied, clearing the well of the primary antibody by pulling it through the 
membrane. The membrane was then washed three times in 10 ml TBS-T 
(0.1 % (v/v) Tween-20 in TBS [Appendix]). The blot was then incubated for 
10mins with the appropriate secondary antibody before applying the vacuum 
to the chamber to remove all liquid from the membrane. Again the membrane 
was washed three times in 10 ml TBS-T. The membrane was then placed in 
a clean container and developed using the colorimetric method described in 
section 2.5.7.  
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2.2.5.9 TLE1 Immunological dual probing method 
 
To detect the nuclear repressor protein TLE1 a method combing classic 
manual probing and the utilisation of the SNAP i.d.TM system was used. The 
membrane was treated according to the manual method 2.5.7, with 2.5 hour 
incubation in 5% blocking buffer (Appendix). Primary antibody incubation 
was described in Table 2.14. After overnight incubation in primary antibody 
the membrane was fitted to the incubation well holder as described in 2.5.8 
for probing using the SNAP i.d. method. The SNAP method was then 
followed repeating the primary antibody application and continuing with 
washings and secondary antibody probing as described in section 2.5.8. The 
membrane was then placed in a clean container and developed using the 
colorimetric method described in section 2.5.7.  
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Chapter 3: Regulation of the Bcl-2 family 
member, Bfl-1, in EBV 
infected B Lymphocytes. 
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3.1 Introduction 
 
Type A EBV and type B EBV differ significantly in their EBNA2 sequence. 
Whilst sequence variation in the EBNA3s and EBNA-LP exists, the difference 
in biological function between the two strains has been attributed to their 
differing EBNA2 isoforms (Cohen, et al. 1989). The two EBNA2 proteins 
share only 55% homology and the most conserved parts of the EBNA2 
protein are the regions known to bind CBF1 and the activation domain 
(Lucchesi, et al. 2008). CBF1 is the key transcription factor associated with 
EBNA2-led gene regulation, although EBNA2 can also associate with Spi-1 
and members of the Ets transcription family (Zimber-Strobl and Strobl 2001). 
It has been shown that the type A strain is far more efficient at B cell 
immortalisation than the type B strain (Rickinson, et al. 1987). To date it has 
been found that EBNA2A is a more efficient trans-activator of CXCR7 and 
Runx3, both genes important in LCL proliferation (Lucchesi, et al. 2008). 
 
Previous work in the laboratory established that the anti-apoptotic bcl-2-
family member bfl-1 is transcriptionally up-regulated by EBV and provides 
the cell with a survival advantage (D'Souza, et al. 2000). Bfl-1 (A1) is a Bcl-2 
family member protein that is comprised of 175 aa. Bfl-1 is classed as an 
anti-apoptotic member of the Bcl-2 family, as it shares the Bcl-2 homology 
domains BH1, BH2 and BH3 (D'Sa-Eipper and Chinnadurai 1998). Functions 
of Bfl-1 include suppression of p53-mediated apoptosis, shielding cells from 
growth factor deprivation induced apoptosis and it also exhibits functionality 
in both cell proliferation and transforming processes (D'Souza, et al. 2000, 
D'Sa-Eipper and Chinnadurai 1998, D'Sa-Eipper, et al. 1996). The bfl-1 gene 
has, in recent years, been acknowledged as a relevant therapeutic target 
due to molecular profiling studies that have identified bfl-1 as up-regulated in 
a gene profile for a diffuse large B cell lymphoma subtype ‘OxPhos’ and in 
primary mediastinal large B cell lymphoma (Feuerhake, et al. 2005; Monti, et 
al. 2005; Dave, et al. 2006). bfl-1 has been shown to be a direct nuclear 
factor-kappa B (NF-κB)  target gene that can suppress apoptosis from a 
number of stimuli including TNFα, Anti-CD95 and chemotherapeutic drugs 
(Wang, et al. 1999; Werner, et al. 2002; Zong, et al. 1999). Brien et al 
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demonstrated that down-regulation of bfl-1 in malignant B cells increases cell 
sensitivity to Anti-CD20 antibodies and to chemotherapeutic drugs such as 
doxorubicin, fludarabine and Cisplatin (Brien, et al. 2007). Previous studies 
have indicated that bfl-1 is an EBV target that can be independently up-
regulated by both EBNA2 and LMP1 (D'Souza, et al. 2004; D'Souza, et al. 
2000). 
 
D’Souza et al have previously determined, using a system in which the 
expression of LMP-1 was inducibly regulated by tetracycline, that LMP-1 
expression alone can up-regulate transcription of the bfl-1 gene in a B cell 
line. Further studies revealed that LMP-1 also trans-activates the bfl-1 
promoter and that the NF-κB signaling pathway may mediate this interaction 
(D'Souza, Rowe and Walls 2000). Furthermore, Pegman et al determined 
that bfl-1 was independently trans-activated by EBNA2 and that this up-
regulation involved the nuclear binding protein, CBF1. Removal of either of 
the EBV latent proteins LMP1 or EBNA2 did not lead to down-regulation of 
bfl-1 expression; however, inhibition of both proteins from the cellular 
environment led to a significant reduction in bfl-1 expression within the cell 
(Pegman, et al. 2006). Due to the body of evidence implicating EBNA2 
variation as a key difference between the two strains, a comparative study of 
the functional activity of the two EBNA2 isoforms was performed in an 
attempt to determine if bfl-1 regulation may be a consequence of the 
divergent biological functions of EBNA2A/EBNA2B. The trans-activation 
capabilities of EBNA2A and EBNA2B with respect to the bfl-1 promoter were 
therefore directly examined. In addition, aspects of the mechanism of bfl-1 
promoter trans-activation by EBNA2 were also investigated. 
 
In this chapter, results are presented that indicate the following; (i) the Notch 
responsive vector pGa981.6 is more responsive to EBNA2B expression than 
EBNA2A, (ii) both EBNA2 isolates trans-activate the bfl-1 promoter to a 
similar degree, (iii) mutation of a consensus CBF1-like binding site in the bfl-
1 promoter consistently prevented EBNA2-trans-activation of the bfl-1 
promoter in EBV-positive BL and LCL backgrounds, (iv) mutating both the 
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CBF1-binding site and a NF-κB-like motif of the bfl-1 promoter leads to 
almost complete inhibition of bfl-1 promoter trans-activation in an EBV-
positive cell line. 
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3.2 Results 
 
3.2.1 Examination of potential functional differences in EBNA2A 
and EBNA2B isolates  
 
It has been firmly established that type A EBNA2 can directly up-regulate bfl-
1 in B cell lines. Bearing in mind that trans-activation of bfl-1 is such an 
important event in the B cell immortalisation process, this study then set out 
to investigate if there was a significant functional difference between the 
capabilities of EBNA2A and EBNA2B, with regards to the transcriptional 
regulation of bfl-1. The objectives in this section were: (i) To characterise two 
mammalian expression vectors containing the different isolates of EBNA2, 
and to confirm the expression of each EBNA2 isotype at the correct size and 
at a similar expression level by Western blotting, (ii) To determine whether 
the Notch-responsive promoter construct, pGa981.6, is preferentially 
regulated by either type of EBNA2 in an EBV-negative BL and (iii) to 
examine the bfl-1 promoter activity in response to EBNA2A and EBNA2B 
expression, in an EBV-negative BL cell line. 
 
Two different EBNA2 expression vectors containing either the EBNA2A open 
reading frame (ORF) (pSG5-EBNA2A) or the EBNA2B ORF (SV-EB2NA2) 
were obtained. PSG5-EBNA2 consists of wild type B95-8 EBNA2 coding 
sequence cloned into the pSG5 expression vector (Ling, et al. 1993) (Figure 
3.1A). SV-pEB2NA2 consists of the EBNA2 coding region from the digested 
EBV BamHI D1 fragment isolated from the AG876 cell line, sub-cloned into 
pSG5 (Wang, et al. 1990). For clarity, the EBNA2B expressing vector SV-
EB2NA2 will be referred to as pSG5-EBNA2B in the remainder of this study. 
These constructs were characterised using restriction digest analysis (Figure 
3.1B). In order to verify the expression of EBNA2A and EBNA2B protein from 
these constructs, the EBV-negative cell line DG75 was transiently 
transfected with pSG5-EBNA2A or pSG5-EBNA2B, or the corresponding 
empty vector (pSG5). Total protein was prepared 48 hours post-transfection 
and the presence of EBNA2A and EBNA2B at the expected size was 
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confirmed by Western blotting (Figure 3.1C). Protein extracts from cell lines 
known to express each EBNA2 isoform were used as positive controls. The 
LCL IB4 contains the type A EBV strain and expresses the EBNA2A protein; 
however, the EBV-positive BL, AG876, carries the type B strain and thus 
expresses the EBNA2B protein (For summary of cell lines see Table 2.1).  
 
Figure 3.1: Characterisation of type A and B EBNA2 expression 
vectors. 
 (A) Schematic circular map of the pSG5 expression vector. Highlighted is the 
region into which the EBNA2A or EBNA2B ORF was sub-cloned. The human 
Simian Virus 40 immediate-early promoter (pSV40) and origin of replication (SV40 
ori) are capable of supporting high-level expression in mammalian cells. The vector 
also contains the ampicillin resistance gene to facilitate selection in bacterial cells. 
(B) Restriction analysis of pSG5, pSG5-EBNA2A and pSG5-EBNA2B using Hinf I 
enzyme. pSG5 (lane 2) yields signature fragments at 1359bp, 1381bp, 517bp, 
396bp and a number of very low molecular weight fragments upon digestion with 
Hinf I. pSG5-EBNA2A (lane 3) encompasses additional fragments at 906bp and 
~200bp. pSG5-EBNA2B (lane 4) contains the key fragments of pSG5 in addition to 
fragments at ~700bp and ~200bp. A 1kb ladder is seen in lane 1. (C) The 
expression of EBNA2 from the constructs was confirmed by transient transfection in 
the EBV-negative cell line DG75. DG75 cells were transfected with either 7µg of 
pSG5-EBNA2A, or 7µg of pSG5-EBNA2B, samples were harvested 48 hours post-
transfection and were detected in the upper panel, using PE2 (Dako, M7004) and 
normalised in the lower panel for the endogenous loading control β-Actin. The 
empty pSG5 expression vector was used as a control. Protein extracts from the cell 
lines IB4 and AG876 were used as positive controls for EBNA2A and EBNA2B 
respectively. 
A B 
C 
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The two EBNA2-expressing plasmids were characterised by restriction digest 
analysis using Hinf I which cuts the construct at several sites, giving a 
distinct fragment pattern that can discriminate between the two EBNA2 
expressing vectors (Figure 3.1B). The EBNA2A construct yields a unique 
band at 906bp which is not present in the empty vector or the EBNA2B 
expression vector. Likewise upon digestion the EBNA2B expression vector 
yields an identifying fragment at approximately 700bp. It can be seen that the 
EBNA2A and EBNA2B proteins were expressed at the anticipated sizes, 
EBNA2A (~86kDA) and EBNA2B (~76kDA) in accordance with the control for 
each protein (Figure 3.1C). Western blot analysis also revealed that both 
vectors expressed EBNA2 at the expected sizes; however, a slightly more 
intense band was observed for EBNA2B. 
 
3.2.2 Differential effect of EBNA2A and EBNA2B isolates on Notch 
responsive promoter activity in the DG75 cell line. 
 
To compare the trans-activation efficiency of the two types of EBNA2, a 
Notch responsive construct, pGa981.6 was employed. pGa981.6 is an 
established luciferase reporter vector that is sensitive to CBF1-driven activity. 
The EBV TP1 Promoter has two CBF1 binding sites that drive its activity. A 
50bp oligonucleotide harbouring both CBF1 binding sites of the EBV TP1 
promoter had been sub-cloned as a hexamer into the plasmid pGa50-7 
(Minoguchi, et al. 1997), and EBNA2 is a well established trans-activator of 
this Notch responsive reporter construct. To compare the trans-activation 
capabilities of EBNA2A and EBNA2B, DG75 was co-transfected with 
increasing quantities of either of the two EBNA2 expression plasmids, pSG5-
EBNA2A and pSG5-EBNA2B (Table 2.5), together with 2 µg pGa981.6 and 
the pCMV-LacZ reporter construct. Forty-eight hours after transfection, cells 
were harvested (Section 2.2.3.13), and reporter enzyme activities (luciferase 
and β-galactosidase) were measured (Sections 2.2.3.14 and 2.2.3.15).  
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Figure 3.2: Both EBNA2 types trans-activate pGa981.6 in a dose 
dependent manner.  
DG75 cells were co-transfected with 2µg pGa981.6 Luc and 2µg pCMV LacZ, along 
with increasing quantities of either the EBNA2A or EBNA2B expression vector. The 
effect of EBNA2 expression on the Notch responsive construct was monitored by 
luciferase assay and β-gal normalisation 48 hours post-transfection. Fold 
differences were calculated relative to pGa981.6 levels in triplicate experiments; 
arbitrarily assigned a value of 1. (Data are mean ±SD). 
 
It can be seen that both EBNA2A and EBNA2B expression in DG75 results 
in a dose responsive trans-activation of the Notch receptive vector pGa981.6 
(Figure 3.2). Furthermore, a more potent level of trans-activation was 
observed due to the expression of EBNA2B in contrast to the expression of 
EBNA2A. 
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3.2.3 Trans-activation of the bfl-1 promoter by EBNA2A and 
EBNA2B in the DG75 cell line. 
 
A similar strategy was used in order to investigate EBNA2A/EBNA2B trans-
activation of the bfl-1 promoter. DG75 cells were co-transfected with 
increasing concentrations of the individual EBNA2 expression plasmids, 
(Table 2.5), together with the reporter construct -1374/+81 bfl-1 Luc (this 
plasmid contains the -1374 to +81 nucleotide sequence flanking the 
transcription start site of the bfl-1 gene joined to the luciferase-coding gene). 
Cells were harvested 48 hours post-transfection and luciferase values were 
determined and normalised for β-galactosidase expression as described.  
 
Figure 3.3: Both EBNA2A and EBNA2B trans-activate the bfl-1 promoter 
in a dose dependent manner.  
DG75 cells were co-transfected with 2 µg bfl-1 Luc and 2µg pCMV LacZ, along with 
increasing quantities of either the EBNA2A or EBNA2B expression vector. The cells 
were harvested 48 hours post-transfection and the effect of EBNA2 expression on 
the bfl-1 promoter construct was monitored by luciferase assay and β-gal 
normalisation. Fold differences were calculated relative to -1374/+81 bfl-1 luc 
activity in triplicate experiments; arbitrarily assigned a value of 1. (Data are mean 
±SD). 
 
In this experiment it was found that co-transfection with increasing quantities 
of each individual EBNA2 expression vector led to dose-dependent increase 
in bfl-1 driven luciferase activity. Furthermore, this trans-activation occurred 
to a similar degree for both EBNA2 isoforms (Figure 3.3).   
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3.2.4 Role of a consensus CBF1 binding site in the bfl-1 promoter 
 
It had been demonstrated previously in the laboratory that bfl-1 is 
transcriptionally regulated by both LMP1 and EBNA2. In an LCL background, 
the loss of either LMP1 or EBNA2 did not result in decreased bfl-1 
expression; however the simultaneous loss of the two proteins resulted in a 
dramatic decrease in bfl-1 mRNA levels (Pegman, et al. 2006). The use of 
NF-κB inhibitors revealed that LMP1-led up-regulation of bfl-1 is NF-κB 
dependent. A putative NF-κB site at (-52 to -43) was identified on the bfl-1 
promoter and mutation of this site (reporter construct -1374/+81 mκB(-52)) 
resulted in the complete loss of LMP1-associated trans-activation (D'Souza, 
et al. 2004). In addition to this, a similar study had been performed to identify 
the mechanism behind EBNA2-led trans-activation of bfl-1. Inhibition of the 
NF-κB pathway did not affect the EBNA2-mediated activation of bfl-1, 
indicating that trans-activation of bfl-1 by LMP1 and EBNA2 were 
mechanistically different. Co-expression with EBNA2 of a dominant negative 
CBF1 mutant revealed that CBF1 involvement was required for EBNA2 
activation of bfl-1.  A consensus CBF1 binding sequence was identified and, 
using a mutated bfl-1 promoter reporter construct (-1374/+81 mCBF1(-249)), 
this site was confirmed as the essential motif required for its regulation by 
EBNA2 (Pegman, et al. 2006). The objective of this part of the study was (i) 
to generate a double mutant encompassing mutations at the NF-κB site (-52) 
and the CBF1 site (-249) and  (ii) to determine how these combined 
mutations affected the transcriptional up-regulation of bfl-1 in an EBV-
infected cell line in which both EBNA2 and LMP1 are co-expressed. 
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3.2.4.1 Generation of two mutant bfl-1 promoter constructs using site 
directed mutagenesis 
 
Site-directed mutagenesis [QuikChange XL site-directed mutagenesis 
(Stratagene)] was used to generate two bfl-1 promoter mutants (i) the 
parental bfl-1 promoter-reporter vector, -1374/+81 bfl-1 luc, was mutated at 
the CBF1 motif to yield -1374/+81 mCBF1(-249) luc and (ii) the 
corresponding vector with its NF-κB-binding site already mutated, -1374/+81 
mκB(-52), was further altered at the CBF1-binding site to generate the 
double mutant construct -1374/+81 mκB(-52) mCBF1(-249) (Figure 3.4). 
 
 
Figure 3.4: Schematic of the four bfl-1 promoter constructs used for 
this study.  
The promoter construct -1374/+81 bfl-1 luc was generated by amplification of the -
1374/+81 region of the bfl-1 promoter from a pCAT based vector, followed by sub-
cloning into the Xho I and Hind III sites of the promoterless pGL2 basic reporter 
vector (D'Souza, et al. 2004). A mutation of the NF-κB motif (-52) was introduced 
into this promoter construct using site directed mutagenesis to generate -1374/+81 
mκB(-52) (D'Souza, et al. 2004). In this study, site directed mutagenesis was 
employed to mutate the CBF1 binding site of the full length bfl-1 promoter to 
generate -1374/+81 mCBF1(-249) luc and in the NF-κB mutated promoter to 
generate -1374/+81 mκB(-52) mCBF1(-249). 
 
 
QuikChange XL site-directed mutagenesis allows mutation of methylated 
double-stranded plasmid DNA. This works by utilising a primer designed with 
significant similarity to the target region such that they can bind and amplify 
the target; however, point mutation/s incorporated into the primers allow 
amplification of a mutated product (Figure 3.5), facilitated by a high fidelity 
DNA polymerase, pfuTurbo. Amplification of the mutated product is followed 
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by digestion with the selective endonuclease, DpnI, which digests only 
methylated and hemi-methylated DNA. The methylated parental DNA is 
digested by DpnI allowing selection of the mutant plasmid. The resulting 
DNA can then be transformed into E. coli XL1-Blue cells, followed by 
purification and screening of the clones. 
 
Figure 3.5: Oligonucleotide incorporating CBF1 Mutation.  
The 40 base oligonucleotide is complementary to the bfl-1 promoter CBF1 
recognition motif. The highlighted centre region indicates the 6 base altered 
sequence for the CBF1 motif, shown in red. This mutation introduces a new 
restriction site for the enzyme Xba I (TCTAG), therefore allowing efficient screening 
of positive clones. 
 
All purified clones were screened by restriction enzyme analysis with the 
enzyme Xba I. The pGL2 reporter construct already contains an Xba I 
restriction site; thus, the introduction of this second Xba I sites yields a DNA 
fragment of approximately 400bp upon digestion with Xba I. Digested clones 
were analysed by agarose gel electrophoresis, and positive clones were 
identified by the presence of an additional fragment at approximately 400bp.  
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Figure 3.6: Screening of clones using Xba I restriction analysis.  
All DNA was digested by Xba I and analysed using a 1% agarose-1X TAE gel and 
electrophoresis was carried out at 100V for 1 hour in 1X TAE. Lane 1 contains a 1 
Kb ladder, lanes 2-7 are Xba1 digests: lane 2 contains -1374/+81 bfl-1 luc; lanes 3 
and 4 contain -1374/+81 mCBF1(-249) luc positive clones yielding the indicative 
fragment at ~400bp; lane 5 contains the -1374/+81 mκB(-52) plasmid, followed by 
the double-mutant clones -1374/+81 mκB(-52) mCBF1(-249) in lanes 6 and 7, also 
yielding the ~400bp fragment due to the incorporation of the second Xba I site. 
 
The consensus CBF1 binding site was successfully altered in the template 
plasmids to generate the two new constructs -1374/+81 mCBF1(-249) luc 
and -1374/+81 mκB(-52) mCBF1(-249). To determine if simultaneous 
inactivation of the NF-κB-binding motif at (-52) and the CBF1-binding motif at 
(-249) altered the EBV-modulation of bfl-1 activity, three different EBV-
positive cell lines were transfected with these constructs and assayed for bfl-
1 promoter activity using the luciferase assay. 
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3.2.4.2 Regulation of bfl-1 promoter constructs in the EBV-positive BL, 
AG876 
 
The EBV-positive BL-derived cell line, AG876, was transiently transfected 
with the four bfl-1 promoter constructs described previously (Figure 3.4). The 
full complement of EBV latent genes is expressed in AG876. Both EBNA2 
and LMP1 are known trans-activators of bfl-1 and as such, within this cell 
line, the bfl-1 promoter activity can be driven by both EBV proteins. Cells 
were harvested 48 hours post-transfection and luciferase levels in the cells 
were quantified using a luminoskan 1400 Luminometer and normalised for β-
galactosidase activity.  
 
Figure 3.7: Mutation of NF-κB-like and CBF1-like binding sites on the 
bfl-1 promoter inhibits trans-activation by EBV.  
The AG876 cell line was transfected with 2 µg of each of the bfl-1 promoter 
constructs (indicated underneath). Cells were harvested 48 hours post-transfection, 
and normalised luciferase values were expressed as percentage activity relative to 
that obtained from the unmutated bfl-1 promoter on -1374/+81 bfl-1 luc, which was 
set at 100% activity. (Data are Mean ±SD, * P<0.05). 
 
It can be seen that mutation of the NF-κB-like binding site alone [-1374/+81 
mκB(-52)] resulted in approximately a 30% decrease in bfl-1 promoter 
activity, while inactivation of the CBF1 binding site alone [-1374/+81 
mCBF1(-249)], caused a 40% decline in bfl-1 promoter activity. Furthermore, 
mutating both site [-1374/+81 mκB(-52) mCBF1(-249)] resulted in an almost 
complete loss of bfl-1 promoter activity. 
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3.2.4.3 Regulation of the bfl-1 promoter in the LCL, ER/EB2.5 
 
ER/EB2.5 is an EBV-infected B cell line, as opposed to a BL-derived cell line. 
ER/EB2.5 cells were transiently transfected with the four bfl-1 promoter 
constructs described above (Figure 3.4). The full complement of EBV latent 
genes is expressed in ER/EB2.5, in an LCL background. Cells were 
harvested 48 hours post-transfection and assayed for luciferase activity as 
previously described.  
 
 
Figure 3.8: Mutation of NF-κB-like and CBF1-like binding sites on the 
bfl-1 promoter reduces trans-activation by EBV.  
The ER/EB2.5 cell line was transfected with 2 µg of each bfl-1 promoter construct 
(indicated underneath each bar). Cells were harvested 48 hours post-transfection 
and normalised luciferase results were expressed as percentage activity relative to 
that obtained from -1374/+81 bfl-1 luc, which was set at 100% activity. (Data are 
Mean ±SD, * P<0.05). 
 
As with the AG876 cell line, the wild type bfl-1 promoter, -1374/+81 bfl-1 luc 
was set as 100% promoter activity. The findings from this experiment 
indicate that transfection with -1374/+81 mκB(-52), resulted in approximately 
a 50% decrease in bfl-1 promoter activity, while the -1374/+81 mCBF1(-249) 
luc construct resulted in approximately a 45% decrease in bfl-1 promoter 
activity. Furthermore, as observed previously in AG876 (Section 3.2.4.2) 
mutating both the NF-κB-like binding site and the CBF1-like binding site, -
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1374/+81 mκB(-52) mCBF1(-249), resulted in a further significant loss of bfl-
1 promoter activity; however in ER/EB2.5 this inhibition was not to the same 
extent as that seen in AG876. It is worth noting that ER/EB2.5 cells were 
also transfected with the empty pGL2 reporter vector, and this gave, on 
average, approximately 18% of the activity observed for the unmutated bfl-1 
promoter-reporter construct. This indicates the production of luciferase from 
the promoterless basal vector in this cell line. 
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3.2.4.4 Regulation of bfl-1 promoter constructs in the EBV-positive LCL, 
IB4 
 
The LCL IB4 was transiently transfected with the four bfl-1 promoter 
constructs described above (Figure 3.4). Cells were harvested 48 hours 
post-transfection and assayed for luciferase activity as previously described.  
 
 
Figure 3.9: Mutation of NF-κB-like and CBF1-like binding sites on the 
bfl-1 promoter inhibits trans-activation by EBV.  
The IB4 cell line was transfected with 2 µg of each of the four bfl-1 promoter 
constructs as indicated above. Cells were harvested 48 hours post-transfection, 
normalised luciferase results were expressed as percentage activity relative to that 
obtained from the wild type bfl-1 promoter on -1374/+81 bfl-1 luc, which was set at 
100% activity. (Data are Mean ±SD). 
 
As with previous experiments in this study, the wild type bfl-1 promoter, -
1374/+81 bfl-1 luc was set as 100% promoter activity. Surprisingly, this 
experiment indicated that transfection with -1374/+81 mκB(-52), had no 
effect on bfl-1 promoter activity, while elimination of the consensus CBF1-
binding site [-1374/+81 mCBF1(-249) luc] resulted in an approximately 68% 
decrease in bfl-1 promoter activity. Furthermore, as observed above in 
AG876 and EREB2.5 cells (Sections 3.2.4.2 and 3.2.4.3), mutating both the 
NF-κB-binding site and the CBF1-binding site [-1374/+81 mκB(-52) mCBF1(-
249)], resulted in a further decline in bfl-1 promoter activity (cumulative loss 
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of 80% relative to the activity observed for the unmutated bfl-1 promoter-
reporter construct). 
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3.3 Discussion 
 
The regulation of bfl-1 by EBV has been demonstrated previously (Pegman, 
et al. 2006; D'Souza, et al. 2004; D'Souza, et al. 2000). In addition, an 
infection of naϊve B cells with EBV was carried out in the present study 
(Described in chapter 4) and an analysis of RNA levels by RT-qPCR 
confirmed the up-regulation of bfl-1 (134-fold increase) at 3 days post-
infection (Table 4.1). The mechanism behind EBV-associated bfl-1 up-
regulation was further examined here. The evidence from this investigation 
indicates that there was no significant difference in the regulation of the bfl-1 
promoter in response to either EBNA2A or EBNA2B in an EBV-negative BL 
background. Bfl-1 expression from each vector was confirmed using Western 
blotting with the EBNA2 specific antibody, PE2, which has been confirmed to 
detect EBNA2A and EBNA2B with approximately equal efficiency (Lucchesi, 
et al. 2008). The expression level of ectopic EBNA2B was marginally higher 
than that of EBNA2A. Reporter studies indicated that EBNA2B trans-
activated the CBF1 responsive vector pGa981.6 to a greater degree than 
EBNA2A, with approximately a 2-fold increase observed in the response to 
EBNA2B in comparison to EBNA2A (Section 3.2.2). The resulting difference 
in the potency of EBNA2A and EBNA2B mediated trans-activation of 
pGa981.6 was not statistically significant. Taking the relative ectopic levels of 
EBNA2A/2B into account, however (Figure 3.1), may account for the 
difference in promoter trans-activation observed. It is unlikely that there is 
any significant difference in the abilities of EBNA2A or EBNA2B to trans-
activate the Notch responsive promoters. 
 
Mutation at the LMP1-responsive consensus NF-κB site in the bfl-1 promoter 
resulted in reduced bfl-1 promoter trans-activation in AG876 and ER/EB2.5. 
However, mutation at the same site resulted in no detectable change in 
activity in the IB4 cell line. Furthermore, in the two cell lines in which 
modulation was observed for the NF-κB mutant the results were below the 
lower significance limit of P<0.05. It has been demonstrated that when LMP1 
is expressed as the sole EBV protein in an EBV-negative BL, that the 
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presence of this NF-κB mutation in the bfl-1 promoter construct prevents 
LMP1-mediated trans-activation (D'Souza, et al. 2004). However, it can be 
determined from published data, combined with the results from this 
experiment, that in these EBV positive cell lines, EBNA2 can compensate for 
the loss of LMP1 with respect to bfl-1 regulation. 
 
The CBF1 recognition site has been shown to be highly conserved, and the 
mutation introduced into the consensus CBF1 site in the bfl-1 promoter was 
chosen because it was a published verified mutation sequence that has been 
shown, via electrophoretic mobility shift assay, to abrogate CBF1 binding 
(Tun, et al. 1994). The inactivation of the CBF1-binding site in the bfl-1 
promoter led to statistically significant down-regulation in bfl-1 promoter 
activity in AG876 and EREB2.5 to a confidence interval of P>0.05. In IB4, a 
consistent reduction in bfl-1 activity of between 40-80% was also observed; 
however the extent of this modulation varied to such a degree so as to not be 
statistically significant. The statistically significant loss of bfl-1 activity from 
the single CBF1 site mutation in comparison to the single NF-κB site 
mutation in the same cell background indicates a more important role for 
EBNA2 here regarding bfl-1 trans-activation. Other published data from our 
laboratory showed that the loss of LMP-1 or EBNA2 resulted in little or no 
reduction in the steady state mRNA levels for bfl-1 (Pegman, et al. 2006). 
Interestingly, in all three cell lines, the combined mutations at the CBF1- and 
NF-κB-binding sites resulted in a minimum of 80% inhibition in bfl-1 promoter 
trans-activation, with almost complete loss of bfl-1 activity in AG876. This 
implies that both sites are required for maximal EBV-mediated bfl-1 
regulation.  
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Chapter 4: Regulation of cellular gene 
expression following EBV 
infection: Transducin-Like 
Enhancer of Split 1 (TLE1) is 
a negative target of EBV. 
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4.1 Introduction 
 
EBV is a ubiquitous human herpes virus that successfully establishes a 
lifelong infection in the host memory B cell compartment (Babcock, et al. 
1998). The survival capacity of EBV is due to its strategy of subverting 
normal cellular signaling pathways, counterbalancing natural processes such 
as host immune detection and inherent cell fate for its own benefit 
(Middeldorp and Pegtel 2008). EBV has evolved many mechanisms to evade 
the host immune response and hematopoietic regulation. EBV latent gene 
products modulate B cell pathways to promote host cell survival, prevent 
differentiation into a plasma cell, and increase the threshold of resistance to 
apoptotic signals. A broad scope of cellular genes has been shown to be 
regulated either directly or indirectly by EBV. 
EBV immortalised LCLs express all known latent viral gene products, 
including six nuclear antigens EBNA1, EBNA2, EBNA3A, -B, -C and EBNA-
LP, three latent membrane proteins LMP1, LMP2A and LMP2B along with 
the non-polyadenylated RNAs, EBER1 and EBER2 (Kerr, et al. 1992). The 
proliferative capacity of these cells is due to EBV and studies with LCLs 
therefore facilitate the examination of the established type III latent infection 
state. In the immortalised LCL, however, EBV has already achieved cellular 
control by subversion of the relevant signaling pathways and regulation of 
EBV-specific cellular targets. It is important, therefore, to study the host-virus 
interactions that occur earlier during B cell activation and LCL outgrowth, and 
to rule out events that occur due to long-term culturing of infected cells. 
In this chapter, the purification and infection of naϊve B lymphocytes with a 
recombinant GFP-expressing EBV strain is described. In that experiment, 
RNA was prepared before and after infection (early during LCL outgrowth), 
and the levels of expression of selected cellular genes were investigated by 
reverse transcription semi-quantitative polymerase chain reaction (RT-
qPCR). Novel genes modulated upon B cell infection were thus identified.  
One interesting negative target of EBV was discovered to be TLE1. Evidence 
is presented that EBV latency growth programme proteins repress the levels 
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of TLE1 mRNA and protein in an LCL. The regulation of TLE family members 
in LCLs and BL cell lines was concluded to be complex. 
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4.2 Results 
4.2.1 Identification of candidate genes whose expression is modulated 
following EBV infection of naϊve B cells in vitro  
 
In order to confirm the infectivity of the stock of GFP-tagged EBV (EBV BX1) 
(a gift of L. Hutt-Fletcher, Feist-Weiller Cancer Center, Louisiana State 
University Health Sciences Center, Shreveport, LA), an EBV-negative B cell 
line, Akata4E3, was first infected with this virus. A mock infection was also 
performed in tandem, in which no EBV was used. Twenty four hours after 
infection the cells were monitored for GFP expressed from the recombinant 
virus using FACS (Figure 4.1A). It can be seen that GFP-expressing cells 
were clearly evident following infection with EBV BX1, but not in the mock-
infected cells (Figure 4.1A). In addition, expression of the early EBV latent 
gene, EBNA2, was confirmed in EBV BX1-infected cells using RT-PCR 
(Figure 4.1C). These experiments confirmed that the stock of EBV BX1 
contained infectious virus particles. 
 
Naϊve B cells were then isolated from human PBMC by negative selection 
with a cocktail of magnetically labelled antibodies against various immune 
cell markers (MACS naive B-cell isolation kit II). Immune cells such as non-
naϊve B cells, T cells, NK cells, dendritic cells display a variety of distinct 
surface (markers not present on naϊve B cells) and therefore bind labelled 
antibodies. One such marker is CD27, which is displayed on memory B cells 
but not naïve B cells. Passage of the labelled cell population through a 
magnetic field led to the depletion of all but unbound naϊve B cells. Naïve B 
cells display CD19, the pan-B cell surface marker, but not CD27 (CD19-
positive, CD27-negative). Naive B cell enrichment was verified by Flow 
Cytometry (FACS analysis) after dual staining with anti-CD19 and anti-CD27 
antibodies (Figure 4.1B). It can be seen that, as expected, the PBMC 
population contained both naive B cells and memory B cells. Following 
enrichment by negative selection, however, naïve B cell enrichment was 
evident from the purified population of CD19-positive/CD27-negative cells 
observed. 
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Figure 4.1: Preparation of recombinant EBV and isolation of untouched 
naïve human B cells. 
 (A) Akata 4E3 BL cells were infected with purified EBV-BXI, harvested at 24 hours 
and analysed by FACS. GFP expression levels were compared in mock-infected 
(upper) and untreated-EBV-infected (lower) cells. (B) Naϊve B cells were separated 
from PBMC by negative selection. PBMC and the naϊve B-cell fractions were 
stained with PE-labeled anti-CD27 antibody (memory B-cell marker) and FITC-
labeled anti-CD19 antibody (pan-B-cell marker) and analysed by FACS. (C) RT-
PCR detection of EBNA2 transcript at various time points following infection with 
GFP-tagged EBV. 
 
EBV BX1 was then used to infect isolated naïve B cells (Section 2.2.3.7). 
Three days following infection, characteristic large blast-like cells were 
frequently in evidence, indicative of B cell growth transformation taking place 
(not shown). No such observations were to be made when mock-infected 
cells were examined. 
 
Total RNA was then prepared from the infected cell population, and the 
relative expression levels of selected gene sets were evaluated using three 
PCR gene arrays: (i) the Human Apoptosis RT² Profiler™ PCR Array; this 
consisted of a panel of 84 key genes associated with apoptosis. The array 
included the TNF ligands and their receptors; members of the bcl-2, TRAF 
and CIDE families, (ii) the Human Notch Signaling Pathway RT² Profiler™ 
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PCR Array, which included 84 genes involved in Notch signaling such as 
those encoding Notch-binding and receptor-processing proteins and several 
putative Notch target genes, and (iii) the Human Wnt Signaling Pathway RT² 
Profiler™ PCR Array which was composed of 84 genes related to Wnt-
mediated signal transduction. Each array consisted of a 384-well plate and 
triplicate analysis was performed for each gene examined. Each array panel 
contained an additional five housekeeping genes for the normalisation of 
results, along with controls for genomic DNA contamination, RNA quality, 
and general PCR performance. In this experiment, analysis of the results 
obtained led to the compilation of a shortlist of fourteen cellular genes that 
showed the most interesting variations in expression in response to EBV 
infection (see table 4.1; other data from the PCR arrays are not the subject 
matter of this thesis). The potential candidates for EBV regulation were 
chosen based on a number of criteria including; (i) change in expression 
levels pre- and post-EBV infection; (ii) association with EBV targeted 
signaling pathways; (iii) structural/functional homology with known EBV 
targets and (iv) novelty with respect to published information on EBV 
regulation. The potential regulation by EBV of one of these selected genes, 
the TLE1 gene, is the subject matter of the rest of this chapter; the other 
genes are discussed in subsequent chapters. 
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Gene 
Name  Description  N  3D  
Up/Down 
Regulation  
bfl-1 Bcl-2 related protein A1 33 26 134 
CCNE1  Cyclin E1  32 24 286 
CIDEB   Cell death-inducing DFFA-like effector b  34 15 502931 
FAS   Fas (TNF receptor superfamily, member 6)  35 26 605 
Fos   V-fos FBJ murine osteosarcoma viral 
oncogene homolog  20 29 648 
Jun   V-jun sarcoma virus 17 oncogene homolog (avian)  23 31 201 
LRP5   Low density lipoprotein receptor-related protein 5  
32 27 57 
32 28 19 
MMP7   Matrix metallopeptidase 7 (matrilysin, 
uterine)  35 27 317 
TNFSF7   Tumor necrosis factor (ligand) superfamily, 
member 7  35 26 626 
TRAF4   TNF receptor-associated factor 4  35 28 133 
NR4A2 Nuclear receptor subfamily 4, group A, 
member 2 26 29 14 
STIL   SCL/TAL1 interrupting locus  31 24 129 
Hey1  Hairy/enhancer of split related with YRPW 
motif 1  34 27 121 
TLE1  Transducin-like enhancer of split 1  25 30 43 
24 30 44 
 
Table 4.1: Fourteen selected genes showing altered regulation by EBV 
infection of Naive B cells.  
Results obtained from the RT Profiler PCR SuperArray. The resulting fold change in 
mRNA expression levels from samples taken from negatively purified Naive B cells 
(N) against cells taken 3 days post-infection with EBV BX1 (3D). Fold regulation can 
be seen in the far right column. Changes highlighted in blue indicate down-regulated 
genes while entries denoted in red signify genes up-regulated after EBV infection. 
LRP5 and TLE1 have two results as they were present in more than one cell 
signaling pathway gene panel.  
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4.2.2 Transducin-Like Enhancer of Split 1 (TLE1) is a candidate novel 
negative target of EBV 
 
TLE1 was identified as a potential cellular EBV target gene from the RT 
Profiler PCR SuperArray results presented in section 4.2.1. Three TLE family 
members were included on the RT Profiler PCR SuperArray: TLE1, TLE2 
and AES, as shown in table 4.2, of which only TLE1 appeared to be 
modulated following EBV infection. Altered TLE1 mRNA levels were obtained 
with comparable potency from two different RT Profiler PCR SuperArrays 
containing signature genes from the Notch and Wnt signaling cascades. 
 
Gene 
Name Description N 3D 
Up/Down 
Regulation 
TLE1 Transducin-like enhancer of split 1 
24.74 30.18 43.4 
24.15 29.6 43.7 
TLE2 Transducin-like enhancer of split 2 31.4   31.1 -  
AES  Amino-terminal enhancer of 
split  22.78  22.81  - 
 
Table 4.2: Expression pattern of TLE family members in naïve B cells 
pre- and post-EBV infection.  
Results obtained from the RT Profiler PCR SuperArray. The resulting fold change in 
mRNA expression levels from samples taken from negatively purified Naïve B cells 
(N) against cells taken 3 days post-infection with GFP-tagged EBV (3D). Fold 
regulation can be seen in the far right column. Changes highlighted in blue indicate 
down-regulated genes while entries denoted in yellow signify genes unaffected after 
EBV infection. Genes that have two results are present in more than one cell 
signaling gene panel.  
 
There was an approximate 43-fold decrease in TLE1 mRNA expression after 
the EBV infection of naïve B lymphocytes. This down-regulation was evident 
in each of the RT Profiler PCR SuperArray experiments. However, no 
changes were observed in the relative mRNA levels of the TLE family 
members, TLE2 and AES. 
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4.2.3 TLE1 is repressed by the EBV growth programme in the 
conditional LCL ER/EB2.5  
 
The isolation and validation of a naϊve B cell population is costly, and the 
continued use of untouched naϊve B cells for analysis was not feasible for the 
duration of this project. Therefore, a well studied cell culture model capable 
of mimicking the B cell infection process was utilised to continue studies on 
the novel candidate EBV target genes. Initially, the gene expression changes 
observed in the freshly infected naϊve B cells, due to EBV infection, were 
corroborated in the chosen cell culture infection model, ER/EB2.5. 
 
The process of EBV-driven B cell proliferation requires the expression of 
EBNA2. ER/EB2.5 is a ‘conditionally immortalised’ LCL in which the EBV 
growth programme is dependent on the presence of β-estradiol (Kempkes, et 
al. 1995b). In this cell line, EBNA2 has been replaced with an ER/EBNA2 
fusion protein whereby the EBV protein is joined to the hormone-binding 
domain of the β-estradiol receptor. It is well established that such fusions can 
cause the function of the individual partner protein to become hormone-
dependent (Picard, et al. 1988; Eilers, et al. 1989). Thus, ER/EBNA2 protein 
is activated by the addition of β-estradiol to the growth medium, leading to 
EBV latency type III gene expression and cell proliferation. When ER/EB2.5 
cells are cultured in the absence of β-estradiol they undergo cell cycle arrest 
and over time will not survive in culture, similar to un-infected resting B cells 
in culture. This permits the modulation of ER/EB2.5 between a resting state 
(-β-estradiol) and a cell cycling state (+β-estradiol). 
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Figure 4.2: Schematic of ER/EB2.5 model.  
ER/EB2.5 is an LCL that contains a mini-EBV plasmid expressing the chimeric 
EBNA2 protein as an autonomously replicating plasmid, plus the P3HR1 viral 
genome, thus complementing the EBNA2 deletion of the P3HR1 virus. EBNA2 
expression and proliferation are dependent on the presence of estrogen (Campion 
2008). 
In this study, ER/EB2.5 cells were cultured in the absence and presence of 
β-estradiol in order to investigate the expression profiles for the panel of 
genes identified in the RT Profiler PCR SuperArray (Section 4.2.1). 
ER/EB2.5 cells were washed four times in PBS prior to re-seeding into β-
estradiol-free supplemented RPMI medium. Twenty-four hours later the cells 
were washed twice in PBS and again cultured in β-estradiol-free medium for 
a further 48 hours so as to ensure complete inactivation of ER/EBNA2 and 
the EBV growth programme. To reactivate the EBV growth programme, 1 µM 
β-estradiol was added to the growth medium and cells were cultured for 48 
hours. Total RNA was prepared from ER/EB2.5 cells at these different 
stages and samples were analysed by RT-qPCR using SYBR green-based 
PCR assays designed for each target gene shown in Table 4.1. In this way, 
the relative mRNA levels of each gene could be compared between 
proliferating ER/EB2.5 cells and those ER/EB2.5 cells in which the EBV 
growth programme has been inactivated. 
 
To determine the effect of EBV driven growth on the expression levels of 
TLE1, RNA samples were harvested from ER/EB2.5 cells cultured as 
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described above in the presence and absence of β-estradiol. TLE1 mRNA 
were assessed by Reverse-Transcription (RT) Real Time PCR (RT-qPCR). 
TATA Binding Protein (TBP) mRNA levels within the cells were also 
monitored in this fashion and allowed for the normalisation of TLE1 
expression levels between samples. 
 
 
Figure 4.3:  Induction of EBV driven proliferation in ER/EB2.5 leads to a 
decrease in the level of TLE1 mRNA.  
RT-qPCR analysis was carried out to determine the levels of TLE1 expression in the 
cell culture model of resting B cells (ER/EB - est) relative to ER/EBNA2 activated 
cells (ER/EB + est). ER/EBNA2 was activated in the ER/EB2.5 cell line by the 
addition of 1 µM β-estradiol to previously β-estradiol-starved cells. RNA samples 
were taken before and after the addition of β-estradiol to the growth medium and 
reverse transcribed using random hexamers and MMLV reverse transcriptase. 
Amplification of cDNA was monitored in real time by detection of fluorescence 
intensity using SYBR green. (A) Fluorescent signals were detected using an ABI 
Prism 7500 Sequence Detection System. Results were normalised using the 
internal control, TBP, and were expressed as relative quantitation as a function of 
the control. In this experiment, the control being EBV cycling cells (ER/EB + est): 
arbitrarily assigned a value of 1. (Data are Mean ±SD, ** P<0.01). (B) Western Blot 
showing activation of ER/EBNA2 in response to β-estradiol. Protein harvested from 
β-estradiol starved cells exhibit the lower ER/EBNA2 band indicating inactive 
ER/EBNA2. After 48 hours of β-estradiol supplementation, this band is detected at a 
higher molecular weight, indicative of active ER/EBNA2. All extracts were 
normalised to the loading control β-Actin. (C) The dissociation curve for the product 
of the TLE1 assay was analysed to ensure a single specific peak, confirming that 
one specific PCR product was present. 
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 The results from this experiment correlated with the data obtained from the 
EBV-B cell infection experiment. 
following activation of the EBV growth programme in ER/EB2.5. In this 
experiment a characteristic shift was observed in the 
weight of chimeric EBNA2. This is thought to be due to either post
translational modifications 
ER/EBNA2 (Figure 4.3B) 
combined, support the negative regulation of
transcriptional level.  
 
Due to difficulties optimising a TLE1 protein detection assay, two Western 
blotting techniques were combined to detect TLE1. This combined method 
utilised classical immunological probing techniques and new 
technology; this method was described in detail in section 2.2.5.8. 
 
Figure 4.4: TLE1 protein expression levels in ER
Protein extracts were taken from ER/EB2.5 cells before an
activation. TLE1 protein expression was investigated via western blot analysis. A 
positive TLE1 expression control for exogenous (pcDNA3 TLE1 BJAB) and 
endogenous (AG876) TLE1 expression was included in the blot, along with a 
negative control (pcDNA3 BJAB). The upper panel illustrates the level of TLE1 
protein detected using a rabbit polyclonal 
the endogenous loading control 
the lower panel.  
 
Down-regulation of TLE1
induction in ER/EB2.5 was confirmed by SDS P
4.4). As a control for antibody specificity, the EBV
was transfected with a 
expression vector, pcDNA3 was also used to transfect the same cell line as a 
negative control. The BL cell line, AG876 demonstrates high expression 
levels of TLE1 and was a positive control for endogenous TLE1. The cellular 
protein β-Actin was probed to ensure equal loading for every sample. 
TLE1 mRNA levels were reduced five
apparent molecular 
or considerable changes in the tertiary structure of 
(Kempkes, et al. 1995b). These data, when 
 TLE1 by EBV at the 
/EB2.5. 
d after ER/EBNA2 
IgG (Abcam, ab15587) and normalised for 
β-Actin, using a mouse monoclonal IgG, depicted in 
 expression at the protein level by 
AGE/western blotting (Figure 
-negative BJAB cell line 
TLE1 expression vector (pcDNA3 TLE1). The empty 
146 
-fold 
-
SNAP i.d.TM 
 
 
β-estradiol 
β-
147 
 
estradiol-deficient ER/EB2.5 cells display a clear and discrete band in the 
correct region when probed with the TLE1 antibody. After activation of the 
EBV growth programme this band is no longer present, implying the loss of 
TLE1 protein expression in these cells (Figure 4.1). These results show that 
TLE1 is a negative target of the EBV growth programme in an LCL. 
 
To further examine whether the modulation of TLE1 expression in ER/EB2.5 
is EBV dependent, an β-estradiol starvation time course experiment was 
performed (Figure 4.5). ER/EB2.5 cells previously cycling in the presence of 
β-estradiol were washed as described in section 4.2.3. These cells were then 
seeded into T75 flasks at a density of 5 X 105 cells/ml (ER/EB – Est 0 hr) and 
passaged every 48 hours. Total mRNA samples were harvested from cells at 
three intervals for the duration of the β-estradiol withdrawal period (Indicated 
in Figure 4.5). Relative TLE1 mRNA expression levels were determined 
using RT-qPCR. It can be seen that as ER/EBNA2 is de-activated in the 
ER/EB2.5 cell line, the TLE1 mRNA levels increase significantly (Figure 
4.5A). The de-activation of the ER/EBNA2 was verified by Western blotting 
(Figure 4.5B).  
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Figure 4.5:  De-activation of ER-EBNA2 by withdrawal of the β-estradiol 
results in a significant increase in TLE1 mRNA levels.  
(A) RT-qPCR was performed to determine the effect on TLE1 mRNA in response to 
ER/EBNA2 de-activation (β-estradiol withdrawal). RNA samples were prepared at 
the post-withdrawal time points indicated on the graph. Assay and normalisation of 
results (relative to TBP) was performed as described in the legend to Figure 4.3. In 
this experiment, the control was designated as ER/EB – Est 0 hr; arbitrarily 
assigned a value of 1. (Data are Mean ±SD, ** P<0.01, *** P<0.001). (B) Western 
Blot showing de-activation of ER/EBNA2 in response to β-estradiol withdrawal. 
Protein harvested from cells cultured from β-estradiol medium (ER/EB2.5 –Est 0 
hour) exhibit the active 120 kDa ER/EBNA2 protein. After 24 hours, this band is 
detected at a lower molecular weight, indicative of inactive ER/EBNA2, due to the 
loss of β-estradiol. All extracts were normalised to the loading control β-Actin. 
 
In an additional experiment with further time points, the modulation of TLE1 
mRNA levels in response to EBV-driven growth was examined (Figure 4.6). 
Comparative TLE1 mRNA levels were monitored at various time points in 
ER/EB2.5 cells (i) as β-estradiol was withdrawn from ER/EB2.5 cells and (ii) 
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after the cell line was once again induced to proliferate due to EBV through 
β-estradiol induction. Proliferating ER/EB2.5 cells cycling continuously in the 
presence of β-estradiol were washed and re-cultured in β-estradiol free 
medium to de-activate the EBV programme. TLE1 mRNA expression peaked 
48 hours following β-estradiol withdrawal. Basal expression for TLE1 
appears to reach a steady state at a level lower than that observed at the 48 
hour time point (ER/EB2.5 –Est 48 hours). The removal of β-estradiol from 
ER/EB2.5 cells halts EBV driven proliferation and causes cellular growth 
arrest. However, even in a resting state, basal TLE1 expression levels are 
elevated significantly in comparison to cycling ER/EB2.5. After 120 hours of 
β-estradiol depletion, 1µM β-estradiol was re-introduced to the growth 
medium and a decrease in TLE1 mRNA expression is once again noted. 
These results show that TLE1 down-regulation coincides with EBV latent 
gene expression in the ER/EB2.5 conditional LCL.  
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Figure 4.6:  Modulation of the EBV growth programme in ER/EB2.5 
correlates with changes in TLE1 mRNA levels.  
To monitor the modulated effect of TLE1 mRNA levels in response to activation and 
de-activation of EBV driven proliferation, an expanded time course of ER/EB2.5 
cycling cells was performed. This involved taking samples from EBV proliferating 
cells, re-culturing these cells in β-estradiol deficient medium (resting B cell) and re-
induction of the EBV growth programme. ER/EB2.5 cycling continuously on the EBV 
growth programme were washed 4 times in PBS and were then re-suspended in β-
estradiol free medium (ER/EB – est 0 hr). Twenty four hours later the cells were 
washed twice in PBS and again the cells were maintained in β-estradiol free 
medium. Samples were taken at the time points indicated while the ER/EB2.5 cell 
line was cultured in β-estradiol deficient medium and β-estradiol supplemented 
medium. RNA samples were monitored and normalised using TBP as described in 
the legend to Figure 4.3. In this experiment, the control was designated as ER/EB 
cycling on β-estradiol; arbitrarily assigned a value of 1. (Data are Mean ±SD, * 
P<0.05, ** P<0.01). 
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4.2.4 EBNA2 trans-activates TLE1 in the conditional BL derived cell line 
BL41-ER/EBNA2 (BL41-K3) 
  
Burkitt’s Lymphoma (BL) cell lines arise from human malignant lymphoma 
cells biopsied from BL patients. Proliferation in these cell lines is driven by C-
Myc (Gruhne, et al. 2009). BL41-K3 is an established EBV-negative cell line 
that is capable of constitutively expressing an β-estradiol receptor-EBNA2 
fusion protein (ER/EBNA2) whose function is dependent on β-estradiol. 
BL41-K3 was derived by stably transfecting an EBV negative BL cell line, 
BL41 with an ER/EBNA2 expression plasmid. ER/EBNA2 can enhance its 
own transcription from the plasmid (Kempkes, et al. 1996), leading to an 
increase in its own expression. BL41-K3, is therefore, an EBV-negative BL 
cell line that can be induced to express ER/EBNA2 but no other latent viral 
proteins. 
 
In order to assess the effect of EBNA2, when expressed as the sole EBV 
protein, on TLE1 expression levels, BL41-K3 cells were prepared for EBNA2 
activation by washing twice in PBS prior to the addition of β-estradiol to a 
final concentration of 1 µM in supplemented RPMI medium.  
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Figure 4.7: ER/EBNA2 positively regulates TLE1 mRNA in BL41-K3.  
ER/EBNA2 was activated in BL41-K3 by the addition of 1µM β-estradiol to the 
growth medium. Protein and total RNA extracts were prepared at the times 
indicated following activation of ER/EBNA2 in BL41-K3. (A) Western Blot analysis 
showing activation and up-regulation of chimeric EBNA2 in response to β-estradiol 
addition (upper panel). The lower panel shows the levels of the internal loading 
control β-Actin (in collaboration with E. Campion). (B) RT-qPCR analysis of TLE1 
mRNA levels in response to ER/EBNA2 activation. The post-induction time points 
are indicated on the graph. The RT-qPCR assay was performed as described in the 
legend to Figure 4.3, results were normalised using the internal control, TBP, and 
were expressed as relative quantitation as a function of the control. In this 
experiment, the control was designated as BL41-K3 0 hr, arbitrarily assigned a 
value of 1. (Data are Mean ±SD, * P<0.05, ** P<0.01). 
 
Western blot analysis confirmed ER/EBNA2 activation as before (Figure 
4.7A). In this experiment it can be seen that the steady-state level of TLE1 
mRNA increased in response to activation of ER/EBNA2 (Figure 4.7B). 
Bearing in mind the previous data generated in this study regarding TLE1 
regulation in an LCL background, it was surprising to observe that in a BL 
background, ER/EBNA2 activation coincided with significant up-regulation of 
TLE1 mRNA levels. TLE1 expression was up-regulated after 24 hours, with a 
4.5-fold increase observed for TLE1 mRNA levels in response to EBNA2. 
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The solitary EBV latent protein present in the BL41-K3 cell line is EBNA2; 
this implies that in a BL background TLE1 is not repressed by EBNA2, but in 
fact is up-regulated by this EBV protein in a BL background.  
 
4.2.5 EBNA2 does not trans-activate TLE1 in a BL-derived cell line 
(BL41-9A) which expresses other EBV latent proteins 
 
BL41-9A is an EBV-positive EBNA2-deletion containing cell line stably 
transfected with an ER/EBNA2 expressing vector. BL41-9A is, therefore, 
similar to BL41-K3 described previously; however, in response to ER/EBNA2 
activation with β-estradiol, BL41-9A goes on to express the full complement 
of EBV latent genes (except LMP1), whereas BL41-K3 expresses only 
activated ER/EBNA2. BL41-9A was generated by infection of the parental 
EBV-negative BL41 cell line with the EBNA2-deficient non-immortalising 
P3HR1 EBV virus strain (Kempkes, et al. 1996), followed by stable 
transfection with an ER/EBNA2 containing recombinant mini-EBV genome. 
Upon activation, ER/EBNA2 trans-activates the full repertoire of EBV latent 
genes. The transcriptional up-regulation of LMP1 is ordinarily a consequence 
of EBNA2 expression; yet, in the BL41-9A cell line, LMP-1 expression never 
transpires and the molecular basis for this is not yet understood. Thus, BL41-
9A is an EBV-positive BL derived from the EBV negative BL41 and serves as 
a useful model for the examination of EBV latent gene activity in a BL cell 
background. 
 
In order to investigate the ability of EBV to regulate TLE1 in BL41-9A, an 
ER/EBNA2 activation time course was undertaken. BL41-9A cells were 
primed for ER/EBNA2 activation by washing cells twice in PBS prior to the 
addition of β-estradiol to a final concentration of 1 µM in supplemented RPMI 
medium. Total mRNA samples were harvested as before and relative TLE1 
mRNA levels were determined using RT-qPCR.  
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Figure 4.8: TLE1 is not significantly regulated by EBNA2 in BL41-9A.  
ER/EBNA2 was activated in BL41-9A by the addition of 1 µM β-estradiol to the 
growth medium. (A) Western blot analysis confirmed activation of chimeric EBNA2 
in response to β-estradiol induction (upper panel). The lower panel is the β-Actin 
loading control. (B) RNA samples were prepared at the time points indicated post-
induction. RT-qPCR analysis of TLE1 mRNA levels in response to ER/EBNA2 
activation was performed as described in the legend to figure 4.3; results were 
normalised using the internal control, TBP, and were expressed as relative 
quantitation as a function of the control. In this experiment, the control was 
designated as BL41-9A 0 hr, arbitrarily assigned a value of 1. (Data are Mean ±SD). 
 
In this experiment, activation of ER/EBNA2 was again observed by Western 
blot analysis, (Figure 4.8A). Surprisingly, addition of β-estradiol to BL41-9A 
cells did not lead to a significant change in TLE1 mRNA levels over the time 
period. In the associated cell line BL41-K3, it was shown that ER/EBNA2 
activation trans-activated TLE1 expression. In BL41-9A, one or more of the 
other EBV latent gene products, or their cellular targets, may therefore impair 
trans-activation of TLE1 by ER/EBNA2.  
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4.2.6 Induction of EBNA2 in the EBV-negative BL cell line, DG75-tTA-
EBNA2, has no significant effect on TLE1 mRNA levels 
 
The cell line DG75-tTA-EBNA2 was used to further investigate a potential 
role for EBNA2 in TLE1 regulation. DG75-tTA-EBNA2 is a stable transfectant 
in which the induction/repression of EBNA2 may be achieved using a non-
toxic concentration of tetracycline in the growth medium (Floettmann, et al. 
1996). DG75-tTA-EBNA2 was previously generated by stably transfecting 
the EBV-negative BL cell line DG75 with two expression vectors, pJEF-3 and 
pJEF-31. Stable integration of these plasmids was achieved by selection 
using hygromycin, geneticin and tetracycline. The effector vector, pJEF-3 
contains a constitutively expressed tetracycline regulated trans-activator 
(tTA). The responsive construct, pJEF-31, can express EBNA2; however, the 
inducible promoter that drives this EBNA2 expression contains several 
binding sites for the tTA. In the presence of tetracycline, the expressed tTA is 
bound by the drug and thus cannot activate the expression of the EBNA2 
promoter. Upon removal of tetracycline from the medium, tTA binds to the 
promoter activating the transcription of EBNA2 (Floettmann, et al. 1996).  
DG75-tTA-EBNA2 cells are maintained in supplemented RPMI medium 
containing 1 µg/ml of tetracycline. The induction of EBNA2 was initiated by 
washing the cells 4 times in PBS followed by re-seeding them in tetracycline-
free culture medium. 
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Figure 4.9: EBNA2 induction did not significantly regulate TLE1 in 
DG75-tTA-EBNA2.  
EBNA2 expression was induced in DG75-tTA-EBNA2 by the removal of tetracycline 
from the supplemented RPMI medium. (A) Western blot analysis confirmed 
induction of EBNA2 expression in response to tetracycline removal. Cells were 
harvested and analysed for EBNA2 expression at the time points indicated (upper 
panel). The lower panel shows the β-Actin loading control. (B) RT-qPCR analysis of 
TLE1 mRNA levels in DG75-tTA-EBNA2 in response to EBNA2 induction. RNA 
samples were prepared at the time points indicated post-induction. RT-qPCR 
analysis was performed as described in the legend to Figure 4.3; results were 
normalised using the internal control, TBP, and were expressed as relative 
quantitation as a function of the control. In this experiment, the control was 
designated as DG75-tTA-EBNA2 0 hr, arbitrarily assigned a value of 1. (Data are 
Mean ±SD). 
 
The induction of EBNA2 in the experiment was confirmed by Western 
blotting (figure 4.9A). Contrary to the previous result obtained with BL41-K3, 
no significant modulation of TLE1 mRNA was seen in response to EBNA2 
induction in DG75-tTA-EBNA2. Although these experiments both involve 
expressing EBNA2 as sole EBV protein in a BL cell background, the results 
obtained are not in agreement. This discrepancy may be due to the different 
induction systems used in each cell line or as a result of acquired genetic 
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differences between BL41 and DG75. It is also possible that there may be a 
potential effect due to the difference in the properties of ER/EBNA2 (BL41-
K3) versus wild-type EBNA2 (DG75-tTA-EBNA2). The results of these 
experiments, therefore, do not concur and it cannot be concluded whether or 
not EBNA2 alone can transcriptionally regulate TLE1. 
 
4.2.7 Relative TLE1 mRNA levels are not repressed due to C-Myc driven 
growth in the conditional LCL P493-6 
 
The conditional LCL P493-6 is a stably transfected derivative of the LCL 
ER/EB2.5 (discussed previously in section 4.2.3) in which the expression of 
ectopic C-Myc may be regulated. In LCLs, EBNA2 drives the expression of 
C-Myc and it has been demonstrated that constitutive C-Myc expression can 
substitute for EBNA2 to maintain proliferation in ER/EB2.5 (Pajic, et al. 
2000). A tetracycline-negatively regulated C-Myc expression construct was 
introduced into the established stable cell line ER/EB2.5. This vector, pMyc-
tet, possesses the ability to express both C-Myc and the tetracycline 
regulated trans-activator, tTA, from two different promoters (Gossen and 
Bujard 1992). The tTA molecule is constitutively expressed from a CMV 
promoter; however, C-Myc is under the control of the TP-tetO7 promoter, 
whose activation is dependent upon the binding of tTA (Pajic, et al. 2001). 
When present, tetracycline binds the free tTA preventing binding to the TP-
tetO7 thus repressing ectopic C-Myc expression (Figure 4.10). Hence 
P493.6 when starved of β-estradiol represents a resting B-cell that can be 
stimulated to proliferate either in response to (i) C-Myc in the combined 
absence of tetracycline and β-estradiol (simulating BL cell growth) or (ii) 
EBNA2 in the presence of both β-estradiol and tetracycline (simulating an 
EBV-driven LCL) (Pajic, et al. 2000; Schuhmacher, et al. 2001). It was 
therefore of interest in this study to utilise the duality of P493.6 to determine 
if TLE1 repression occurred in B cells driven to proliferate due to C-Myc 
and/or EBV. 
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Figure 4.10: Conditional expression in P493-6.  
Schematic illustrating pMyc-tet, the C-Myc expression construct. The two coding 
exons of C-Myc (depicted by black boxes II and III) were cloned under the control of 
the promoter TP-tetO7. The construct also includes an expression cassette for the 
trans-activator tTA regulated by the CMV promoter (CMV-tTA). Tetracycline inhibits 
TP-tetO7 trans-activation by sequestering tTA, rendering it unavailable for promoter 
binding. pMyc-tet is based on the EBV-derived vector pHEBO. Selection marker 
genes for ampicillin and hygromycin are illustrated along with the origin for latent 
replication by oriP (adapted from Pajic, et al. 2001). To activate ER/EBNA2, β-
estradiol is added to the culture medium to a final concentration of 1 µM. Expression 
of ectopic C-Myc is repressed by treatment with 0.1 µg/ml tetracycline as described 
previously (Pajic, et al. 2000; Pajic, et al. 2001). 
 
 
A time course experiment was carried out in which the P493.6 cell line was 
cultured on the EBV growth programme (+ β-estradiol, + Tet; reminiscent of 
parental ER/EB2.5) or the C-Myc growth programme (- β-estradiol, - Tet; 
reminiscent of an EBV-negative BL cell line). In the latter case, P493-6 cells 
were washed twice in PBS and cultivated in the absence of tetracycline and 
β-estradiol for a period of 72 hours.  
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Figure 4.11: Negative regulation of TLE1 by EBNA2 in the conditional 
EBV-immortalised LCL, P493-6.  
The steady state levels of TLE1 mRNA and protein were significantly higher in 
P493-6 cells proliferating due to C-Myc than in their EBV-driven counterparts. P493-
6 cells were divided and separately cultured to permit cycling on the EBV growth 
programme (+ β-estradiol, + Tet) or C-Myc programme (- β-estradiol, - Tet).  Total 
protein and RNA samples were taken during each growth programme. RT-qPCR 
and Western blotting were performed to determine the relative levels of TLE1 
expression in the p493-6 cells proliferating due to EBV (P493-6 EBNA2) relative to 
C-Myc driven cells (P493-6 Myc). (A) At the cycling programme indicated, RT-qPCR 
was performed as described in the legend to Figure 4.3. Results were normalised 
using the internal control, TBP, and were expressed as relative quantitation as a 
function of the control. In this experiment the control set was P493-6 EBNA2 cells, 
arbitrarily assigned a value of 1. (Data are Mean ±SD, ** P<0.01). (B) Western blot 
analysis confirmed higher TLE1 protein expression levels in the P493.6 Myc cells in 
comparison to the EBV cycling cells. 
 
It was determined from the RT-qPCR analysis that the steady state level of 
TLE1 mRNA was significantly lower in cells proliferating due to EBV (+ β-
estradiol, + Tet)  in contrast to the cells proliferating due to C-Myc (- β-
estradiol, - Tet) (see Figure 4.11A).  This result was corroborated by Western 
blot analysis (Figure 4.11B), confirming that cells proliferating due to the C-
Myc programme display a higher quantity of TLE1 protein relative to the 
same cell line cycling due to EBV. EBV-driven P493-6 cells are like the 
parental cell line ER/EB2.5. Thus these results show once again that, when 
the EBV-driven growth programme is switched off in ER/EB2.5 cells, the 
level of TLE1 increases. As P493-6 is a clonal derivative of ER/EB2.5, the C-
Myc driven growth programme can be uncoupled from the EBV growth 
programme in the same isogenic background. These results show increased 
TLE1 expression when the P493.6 cell line is proliferating due to the C-Myc 
programme relative to the EBV programme. It must be noted that in LCLs, 
** 
A 
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EBNA2 positively trans-activates C-Myc; thus, the EBNA2 proliferating 
P493.6 cells also express endogenous C-Myc expression. However, in the 
absence of EBNA2 this expression is lost, hence the requirement for ectopic 
C-Myc to drive proliferation. Therefore C-Myc activity is present in both cell 
lines but at different levels. In P493.6 cells cycling due to C-Myc, TLE1 is up-
regulated by the loss of EBV-driven proliferation in ER/EB2.5. Consequently 
the increase in TLE1 expression in the C-Myc-maintained cells may be due 
to alleviation of the negative modulation derived from EBV latent proteins 
rather than attributable to positive regulation by C-Myc. However a positive 
C-Myc effect on TLE1 expression cannot be discounted in this model. 
 
4.2.8 TLE1 mRNA expression levels in a panel of BLs and LCLs 
 
In this study, two types of B cell lines were utilised, BLs and LCLs. Primary B 
lymphocytes proliferate during only a very limited time in culture (Hahn 
2002). However if these cells are infected with EBV in vitro it leads to the 
establishment of continuously proliferating LCLs. LCLs display the full 
complement of EBV latent genes, and induce changes that include (i) the 
formation of cell clumps in culture, (ii) display of cell surface adhesion and 
(iii) activation markers and resilience against apoptosis (Bornkamm 2009b). 
In addition to growth transformation, sustained EBV activity is required to 
maintain an immortalised LCL. Thus LCLs exhibit growth and expression 
profile characteristics directed by EBV not only for the initial process of 
immortalisation but also on an ongoing basis. Burkitt’s lymphoma, on the 
other hand, is a B cell malignancy in which the cells contain characteristic 
chromosomal translocations of the long arm of chromosome 8 along with the 
Ig heavy or κ and λ light chain loci on chromosome 14, 2 or 22 respectively, 
bringing C-Myc regulation under the Ig transcriptional control (Bornkamm 
2009b). BLs exhibit significant shared characteristics although they do 
display cell line to cell line variation in characteristics such as EBV status and 
the precise chromosomal breakpoint translocation. Generally BLs grow in 
single cell suspension as they display no cell adhesion molecules. In addition 
they lack B cell activation markers, and EBNA1 is the only EBV latent gene 
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expressed (EBV positive BL only) and BL cells are sensitive to apoptosis 
arising from adverse growth conditions and toxic agents (Bornkamm 2009a). 
These features of the BL phenotype are present during in vitro culture of all 
BL cells from biopsies. However over time some of these have been shown 
to ‘drift’ towards type II and type III latency (group-II and group-III phenotypes 
respectively) (Reviewed by Bornkamm 2009a). The group-III BL cell lines are 
phenotypically altered compared to the group-I cells due to the presence of 
the EBV growth programme proteins. Group-III BLs, reminiscent of LCLs, 
express the complete EBV repertoire of latent genes including six EBV 
nuclear antigens (EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, EBNA-LP) 
three virus-encoded latent membrane proteins (LMP1, LMP2A, LMP2B) and 
the EBERs (Middeldorp, et al. 2003). Group-III BLs also display enhanced 
cell survival. These two phenotypically differing types of cell lines permit the 
study of EBV in two situations, one in which EBV is vital to the initiation and 
maintenance of the cell line (LCLs), and in the other wherein it may provide 
advantages to the cell but was not a key factor that led to the immortalisation 
of the cell (BL). 
 
In this part of the study TLE1 expression in a panel of B cell lines was 
evaluated. This panel consisted of cell lines with group-I phenotype 
(Akata4E3, DG75, Ramos and BJAB) along with EBV-positive cell lines 
displaying the group-III phenotype (AG876 and IB4). DG75 and Ramos are 
both EBV-negative BLs. The cell line Akata4E3 was an EBV-positive BL that 
spontaneously lost the EBV genome to give rise to an EBV-negative BL cell 
line (Shimizu, et al. 1994). BJAB is an EBV-negative non-Burkitt, B 
lymphoma cell line (Menezes, et al. 1975; Yamamoto, et al. 2000). IB4 is an 
EBV-immortalised LCL generated by infecting cord blood with the B95.8 
strain of EBV (King, et al. 1980). The EBV-positive BL AG876 exhibits an 
activated B cell phenotype expressing the latency III growth programme 
(group-III phenotype). All cell lines were maintained in the appropriate growth 
medium and passaged every 48 hours. Protein and total RNA samples were 
harvested during the exponential phase of growth for each cell line 
(approximately 24 hours post-passaging once the cell population had almost 
completely doubled).  
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4.2.9 Expression of other TLE family genes in ER/EB2.5  
 
A recent report concerning the Runx transcription factor included an analysis 
of TLE family gene expression in a range of B cell lines (Brady, et al. 2008). 
In agreement with the results presented here, it was shown that TLE1 is 
expressed at a higher level in LCLs in contrast to BL type I cells. Additionally, 
this group demonstrated results indicating that TLE2 was not detectably 
expressed in a range of B cell lines, and that both TLE3 and TLE4 were 
expressed in high levels in both LCLs and BLs. This prompted an analysis of 
TLE family gene expression in the present study to determine if TLE1 was 
differentially-regulated by EBV relative to the other TLE family members. The 
RT Profiler PCR SuperArray results presented earlier (Section 4.2.1) 
indicated that TLE1 was repressed by EBV during B cell infection, and that 
AES and TLE2 mRNA levels remained unchanged. TLE family members are 
quite closely related, and for this reason a discriminatory SYBR green assay 
for each family member was designed in this study. Primers were designed 
with high specificity to their target but with significant discrepancy to the other 
family members so as to avoid detection of the latter in the absence of the 
primary target. Each assay was verified to produce a single PCR product 
following melt curve analysis and agarose gel electrophoresis of the RT-
qPCR product generated. Each product was then sequenced to confirm the 
specific identity of the target (data not shown). 
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Figure 4.13: Effect of the EBV growth programme on the TLE family 
gene expression.  
A β-estradiol induction experiment was carried out using ER/EB2.5 to assess the 
effect of ER/EBNA2 activation on the mRNA levels of the TLE family members. 
RNA samples were taken during β-estradiol induction at the time points indicated. 
RT-qPCR analysis was performed as described in the legend to Figure 4.3, results 
were normalised using the internal control, TBP, and were expressed as relative 
quantitation as a function of the control. In this experiment, the control was 
designated as ER/EB + Est 24 hr; arbitrarily assigned a value of 1. (Data are Mean 
±SD, * P<0.05).  
 
The results generated from the TLE family study following activation of the 
EBV growth programme in ER/EB2.5 indicated that all TLE family members 
were to some degree negatively regulated by EBV. This was an unexpected 
observation bearing in mind the results from the RT Profiler PCR SuperArray 
which indicated no change in expression level for AES or TLE2 post-
infection. This may represent a shortcoming of the ER/EB2.5 cell culture 
model as a true representation of an infected naïve B cell. It was shown 
previously in this study that TLE1 undergoes significant transcriptional 
repression and de-repression following ER/EBNA2 activation and inactivation 
respectively in ER/EB2.5 (Section 4.2.3). In a second experiment in which 
EBV-driven growth was de-activated following deprivation of β-estradiol, total 
RNA samples were again taken and analysed for mRNA levels from TLE 
family genes.  
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Figure 4.14:  Withdrawal of the EBV growth programme positively 
regulates several TLE family members.  
ER/EBNA2 function was deactivated in the ER/EB2.5 cell line by withdrawal of β-
estradiol from the culture medium. RNA samples were prepared at the time points 
indicated post-deactivation. RT-qPCR analysis was performed as described in the 
legend to Figure 4.3, results were normalised using the internal control, TBP, and 
were expressed as relative quantitation as a function of the control. In this 
experiment, the control was designated as ER/EB –est 0 hr; arbitrarily assigned a 
value of 1. (Data are Mean ±SD).  
 
 
It can be seen from this experiment that relief of transcriptional suppression 
was most potent for TLE1, relative to the other family members, in response 
to EBV growth programme inhibition. The TLE1 mRNA level increased 32-
fold as a result of ER/EBNA2 deactivation. In agreement with the results from 
the induction of EBV-driven proliferation in ER/EB2.5 (Figure 4.13), TLE2 
and TLE3 exhibited greater transcriptional de-repression than TLE4 and 
AES. Neither TLE4 nor AES displayed any de-repression after the de-
activation of ER/EBNA2, although both appeared to be repressed by the 
activation of ER/EBNA2. These results confirm that EBV transcriptionally 
modulates a number of TLE family members in ER/EB2.5; however, TLE1 
appears to be the most potently regulated and the de-activation of β-estradiol 
elicited no significant modulation of AES or TLE4 family members over the 
time period of the experiment. 
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4.2.10 Regulation of TLE family members in the P493-6 cell line  
 
The results of this investigation have so far indicated that EBV differentially 
regulates members of the TLE family to some extent in an LCL background. 
Activation of EBV-driven proliferation in the LCL, ER/EB2.5, appears to 
repress the transcriptional expression of each TLE family member. The 
P493-6 cell line, described previously in section 4.2.7, was next employed to 
further examine the modulation of the TLE family in response to EBV-driven 
growth in an LCL. The P493-6 cell line can be induced to undergo, (i) EBV 
driven proliferation [due to the induction of ER/EBNA2 by β-estradiol and the 
repression of ectopic C-Myc expression by the presence of tetracycline (+β-
estradiol, + Tet)], reminiscent of the parental cell line ER/EB2.5 when β-
estradiol induced, or (ii) C-Myc driven growth [stimulated by the absence of 
β-estradiol and tetracycline (-β-estradiol, - Tet)]. P493.6 therefore allows a 
comparative analysis of the EBV and C-Myc growth programmes in an 
isogenic cell background. 
 
 
Figure 4.15: Steady state TLE mRNA levels in P493.6 cells driven to 
proliferate on the EBV growth programme (P493.6 EBNA2) or due to 
ectopic C-Myc (P493.6 Myc).  
RT-qPCR was performed to determine TLE family mRNA levels in the p493-6 cell 
line proliferating due to C-Myc (P493.6 Myc) relative to cells proliferating due to EBV 
(P493.6 EBNA2). At the cycling programme indicated, RT-qPCR was performed as 
described in the legend to figure 4.13. Results were normalised using the internal 
control, TBP, and were expressed as relative quantitation as a function of the 
control. In this experiment the control was set at P493-6 Myc cells; arbitrarily 
assigned a value of 1. (Data are Mean ±SD, *P<0.05, ** P<0.01, *** P<0.001). 
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It was observed that there were significant variations in the steady-state 
levels of mRNA from TLE family members in P493.6 cycling on the EBV 
versus C-Myc growth programmes. The mRNA levels of both TLE1 and 
TLE2 were higher in cells cycling due to C-Myc in contrast to cells 
proliferating due to EBV. In contrast to this, the steady state levels of AES 
and TLE4 were lower in C-Myc-driven cells. Although readily detectable in 
the parental ER/EB2.5, TLE3 mRNA could not be detected at all in P493.6. 
This unanticipated problem remains to be explained and it was not, 
therefore, possible to conclude on TLE3 expression in this case. Taking into 
consideration the results obtained from the P493.6 and ER/EB2.5, EBV-
driven growth appears to have a stronger negative impact on the 
transcriptional activity of both TLE1 and TLE2 in comparison to the remaining 
TLE family members, AES and TLE4.   
 
Figure 4.15 shows that TLE4 and AES mRNA levels are higher in P493.6 
cells driven to proliferate due to EBV in comparison to those cycling on the 
C-Myc growth programme. Interestingly, while it has been shown that 
activation the ER/EBNA2 by β-estradiol in ER/EB2.5 leads to the repression 
of AES and TLE4 at the transcriptional level, inhibition of ER/EBNA2 by 
withdrawal of β-estradiol from the growth medium led to little change in the 
mRNA levels of TLE4 and AES. In contrast to this, the TLE family members 
TLE1, TLE2 and TLE3 are modulated by both the β-estradiol-dependent 
activation and deactivation of the EBV growth programme in ER/EB2.5.  
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4.2.11 Expression of TLE genes in a panel of BL and LCL cell lines 
 
Previously in this study a trend was discerned with respect to TLE1 
expression in B cell lines available within the laboratory (Section 4.2.8). TLE1 
mRNA levels were generally considerably lower in EBV-negative BLs than in 
the EBV positive BLs and LCLs. To determine if any such trend exists with 
respect to regulation of the other TLE family members in the same panel of B 
cell lines, total RNA was extracted as before from each cell line 24 hours 
after passaging, and RT-qPCR was employed to examine the relative mRNA 
levels of each TLE family member.  
 
 
Figure 4.16: RT-qPCR analysis of the relative mRNA levels of TLE 
family members in a range of EBV-associated B cell lines.  
RT-qPCR was used to monitor the expression of the TLE family in a range of B cell 
lines including EBV-negative B cell line extracts for DG75, Ramos, BJAB and 
Akata4E3, EBV-positive BL AG876, and the EBV-immortalised LCL, IB4.  RNA 
samples were prepared from each cell line in the same time frame, and RT-qPCR 
analysis of TLE1 mRNA levels was performed as described in the legend to Figure 
4.3. Results were normalised using the internal control, TBP, and were expressed 
as relative quantitation as a function of the control. The Control cell line was 
arbitrarily assigned a value of 1. (Data are Mean ±SD). 
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No correlation was observed for any of these genes between the different B 
cell lines (Figure 4.16).  
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4.3 Discussion 
 
In the search to elucidate the mechanisms behind EBV infection, a number 
of large-scale studies have been performed using technology such as DNA 
microarrays, and RT-QPCR arrays. These experiments give rise to large 
volumes of data that can simultaneous identify genes associated with the 
spectrum of EBV products or with individual products. However, many of 
these published studies have utilised inducible cell culture systems in which 
selected or complete EBV expression can be controlled in an immortalised 
cell background. The present study was unique as it was performed using 
primary untouched naϊve B cells for comparison. This ensured that any 
irreversible changes that occur in the naive B cell post-infection could be 
identified in addition to reversible gene modulation. This method facilitated 
the analysis of EBV infection from the initial contact through to the EBV 
immortalised cell lines, which are so intensively studied. A number of 
previously unidentified genes such as TLE1, STIL and Nurr1 were implicated 
as being modulated in response to EBV infection, in untouched naϊve B cells, 
using the RT Profiler PCR SuperArray. 
 
In this study, a naϊve B cell pool was infected with EBV in an attempt to 
identify novel cellular gene targets of this virus. A selection of differentially 
regulated candidate cellular genes was then examined in a cell culture model 
(ER/EB2.5) that permits activation/inactivation of EBV latent gene expression 
with β-estradiol. Like any LCL, ER/EB2.5 cells proliferate due to the effects of 
EBV latent gene products, and ER/EBNA2 inactivation (in the absence of β-
estradiol) leads to a cessation of the EBV growth programme. The ER/EB2.5 
system may have shortcomings, however, in terms of its ability to ‘mimic’ 
what happens during EBV infection and B cell immortalisation. Firstly, there 
is evidence that ER/EB2.5 cells, in the absence of β-estradiol, mimic a 
resting B cell but not a true naϊve B cell. Once a naϊve B cell has come into 
contact with antigen, irreversible changes occur within the cell to generate a 
memory B cell. When the naϊve B cell associates with its cognate antigen the 
BCR becomes endocytosed allowing the internalisation of the antigen. The 
antigen is then degraded and formed into complexes with major 
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histocompatibility complex (MHC) II to facilitate presentation by the B cell. 
Once infected by EBV, naϊve B cells proceed to differentiate just as the 
uninfected cells. Secondly, unlike naϊve B cells, ER/EB2.5 cells may be 
epigenetically programmed, thus restricting the potential to undergo changes 
in gene expression (Gordadze, et al. 2004). Thirdly, β-estradiol has been 
found to activate PI3K signaling from the endoplasmic reticulum, which in 
turn may complicate the analysis of some genes (Spender, et al. 2006). 
Despite these inconsistencies, ER/EB2.5 is a widely used cell culture model 
that facilitates analyses of the roles of EBV latent genes in infected B cells. 
 
Regulation of TLE1 by EBV 
 
The discovery of new cellular genes that are EBV targets was of particular 
interest in this study. Traditionally, emphasis has been placed on 
transcriptional activation of cellular genes; however, over time it has become 
clear that gene repression plays an equally important role in cell fate 
(Cinnamon and Paroush 2008a). One noteworthy gene that displayed 
potential as a novel EBV negatively-regulated target in the naϊve B cell 
infection RT Profiler PCR SuperArray study was TLE1. In conditional LCLs 
the negative effect of EBV on TLE1 expression was also consistently 
demonstrated; thus, it can be surmised from the evidence available that EBV 
down-regulates TLE1 in an LCL. The results from the RT Profiler PCR 
SuperArray and the conditional LCL ER/EB2.5 were in agreement and 
suggest that TLE1 is a novel negative target of EBV. Conflicting results were 
obtained, however, for the regulation of two other TLE family members, AES 
and TLE2. In the RT Profiler PCR SuperArray the mRNA levels for AES and 
TLE2 did not change following the infection of naϊve B cells with EBV; 
however, activation of ER/EBNA2 in ER/EB2.5 resulted in down-regulation of 
both family members (Figure 4.13). Furthermore, the removal of β-estradiol 
from the growth medium resulted in the up-regulation of TLE2, although AES 
expression remained relatively unchanged after ER/EBNA2 de-activation 
(Figure 4.14). These inconsistencies may highlight the inadequacy of 
comparing a growth-arrested ER/EB2.5 cell to a true resting naïve B cell. 
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Interestingly, EBNA2 trans-activated TLE1 when activated (in the form of 
ER/EBNA2) in one BL cell line, but this effect was not corroborated in a 
second such cell line in which EBNA2 expression was controlled from a 
tetracycline-regulated promoter (Section  4.2.6). In BL41-9A, a conditional 
cell line in which an almost complete repertoire of EBV latent genes is 
expressed in response to activated ER/EBNA2, TLE1 mRNA levels remained 
unchanged throughout ER/EBNA2 activation. However in the isogenic cell 
line, BL41-K3, in which EBNA2 is the sole EBV protein, TLE1 mRNA levels 
increased significantly following ER/EBNA2 activation. The EBNA3 family 
negatively regulate EBNA2 targets by competitively binding to CBF1, 
sequestering the transcription factor and preventing its utilisation by EBNA2 
(Waltzer, et al. 1996). It may, therefore, be the case that the co-expression of 
the EBNA3 family in the conditional BL tempers the ability of EBNA2 to trans-
activate TLE1. The lack of LMP1 induction following EBNA2 activation in 
BL41-9A may also imply a role for LMP1 in TLE1 repression. 
 
Fundamental differences between BL-derived cancer cells and LCLs may 
account for the discord observed regarding TLE1 regulation in response to 
EBV proteins in these two cell types. LCLs are immortalised cell lines that 
were transformed by infection of naϊve B cells by EBV. Cancerous cell lines 
occur due to immortalisation arising from a different source or sources. This 
malignant transformation is generally due to a collection of aberrant events 
that allow cell survival and proliferation. As such LCLs and tumour derived 
cell lines are quite different in origin but can display many of the same pro-
survival characteristics. From the experiments performed in this study it can 
be concluded that in an LCL, TLE1 expression is down-regulated following 
EBV infection and latent gene expression. This is in agreement with the 
observations of TLE repression in haematological oncogenic cells. The basis 
of cell line transformation of the two cell sources used here, malignant BLs 
and non-malignant LCLs, could be the causative factor for the lower levels of 
TLE1 expression observed in EBV-negative B cell lines when compared to 
LCLs. 
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TLE family proteins 
 
TLE1 is a member of the human transducin-like enhancer of split (TLE) 
family. The TLE family is composed of five members; amino terminal 
enhancer of split (AES), TLE1, TLE2, TLE3 and TLE4. This family contains 
the first characterised vertebrate homologues of the well studied Drosophila 
gene known as groucho (Stifani, et al. 1992). In 1968, groucho was the first 
metazoan co-repressor identified and was so named due to a viable mutation 
in the gene resulting in supernumerary bristles growing above the eyes of 
adult Drosophila. This growth was reminiscent of the thick eyebrows of 
Groucho Marx and the gene took its name from there (Buscarlet and Stifani 
2007). Groucho was mischaracterised when initially identified as a 
‘transducin-like enhancer of split’, as it was mapped to the enhancer of split 
chromosomal region, and although it did not show significant relation to 
known proteins it contained a 330 amino acid stretch that shared likeness 
with the β subunit of Transducin. However several years later this subunit 
was found to have no functional relation to the β subunit and Groucho was 
identified as a nuclear protein that mediated transcriptional repression. The 
impact of the mis-classification was to lead to the naming of the human 
homologues of groucho as transducin-like enhancer of split 1, 2, 3 and 4 
(Buscarlet and Stifani 2007).  
 
Most TLE family members are approximately 80-95 kDa with the exception of 
AES, which is a shorter version at approximately 25 kDa. Thus, the TLE 
family can be divided into two subgroups according to their structure. TLE 
family members 1-4 share the same full length structural features (Figure 
4.17). These include a five-domain structure characterised by two highly 
conserved N-and C-terminal regions, designated the Q and WDR domains 
respectively, and three less conserved internal domains denoted Gp, CcN 
and SP (Stifani, et al. 1992). The WDR is the most highly conserved region 
with 86% amino acid identity among species (Bajoghli 2007). The most 
divergent of the full length TLE family members is TLE2 (Stifani, et al. 1992). 
The second subgroup is composed of truncated versions of TLE1-4, 
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including AES, which lack either the WDR or Q domain (Zhang, et al. 2008). 
The highly conserved amino terminal Gln-rich (Q) and Trp-Asp-repeat (WDR) 
domains are essential for (i) the ability of Gro/TLE to homo/heterodimerise 
and (ii) to interact with a variety of DNA-binding proteins to mediate 
transcriptional repression (Buscarlet and Stifani 2007). As such these 
‘truncated’ TLE members are thought to play a role in tandem with their full 
length counterparts. 
 
 
Figure 4.17: Structure of Gro/TLE.  
Gro/TLE proteins have five evolutionarily conserved domains. These include: (i) the 
N-terminal Q domain (Red), which mediates Gro/TLE oligomerisation (Song, et al. 
2004); (ii) The yellow GP region, that does not demonstrate significant conservation 
among the vertebrates or invertebrates; (iii) The blue CcN region, comprising of 
phosphorylation sites for CK2 and cdc2 (hence ‘CcN’). These sites are adjacent to 
nuclear localisation signals; (iv) The brown SP domain, which is a serine/proline rich 
zone believed to be part of the repressor activity of Gro/TLE (Chen and Courey 
2000), and (v) the WDR. This is the most substantially conserved region of the 
Gro/TLE protein (green domain). This mediates interactions with a variety of DNA-
binding transcription factors that belong to either the WRPW or Eh1 motif family 
(Stifani, et al. 1992). Figure adapted from (Buscarlet and Stifani 2007). 
 
AES retains only the Q and GP domains (Figure 4.18). The N-terminal region 
of AES is approximately 130 aa in size with 70-75% familial homology to the 
Q domain, followed by weak likeness to the GP region (See Figure 4.17). 
Due to a lack of a WDR domain, it cannot directly bind many TLE associated 
target proteins such as Hes and Pax. AES is believed to have two functions: 
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firstly to act with a similar function to other TLE members in certain contexts, 
and secondly to exist as a dominant/negative TLE family regulator by hetero-
dimerising via the Q region of TLE and its Q domain-mediated targets 
(Buscarlet and Stifani 2007).  
 
 
 
Figure 4.18: Schematic of TLE and AES structural Domains.  
(A) The structure of full length TLE family members (TLE1-4) consists of 770 
residues spanning five domains. The N terminal Q region, followed by the internal 
GP, CcN and SP domains, terminated at the WDR domain. (B) AES is a truncated 
family member composed of 130 residues. AES contains only the Q and GP 
domains. 
 
 
TLE1 has been mapped to the chromosomal location 9q21.32 (Buscarlet and 
Stifani 2007), and TLE4 has been mapped to 9q22.31, neighbouring TLE1 
(Hancock, et al. 2009). AES has been mapped to an apparent TLE gene 
cluster at chromosomal location 19p13.3. TLE2 has been mapped in a 
tandem array with AES at this chromosomal location (Liu, et al. 1996). TLE3 
has been mapped to the chromosomal location 15q22 (Liu, et al. 1996). 
 
The TLE proteins are near ubiquitous complex repressive nuclear factors 
that lack the ability to bind DNA. They can nonetheless interact with a 
diverse repertoire of transcription factors capable of binding DNA such as 
Hes, Runt domain proteins (Runx), LEF1/Tcf, Pax and C-Myc to elicit their 
response via specific gene regulatory sequences (Jennings and Ish-
Horowicz 2008). TLE1-4 expression has been observed in a wide range of 
tissues; however, expression levels can vary significantly between each 
family member in the same tissue (Buscarlet and Stifani 2007; Jennings and 
Ish-Horowicz 2008). This variation in the expression levels of each TLE 
member in the same cell indicates differential regulation of each gene, thus 
implying a non-redundant function for each (Yao, et al. 1998). Gro/TLE family 
members appear to be highly conserved in both invertebrates and 
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vertebrates. It may be surmised that each individual TLE family member has 
a unique function which is cell and context dependent. The persistence of 
this highly conserved family signifies a crucial role for them in mammals 
(Buscarlet and Stifani 2007; Jennings and Ish-Horowicz 2008). TLE family 
members have been implicated as core repressor proteins in the absence of 
activated signaling in pathways such as Wnt and Notch. To ensure that 
targets of the Wnt and Notch signaling pathway are silenced in the absence 
of the appropriate signal, TLE family members bind to these targets as a 
repressor complex, thus preventing their transcription. This TLE-mediated 
repression is only alleviated in the presence of the activated effector protein. 
Evidence suggests that while TLE family members possess specialised roles 
in the cell, the remaining TLE family members may have the ability to elicit a 
similar response in the absence of the principal effector TLE in that cell type. 
This response may partially compensate for the loss of a family member but 
may not be sufficient for long-term or complete TLE-led repression. TLE2 
interacts with the transcription factor Hes1 to stimulate repression; however, 
this repression is quantitatively weaker than the TLE1/Hes1 mediated effect 
(Grbavec and Stifani 1996; Fisher, et al. 1996; Grbavec, et al. 1998). 
 
The regulation and function of TLE family proteins and association with 
malignant disease 
 
EBV target genes are generally important players in signaling pathways that 
can influence the fate of the cell, such that EBV can promote survival and 
proliferation, whilst simultaneously averting cell death, terminal differentiation 
and detection by the immune surveillance. In this section the role of the TLE 
family will be discussed in an attempt to determine the possible advantages 
EBV could acquire by modulating the expression of the TLE family member, 
TLE1.  
 
Due to the widespread expression of the TLE family, it was assumed that 
TLE activity was regulated by the distribution of their co-repressor partners. 
However, it has now emerged that TLE regulation is much more complex 
and it has been shown that TLEs can be regulated in a signal-induced 
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context dependent manner. To date, three main mechanisms by which TLE 
can regulate the expression of target genes have been identified: (i) 
availability of dependent co-repressors, (ii) competitive displacement of TLE 
by appropriate co-activators and (iii) post-translational modifications such as 
phosphorylation (Cinnamon and Paroush 2008b), (see Figure 4.19). In 
addition, although almost ubiquitously expressed, transcriptional regulation of 
TLE has also been observed in transcriptomic studies.  A number of studies 
have demonstrated de-regulated TLE expression levels in malignant cells 
relative to their normal counterparts (Terry, et al. 2007, Allen, et al. 2006). 
Nevertheless, the regulators responsible for this transcriptional modulation 
have yet to be identified. 
 
 
Figure 4.19: Mechanisms of TLE mediated repression.  
Gro represents TLE1; (A) Co-repressor-dependent TLE activity. Notch activation 
stimulates the expression of TLE co-repressor proteins such as Hes/E(Spl). Hes 
can then recruit TLE and fulfil its role in Notch signaling. (B) Regulation in response 
to co-activator competition demonstrated in the Wnt signaling pathway. TCF and 
TLE co-operate to repress target genes in an un-stimulated cell. Wnt signaling 
activates the stabilisation of β-catenin; this co-activator can then displace TLE 
creating an activator complex that induces gene expression. (C) RTK signaling 
promotes the phosphorylation of TLE; this prevents TLE activity, thus activating 
RTK target gene expression. R represents a DNA binding repressor. Figure adapted 
from (Cinnamon and Paroush 2008a). 
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Evidence has shown that activity of TLE can be up or down-regulated by 
post-translational modifications such as residue specific phosphorylation 
(Jennings and Ish-Horowicz 2008). However, data have indicated that 
phosphorylation can have opposing effects on TLE1 function. Grg1, the 
murine TLE1 homologue, is found as part of a Hes1-associated protein 
repressor complex in rat neuronal cells. Phosphorylation of this complex 
leads to the dissociation of Grg1, leading to a decline in repression (Jennings 
and Ish-Horowicz 2008). Conversely, studies in Drosophila have shown that 
phosphorylation of the CcN region of TLE1 by CK2 kinase actually promotes 
the binding of transcription factors and chromatin, thereby in turn promoting 
repressor complex formation leading to increased repressional activity of 
TLE (Nuthall, et al. 2004). Thus, the effect of post-transcriptional regulation 
on TLE appears to be context-dependent. 
 
Monitoring of the transcriptional and protein expression levels of these 
proteins has identified a link between altered TLE family expression and a 
number of malignant diseases (Jennings and Ish-Horowicz 2008). Indeed, 
de-regulated TLE expression has been directly associated with both cervical 
and colonic neoplasias. This aberrant expression of TLE appears to go hand 
in hand with elevated Notch expression levels (Liu, et al. 1996; Zagouras, et 
al. 1995). Elevated TLE2 and TLE3 expression has been shown to be a 
specific feature of higher grade meningiomas. Dys-regulated Notch 
expression is a key step for meningioma development and the evidence 
suggests that modulation of the Notch pathway by TLE expression signals a 
more malignant phenotype (Cuevas, et al. 2005). In addition to TLE2 and 
TLE3, amplified expression of TLE1 in mouse models has implicated TLE1 
as a causative factor in murine lung adenocarcinoma (Allen, et al. 2006). 
Furthermore, TLE1 protein expression alone has been highlighted as a 
signature marker for synovial sarcoma (Terry, et al. 2007). A considerable 
body of evidence, therefore, suggests that TLE expression may act as a 
promoter of oncogenesis. Many of the studies discussed so far recognise 
elevated TLE expression as a causative or sustaining factor in a number of 
malignancies; however, none of these studies have linked over expression of 
TLE to hematopoietic malignancy. Recent work utilising transcriptomic 
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microarray expression profiles comparing hematopoietic malignancies to 
healthy cells has revealed a very different scenario regarding TLE regulation 
and tumourgenesis in hematopoietic cells, TLE repression has been 
implicated as a key factor in cancer development such as AML (Dayyani, et 
al. 2008) and several other haematological malignancies (Fraga, et al. 2008). 
These findings suggest that TLE repression plays a role in the malignant 
transformation of hematopoietic cells or tumour maintenance thereof. These 
findings, therefore, lend support to the notion that EBV down-regulation of 
TLE1 might elicit similar survival advantages in the EBV-infected cell.  
 
Two TLE family members, TLE1 and TLE4 have been found to function as 
tumour suppressor genes in some translocation types of Acute Myeloid 
Leukemia (AML). The t(8:21) AML translocation is one of the most widely 
found genetic anomalies in acute myeloid leukemia. This translocation forms 
an AML-ETO fusion gene. Evidence has shown that this translocation alone 
cannot initiate leukemogenesis, implying that a second event must occur to 
stimulate the malignancy. Analysis of structural genomic stability in malignant 
AML cells indicated that the single most common genetic aberration in 
t(8:21) AML cells was deletion events concerning the long arm of 
chromosome 9, del(9q) on which both TLE1 and TLE4 have been mapped. 
This chromosomal abnormality, coupled with expression studies in t(8:21) 
AML cells, led to the identification of TLE1 and TLE4 as down-regulated 
targets occurring frequently in this subset of AML. Experimental analysis 
determined that complete knockdown of TLE1 and TLE4 using short hairpin 
RNA (shRNA) was sufficient to rescue these t(8:21) AML cells from 
apoptosis. Furthermore, TLE1 and TLE4 silencing led to increased 
proliferation of the AML cells in culture. In contrast to these results, the 
enforced expression of TLE1 and TLE4 in t(8:21) AML cells led to apoptosis 
and cell death (Dayyani, et al. 2008). These results implicate TLE1 
expression as a negative influence on the survival of a malignant T cell. 
 
Further evidence from studies in a panel of B and T cell malignancies 
indicates that TLE1 has a function in the acute myelogenous leukemia 1 
(AML1) signaling pathway (Fraga, et al. 2008). To date it has emerged that, 
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in diffuse large B cell lymphoma, acute myeloid leukemia and other 
haematological malignancies, hypermethylation of the CpG island in the 
TLE1 promoter is present, leading to silencing of the TLE1 gene. Re-
introduction of TLE1 into these leukemia and lymphoma cells caused growth 
inhibition. This implies that the loss of TLE1 in these malignancies may have 
been a contributing factor in the instigation and/or maintenance of the 
oncogenic condition. Leukemia and lymphoma tumours in which the TLE1 
promoter remains un-methylated were also studied to determine the 
contribution of modulated TLE1 expression on the malignant hematopoietic 
cell phenotype. shRNA knockdown was performed in these tumourgenic 
hematopoietic cells expressing TLE1, and this knockdown caused an 
increased growth rate in the malignant cells (Fraga, et al. 2008). The 
evidence available for the role of TLE1 in haematological malignancies 
indicates that in this context, TLE1 may drive a negative cell fate, hence 
acting as a tumour suppressor gene.  Being a negative target of EBV, it may 
therefore be the case that TLE1 down-regulation is an important host-virus 
interaction that contributes to B cell growth transformation. 
 
The expression levels of TLE1 at both the mRNA and protein level were 
significantly lower in the EBV negative BLs when compared to the EBV 
positive cell lines (Figure 4.12). This was initially unexpected as it had 
previously been demonstrated that in an LCL, EBV activation resulted in 
down-regulation of TLE1 expression at both the mRNA and protein level. 
However, bearing in mind the published data from Fraga et al 2008, it can be 
seen that TLE1 silencing was found to be a feature of several types of 
malignancies of lymphoid origin. The results of the current study indicate that 
in addition to the malignancies studied by Fraga’s group, a number of BL cell 
lines also appear to demonstrate significantly diminished levels of TLE1 
expression.  It would be highly beneficial in the future to determine if the 
down-regulation of TLE1 plays a role in the malignant state of these BL cell 
lines. The effect of re-introduction of TLE1 expression in these cell lines 
using an ectopic TLE1 expression vector could expose TLE1 silencing as 
one of the mechanisms that enables cell proliferation in these cases. 
Although c-myc translocation is the characteristic feature of BL tumours, c-
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myc translocation alone cannot cause BL. It has been shown that TLE1 has 
been silenced in a number of lymphatic malignancies due to promoter 
methylation (Fraga et al 2008). This could be pursued in these cell lines, 
simple treatment of these cell lines with methylation inhibitors such as 5-Aza-
cytidine may result in TLE1 modulation.  
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Enhancer of Split 1 (TLE1) in 
an LCL 
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5.1 Introduction 
 
The infection of primary B cells by EBV induces cell activation and 
proliferation, an efficient process that leads to the outgrowth of permanently 
growing LCLs. Central to this B-cell immortalisation process is the 
modulation of host cellular gene expression by EBV viral gene products. The 
characterisation of these host-virus interactions has the potential to shed 
light on the mechanisms that drive cell transformation and the potential role 
of EBV in the development of EBV-associated malignancies.  In this study, 
for the first time, the cellular gene Transducin-Like Enhancer of Split 1 
(TLE1) has been identified as a candidate novel negative target of EBV. This 
study will now focus on identifying a role for TLE1 in an LCL in an effort to 
determine the rationale for EBV-associated TLE1 repression.  
 
Studies have demonstrated that TLE family proteins are key negative 
regulators of several important cell signaling pathways including the Notch 
and wingless/Wnt signaling pathways (Reviewed in Buscarlet and Stifani 
2007; Jennings and Ish-Horowicz 2008). TLE participates in these pathways, 
playing many critical roles in development, neurogenesis, and oncogenesis 
(Chen and Courey 2000, Dayyani, et al. 2008, Fraga, et al. 2008). However, 
contradictory evidence exists pertaining to the role of TLE1. Examples of 
TLE1 inducing both a protective or destructive impact on cell fate have been 
shown. For instance, the TLE family member AES has been found to induce 
apoptosis in cerebellar granule neurons (CGNs). As a TLE1 agonist, the 
apoptotic effect of AES in CGNs can be negated by the forced expression of 
TLE1 (Zhang, et al. 2008). In the context of CGNs, TLE1 asserts a protective 
role in the fate of the cell. Furthermore, substantiating the concept of TLE1 
as a pro-survival factor in cell fate, it has been shown that TLE1 is up-
regulated in 96% of synovial sarcoma tumours. TLE1 expression is now 
being signalled as a pathological marker for the identification of synovial 
sarcoma. The possibility of therapeutically targeting TLE1 in synovial 
sarcoma is also being investigated (Knosel, et al. 2010). In complete contrast 
to these findings are those discussed in Section 4.3, in which TLE1 has been 
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found to possess a distinct negative role in the survival of hematopoietic cells 
compared to other cells types in which the TLE family has been studied. 
Thus TLE1 functions in a context-dependant manner in cell survival and 
disease, and the potential role played by TLE1 in an EBV-transformed 
haematopoietic cell line shall be examined further in this study.  
 
Recruitment of TLEs to promoters by their DNA-binding associates induces 
repression of the bound target gene. An exact model has not yet been 
agreed, but repression is believed to occur by one of three possible routes: 
(i) TLE may act directly by preventing the ‘activators’ from binding to DNA, (ii) 
it could function by interruption of the basal transcriptional machinery, or (iii) 
it might act through its interaction with histone proteins. The models for TLEs’ 
mode of action conflict with one another, leaving open the possibility that 
these proteins may utilise more than one distinct molecular mechanism to 
repress transcription (Jennings and Ish-Horowicz 2008). It has been 
speculated that TLE may encompass the intrinsic ability to bind, modulate 
and protect chromatin to facilitate transcriptional repression. This proposal 
was based on the known ability of the TLE family to exert their repressive 
effects by blocking the basal transcriptional machinery, recruiting HDAC’s 
and interacting with the tails of core histones H3 and H4 (Sekiya and Zaret 
2007). 
 
TLE proteins have been shown to form homotetramers through interaction of 
the helices in their Q domains (Chen, et al. 1998). Studies in Drosophila 
have indicated that oligomerisation is required for TLE repression (Song, et 
al. 2004; Chen, et al. 1998). However, work recently carried out involving 
mutation of the Q domain (which is required for oligomerisation) indicated 
that oligomerisation occurs on a context-to-context basis and is not always 
necessary (Jennings and Ish-Horowicz 2008).  
 
TLE1, like the other TLE family members has a role in both the Wnt and 
Notch signaling cascades. The overlapping expression of Notch and TLE 
proteins led to the suggestion that these proteins may play a co-operative 
role in cell maintenance (Liu, et al. 1996). Upon activation of the Notch 
185 
 
pathway, activated transcription complexes containing intracellular Notch 
(NIC) and CBF1 initiate transcription of their cellular targets. The best 
characterised Notch targets are the members of the Hes family which 
encodes basic helix-loop-helix proteins (bHLH). TLE1 has been shown to act 
as a Notch antagonist by binding to the Notch co-repressors in the absence 
of Notch, thus silencing rather than activating the Notch target gene 
(Reviewed in Buscarlet and Stifani 2007). The Notch signaling pathway was 
described in detail in Chapter 1. 
 
Wnt is a key signaling pathway for cell maintenance and oncogenic control in 
adult differentiated cells. Wnt activity has been linked to cellular functions 
such as apoptosis, survival, proliferation and cell motility (Reviewed in Willert 
and Jones 2006). It has been determined that defects in the wnt canonical 
pathway contribute to the pathogenesis of a variety of malignant states 
(Gelebart, et al. 2008) and also play a major role in osteoporosis (Patel and 
Karsenty 2002). The Wnt effector protein Tcf/Lef acts as a transcriptional 
repressor when bound to TLE1; however, once Wnt is activated β-Catenin 
directly displaces TLE1 from the Tcf/Lef repression complex, alleviating the 
TLE/Lef mediated repression. β-Catenin transforms the complex into an 
activator complex rather than a TLE-associated repressor complex. This 
confirms that TLE plays the role of a repressor in at least one key cellular 
pathway (Daniels and Weis 2005). 
 
Here, evidence is presented that (i) TLE1 drives the activation of a CBF1-
regulated promoter in an LCL, (ii) TLE1 does not significantly regulate the 
activity of an NF-κB responsive promoter in the same LCL, (iii) enforced 
expression of TLE1 in an LCL leads to a decrease in the rate of cell 
proliferation, (iv) ectopic TLE1 modulates expression of the key EBV latent 
gene EBNA2 and cellular Notch target genes such as Cyclin D1, E2A, Pax5, 
Runx3, and CD23, (v) knockdown of TLE1 in an LCL using shRNA 
expression vectors leads to an increase in the rate of cell proliferation and 
(vi) TLE1 knockdown also results in the up-regulation of the Notch target 
genes, Cyclin D1, E2A, Pax5, Hes1 and Hey1. 
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5.2 Results 
 
5.2.1 TLE1 trans-activates a CBF1-regulated promoter in an LCL 
 
The pGa981.6 plasmid is a reporter vector that contains multimerised copies 
of a CBF1-binding sequence placed upstream of a minimal promoter that 
drives expression of a downstream luciferase gene (Minoguchi, et al. 1997). 
The transcription factor CBF1 is a primary nuclear effector of the Notch 
signaling pathway and expression of the reporter enzyme is therefore 
dependent on this Notch/EBNA2-regulated enhancer. TLE family proteins 
have been identified as repressor complex participants for Notch target 
genes (Fortini 2009). 
 
To investigate a role for TLE1 in the Notch signalling pathway in an LCL 
background, the IB4 cell line was co-transfected with pCMV2 FLAG TLE1 (a 
TLE1 expression vector) and pGa981.6. As before, and to allow for 
normalisation of results between individual transfections, a small quantity of 
β-galactosidase expression vector (pCMV LacZ) was also co-transfected in 
each case. The cells were harvested 48 hours post-transfection and 
luciferase levels expressed from the pGa981.6 luciferase reporter construct 
were quantified using a Luminoskan 1400  luminometer. These results were 
normalised against β-galactosidase values to compensate for variations in 
transfection efficiency. 
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Figure 5.1: TLE1 positively regulates a CBF1-dependent promoter. 
IB4 cells were co-transfected with increasing quantities of pCMV2 FLAG TLE1; 0 
µg, 1 µg, 5 µg and 10 µg, along with 2 µg of the luciferase reporter construct 
pGa981.6. Cells were harvested 48 hours post-transfection and assayed for 
luciferase activity. Luciferase values were evaluated based on the β-galactosidase 
activity measured from a co-transfected pCMV-LacZ reporter, which was included in 
all transfections. Normalised values were expressed as percentage trans-activation 
relative to the corresponding data obtained from co-transfection with the empty 
expression vector pCMV and pGa981.6 vector. Data are presented as the average 
of three independent experiments (Data are Mean ±SD, * P<0.05).  
 
Transient transfection of the LCL IB4 showed that co-transfection of the 
pGa981.6 luciferase reporter plasmid with increasing quantities of pCMV2 
FLAG TLE1 expression vector led to a dose-dependent increase in 
promoter-driven luciferase values. Trans-activation was at its most potent, 
with an approximate 250% increase in activity upon co-transfection with 5 µg 
of the TLE1 effector plasmid. Although the extent to which TLE trans-
activated expression of the luciferase reporter varied between experiments, 
these results nonetheless indicated that TLE1 could modulate the CBF1-
regulated promoter in an LCL. 
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5.2.2 An NF-κB responsive promoter was not consistently regulated by 
TLE1 expression in an LCL 
 
The NF-κB signaling cascade is triggered by a broad selection of stimuli and 
has been found previously to be modulated by EBV. In addition to driving 
EBV growth transformation and LCL proliferation, activated NF-κB plays a 
major role in the co-ordination of the immune and inflammatory responses 
(Tripathi and Aggarwal 2006). To investigate if TLE1 could also influence NF-
κB-regulated gene expression, a co-transfection experiment with pCMV2 
FLAG TLE1 and an established NF-κB-responsive luciferase reporter 
construct, 3xEnh-Luc, was carried out. The 3xEnh-Luc vector contains 3 κB 
binding elements upstream of a minimal conalbumin promoter with a linked 
firefly luciferase gene. The LCL IB4 was co-transfected with 3xEnh-Luc and 
increasing quantities of the TLE1 expression vector pCMV2 FLAG TLE1.  
 
   
Figure 5.2: TLE1 does not consistently regulate an NF-κB-dependent 
promoter.  
IB4 cells were co-transfected with increasing quantities of pCMV2 FLAG TLE1; 0 
µg, 1 µg, 5 µg and 10 µg, along with 2 µg of the luciferase reporter construct 3xEnh-
Luc. Cells were harvested 48 hours post-transfection and assayed for luciferase 
activity. Luciferase values were calculated as previously described and normalised 
values were expressed as percentage trans-activation relative to the corresponding 
data obtained from co-transfection with the empty expression vector pCMV and 
3xEnh-Luc vector. Data are presented as the average of three independent 
experiments (Data are Mean ±SD, * P<0.05). 
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Co-transfection of 3xEnh-Luc with 5 µg pCMV2 FLAG TLE1 gave a 
consistent 35% decrease in luciferase activity within the triplicate 
experiments performed in this study. It can be seen however that the effect 
was neither consistent between experiments nor dose-dependent for the 
regulation of the κB-dependant reporter due to TLE1 co-expression. Co-
transfection with 1 µg and 10 µg of effector plasmid co-incided with 
inconsistent reporter enzyme activity readings over a number of experiments. 
In some experiments 1 ug of pCMV2 FLAG TLE1 was sufficient to elicit a 
repressional effect on 3xEnh-Luc, but repeat experiments did not always 
concur. Given the inconsistencies and the modest scale of repression 
observed, a role of TLE1 in the regulation of NF-κB target genes in LCLs 
was not pursued. 
 
5.2.3 Expression of ectopic TLE1 in an LCL 
 
The evidence presented so far in this study suggests that EBV down-
regulates TLE1 in an LCL. In order to investigate a role for this virus-host 
interaction, the pcDNA3-TLE1 plasmid was used to transfect the IB4 LCL 
and ectopically produce TLE1 protein. Transfected cell pools were 
established by transfecting IB4 with 5 µg of plasmid followed by drug 
selection to establish a stable pool of cells expressing exogenous TLE1. A 
similar pool of cells was simultaneously established with the corresponding 
empty vector, pcDNA3, to act as a negative control. The mammalian 
expression vector pcDNA3 possess the neomycin resistance gene (Figure 
5.3A) that confers resistance to the antibiotic geneticin (G418). The ectopic 
expression of TLE1 in G418-selected cell pools was confirmed by Western 
blotting, immunostaining and RT-qPCR, and phenotypic properties were 
compared with those transfected with the empty vector control.  
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Figure 5.3: Expression of TLE1 from pcDNA3-TLE1.  
(A) Schematic circular map of the pcDNA3-TLE1 expression vector. Highlighted is 
the region into which the TLE1 ORF, encompassing the DNA sequence for residues 
1-770, was sub-cloned. The human cytomegalovirus immediate-early promoter 
(pCMV) is capable of supporting high-level expression in mammalian cells. The 
vector also contains the neomycin resistance gene to facilitate stable mammalian 
cell line selection. (B) The expression of ectopic TLE1 from transfected plasmid was 
confirmed by transient transfection in the low TLE1-expressing cell line BJAB, 
followed by Western blotting. TLE1 is shown in the upper panel. The lower panel 
shows β-Actin expression as a loading control. The empty pcDNA3 expression 
vector was used as control. 
 
To confirm the expression of TLE1 from the pcDNA3-TLE1 vector, the BJAB 
cell line was transiently transfected with 5 µg pcDNA3-TLE1, along with a 
negative control transfection using 5 µg pcDNA3 empty vector. After 48 
hours protein was harvested from the transfected cells and analysed by 
Western blotting (Figure 5.3B). To establish the stable cell pool, the IB4 cell 
line was transfected by electroporation with either 5 µg pcDNA3-TLE1 or 5 
µg pcDNA3 expression vector. After 24 hours the cells were sub-cultured into 
fresh medium containing 800 µg/ml G418. Following three weeks selection 
cell pools were examined to determine the relative TLE1 expression levels in 
each population.  
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Enhanced TLE1 expression in pcDNA3-TLE1-IB4 cell pool 
 
 
Figure 5.4:  Enhanced TLE1 expression in pcDNA3-TLE1-IB4 cell pool.  
Protein and total RNA were extracted from each cell pool and TLE1 expression 
levels were verified using Western blot analysis and RT-qPCR respectively. (A) 
Western Blot showing TLE1 expression. The upper panel shows the levels of TLE1 
protein in various cell extracts as indicated underneath the panel. All extracts were 
normalised to the loading control β-Actin (lower panel). TLE1 protein levels can be 
compared for the parental IB4 cell line, pcDNA3-TLE1-IB4 and pcDNA3-IB4. 
Controls included AG876 (positive control) and DG75 (negative control). (B) RNA 
samples from each pool were monitored by RT-qPCR and results were normalised 
as before (relative to TBP). In this experiment, the control pcDNA3 IB4 was 
arbitrarily assigned a value of 1. (Data are Mean ±SD, ** P<0.01). 
 
Western blot analysis of protein extracts prepared from the two cell pools 
pcDNA3-TLE1-IB4 and pcDNA3-IB4, showed that TLE1 protein was 
expressed at a considerably higher level when the TLE1-expression vector 
was used. The parental IB4 cell line can be seen to express endogenous 
TLE1 at a lower level and equivalent to that seen in the pcDNA3-transfected 
cell pool. These observations were corroborated by RT-qPCR which 
demonstrates more than a two-fold increase in the level of TLE1 mRNA 
when the TLE1 expression vector was used. 
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Figure 5.5: Increased immuno-staining for TLE1 in pcDNA3-TLE1-IB4 
cell pool.  
TLE1 staining of fixed cells sampled from the ectopic cell pool and the negative 
control at a magnification of 70x. TLE1 protein detected using a rabbit polyclonal 
IgG (Abcam, ab15587) at a dilution of 1:50 in conjunction with a secondary Goat 
Anti-rabbit IgG HRP Conjugate (Santa Cruz sc-2301) (A) pcDNA3-IB4 cells display 
low level staining for TLE1 (B) Exogenous TLE1 expression is detected by 
enhanced staining in the pcDNA3-TLE1-IB4 cells. 
 
Immunostaining was then used to determine the relative TLE1 protein 
expression within each cell pool. Cells were fixed to a glass slide and 
incubated with a TLE1 specific antibody (Abcam) prior to probing with a 
HRP-conjugated secondary antibody (Santa Cruz). Images from figure 5.5 
illustrate direct immuno-staining results for both the empty pcDNA3 IB4 cell 
pool and the ectopic TLE1-expressing pool. The results show that cells with 
elevated TLE1 (see arrows for an example) were present in high frequency 
in the pcDNA3 TLE1-transfected cell pool. 
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5.2.4 Ectopic TLE1 reduces LCL proliferation 
 
In order to determine the consequence of increased TLE1 expression on 
LCL growth, cell counts and an MTS proliferation assay were performed on 
the IB4-derived cell pools, generated as described in section 5.2.3. Cell 
numbers were calculated using an Adam Counter, a desktop machine that 
determines total viable cell numbers and by utilising the vital cell dye, 
propidium iodide (PI). This was performed in tandem with the MTS-based 
cell titre proliferation assay. MTS is a tetrazolium salt that is reduced to 
purple formazan crystals by mitochondrial succinate dehydrogenase This 
method evaluates relative cell activity by quantifying the mitochondrial 
activity in a cell sample. Cells were seeded at 2 x 105 cells/ml and monitored 
over 48 hours according to manufacturer’s recommendations. 
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Figure 5.6: Effect of TLE1 on cell proliferation using MTS and ADAM 
counting methods.  
Both cell pools were seeded at the same density and maintained under the same 
conditions. (A) cell numbers were determined using an Adam counter at three time 
points. This was performed in triplicate and the results were depicted as fold 
increase in cell number. The pcDNA3-TLE1-transfected pool showed lower cell 
population numbers than the empty vector control cell pool. (B) Cell pool 
mitochondrial activity was determined using the MTS assay at 24 hour intervals in 
triplicate. No difference could be seen in the overall rates of proliferation of the two 
cell pools by this method.  
 
Direct viable cell counts performed using the ADAMTM counter repeatedly 
produced the same trend, showing higher cell numbers for the empty vector-
transfected pool in comparison to the population expressing ectopic TLE1 
(Figure 5.6A). However over time, although antibiotic selection was 
maintained, it became apparent in subsequent experiments that ectopic 
TLE1 mRNA levels declined over time (Confirmed by RT-qPCR, data not 
0
1
2
3
4
5
0hr 24hr 48hr
Fo
ld
 
in
cr
e
as
e
Time (hr)
Effect of TLE1 on cell proliferation 
(ADAM Counter) pcDNA3 
IB4 Pool
TLE1 IB4 
Pool
0
0.5
1
1.5
2
2.5
0hr 24hr 48hr
R
el
at
iv
e
 
Pr
o
lif
e
ra
tio
n
Time (hr)
Effect of TLE1 on cell proliferation 
(MTS)
pcDNA3 IB4 
pool
pcDNA3 TLE1 
IB4 Pool
A 
B 
195 
 
shown). This may have been due to the outgrowth of non-TLE1-expressing 
drug-resistant cells. The evidence therefore suggests that TLE1 expression 
had a negative effect on LCL cell growth. On the other hand, results from the 
MTS assay (Figure 5.6B), do not suggest any significant difference in the 
overall rates of mitochondrial activity between the two cell pools.  The MTS 
assay measures total mitochondrial activity however and gives an indirect 
reflection of viable cell numbers. Limitations to the MTS assay have been 
widely accepted, and it is possible that the presence of G418 in the growth 
medium may have interfered with the efficacy of the assay (Wang, et al. 
2010). 
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5.2.5 Ectopic TLE1 modulates the EBV EBNA2 gene but has no effect 
on EBNA1 
 
EBNA2, as described in detail in chapter one, is a master regulator that is 
critical for the initiation of EBV-associated B lymphocyte transformation. 
Furthermore, ongoing EBNA2 expression is required to maintain LCL growth.  
 
 
Figure 5.7:  Ectopic TLE1 induces EBNA2 expression.  
Total RNA and protein was prepared from each cell pool, pcDNA3 IB4 and pcDNA3 
TLE1 IB4 (A) EBNA2 protein expression was investigated via western blot analysis. 
The upper panel illustrates the level of EBNA2 and normalised for the endogenous 
loading control β-Actin. EBNA2 protein levels were strong at normal loading 
concentrations (15 ul). For this reason, a lower protein concentration was also used 
(7 ul) so that any subtle differences in protein levels can be clearly observed. (B) 
EBNA2 expression levels were quantified using RT-qPCR. Results were normalised 
as before (relative to TBP). Analysis was performed as previously described. In this 
experiment, the control pcDNA3 IB4 was arbitrarily assigned a value of 1. (Data are 
Mean ±SD, * P<0.05). 
 
 
The LCL IB4 expresses wild type EBNA2 as part of the EBV latency III 
programme. However, Western blot analysis of the two cell pools pcDNA3-
TLE1-IB4 and pcDNA3-IB4 showed that EBNA2 was expressed at a 
considerably higher level in response to ectopic TLE1 (Figure 5.7A). These 
results were confirmed by RT-qPCR (Figure 5.7B). In addition to EBNA2, 
EBNA1 transcription was also examined in the two cell pools. However, no 
change was observed in the EBNA1 mRNA level in response to ectopic 
TLE1 (Figure 5.8). 
 
* 
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Figure 5.8:  Ectopic TLE1 does not alter EBNA1 mRNA levels.  
Total RNA was prepared from the ectopic TLE1-expressing cell pool (pcDNA3 TLE1 
IB4) and the negative control cell pool (pcDNA3 IB4). RT-qPCR was employed to 
monitor EBNA1 mRNA levels. The analysis was performed as previously described 
for RT-qPCR experiments. The level of EBNA1 mRNA in the control pcDNA3 IB4 
was arbitrarily assigned a value of 1. (Data are Mean ±SD). 
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5.2.6 Ectopic TLE1 modulates a range of potential and known Notch 
target genes 
 
To determine the rationale for EBV-led regulation of TLE1, several known 
Notch target genes were monitored after the modulation of TLE1 expression 
within an LCL. These Notch targets were chosen due to their known 
association with EBV, and their potential to interact with TLE1. Correlating 
changes in Notch target expression due to TLE1 or EBV activity may help to 
elucidate some of the mechanisms behind EBV B cell immortalisation.  
 
5.2.6.1 Ectopic TLE1 modulates Cyclin D1 
 
Cell cycle progression requires activation by a family of proteins called the 
cyclins. Cyclin D1, a member of this family, plays a fundamental role in 
cellular proliferation and as such is regulated by multiple cell signaling 
pathways including NF-κB, Notch and Wnt signaling. Cyclin D1 must be 
activated for the cycling cell to progress from the G1 phase to the S phase. 
Conversely, Cyclin D1 repression leads to terminal cell differentiation 
(Reviewed in Klein and Assoian 2008).  
 
 
Figure 5.9:  Ectopic TLE1 represses Cyclin D1 expression.  
Total RNA was extracted from each cell pool and Cyclin D1 expression levels were 
verified using RT-qPCR. The results were normalised as before (relative to TBP). In 
this experiment, the level of CyclinD1 mRNA from pcDNA3 IB4 was arbitrarily 
assigned a value of 1. (Data are Mean ±SD, **P<0.01). 
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This experiment showed that Cyclin D1 mRNA levels were reduced by 
approximately 70% in the cell pools that expressed ectopic TLE1 (Figure 
5.9). This implies that TLE1 either directly or indirectly negatively regulates 
Cyclin D1 in an LCL.  
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5.2.6.2 Ectopic TLE1 modulates E2A 
 
E2A (also called TCF-3) is composed of two bHLH transcription factor 
proteins E12 and E47, arising from alternative splicing of the bHLH-coding 
exon. These proteins form homo- and heterodimers with other bHLH factors 
to modulate the expression of their target genes (Slattery, et al. 2008). It has 
been speculated that E2A proteins appear to be found more frequently in 
areas of rapid cell proliferation and differentiation (Rutherford and LeBrun 
1998). E2A activity has been shown to be required for class-switch 
recombination after B cell activation (Portis and Longnecker 2003) and Notch 
signaling has been demonstrated to indirectly induce the degradation of E2A 
within T and B cells (Huang, et al. 2004b).  
 
 
 
Figure 5.10:  Ectopic TLE1 represses E2A at the transcriptional level.  
Total RNA was extracted from each cell pool and E2A expression levels were 
verified using RT-qPCR. The results were normalised as before (relative to TBP). In 
this experiment, the level of E2A mRNA from pcDNA3 IB4 was arbitrarily assigned a 
value of 1. (Data are Mean ±SD, **P<0.01). 
 
A significant down-regulation of approximately 70% was observed for E2A at 
the mRNA level in the ectopically-expressing TLE1 cell pool, in comparison 
to the negative control cell pool (Figure 5.10).  
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5.2.6.3 Ectopic TLE1 modulates Pax5 
 
The expression of Pax5 is found almost exclusively in B lymphocytes. Pax5 
is a paired-domain transcription factor critical for both the initiation and 
maintenance of B cell lineage commitment (Decker, et al. 2009; Nutt and 
Kee 2007). The activity of Pax5 promotes key B cell features such as pre-
BCR and BCR signaling, along with CD19 and CD21 stimulation (Reviewed 
in Cobaleda, et al. 2007). In addition to this, Pax5 activity has been shown to 
repress Notch1 transcription in B cells (Souabni, et al. 2007). Pax5 has also 
been associated with EBV as it has been proven to be a crucial factor for Wp 
(EBNA promoter) activation (Tierney, et al. 2007) and a recent comparative 
study has indicated that Pax5 expression, usually restricted to B cells, can be 
detected in non-B lymphocyte cases of PTLD in which EBV infection plays a 
role in pathogenesis (León, et al. 2009). These findings made Pax5 an 
interesting target for this study. 
 
 
Figure 5.11:  Ectopic TLE1 represses Pax5 expression.  
Total RNA was extracted from each cell pool and Pax5 expression levels were 
verified using RT-qPCR. The results were normalised as before (relative to TBP). In 
this experiment, the level of Pax5 mRNA from pcDNA3 IB4 was arbitrarily assigned 
a value of 1. (Data are Mean ±SD, ***P<0.001). 
 
In this experiment it can be seen that Pax5 mRNA levels were significantly 
reduced (approximately 35% lower) in IB4 cells expressing ectopic TLE1 
when compared to cells transfected with empty vector alone (Figure 5.11).  
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5.2.6.4 Ectopic TLE1 modulates Runx3 
 
Runx3 is a transcription factor that can act as both a positive and negative 
mediator in a context dependent manner (Gao, et al. 2010). It belongs to the 
Runt family of transcription factors that includes Runx1 and Runx2 (Kania, et 
al. 1990). Human Runx proteins have a common structure comprising: (i) a 
crucial N-terminal Runt domain, which is key for the hetero-dimerisation 
function of Runx and mediates direct DNA binding to elicit regulation, (ii) 
followed by a trans-activation domain, and (iii) several repression linked 
domains, one of which is the TLE-linked recruitment motif, VWRPY, located 
in the C-terminal domain. TLE family members have been shown to bind the 
VWRPY region of Runx to act as a co-factor for Runx-led repression (Imai, et 
al. 1998; Levanon, et al. 1998; McLarren, et al. 2001). Runx proteins regulate 
cell differentiation and proliferation; furthermore, they possess a critical role 
in haematopoiesis (Gao, et al. 2010). 
 
 
Figure 5.12:  Ectopic TLE1 represses Runx3 expression.  
Total RNA was harvested from each cell pool as indicated. RNA samples were 
monitored by RT-qPCR and results were normalised as before (relative to TBP). In 
this experiment, the level of Runx3 mRNA from pcDNA3 IB4 was arbitrarily 
assigned a value of 1. (Data are Mean ±SD, *P<0.05). 
 
It was observed that Runx3 mRNA levels were down-regulated 
(approximately 20% lower) in the ectopic TLE1-expressing cell pool (Figure 
5.12). 
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5.2.6.5 Ectopic TLE1 down-regulates CD23 
 
CD23 is a low affinity IgE receptor; a trans-membrane protein of 46 kDa 
expressed on both B lymphocytes and cells of the myeloid compartment 
(Lemieux, et al. 2007). Human CD21 is the natural ligand for CD23 (Gorelik, 
et al. 2004), and both CD21 and CD23 are induced by EBV infection 
(Cordier, et al. 1990). CD23 was first implicated as a direct EBV target in 
1987 by Wang and colleagues (Wang, et al. 1987) and over time EBNA2 
was found to be the EBV protein responsible for CD23 induction.  
 
 
Figure 5.13:  Ectopic TLE1 represses CD23 expression.  
Total RNA was extracted from each cell pool and CD23 expression levels were 
verified using RT-qPCR. The results were normalised as before (relative to TBP). In 
this experiment, the level of CD23 mRNA from pcDNA3 IB4 was arbitrarily assigned 
a value of 1. (Data are Mean ±SD, **P<0.01). 
 
In the experiment ectopic TLE1 was observed to exhibit a negative 
regulatory effect on CD23 mRNA levels (approximately 17%; Figure 5.13). In 
an EBV infected cell, EBNA2 is the main driving force behind CD23 
expression. However in IB4, although TLE1 appears to positively regulate 
EBNA2, CD23 –itself an EBNA2 positive target- is modestly down-regulated 
in response to ectopic TLE1.  
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5.2.6.6 Ectopic TLE1 does not significantly modulate Hes1, Hey1 or 
Runx1 
 
The mRNA levels of a number of prominent Notch target genes such as 
Hey1, Runx1 and Hes1 were not found to be significantly altered by the 
expression of ectopic TLE1 in an LCL. Hey1 is a key protein critical for 
managing embryonic development and differentiation (Steidl, et al. 2000). 
The Hey1 protein displays a carboxy-terminal YRPW motif that is similar to 
the TLE recognition site (Steidl, et al. 2000). Runx1 was chosen as a target 
for investigation as it is a negative target of EBV and exists in B cells as a 
Runx3 agonist.  
 
 
Figure 5.14:  Ectopic TLE1 has no statistically significant 
transcriptional effect on Hey1, Runx1 and Hes1 expression in an LCL.  
Total RNA was extracted from each cell pool and Hes1, Hey1 and Runx1 
expression levels were verified using RT-qPCR. The results were normalised as 
before (relative to TBP). In this experiment, the level of Hes1, Hey1 and Runx1 
mRNA from pcDNA3 IB4 was arbitrarily assigned a value of 1. (Data are Mean 
±SD).  
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Endogenous TLE1 is produced at low levels in both of these cell pools and 
so it cannot be definitively established from this experiment if these genes 
are regulated by TLE1, as the threshold for an effective concentration of 
TLE1 may already be met. However, it can be concluded that ectopic TLE1 
expression in an LCL does not modulate further the expression of Hey1, 
Runx1 or Hes1 at the transcriptional level. 
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5.2.7 shRNA knockdown of TLE1 expression in the IB4 LCL 
 
In this study, evidence of decreased cell proliferation was observed for an 
LCL cell pool expressing ectopic TLE1. Gene knockdown technology was 
next employed to determine if reducing the level of endogenous TLE1 might 
have a pro-proliferative effect in the same cell line. Plasmid vectors 
expressing short hairpin RNAs (shRNA) specific to TLE1 mRNA were 
therefore obtained. A panel of such plasmids were first evaluated for efficacy 
of TLE1 knockdown. An shRNA of scrambled sequence, expressed from the 
same parental vector was used as a negative control in every experiment. 
These plasmids were used to transfect IB4 and the growth/proliferation of 
transfected cells exhibiting decreased TLE1 expression was then 
investigated using a number of assays including trypan exclusion cell counts, 
and the MTS proliferation assay.  
 
 
Figure 5.15: shRNA expression vectors.  
Schematic illustrating the fundamental components of the shRNA vectors 
(Origene™). The amplified region of the construct indicates the shRNA-coding 
sequence in each plasmid. This region lies directly downstream of a U6 promoter 
and contains 29 nucleotides of target recognition sequence lying either side of a 7 
nucleotide loop. The plasmids contain the ampicillin resistance gene for bacterial 
selection. The puromycin resistance gene to allow for selection of transfected 
mammalian cell lines is found downstream of an SV40 early promoter. shRNA 
vectors assigned the names sh205-sh208 denote vectors expressing differing, albeit 
functioning shRNAs against the same target, TLE1. All experiments were performed 
with an additional construct expressing scrambled shRNA as a control.  
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An experiment was performed to first determine the efficiency of the panel of 
shRNA expression vectors with regard to TLE1 knockdown. The transfection 
efficiency of IB4 was determined to be approximately 15%. Due to this low 
overall efficiency, subtle differences in the effectiveness of the shRNA 
plasmids may have been masked by the remaining population of 
untransfected cells. To circumvent this issue a preliminary experiment was 
performed in which the TLE1 expression vector pcDNA3-TLE1 was co-
expressed with the shRNA vectors in IB4. Inclusion of the TLE1 expression 
vector would, therefore, give an enhanced level of TLE1 mRNA in the 
transfected cells, thereby making any knockdown effect of the co-expressed 
shRNA more obvious. IB4 cells were co-transfected with 2 µg of one of each 
shRNA vector along with 3 µg of pcDNA3-TLE1. Total RNA and protein are 
harvested from cells 48 hours post-transfection. TLE1 mRNA and protein 
were monitored as before by RT-qPCR and Western blotting. 
 
 
Figure 5.16: Topological analysis of shRNA vectors.  
Agarose gel electrophoresis (1% agarose gel) was used to determine the 
topological condition of the shRNA vectors and pcDNA3-TLE1. Lane 1 and 8 
contain 1 kb ladder (Fermentas). Lane 2-5 contains 500ng of the shRNA-expressing 
vectors sh205, sh206, sh207 and sh208 respectively. Lane 6 contains 500ng of the 
scrambled shRNA vector, sh30003 and Lane 7 contains 500ng of pcDNA3-TLE1.  
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Figure 5.17: TLE1 knockdown by shRNA vectors.  
Preliminary analysis in IB4 cells to determine the efficacy of the shRNA expressing 
vectors co-transfected with pcDNA3-TLE1. The functioning shRNA vectors are 
designated sh205, sh206 and sh208. Results indicate that both sh205 and sh208 
can reduce TLE1 mRNA levels. (A) Protein extracts taken 48 hours after 
transfection were analysed by Western blot analysis. The upper panel illustrates the 
level of TLE1 protein and normalised for the endogenous loading control β-Actin in 
the lower panel. (B) RNA samples were monitored for TLE1 transcripts by RT-qPCR 
and results were normalised as before (relative to TBP). In this experiment, the 
scrambled shRNA vector was appointed the control and arbitrarily assigned a value 
of 1. (Data are Mean ±SD, ** P<0.01, *** P<0.001). 
 
Co-expression of shRNA expressing vectors sh205 and sh208 showed 
significant knockdown of TLE1 in comparison to the scrambled shRNA 
control, at both the mRNA and protein level (Figure 5.17). Sh206 co-
expression did not lead to a decrease in TLE1 protein and in fact coincided 
with an increase in the level of TLE1 mRNA. In a second experiment, IB4 
was once again transfected with the full panel of shRNA vectors, but this 
time without the presence of the exogenous TLE1 expression vector 
pcDNA3-TLE1. Again IB4 cells were transfected with 2 µg of each shRNA 
vector by nucleofection. Total mRNA and protein were prepared from cells 
48 hours post-transfection and TLE1 expression was investigated as before 
by RT-qPCR and Western blotting.  
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Figure 5.18: TLE1 knockdown using shRNA expression vectors.  
The IB4 cell line was transfected with the panel of shRNA vectors using 
electroporation to determine the most potent of the supplied shRNA vectors. The 
shRNA vectors designated were sh205, sh206, sh207 and sh208. (A) As previously 
described, protein extracts were taken 48 hours post-transfection and investigated 
through Western blot analysis. The level of TLE1 protein was detected as before 
and normalised to the loading control, β-Actin. (B) RNA samples were monitored for 
TLE1 transcripts by RT-qPCR and results were normalised as before (relative to 
TBP). In this experiment, the scrambled shRNA vector was designated as the 
control; arbitrarily assigned a value of 1. (Data are Mean ±SD, * P<0.05). 
 
In both experiments it was demonstrated that the shRNA vectors sh205 and 
sh208 were capable of reducing TLE1 expression significantly in comparison 
the non-specific scrambled vector (Figure 5.18). For further studies the 
shRNA knockdown vectors, sh205 and sh208, were utilised for TLE1 
inhibition in conjunction with the scrambled shRNA expressing vector, as a 
control. 
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5.2.8 RT-qPCR analysis of mRNA in IB4 cells transfected with shRNA-
expressing vectors 
 
In order to determine the transcriptional effect of TLE1 knockdown in an LCL, 
the IB4 cell line was transfected with 5 µg of one of three shRNA vectors; (i) 
scrambled shRNA, (ii) sh205 or (iii) sh208. Cells were purified by Ficoll 
gradient separation 24 hours post-transfection to remove unwanted dead 
cells and debris. Total RNA was harvested 72 hours post-transfection and 
RT-qPCR was used to determine the expression profile for a select panel of 
Notch target genes.  
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5.2.8.1 TLE1 knockdown modulates EBNA1 
 
It was previously determined in this study that ectopic TLE1 did not alter the 
steady state levels of EBNA1 in IB4 cells (Section 5.2.5). However, in this 
part of the study, TLE1 knockdown had a negative effect on the levels of 
EBNA1 mRNA. It can be seen that reducing TLE1 expression using shRNA 
led to a decrease in the level of EBNA1 mRNA (Figure 5.19). Together, 
these results indicate that the endogenous level of TLE1 is sufficient to 
mediate EBNA1 regulation, but that ectopic TLE1 does not lead to further 
EBNA1 modulation. 
 
 
 
Figure 5.19:  TLE1 knockdown down-regulates EBNA1 expression.  
Total RNA was extracted from each shRNA-expressing cell pool 72 hours post-
transfection and EBNA1 expression levels were verified using RT-qPCR. The 
results were normalised as before (relative to TBP). In this experiment, the level of 
EBNA1 mRNA from the scrambled vector was arbitrarily assigned a value of 1. 
(Data are Mean ±SD, *P<0.05). 
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5.2.8.2 TLE1 knockdown modulates Cyclin D1 
 
It was previously determined in this study that ectopic TLE1 down-regulated 
Cyclin D1 at the transcriptional level in IB4 cells (Section 5.2.6.1). In this part 
of the study, the effect of TLE1 knockdown on Cyclin D1 mRNA levels was 
examined. It can be seen that reducing TLE1 expression using shRNA led to 
an increase in the level of Cyclin D1 mRNA (Figure 5.20). This finding is in 
agreement with the results previously obtained in this study, and indicates 
that TLE1 negatively regulates Cyclin D1. 
 
 
Figure 5.20:  TLE1 knockdown induces Cyclin D1 expression.  
Total RNA was extracted from each shRNA-expressing cell pool 72 hours post-
transfection and Cyclin D1 expression levels were verified using RT-qPCR. The 
results were normalised as before (relative to TBP). In this experiment, the level of 
Cyclin D1 mRNA from the scrambled vector was arbitrarily assigned a value of 1. 
(Data are Mean ±SD, *P<0.05). 
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5.2.8.3 TLE1 knockdown modulates E2A 
 
It has been shown earlier in this study that ectopic TLE1 leads to significant 
down-regulation of E2A in IB4 cells (Section 5.2.6.2). Here, the effect of 
TLE1 knockdown on E2A expression was next examined. It can be seen that 
TLE1 knockdown using shRNAs led to an increase in E2A mRNA levels 
(Figure 5.21). These findings are in agreement with the results previously 
obtained in this study and indicate that TLE1 negatively regulates E2A at the 
transcriptional level. 
 
 
Figure 5.21:  TLE1 knockdown induces E2A.  
Total RNA was extracted from each shRNA-expressing cell pool 72 hours post-
transfection and E2A expression levels were verified using RT-qPCR. The results 
were normalised as before (relative to TBP). In this experiment, the level of E2A 
mRNA from the scrambled vector was arbitrarily assigned a value of 1. (Data are 
Mean ±SD, *P<0.05). 
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5.2.8.4 TLE1 knockdown modulates Pax5 
 
Results obtained earlier in this study showed that ectopic TLE1 led to Pax5 
down-regulation in IB4 cells (Section 5.2.6.3). In this part of the study, the 
effect of TLE1 knockdown on Pax5 mRNA levels was examined. It was 
determined that TLE1 knockdown using shRNA led to an increase in Pax5 
mRNA levels (Figure 5.22). These findings are in agreement with the 
previously obtained results in this study, and indicate that TLE1 negatively 
regulates Pax5 at the transcriptional level. 
 
 
Figure 5.22:  TLE1 knockdown induces Pax5.  
Total RNA was extracted from each shRNA-expressing cell pool at 72 hours post-
transfection and Pax5 expression levels were verified using RT-qPCR. The results 
were normalised as before (relative to TBP). In this experiment, the level of Pax5 
mRNA from the scrambled vector was arbitrarily assigned a value of 1. (Data are 
Mean ±SD). 
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5.2.8.5 TLE1 knockdown does not modulate Runx3 
 
It was shown earlier in this study that ectopic TLE1 led to down-regulation of 
Runx3 at the transcriptional level in IB4 cells (Section 5.2.6.4). Here, the 
effect of TLE1 knockdown on Runx3 mRNA levels was examined. It was 
determined that reducing TLE1 expression using shRNA technology had no 
significant effect on the mRNA level from Runx3 (Figure 5.23). Together, 
these results imply that although enforced TLE1 over-expression does 
repress Runx3, the endogenous level of TLE1 in IB4 appears not to have a 
regulatory effect on Runx3. 
 
 
Figure 5.23:  TLE1 knockdown does not modulate Runx3.  
Total RNA was extracted from each shRNA-expressing cell pool at 72 hours post-
transfection and Runx3 expression levels were verified using RT-qPCR. The results 
were normalised as before (relative to TBP). In this experiment, the level of Runx3 
mRNA from the scrambled vector was arbitrarily assigned a value of 1. (Data are 
Mean ±SD). 
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5.2.8.6 TLE1 knockdown does not modulate CD23 
  
It was shown earlier in this study that ectopic TLE1 led to up-regulated CD23 
in IB4 cells (Section 5.2.6.5). Here, the effect of shRNA-mediated TLE1 
knockdown on CD23 was next examined. No significant change in CD23 
mRNA levels was observed in response to TLE1 knockdown (Figure 5.24). 
Together, these results imply that although enforced TLE1 over-expression 
does repress CD23, the endogenous level of TLE1 in IB4 appears not to 
have a regulatory effect on this gene. 
 
 
Figure 5.24:  TLE1 knockdown does not modulate CD23.  
Total RNA was extracted from each shRNA-expressing cell pool at 72 hours post-
transfection and CD23 expression levels were verified using RT-qPCR. The results 
were normalised as before (relative to TBP). In this experiment, the level of CD23 
mRNA from the scrambled vector was arbitrarily assigned a value of 1. (Data are 
Mean ±SD). 
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5.2.8.7 TLE1 knockdown modulates Hes1 
 
It was shown earlier in this study that ectopic TLE1 had no effect on Hes1 
mRNA levels in IB4 (Section 5.2.6.6). Here however, TLE1 knockdown was 
seen to correlate with increased Hes1 mRNA levels (Figure 5.25). Together, 
these results imply that the endogenous level of TLE1 is sufficient to have a 
repressive effect on Hes1 but that additional (ectopic) TLE1 does not lead to 
further Hes 1 repression. 
 
 
Figure 5.25:  TLE1 knockdown induces Hes1.  
Total RNA was extracted from each shRNA-expressing cell pool at 72 hours post-
transfection and Hes1 expression levels were verified using RT-qPCR. The results 
were normalised as before (relative to TBP). In this experiment, the level of Hes1 
mRNA from the scrambled vector was arbitrarily assigned a value of 1. (Data are 
Mean ±SD, **P<0.01). 
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5.2.8.8 TLE1 knockdown modulates Hey1 
 
It was shown earlier that ectopic TLE1 had no effect on Hey1 transcription in 
IB4 (Section 5.2.6.6), and so the effect of TLE1 knockdown on Hey1 mRNA 
levels was next examined. In this experiment, Hey1 mRNA levels were seen 
to increase in response to TLE1 knockdown (Figure 5.26). These findings 
imply that the endogenous level of TLE1 is sufficient to have a repressive 
effect on Hey1 but that additional (ectopic) TLE1 does not lead to further 
repression of this gene. 
 
 
Figure 5.26:  TLE1 knockdown induces Hey1.  
Total RNA was extracted from each shRNA-expressing cell pool at 72 hours post-
transfection and Hey1 expression levels were verified using RT-qPCR. The results 
were normalised as before (relative to TBP). In this experiment, the level of Hey1 
mRNA from the scrambled vector was arbitrarily assigned a value of 1. (Data are 
Mean ±SD). 
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5.2.8.9 TLE1 knockdown does not modulate Runx1  
 
It was shown earlier here that ectopic TLE1 had no effect on Runx1 mRNA 
levels in IB4 (Section 5.2.6.6). Here, TLE1 knockdown was observed not to 
have any significant effect on Runx1 mRNA levels in IB4 (Figure 5.27).  
 
 
Figure 5.27:  TLE1 knockdown does not modulate Runx1.  
Total RNA was extracted from each shRNA-expressing cell pool at 72 hours post-
transfection and Runx1 expression levels were verified using RT-qPCR. The results 
were normalised as before (relative to TBP). In this experiment, the level of Runx1 
mRNA from the scrambled vector was arbitrarily assigned a value of 1. (Data are 
Mean ±SD). 
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5.2.9 Phenotypic investigations on IB4 cells transfected with shRNA-
expressing vectors 
 
Although transfection efficiencies of between 8-15% were achieved in IB4, 
the survival rate of puromycin-resistant transfectants was very low, making 
stable cell pool establishment using drug selection an ineffective process. 
While drug-resistant viable cells did remain following puromycin selection, 
cell numbers did not significantly increase so as to yield a workable 
population of cells. In cell lines in which the transfection efficiency is low, 
there is a rapid accumulation of dead cells following transfection, relative to 
the lower numbers of surviving drug-resistant cells. There are damaging 
effects associated with dead cell populations produced during the drug 
selection/transfection process, including increased pressure exerted on the 
resistant cells from degrading enzymes and necrotic factors secreted by the 
dying and dead cells. Furthermore, suspension cells proliferate optimally at 
specific cell densities at which the population generates sufficient levels of 
products such as growth factors. IB4 also displays an adhesive (clumping) 
morphology that may be hindered at low live cell densities. Reducing the 
culture volume to increase live cell density does not improve conditions for 
cell expansion as it has the side effect of also increasing the concentration of 
dead cells and enhancing the associated negative effects of secreted factors 
from the dead and dying population. In order to circumvent this problem, 
attempts were made to enrich the live cell population in transfected cell 
pools. A protocol was therefore first established in this study employing two 
different purification methods to extract live cells from cell pools with 
significant dead cell populations.  
 
5.2.10 Stable knockdown of TLE1 in IB4 using shRNA-coding plasmids 
 
As the transfection efficiency of IB4 using the shRNA vectors was at such a 
low level, determining the effect of the repression of TLE1 expression on 
cellular targets benefitted from an enrichment step for transfected cells. The 
shRNA expression vectors carry a puromycin resistance marker (Figure 
5.15). Puromycin is a potent translational inhibitor and resistance is 
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conferred by the puromycin N-acetyl-transferase gene (pac), the product of 
which inactivates puromycin by acetylation of the drug. IB4 cells were first 
transfected with 5µg of each shRNA vector. After 24 hours, transfected cell 
pools were passaged in growth medium containing 1 µg/ml puromycin 
(concentration determined from a drug curve assay). Under these conditions, 
the majority of non-transfected cells are killed within 72 hours, after which the 
concentration of drug was reduced to 0.5 µg/ml. During the drug selection 
process, cells were passaged and sub-cultured into fresh medium every 2-3 
days. However, a significant portion of dead cells remained in the population 
throughout selection. These cell pools were utilised (i) to demonstrate the 
transcriptional effect of TLE1 knockdown on significant EBV-associated 
genes, and (ii) to determine if TLE1 repression elicited any effect on the 
phenotype of the IB4. 
 
5.2.11 Enrichment of live cell population via Lymphoprep™ and 
Concanavalin A (Con A) purification 
 
The process of electroporation damages between 10-15% of the total IB4 
cells beyond repair (determined from FACS analysis performed following 
transfections in this study). Piñero and colleagues determined that 
electroporation results in cell death arising from both necrosis and apoptosis 
to an equivalent degree (Piñero, et al. 1997) Apoptosis is a systematic 
controlled process that terminates the cell while endeavouring to bring forth 
negligible negative effects on neighbouring cells. However, necrosis is an 
unintentional form of cell death in which the cell unrestrictedly swells and 
bursts permitting the release of cellular components causing death signals 
that can be detected by adjacent cells (Fink and Cookson 2005).  
 
Many studies use Ficoll gradient separation, following transfection of 
suspension cells, as an extra step that discriminates between live cells and 
dead cells based on their density (Guidicelli, et al. 2009; Pachernik, et al. 
2002; Bénéteau, et al. 2007). Enhancement of the live cell population 
improves efficacy of results obtained in from transfected cells. Ficoll is a 
neutral, water soluble synthetic polymer of sucrose and epichlorohydrin 
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possessing a high molecular weight. Ficoll has a density of 1.077 ± 
0.001g/ml, this can be overlaid with medium containing lymphocytes. After 
rapid centrifugation at room temperature the sample becomes segregated 
according to the densities of the components therein. Healthy lymphocytes 
are not dense enough to penetrate the Ficoll layer. Viable lymphocytes 
concentrate at the interface of the growth medium and separation fluid, but 
dead cells, which are more dense, pass through the medium and gather 
below the Ficoll layer (Boyum 1968). Ficoll is commercially available as a 
ready-to-use separation medium under a number of product names, the two 
most widely accepted for lymphocyte purification are Ficoll-PaqueTM and 
LymphoprepTM. These products vary slightly in the aqueous component of 
the medium. However, Yeo et al performed a comparative study on the 
standard commercially available Ficoll-PaqueTM and LymphoprepTM 
confirming that the two solutions gave no significant difference in lymphocyte 
recovery, and showing that the condition of cells post-treatment was 
equivalent (Yeo, et al. 2009). For the duration of this study all Ficoll 
separations were performed using LymphoprepTM (referred to henceforth as 
‘Ficoll’). 
 
IB4 cells were first transfected with 2 µg of pmaxGFP in order to express the 
GFP as a marker for successful transfection. After 24 hours the transfected 
cell pool was split into two, and one half of the pool was purified using Ficoll. 
Viabilies of purified and un-purified transfected cell populations were 
analysed by FACS. The distribution profile of the cell population is 
categorised by the analysis of overall size and granularity of the cells from 
each sample (Figure 5.28). Forward scatter (FSC), assigned to the X-axis, 
corresponds to approximate cell size and side scatter (SSC) is represented 
by the Y-axis, denoting cell granularity. The highlighted region (R1) 
represents the gated zone where a healthy population of IB4 cells is to be 
found. Cells situated to the left and below the R1 area are not 
morphologically representative of IB4 cells as they are smaller in size and 
possess less intracellular complexity. Cells outside the gated region are 
composed of dead and dying cells along with cellular debris. As can be 
observed in figure 5.28A and B, the Ficoll purified population showed 
 considerably less cells outside the gated region, thus representing an 
unmistakably healthier population in comparison the un
cells. 
Figure 5.28: Purification of
IB4 cells transfected wit
populations at 24 hours following electroporation. One fraction remained unenriched 
while the second was purified by Ficoll gradient separation. Forward (x axis) and 
Side (y axis) scatter plots are shown 
transfection displaying size and granularity distribution of the cell population, 
identical cell population subsequent to Ficoll enrichment
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 Figure 5.29: Removal of dead cells following Ficoll purificati
IB4 cells transfected with 2 µg pmaxGFP were split 24 hours after transfection. One 
fraction remained untouched while the second was purified using a Ficoll gradient. 
Both populations were stained with 7
survival/apoptotic profiles. Quadrant markers were based on healthy 
stained/unstained controls and the numbers shown are the percentage of cells in 
each quadrant. Green dots indicate GFP
not-expressing GFP. (A)
population following Ficoll enrichment
 
Samples of input cells and Ficoll treated cells were stained with 7
Annexin V-PE. Ten thousand cells from the R1 region were analysed for their 
staining profile. From figure 
quadrant, that Ficoll removed approximately 6% of the dead cells in the 
population. Thus the viable cell pool was enriched from 88% viable cells to 
94%. In addition, no adverse effects were observed 
post-Ficoll treatment (data not shown).
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exclusively extract the small live population was therefore required. A 
method based on the lectin Concanavalin A (Con A), which has been shown 
to exclusively bind to live B cells, was therefore investigated. 
 
5.2.12 Selection with Con A as a tool for the purification of viable B 
cells following transfection 
 
Con A is a plant-derived lectin that binds to the α-glucosyl and α-mannosyl 
residues presented by glycoproteins on mammalian cell membranes 
(Reviewed in Thøger-Andersen and Junker 1994; Sharon and Lis 1972). 
Lectins were first identified by their capacity to agglutinate red blood cells 
following binding to cell surface saccharides. The specificity of lectin 
recognition for their target saccharide allows discrimination between 
mammalian blood types. Con A binds exclusively to the mannose moiety of B 
cell surface glycoproteins (Thøger-Andersen and Junker 1994; Lei and 
Chang 2009). Along with agglutination, some lectins possess additional 
properties such as mitogenic activity. Con A has been widely used in 
lymphocyte research as a T cell mitogen, and although it exhibits an equal 
affinity for B lymphocytes, Con A fails to trans-activate the B cells into a 
proliferative state (Lei and Chang 2009; Stobo, et al. 1972). It has been 
found that Con A binds live B cells but cannot specifically associate with 
dead B lymphocytes (Thøger-Andersen and Junker 1994). The 
lectin/carbohydrate association is a reversible process that has enabled 
lectin utilisation for cell identification and enrichment (Lei and Chang 2009).  
 
Here, the ability of Con A to selectively ‘pull out’ healthy B cells following 
transfection was assessed. IB4 cells were first electroporated with pcDNA3 
plasmid. Electroporation is a mechanical process that introduces a temporary 
electric pulse across the cell membrane. This disturbs the phospholipid 
bilayer creating transient pores, allowing molecules such as DNA to 
permeate the cell. Once the voltage is removed, the membrane quickly 
reassembles to restore the viable cell. However, some pores may be too 
large to reform, and others may take in molecules that disrupt the ion 
balance within the cell, both resulting in ruptured non-viable cells (Weaver 
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1995). When using electroporation, equilibrium between transfection 
efficiency and cell viability must be maintained. Thus, the resulting 
transfected cell pool will contain both viable and non-viable cells. Here, 
panning of such cell populations involved first coating cell culture plates with 
Con A using coating buffer solution containing either 300 µg/ml Con A or 100 
µg/ml Con A (performed as described in chapter 2, (Section 2.2.3.20). Cells 
were then allowed to adsorb to these plates, followed by elution/washing in 
fresh warmed medium with gentle mechanical pressure from a pipette 
(p1000). Cells thus eluted were then cultured in new six-well plates under 
standard conditions. Trypan blue staining was used to determine the 
numbers of viable/non-viable cells that were ‘panned out’ by this method.  
 
 
Figure 5.30: Live cell enrichment by Con A selection as determined by 
trypan blue staining.  
Transfected IB4 cells were split 24 hours post-transfection. One cell fraction was 
maintained as an input control, another two samples were purified on plates that 
had been coated using two different concentrations of Con A (100 µg/ml and 300 
µg/ml). Trypan blue exclusion was used to establish the live/dead cell numbers after 
panning with Con A. 
 
Transfection by electroporation was seen to reduce the overall population 
viability to 75% (Figure 5.30). It can also be seen that panning with plates 
coated using the solution of 100 µg/ml Con A gave maximal live cell 
enrichment with the percentage of viable cells rising to 91%, in comparison 
to 86% viability when coating buffer with 300 µg/ml Con A was used. This 
shows that Con A-panning substantially enriched for viable cells. Initial 
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 recoveries were low however (approximately 28% of the total live cell 
population). Examination of coated 
cell adsorption indicated that these 
limitation in this experiment was the lack of cell surface area for live cell 
adsorption. This was subsequently
supernatants on the same plates or by coating plates with a larger surface 
area. These steps raised overall cell recoveries to approximately gross 50% 
of the live starting cell population.
 
Figure 5.31: Live cell enrichment by Con 
IB4 cells were transfected with an empty mammalian expression vector (pcDNA
as per the standard protocol.
and two fractions were purified in two different concentrations of the lectin
(A) Represents untreated cells 24 hours post
selected in the absence of Con A to ensure specificity of the Con A selection. 
Demonstrates the transfected cell population after panning in plates coated with 
100µg/ml Con A. (D) Represents the transfected cell population after panning in 
plates coated with 300µg/ml Con A.
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outside the gated region R1 (Figure 5.31A). Panning with Con A however 
was seen to remove a significant portion of dead cells and debris by 
positively selecting for live B lymphocytes (compare figure 5.31, parts A, C 
and D). Con A selection resulted in a smaller population outside the gated 
region, reduced from 35% to approximately 17% and 19% when using plates 
coated with Con A at 100 µg/ml and 300 µg/ml respectively. The overall cell 
pool after Con A selection could now be seen to be composed of cells of 
typical viable IB4 profile (Figure 5.31C and D). The similar degrees of 
enrichment obtained at both coating concentrations of Con A indicated that 
saturation of the surface with lectin had probably been reached at 100 µg/ml. 
N-Ethyl-N′-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDAC), is a 
water soluble carbodiimide that activates Con A, facilitating the coating of cell 
culture grade plates via amine bonds. To verify that the result of selection 
was due to Con A binding, and not a non-specific effect of the activator 
compound, an EDAC-only treated plate was included in the experiment. It 
can be seen that negligible cell numbers were detected after panning with 
EDAC alone (Figure 5.31B). In addition, the EDAC-extracted population were 
of mixed morphology showing equal numbers of live and dead cells. These 
results showed that Con A could be used to successfully select viable B 
lymphocytes from transfected cell populations. 
 
FACS analysis also showed clear evidence for the selective enrichment of 
live lymphocytes by Con A, corroborating the scatter plots and trypan blue 
exclusion assays. It can be seen that Con A-panning reduced the necrotic 
population from 15% to fewer than 2% of the total transfected cell pool 
(upper left quadrant, Figure 5.32).  
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Figure 5.32: Con A-panning selects for viable cells following 
transfection of an LCL.  
Twenty-four hours after transfection, IB4 cells were Con A-panned and their survival 
profile determined by 7 AAD/Annexin V PE staining. Quadrant markers were based 
on healthy stained/unstained controls and values reflect the percentage of cells in 
each quadrant. (A) Untreated cells; (B) and (C) Con A-selected cells. 
 
After seven days, Con A-selected populations were again monitored by 
trypan blue staining and 7-AAD/Annexin V-PE staining and displayed no ill 
effects from the procedure (Figure 5.33).  
 
 
 
Figure 5.33: Con A selection displays no cytotoxic effects on enriched 
cell populations.  
(A-C) Forward and Side scatter plots of cell populations as indicated above in each 
case. (D-F) 7 AAD/Annexin V PE staining of the corresponding cell populations 
(directly underneath the corresponding scatter plot). Quadrant markers were based 
on healthy stained/unstained controls and values reflect the percentage of cells in 
each quadrant. 
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5.2.13 The selection of cell pools expressing anti-TLE1 shRNAs: 
comparison of two live cell enrichment protocols 
 
IB4 cells were next transfected with plasmids encoding the shRNAs sh205, 
sh208 and the scrambled control sh30003. In addition, 1 µg of pmaxGFP 
was incorporated into each transfection to permit monitoring of the 
transfected population. Following transfection, each cell pool was split into 
three and each fraction then treated in one of the following ways: (i) cells 
were allowed to recover for twenty four hours, followed by passaging in fresh 
medium containing 1 µg/ml puromycin (control; no additional live cell 
enrichment steps); (ii) a Ficoll purification step at 24 hours post-transfection, 
and a second Ficoll enrichment 3 days after drug selection in medium 
containing 1 µg/ml puromycin (Ficoll/Ficoll enrichment); (iii) Ficoll/Con A 
treatments consisting of two purification steps -Ficoll enrichment was 
performed 24 hours post-transfection followed by selection in 1 µg/ml 
puromycin; then Con A selection after 3 days. The relative success of each 
method was determined by FACS as before. 
  
  
Figure 5.34: Survival profiles of shRNA
IB4 cells were co-transfected with pmaxGFP and one shRNA
described (only the results for shRNA205 are shown in the figure). Following 
selection (method named above each plot), survival profiles were determined by 7 
AAD/Annexin V PE staining. Quadrant markers were based on healthy 
stained/unstained controls and values reflect
quadrant. Green dots represent GFP expressing cells. 
post-selection with 1µg/ml puromycin; 
transfection and again at 3 days after puromycin selectio
population enriched 24 hours later using Ficoll followed by panning on Con A
coated plates following 3 days of selection with puromycin; 
remaining in the supernatant following depletion with Con A.
 
As before, it can be seen that the combined Ficoll/ConA method selected a 
population with higher viability (76.8%; Figure 5.34C) relative to the 
Ficoll/Ficoll method (44%; Figure 5.34B
population (and hence puromycin resistant)
approximately 40% of the cells in this region expressing 
with A and B, Figure 5.34).  
Con A-panning (see D, Figure 5.34) displays negligible numbers of GFP
expressing cells, suggesting that Con A
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A 
C 
 
-expressing cell pools
-coding plasmid as 
 the percentage of cells in each 
(A) un-enriched cells 3 days 
(B) cells purified with Ficoll 24 hours after 
n; (C) the transfected cell 
(D) the cell population 
 
). In addition, the GFP
 is largely seen to be viable with 
GFP (compare C 
 Moreover, the supernatant remaining following 
-panning preferentially 
-expressing population. 
B 
D 
231 
 
.  
-
-expression 
-
selected 
232 
 
 
When 7AAD-staining was plotted against GFP, it can be seen that the un-
enriched and Ficoll-only enriched populations display a scattering of GFP-
expressing cells across the top two quadrants, indicating both significant 
death and heterogeneity of GFP expression therein (Figure 5.35A and B). 
The unpurified cells showed the smallest transfected population (Figure 
5.35A). It can be seen that Ficoll/Ficoll enrichment gave an increase in the 
fraction of transfected cells from 1.5% to 4% (Figure 5.35A and B). However, 
Ficoll/Con A enrichment gave by far the greatest yield of viable transfected 
cells, with 40% of cells expressing GFP therefore representing the 
transfected population. Finally, in the supernatant pool containing cells not 
bound during Con A selection (Figure 5.35D) only 0.05% of the total 
population were live GFP-expressing cells, indicating that Con A captured 
virtually the entire viable transfected cell population. The residual cells that 
did not bind to Con A were 84% dead cells, supporting the specificity of live 
selection by the lectin.  
  
  
Figure 5.35: Con A selection enriched for the GFP expressing 
population.  
IB4 cells were transfected with pmaxGFP and enriched using the methods shown 
above each plot. Transfected cell pools were stained with 7AAD to determine 
viability and plotted as GFP versus 7AAD. Green dots denote cells expressing GFP, 
pink dots represent cells th
based on non-transfected stained/unstained controls and values reflect the 
percentage of cells in each quadrant. The upper quadrants contain GFP
cells while the lower quadrants denote non
cells in the lower left quadrant are viable but do not express GFP, cells in the lower 
right quadrant are non-GFP expressing dead cells, cells in the upper right quadrant 
are dead GFP expressing cells and cells in the upper le
expressing cells.  The numbers in each quadrant correspond to the percentage of 
the total cell population found in that region. 
days post-selection with 1µg/ml puromycin. 
Ficoll 24 hours post-transfection and again 3 days after puromycin selection 
This shows the transfected cell population enriched 24 hours after transfection with 
Ficoll, followed by Con A
This shows the unselected
Con A  selection. 
 
IB4 cells were co-transfected with pmaxGFP and plasmid expressing either 
scrambled shRNA vector or sh205 and were then selected using the 
Ficoll/Con A method described above. A modest difference in apoptosis 
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between the two cell pools could be seen; the GFP-expressing population in 
the late apoptotic region was 24.0% (sh205) compared to 15.3% (scrambled 
shRNA control; Figure 5.36A). This may imply that knockdown of TLE1 leads 
to a reduced level of apoptosis when compared to the scrambled control; 
however, the distribution of the GFP populations is comparable in the two 
cell pools, indicating that there was no increased level of apoptosis in the 
positive transfectants (Figure 5.36 A-D). Cell populations are maintained by a 
fine balance of apoptosis and cell growth. When the proliferation rates of 
these two cell pools were compared, it was found that the sh205 transfected 
cell pool had a more rapid rate of cell growth in comparison to the scrambled 
cell pool. Therefore, taking into account these results, it is most likely that a 
decrease in TLE1 expression results in an increase in the proliferative 
capacity of an LCL.  
 
Treatment of un-transfected IB4 cells with puromycin results in approximately 
80% cell death after 72 hours. This implies that the majority of the live cells in 
the selected pools have retained the puromycin resistance conferred by the 
shRNA expressing vectors. The amount of healthy cells in both the sh205 
and scrambled cell pool are similar; however, the sh205 population retained 
more GFP expressing cells than the scrambled cell pool. Therefore, it 
appears that the scrambled shRNA cell pool retained the drug resistance 
without the second plasmid expressing GFP. This may be a consequence of 
the growth advantage awarded to the LCL by reduced TLE1 expression.  
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Figure 5.36: Comparison of scrambled and sh205 Con A enriched cell 
populations.  
IB4 cells were co-transfected with pmaxGFP and either the scrambled shRNA 
vector or the sh205 vector. These cell pools were drug selected using puromycin 
and enriched using the Ficoll/Con A method. Transfected cell pools were analysed 
with either (i) by 7 AAD/Annexin V PE staining (Described in the legend to figure 
5.34) or (ii) by using 7AAD staining to determine viability and plotted as GFP versus 
7AAD. Green dots denote cells expressing GFP, pink dots represent cells that are 
not expressing GFP. Quadrant markers and staining described as per legend to 
figure 5.35. The numbers in each quadrant correspond to the percentage of the total 
cell population found in that region. (A) This shows the survival profile, determined 
by 7 AAD/Annexin V PE staining, of enriched scrambled shRNA cells 3 days post-
selection with 1µg/ml puromycin. (B) Corresponds as per (A) for sh205 enriched 
cells. (C) This shows enriched scrambled shRNA cells stained with 7AAD to 
determine viability and plotted as GFP versus 7AAD. (D) Corresponds to sh205 
enriched cells stained and plotted as per legend (C). 
 
 
5.2.14 TLE1 knockdown increases the rate of IB4 cell proliferation 
 
Trypan blue staining and MTS assays were next used to investigate the 
potential effect of shRNA-mediated TLE1 knockdown on the proliferation of 
IB4 cells. In an attempt to minimize interference with the MTS assay, 
puromycin was withdrawn from the culture medium twenty four hours prior to 
A B 
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sampling. Cells were monitored over a 48 hour period and three independent 
experiments were performed in each case (Figure 5.37). 
 
 
 
Figure 5.37: TLE1 knockdown in IB4 cells correlates with increased 
proliferation.  
(A-C) Cell numbers in each transfected cell pool were determined by trypan blue 
staining at three time points in three independent experiments. This was performed 
in triplicate and each individual experiment was plotted independently above, the 
results were represented as fold increase in cell number; (D-F) As per A-C except 
using MTS assay. 
 
These experiments consistently showed higher cell numbers and rates of 
proliferation in the two cell pools expressing anti-TLE1 shRNAs when 
compared to the control cell pool expressing scrambled shRNA (Figure 5.37 
A-F). After 24 hours for instance the rate of proliferation, as determined by 
MTS assay, was 20% higher on average in the cases of TLE1 knockdown. 
These results imply that the inhibition of TLE1 expression had a positive 
impact on the growth and proliferation of IB4 cells. Interestingly, they are in 
agreement with similar published studies for the knockdown of TLE1 by 
shRNA in AML1-ETO myeloid leukemia cells (Dayyani, et al. 2008). Dayyani 
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and colleagues found that knockdown of TLE1 in the Kasumi T cell line led to 
increased cell cycle progression and division. In addition, they demonstrated 
that, conversely, enforced expression of TLE1 in that situation led to 
apoptotic cell death (Dayyani, et al. 2008). Here, enforced expression of 
TLE1 in IB4 was not seen to have a significant apoptotic impact (Figure 
5.37). 
 
5.2.15 Analysis of TLE1 knockdown cell pools by RT-qPCR 
 
Unexpectedly, significant problems were encountered using RT-qPCR on 
RNA samples prepared from the puromycin selected shRNA knockdown cell 
pools. During each experiment, melt curve analysis is employed to confirm 
the amplification of a single product at the correct temperature. This involved 
a stepwise 1ºC incremental increase in temperature over a set range, and 
fluorescence exhibited by the sample is monitored during this time. SYBR 
green dye associates with double-stranded DNA; therefore, at the 
temperature threshold at which the generated PCR product dissociates, 
yielding single stranded product, there is a drop in the fluorescence activity. 
Thus, a sample with a single PCR product will demonstrate only one peak 
corresponding to the melting temperature of the product (Example in Figure 
5.38A). The TLE1 primers used in this study had been optimised and 
consistent PCR conditions were maintained in all experiments. However, 
melt curve analysis on RT-qPCR products obtained from puromycin-selected 
cells showed dissociation curves that were different relative to melt curves 
previously obtained from TLE1 RT-qPCR products. 
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Figure 5.38: Melt curve analysis for TLE1 PCR products.  
Melt curve analysis was performed during each experiment to verify the production 
of a single specific product at the temperature anticipated for the TLE1 PCR 
product. Melt curves obtained using (A) cDNA prepared from a panel of B cell lines, 
(B) IB4 cells transfected with pcDNA3-TLE1, (C) puromycin-selected shRNA-
expressing IB4 cells, and (D) shRNA-expressing IB4 cells without puromycin 
selection. Identical conditions for RT-PCR were used in all experiments. 
 
Sample preparation and experimental steps were scrutinised and compared 
to ensure that the observed unpredicted melt curve was not due to reagent 
interference. RT-qPCR analysis demonstrated that the expected melt curve 
for TLE1 PCR product was not obtained only in the case of cells treated with 
puromycin. To determine the identity of the product generated from the 
samples with irregular melt curves, PCR products were purified following RT-
qPCR and their DNA sequences determined. 
 
A B 
C D 
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Figure 5.39: DNA sequencing analysis for TLE1 cDNA products 
generated during RT-qPCR.  
(A) and (B) DNA sequencing was performed on purified RT-qPCR products from 
puromycin-selected transfected IB4 cell pools (using sh205 and the scrambled 
sh30003 vector). The non-selected sample containing pcDNA3 TLE1 was included 
as a positive control for the correct TLE1 RT-qPCR product. The alignment of the 
PCR products shows that the three products are the same. Red bases indicate 
perfect alignment between all three sequences, while blue bases indicate alignment 
for two of the three sequences under analysis. 
 
DNA sequence alignments confirmed that the PCR products generated were 
in fact the same in every case, in spite of the fact that the dissociation curves 
for the puromycin-selected cells were different (Figure 5.39). BLAST analysis 
was used to confirm PCR product identity as that of the anticipated portion of 
TLE1. Thus, the TLE1 PCR assay as previously validated was continuing to 
perform successfully.  
 
 
  
A 
B 
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5.3 Discussion 
 
TLE1 is potentially an interesting negative target of EBV. A possible role for 
TLE1 in the regulation of two signaling pathways key to EBV latency, Notch 
and NF-κB, was therefore investigated in the LCL IB4. Promoter co-
transfection studies demonstrated that ectopic TLE1 (i) trans-activated a 
Notch/CBF-1 responsive promoter in a dose-responsive manner, and (ii) was 
not concluded to affect the activity of an NF-κB-dependent promoter, in that 
the effect was neither consistent between experiments nor dose-dependent. 
The potential for TLE1-mediated regulation of Notch/CBF-1 target genes was 
therefore pursued.  
 
An IB4 cell pool expressing ectopic TLE1 was then established and from this 
it could be seen that the rate of increase in cell numbers declined due to the 
transfected gene. Furthermore, ectopic TLE1 expression was seen to be lost 
over time (Section 5.2.4). Based on these observations it was reasoned that 
TLE1 had a negative impact on the LCL phenotype. The results obtained in 
section 5.2.14, in which TLE1 knockdown cells appear to lead an increased 
growth rate relative to control cells (Figure 5.37) substantiates this 
conclusion. These observations are at odds with the general published data 
relating to the impact of TLE1 on phenotype, such as the over-expression of 
TLE1 as a feature of higher grade meningiomas (Cuevas, et al. 2005) and 
synovial sarcoma (Terry, et al. 2007). However, recent studies on 
haematological malignancies have indicated a contrasting role for TLE1 in 
oncogenesis within hematopoietic cells. Fraga and colleagues studied a 
panel of 49 human malignancies arising from 14 different cell types and 
found that TLE1 silencing by hypermethylation was a feature of a number of 
haematological malignancies such as AML, non-Hodgkin’s lymphoma, 
chronic myeloid leukaemia (CML) and B-cell diffuse large cell lymphoma (B-
DLCL) (Fraga, et al. 2008). They confirmed that TLE1 silencing was a 
feature of malignant cells and not healthy peripheral cells. In addition, 
restoration of TLE1 activity to three leukaemia or lymphoma cell lines led to a 
reduction in the rate of cell growth (Fraga, et al. 2008). The tumour-
suppressor activity of TLE1 was further corroborated by the knockdown of 
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TLE1 in lymphoma cell lines which expressed TLE1 which in turn led to 
increased cell growth. The published findings of the investigations by 
Dayyani and colleagues and Fraga’s laboratory are in agreement with the 
findings in this study, which implicate TLE1 as a negative regulator of 
haematological cell fate. 
 
An analysis of the expression of selected cellular genes in the cell pool 
expressing ectopic TLE1 showed that TLE1 modulated the transcription of 
EBNA2, Pax5, CD23, E2A, Runx3 and Cyclin D1. That these events impact 
on the levels of those individual proteins concerned, with the exception of 
EBNA2, awaits confirmation by western blotting. TLE1 is a transcription-
associated protein however, and these findings very likely indicate that TLE1 
does affect the expression of these cellular genes. TLE1 was seen to 
positively regulate the crucial EBV latent gene EBNA2; however, the 
regulation of EBNA2 in response to TLE1 knockdown could not be 
ascertained in this study due to difficulty with the RT-qPCR assay. 
Dissociation curve analysis indicated that a second product appeared to be 
generated upon the down-regulation of the characteristic EBNA2 product. In 
the same LCL background EBNA1 expression remained unchanged due to 
ectopic TLE1 (Section 5.2.5), but demonstrated significant down-regulation in 
response to TLE1 knockdown (Section 5.2.8.1). Furthermore, Generally, in 
LCLs, both EBNA2 and EBNA1 are transcribed primarily from the Cp 
promoter as one unprocessed transcript (Reviewed in Palermo, et al. 2008). 
However, in IB4 only the Wp promoter is active and all EBNA transcripts 
(with the exception of EBNA3B which is not expressed) are transcribed from 
this promoter (Hurley, et al. 1991). If EBNA2 was independently regulated 
relative to EBNA1 it could be speculated that this differential regulation must 
occur through EBNA2’s second promoter, the Wp. Although, it is also 
possible that TLE1 affects the differential splicing of EBNA RNAs. 
 
It was also demonstrated that TLE1 regulated several key EBV known and 
potential Notch target genes. 
(i) Cyclin D1 is another positive EBV target found to be down-regulated by 
TLE1 in IB4 cells (Section 5.2.6.1). Cyclin D1 has been shown to be 
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transcriptionally up-regulated by EBV via c-Jun up-regulation of the Cyclin 
D1 promoter (Herber, et al. 1994). The results obtained in this study are in 
agreement with published data that suggests that knockdown of TLE1 by 
shRNA in a myeloid cell line leads to the up-regulation of the cell cycle 
proliferation marker, Cyclin D1 (Dayyani, et al. 2008). This EBV-mediated 
positive regulation of Cyclin D1 has been found to be mediated by LMP1 
(Zhao, et al. 2001, Zhao, et al. 2000). A measure of the importance of Cyclin 
D1 regulation is the wide spectrum of transcription factors that can bind to 
and/or regulate Cyclin D1 at the transcriptional level (Review in (Wang, et al. 
2004)). In addition, due to the broad range of Cyclin D1 regulators, Cyclin D1 
can be regulated by a number of diverse mechanisms. Dys-regulation of 
Cyclin D1 is a hallmark of a number of proliferative diseases such as cancer 
and atherosclerosis (Reviewed in Klein and Assoian 2008). Cyclin D1 is 
classified as a proto-oncogene and it functions by driving the cell cycle 
progression of the cell from G1 through S phase. Therefore, if TLE1 reduces 
the expression of Cyclin D1 this is likely to lead to a reduced proliferation 
rate, as was observed in the ectopic TLE1 expressing cell pool (Section 
5.2.6.1). Furthermore, in agreement with these results, Cyclin D1 was 
conversely significantly up-regulated in the same LCL when TLE1 expression 
was knocked down by shRNA (Section 5.2.8.2). In addition, the rate of 
proliferation in the shRNA knockdown cell pool increased in comparison to a 
cell pool carrying a scrambled shRNA-expressing vector (Section 5.2.14). 
 
(ii) E2A, a transcription factor crucial to B cell identity, was found to be a 
negatively regulated by ectopic TLE1 in an LCL (Section 5.2.6.2). These 
results were then corroborated by the TLE1 shRNA knockdown experiment 
in which E2A mRNA levels were induced by the knockdown of TLE1 (Section 
5.2.8.3). E2A is expressed throughout B cell development from the earliest 
lymphoid stage to the mature B cell (Decker, et al. 2009). B cells arise from 
multi-potent progenitor cells (MPPs) generated in the post natal bone 
marrow. The E2A transcription factor is critical to bring about the correct 
formation of common lymphoid progenitors (CLPs) from MPPs (Nutt and Kee 
2007). Three transcription factors essential for the commitment of CLPs to 
the B cell lineage are E2A, Ebf1 and Pax5 (Decker, et al. 2009). E2A is a 
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bona fide early B cell factor (Ebf1) regulator, and is required to initiate Ebf1 
induction (Smith, et al. 2002). Whilst this lends a critical role to E2A in the 
initiation of B cell development, loss of the factor is not detrimental to mature 
B cell maintenance. This redundancy is due to the presence of dual Ebf1 
promoters, the α (or distal) promoter and the β (or proximal) promoter 
(Roessler, et al. 2007). The E2A transcription factor binds the distal Ebf1 
promoter, leading to the induction of Ebf1. The Pax5 promoter contains an 
Ebf1 binding site, binding to this site activates Pax5 expression. Pax5 
expression is critical for both the initiation and maintenance of the B cell 
lineage (Nutt and Kee 2007) and has been implicated as a requirement for 
EBNA2 expression (Klein, et al. 2010). To further potentiate the induction 
loop, Pax5 binds to the proximal Ebf1 promoter accelerating Ebf1 
transcription by triggering activity off the second promoter (Nutt and Kee 
2007). Due to this positively regulated loop, E2A is indispensible only for the 
initiation step of the B cell lineage. After this Ebf1 and Pax5 can maintain an 
adequate level of activity to conserve cell line lineage. In addition to the 
critical role for E2A in lineage commitment, E2A has furthermore been 
implicated in mature B cell survival and it has been demonstrated that 
knocking out E2A activity results in enhanced apoptosis in non-transformed 
cells (Lazorchak, et al. 2006). E2A is a positive regulator for transcription 
factors required for BCR expression; thus, it has been speculated that 
reduced E2A expression could lead to reduced survival due to loss of BCR 
signaling. However, it must be noted that E2A can protect pre-B cells from 
apoptosis in a BCR-independent manner; thus, E2A may confer survival 
advantages to B lymphocytes involving a novel mechanism (Lazorchak, et al. 
2006). 
 
(iii) The Pax5 transcription factor performs a dual role in the cell, as it can 
positively and negatively regulate transcription through direct DNA binding 
via its N-terminal paired-domain motif (Cobaleda, et al. 2007). The regulatory 
effect of Pax5 is dictated by the presence of repressive binding partners. 
Pax5 alone elicits transcriptional trans-activation through association with the 
basal transcriptional machinery protein, TBP and the likely recruitment of 
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histone acetyltransferases (HATs) (Emelyanov, et al. 2002). However, TLE-
containing repressor complexes can interact with Pax5 via a TLE-binding 
motif in the Pax5 protein, converting it to a transcriptional repressor 
(Eberhard, et al. 2000). In this study, Pax5, a down-stream effector of E2A 
activity, was found to be down-regulated by ectopic TLE1 in an LCL 
background (Section 5.2.6.3) and up-regulated following shRNA-mediated 
TLE1 knockdown in the same cell line (Section 5.2.8.4). Pax5 is one of three 
transcription factors vital to the B cell lineage commitment. Continued Pax5 
activity is required to retain B lymphocyte identity. In addition, Pax5 also 
positively regulates the early latent promoter, Wp. The TLE family have been 
found to act as co-factors along with Pax5 to elicit a repressional effect within 
a B cell.  Pax5 activity is responsible for regulating many B cell features 
prominent in an EBV infected lymphocyte such as BCR signalling and CD21 
stimulation (Reviewed in Cobaleda, et al. 2007). Although Pax5 is essential 
for B lineage commitment, surprisingly little is known about the regulatory 
mechanisms behind Pax5 expression. One defined trans-activator of Pax5 is 
the early B cell factor (Ebf1). The E2A transcription factor stimulates the 
activity of Ebf1; this in turn induces Pax5 expression which is essential for 
the initiation and maintenance of B cell lineage commitment (Nutt and Kee 
2007). Earlier results in this study indicated that TLE1 expression led to the 
repression of E2A mRNA expression in an LCL (Section 5.2.6.2). As Pax5 is 
an indirect target of E2A it remains to be determined in this situation whether 
Pax5 down-regulation is a result of direct regulation by TLE1, or whether it is 
an impact of the reduced level of E2A. A recent study has indicated that a 
10-fold transcriptional knockdown of E2A expression using shRNA results in 
a 2-fold reduction in Pax5 mRNA levels in the EBV-negative BL-derived 
DG75 cell line (Hauser, et al. 2009). Whether or not Pax5 repression is a 
direct or indirect effect of TLE1, it is noteworthy that plasma cell 
differentiation is inhibited by Pax5 (Fuxa and Busslinger 2007) and EBV 
immortalised LCLs do not readily succumb to terminal differentiation. 
Inhibiting the plasma cell fate provides a possible explanation for the EBV 
mediated down-regulation of TLE1, if the downstream effect of TLE1 
expression is Pax5 repression. 
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(iv) Runx3, a positively-regulated EBV cellular target gene, has been found 
in this study to be negatively regulated by ectopic TLE1 (Section 5.2.6.4). 
Runx3 is a known target of EBNA2, although TLE1 was shown to up-regulate 
EBNA2 in the ectopic cell pool, the transcription of Runx3 was down-
regulated. This implies that TLE1 may directly target Runx3. Circulating 
resting B cells are in a non-proliferative state and express Runx1 (Spender, 
et al. 2005). Upon EBV infection of resting B cells, Runx3 expression is 
induced by EBNA2, leading to a direct decrease in Runx1 expression 
(Spender, et al. 2002). Ectopic expression of Runx1 in an LCL inhibits cell 
proliferation (Brady and Farrell 2009). Moreover, it has been confirmed that 
one function of Runx3 in an EBV immortalised LCL is to repress the negative 
regulator of proliferation, Runx1 (Brady and Farrell 2009). The TLE 
recognition motif VWRPY is essential for this Runx3 led repression; as 
VWRPY Runx3 deletion mutants cannot down-regulate Runx1 activity in an 
LCL (Brady and Farrell 2009), implicating a TLE family member as an 
associated factor in Runx3 down-regulation of Runx1. Once infection of the 
LCL is established and Runx1 expression is negatively regulated, the 
infected cells can then move into a proliferative growth programme (Spender, 
et al. 2002). Evidence points to a role for c-myc as a downstream negative 
target of Runx1. Moreover it has been verified that forced c-MYC expression 
in a B cell line can overcome the Runx1 elicited proliferation repression. It 
can be noted that BLs characteristically encompasses c-myc translocation 
that instigates over-expression of the c-MYC protein. This over-expression of 
c-MYC overcomes the Runx1 activity and allows BLs to proliferate in culture 
in the presence of Runx1 (Reviewed in Brady and Farrell 2009). The 
modulation of Runx3 by TLE1 epitomises the fine balance of gene regulation 
in an EBV infected cell, as it appears that EBV may down-regulate TLE1 to 
potentially enhance activation of positive EBV target genes (Such as Runx3 
and CD23), but TLE1 is also a factor required for the function of said positive 
EBV targets (e.g. Runx3). Therefore it is logical that TLE1 expression is 
detected in EBV infected cells, but that the expression of the transcription 
factor is attenuated by EBV. However, it was also determined in this study 
that transient TLE1 knockdown using shRNA did not result in significant 
modulation of Runx3 activity (Section 5.2.8.5). This may have been due to 
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the limited time frame in which TLE1 knockdown was elicited, or a threshold 
for Runx3 expression may already have been met preventing further 
potentiated Runx3 expression. In addition, no TLE1 elicited regulation of 
Runx1 was observed in this study during ectopic expression of TLE1 nor 
during TLE1 knockdown, this is in agreement with published studies that 
indicate that although AML1 (Runx1) utilises TLE1 to elicit function, it is not 
itself regulated by TLE1 (Imai, et al. 1998; Levanon, et al. 1998).  
 
(v) The known positive EBV target, CD23, a direct target of EBNA2, was 
found to be down-regulated by ectopic TLE1 in an LCL in this study (Section 
5.2.6.5). CD23 expression promotes the activation and proliferation of B 
lymphocytes (Jurisic, et al. 2008), and thus is a logical EBV target. Two 
isoforms of CD23 exist that demonstrate variation in the cytoplasmic domain 
of the protein and are expressed from two different promoters: (i) CD23a 
arising from the proximal promoter is expressed only in B lymphocytes and 
(ii) CD23b originating from the distal promoter expressed in B lymphocytes 
and other cells of myeloid lineage in response to IL4 stimulation (Lemieux, et 
al. 2007). This was concluded in part by the fact that B lymphocytes infected 
by the EBV EBNA2 deletion mutant, P3HR1, failed to activate CD23 
expression (Cordier, et al. 1990). It was then established that EBNA2 
subverts the Notch signaling pathway to stimulate CD23 expression through 
the CBF1 binding domain in the CD23a proximal promoter (Ling, et al. 1994). 
If TLE1 expression were to down-regulate CD23, this would result in reduced 
proliferation, coinciding with the results for the growth rate in the ectopic 
TLE1 expression cell pool, pcDNA3 TLE1 IB4 (Section 5.2.8.6). However, 
the knockdown of TLE1 did not lead to the expected rise in CD23 
expression. No change in transcriptional activity was observed for CD23 
between the TLE1-shRNA knockdown cell pool and that pool expressing 
scrambled shRNA.  
 
(vi) Hes1 expression is known to be up-regulated in LCLs (Callahan, et al. 
2000). In this study Hes1 was not found to be regulated due to the ectopic 
expression of TLE1 in an LCL (Section 5.2.6.6), however, knockdown of 
TLE1 in the same LCL resulted in up-regulation of Hes1 activity (Section 
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5.2.8.7). Hes1 is a bHLH transcription factor that binds DNA and is directly 
trans-activated by Notch to elicit Notch stimulated regulation (Ross, et al. 
2003). Hes1 elicits negative regulation by associating with members of the 
TLE1 family through the TLE recognition sequence, WRPW (Buscarlet and 
Stifani 2007). Recent studies have established a strong link between Hes1 
expression and quiescence. Quiescence is a reversible state in which the 
cell is not dividing but can be stimulated to proliferate in response to the 
appropriate stimuli. Quiescent cells can either be stimulated to proliferate or 
they can move into an irreversible terminal state (differentiation, apoptosis or 
senescence). Quiescence was widely accepted to be a passive state; 
however, accumulating evidence indicates that it may be maintained by 
active molecular mechanism. Hes1 has recently been shown to be 
expressed in quiescent cells to prevent terminal differentiation. Furthermore, 
Hes1 expression has also been found to be up-regulated in several types of 
tumours to protect against differentiation. Thus, it is feasible, considering that 
EBV infected cells are blocked from undergoing differentiation, that EBV up-
regulates Hes1 to protect the infected cell from the plasma cell fate which 
would otherwise lead to virus production and immune visibility (Reviewed in 
Sang, et al. 2010). 
 
(vii) In this study it was observed that Hey1 was not regulated by ectopic 
TLE1 in an LCL (Section 5.2.6.6); however, upon TLE1 shRNA knockdown, 
the mRNA levels of Hey1 became elevated (Section 5.2.8.8). It may be the 
case that in the cell pool expressing ectopic TLE1, the threshold level of 
endogenous TLE1 was already sufficient to modulate Hey1. It is 
acknowledged that although the proteins of the Hey family contain a 
conserved C-terminal motif (YRPW), strikingly similar to the TLE recognition 
sequence (WRPW), TLE1 cannot associate with the Hey family (Buscarlet 
and Stifani 2007). The association between EBV and Hey1 will be discussed 
in more detail later in this study (Section 6.2.1). However, from the results 
obtained in these experiments it appears that TLE1 may have a role in Hey1 
regulation.  
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There is endogenous TLE1 in LCLs, and this basal level of expression may 
have already reached the threshold for eliciting its effect on some TLE1 
targets. Ectopic TLE1 might not therefore further modulate the expression of 
some TLE1 target genes. Gene knockdown served to lower the level of 
endogenous TLE1 and, therefore, results with any one target gene using the 
two approaches might not necessarily always appear to agree. Endogenous 
TLE1 in LCLs, present in lower levels than in resting B cells, may interact 
with transcription factors that play roles in cell subversion by EBV, given the 
requirement for TLE to act as a co-factor in the activities of Runx1, Runx3 
and Pax5. Indeed, TLE can be recruited by positive EBV targets to elicit the 
repression of unwanted gene expression. One such example of this is the 
previously mentioned co-operation between Runx3 and a TLE family 
member to down-regulate Runx1 in an LCL (Spender, et al. 2005; Brady and 
Farrell 2009).  
 
The transfection efficiency of suspension cell lines of lymphoid and myeloid 
origin have a tendency to be quite low and thus for this project a novel 
method for establishing an enriched transfected cell pool was established. 
Using an LCL it was found that removing excess dead cells 24 hours after 
transfection improved the overall viability of the transfected cell pool (Section 
5.2.11). A B cell-specific lectin (Con A) was also used to further ‘pan-out’ 
viable lymphocytes following transfection/drug-selection (Section 5.2.11). 
This novel approach greatly facilitated the isolation of cell pools enriched in 
drug-resistant (and hence transfected) cells. This method may have potential 
for improving the success of establishing stably transfected B cell lines. Con 
A, although unable to activate B cells, is a potent activator of T lymphocytes 
however, thus restricting the use of this approach to B cells. Due in large part 
to the success of this method, it was possible to establish cell pools 
transfected with individual shRNA-expressing plasmids. The cell pool 
exhibiting TLE1 knockdown appeared to have a higher rate of proliferation 
than the LCL expressing the scrambled shRNA (Figure 5.37). These results 
indicated that TLE1 had a negative impact on the growth rate of cells in an 
LCL background. 
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A previous association has been made linking TLE1 and EBV-immortalised 
cells (Almqvist, et al. 2005). As described in Chapter 1, EBV has four latency 
types (0-III) and three promoters for the activation and maintenance of these 
growth programmes (Cp, Qp and Wp). The activation of the Cp requires the 
binding of EBNA1 to a family of repeats (FR) upstream of the promoter. The 
FR is composed of a 30 bp sequence with a variable number of repeats and 
between seven and nine of these are required for EBNA1 activation of the 
Cp (Lindner and Sugden 2007). When bound to Cp, EBNA1 does not occupy 
the full FR sequence, and other proteins such as Oct1, Oct2 and Bob1 also 
associate with the FR. Indeed, even in the absence of EBNA1, Oct2 is a 
potent inducer of activity and can bind the Cp promoter unaccompanied to 
elicit up-regulation of the promoter. Oct1 gives a weaker response than Oct2, 
requiring the co-repressor Bob1 to elicit positive regulation on the promoter. 
TLE binds to Oct transcription factors thus modifying their function from 
transcriptional activators to transcriptional repressors. Studies have 
demonstrated the ability of TLE to regulate Oct function in relation to the 
EBNA Cp promoter. It was shown that all TLE proteins were capable of 
repressing Oct2-mediated enhancement of Cp. The effect of TLE proteins on 
Oct1-mediated induction varied and was at times contradictory to the 
Oct2/TLE function. The effect of Oct1/Bob1 was unchanged by the 
expression of TLE2 and TLE3, and surprisingly expression of TLE1 and 
TLE4 actually enhanced Cp activity. The effect of the TLE proteins on 
EBNA1-driven Cp promoter activity was also looked at in that study. It was 
found that co-transfection of EBNA1 with TLE3 or TLE4 led to up-regulated 
Cp activity. However, TLE1 and TLE2 had no impact on EBNA1-mediated 
Cp regulation (Almqvist 2005). EBV tightly regulates the expression of its 
latent genes, thus making the repression of a Cp deregulator, such as TLE1, 
a logical host-virus interaction. 
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Chapter 6: Regulation of other candidate 
EBV cellular target genes following EBV 
infection in B lymphocytes. 
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6.1 Introduction   
 
The RT Profiler PCR SuperArray experiment (Chapter 4) identified a 
spectrum of potential cellular genes as targets of EBV. These candidate 
targets were reduced to a panel of fourteen based on possible relevance to 
EBV biology and also novel association with EBV. Here, a role for EBV in the 
regulation of several cellular genes from this panel, shown to be modulated 
in naϊve B cells following infection by EBV (determined using an RT Profiler 
PCR SuperArray) (Table 4.1), was pursued using the conditional LCL 
ER/EB2.5 (described in Chapter 4). In this chapter the remaining genes were 
investigated, namely (i) Hey1, (ii) NR4A2, (iii) STIL, (iv) Cyclin E1, (v) LRP5, 
(vi) CIDEB, (vii) c-Fos, (viii) c-Jun, (ix) TNFSF7, (x) MMP7, (xi) TRAF4 and 
(xii) Fas. Their possible relevance in EBV latency is discussed. 
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6.2 Results 
6.2.1 Up-regulation of Hey1 by EBV in the conditional LCL, ER/EB2.5. 
 
A gene of particular interest in this study was Hairy/enhancer of split related 
YRPW motif 1 (Hey1). Hey1 (also denoted HERP2, Hesr1, HRT1 or CHF2), 
is a member of the hairy/Enhancer of Split-related bHLH orange family of 
transcription factors that mediate Notch signaling (Fischer, et al. 2002). The 
family comprises the three members Hey1, Hey2 and HeyL (Steidl, et al. 
2000; Leimeister, et al. 1999). Hey1 was identified as a potential cellular EBV 
target gene from the Notch RT Profiler PCR SuperArray in which a 121-fold 
increase in the level of Hey1 mRNA was observed 4 days post-infection of 
freshly isolated naïve B cells (Section 4.2.1). Primers for two Hey family 
members were included on the RT Profiler PCR SuperArray -Hey1 and 
HeyL, of which only Hey1 appeared to be modulated following EBV infection. 
Indeed, no mRNA from HeyL was detected in either sample.  
 
This aim of this study was to (i) confirm that Hey1 is an EBV target, (ii) 
determine which of the EBV latent proteins may be responsible for this 
regulation, (iii) to establish if there is a trend, with respect to Hey1 
expression, in a panel of B cell lines and (iv) attempt to assess the impact of 
Hey1 expression in a B cell. 
 
To confirm that EBV regulates Hey1 activity, the expression of Hey1 in the 
cell culture model, ER/EB2.5 was examined. ER/EB2.5 permits 
activation/inactivation of EBV latent gene expression with β-estradiol. Like 
any LCL, ER/EB2.5 cells proliferate due to the effects of EBV latent gene 
products, and ER/EBNA2 inactivation (in the absence of β-estradiol) leads to 
a cessation of the EBV growth programme. Cells were prepared for 
ER/EBNA2 activation as described in Section 4.2.3.  
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Figure 6.1:  Induction of EBV-driven proliferation in ER/EB2.5 leads to 
an increase in the level of Hey1 mRNA.  
RT-qPCR analysis was carried out to determine the levels of Hey1 expression in the 
cell culture model of resting B cells (ER/EB2.5 - est) relative to ER/EBNA2 activated 
cells (ER/EB2.5 + est). ER- EBNA2 was activated by the addition of 1µM β-estradiol 
to previously β-estradiol-starved cells. RNA samples were taken before and after 
the addition of β-estradiol to the growth medium and reverse transcribed using 
random hexamers and MMLV reverse transcriptase. Amplification of cDNA was 
monitored in real time by detection of fluorescence intensity using SYBR green. (A) 
Fluorescent signals were detected using an ABI Prism 7500 Sequence Detection 
System. Results were normalised using the internal control, TBP, and were 
expressed as relative quantitation as a function of the control. In this experiment, 
the control being EBV cycling cells (ER/EB - est): arbitrarily assigned a value of 1. 
(Data are Mean ±SD, *** P<0.001). (B) The dissociation curve for the product of the 
Hey1 assay was analysed to ensure a single specific peak, confirming that one 
specific PCR product was present. 
 
The results from this experiment correlated with the data obtained from the 
EBV-naϊve B cell infection experiment (Section 4.2.1). The level of Hey1 
expression within the ER/EB2.5 cell line increased 8-fold due to ER/EBNA2 
activation (Figure 6.1). Taken together, these experiments support the 
positive regulation of Hey1 by EBV at the transcriptional level.  
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6.2.1.1 Up-regulation of Hey1 by EBNA2 
 
The conditional BL, BL41-K3, described in Section 4.2.4, can be induced to 
express ER/EBNA2, whose function is dependent on β-estradiol, but no 
other latent viral proteins. Total RNA samples were prepared at time points 
during β-estradiol activation of ER/EBNA2 in BL41-K3 and the expression of 
Hey1 at the transcriptional level was investigated using RT-qPCR. BL41-K3 
cells were prepared for ER/EBNA2 activation by washing twice in PBS prior 
to the addition of β-estradiol to a final concentration of 1 µM in supplemented 
RPMI medium.  
 
 
Figure 6.2: ER/EBNA2 positively regulates Hey1 mRNA in BL41-K3.  
ER/EBNA2 was activated in BL41-K3 by the addition of 1µM β-estradiol to the 
growth medium. RNA extracts were prepared at the times indicated following 
activation of ER/EBNA2 in BL41-K3. RT-qPCR analysis was performed for Hey1 
mRNA levels in response to ER/EBNA2 activation. The post-induction time points 
are indicated on the graph. The RT-qPCR assay was performed as described in the 
legend to figure 6.1; results were normalised using the internal control, TBP, and 
were expressed as relative quantitation as a function of the control. In this 
experiment, the control was designated as BL41-K3 0 hr, arbitrarily assigned a 
value of 1. (Data are Mean ±SD, ** P<0.01). 
 
Results from the RT-qPCR investigation indicated that ER/EBNA2 activation 
coincided with up to a 6-fold increase in the steady state levels of Hey1 
mRNA during a 48 hour period (Figure 6.2). These findings imply the 
ER/EBNA2 is capable of transcriptionally driving Hey1 in an EBV-negative 
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BL cell line. The established conditional cell line DG75 tTA-EBNA2 
(described in detail in Section 4.2.6) was next used to confirm the ability of 
EBNA2 to trans-activate Hey1. Here, EBNA2 can be induced as sole EBV 
protein in an EBV-negative BL background in response to tetracycline. 
DG75-tTA-EBNA2 cells were maintained in supplemented RPMI media 
containing 1 µg/ml of tetracycline. To induce EBNA2, the cells were washed 
4 times in PBS and re-cultured in tetracycline free medium. Total RNA 
samples were prepared at time points following tetracycline withdrawal and 
the level of Hey1 mRNA was investigated using RT-qPCR.  
 
 
Figure 6.3: EBNA2 induction stimulates the up-regulation of Hey1 in 
DG75-tTA-EBNA2.  
EBNA2 expression was induced in DG75-tTA-EBNA2 by the removal of tetracycline 
from the supplemented RPMI medium. The figure shows RT-qPCR analysis of Hey1 
mRNA levels in DG75-tTA-EBNA2 in response to EBNA2 induction. RNA samples 
were prepared at the time points indicated post-induction. RT-qPCR analysis was 
performed as described in the legend to figure 6.1; results were normalised using 
the internal control, TBP, and were expressed as relative quantitation as a function 
of the control. In this experiment, the control was designated as DG75-tTA-EBNA2 0 
hr, arbitrarily assigned a value of 1. (Data are Mean ±SD, ** P<0.01). 
 
Increased Hey1 mRNA levels were observed to coincide with the induction of 
EBNA2 (Figure 6.3). Forty eight hours after the removal of tetracycline from 
the growth medium, the Hey1 mRNA level had increased seven fold. 
Together, these experiments show that Hey1 is trans-activated by EBNA2.  
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6.2.1.2 Hey1 mRNA expression levels in a panel of BLs and LCLs  
 
Relative Hey1 mRNA levels were determined in a panel of B cell lines 
including EBV-positive and EBV-negative BL-derived cell lines and an LCL. 
 
 
Figure 6.4: Comparative Hey1 mRNA levels in B cell lines.  
RT-qPCR was used to monitor Hey1 mRNA levels in a range of B cell lines 
including the EBV-negative B cell lines DG75, BJAB, Ramos and Akata4E3, the 
EBV-positive AG876 (group-III BL cell line), and the EBV-immortalised LCL IB4. 
RNA samples were prepared from each cell line in the same time frame, and RT-
qPCR analysis of Hey1 mRNA levels was performed as described in the legend to 
figure 6.1. Results were normalised using the internal control, TBP, and were 
expressed as relative quantitation as a function of the control. In this experiment 
Ramos cells were set as control cells, arbitrarily assigned a value of 1. (Data are 
Mean ±SD). 
 
From the results obtained, and taking into consideration the previous data 
presented in this study indicating that EBV up-regulates Hey1 (Section 
6.2.1), it was surprising to observe basal Hey1 mRNA levels at a lower level 
in the EBV-positive BL, AG876, in contrast to the EBV-negative BLs DG75 
Ramos and Akata4E3. Overall, no correlation between EBV/EBV gene 
expression appears to exist regarding Hey1 expression in the cell lines 
examined. 
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6.2.1.3 Hey1 represses a CBF1-regulated promoter  
 
The pGa981.6 construct is a Notch responsive reporter vector that has been 
described previously in section 3.2.2. To confirm the role for Hey1 in the 
Notch signalling pathway in a B cell background, the EBV-negative BJAB cell 
line was co-transfected with the Hey1 expression vector, pSG5-hHey1, and 
pGa981.6.  
 
 
Figure 6.5: Hey1 negatively regulates a CBF1-dependent promoter.  
BJAB cells were co-transfected with increasing quantities of pSG5 hHey1 (0µg, 1µg, 
5µg and 10 µg) along with 2 µg of the luciferase reporter construct pGa981.6. Cells 
were harvested 48 hours post-transfection and assayed for luciferase activity. 
Luciferase values were evaluated based on the β-galactosidase activity measured 
from a co-transfected pCMV-LacZ reporter, which was included in all transfections. 
Normalised values were expressed as percentage trans-activation relative to the 
corresponding data obtained from co-transfection of pSG5 and pGa981.6 vector. 
Data are presented as the average of three independent experiments (Data are 
Mean ±SD, * P<0.05, **P<0.01).  
 
Transient transfection of the EBV-negative cell line, BJAB showed that co-
transfection of the pGa981.6 luciferase reporter plasmid with increasing 
quantities of a Hey1 expression vector demonstrated a dose-responsive 
repressive effect elicited by Hey1 on promoter-driven luciferase values 
(Figure 6.5). These results show that Hey1 represses transcription from a 
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CBF1-regulated promoter. These data supports a role for Hey1 as a 
regulator of Notch-responsive genes in this non-BL B cell line. 
6.2.1.4 An NF-κB responsive promoter is negatively regulated by Hey1 
expression  
 
EBV subversion of the NFκB signaling pathway is a widely accepted 
requirement for successful establishment of EBV infection. To determine if 
Hey1 can also influence the NFκB pathway, BJAB was co-transfected with 
pSG5 hHey1 and the previously described NFκB-regulated reporter 
construct, 3x enh κB luc (Section 5.2.2).  
 
 
Figure 6.6: Hey1 negatively regulates an NF-κB-dependent promoter.  
BJAB cells were co-transfected with increasing quantities of pSG5 hHey1 (0 µg, 1 
µg, 5µg and 10 µg) along with 2 µg of the luciferase reporter construct 3xEnh-luc. 
Cells were harvested 48 hours post-transfection and assayed for luciferase activity. 
Luciferase values were calculated as previously described in the legend to figure 
6.5 and normalised values were expressed as percentage trans-activation relative 
to the corresponding data obtained from co-transfection with pSG5 and 3xEnh-Luc 
vector. Data are presented as the average of three independent experiments (Data 
are Mean ±SD, * P<0.05, ** P<0.01, *** P<0.001). 
 
Co-transfection of BJAB cells with 3xEnh-Luc and increasing quantities of 
pSG5 hHey1 gave a consistent dose-responsive decrease in luciferase 
activity within the triplicate experiments performed in this study (Figure 6.6). 
This indicates that Hey1 plays a role in regulating NF-κB signaling in BJAB. 
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6.2.1.5 Determining a role for Hey1 in an LCL 
 
The results obtained so far in this study indicate that EBV up-regulates the 
cellular gene Hey1. This part of the study involved investigating the impact of 
ectopic Hey1 expression on the phenotype of an LCL. To express Hey1 in an 
inducible manner within the cell, a Hey1 cDNA was sub-cloned into a 
tetracycline (Tet) regulated expression vector, pRTS-1 (Figure 6.7). The 
resulting plasmid pRTS-1-hHey1 could be induced to simultaneously co-
express both Hey1 and GFP. 
 
 
 
 
 
 
 
 
 
 
Figure 6.7: Schematic circular map illustrating pRTS-1.  
pRTS-1 is an EBV-derived episomally replicating plasmid that is designed to allow 
tetracycline controlled regulation of expression of a gene of interest from the vector. 
pRTS-1 possesses a bi-directional promoter Ptetbi-1 from which GFP and Luc (or an 
inserted target gene) is expressed. The luciferase gene is designated as luc. The 
bicistronic expression cassette driving expression of rtTAs-M2 and tTSKRAB, 
separated by an internal ribosomal entry site (IRES), is located down-stream of the 
chicken β-actin intron and transcribed from a promoter/enhancer consisting of the 
mouse heavy chain intron enhancer (Eµ) and the chicken β-actin promoter (CAGp). 
OriP is the EBV episomal origin of replication which can be driven by EBNA1, the 
EBV gene EBNA1. SVp denotes the SV40 early promoter; ori, the bacterial origin of 
replication derived from pMB1; and hyg, the hygromycin phosphotransferase gene 
(Adapted from Bornkamm, et al. 2005). 
 
The tetracycline-regulatable pRTS-1 vector, a novel EBV-derived episomally 
replicating plasmid, allows simultaneous expression of two genes 
(Bornkamm, et al. 2005). The pRTS-1 construct encompasses two 
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regulational factors, a transcriptional silencer tTSKRAB and a transcriptional 
activator rtTA2S-M2. In the absence of tetracycline, the vector-derived 
silencer, tTSKRAB binds to Ptetbi-1 preventing expression from the bi-
directional promoter. Addition of tetracycline alleviates this repression, and 
binding of rtTA2S-M2 then activates the Ptetbi-1.  
 
6.2.1.6 The construction of pRTS-1 Hey1  
 
To generate pRTS-1-Hey1, a cloning strategy was employed that involved 
amplification of the Hey1 target sequence from pSG5 FLAG hHey1 (a gift 
from Belandia, et al. 2005) by PCR (Figure 6.8A) and subsequently sub-
cloneing into pRTS-1 in place of the excised luc gene. The pRTS-1 vector 
was first linearised by digestion with Sfi I to excise the luc gene (Figure 
6.8B), followed by de-phosphorylation using CIP to prevent re-circularisation 
of the linearised DNA, and additionally to prevent re-cloning of the excised 
luc gene. The linearised, CIP-treated DNA was then purified by 
phenol:chloroform extraction followed by ethanol precipitation (Section 
2.2.1.2).  The primers used to amplify hHey1 included Sfi I restriction sites for 
cloning. Following PCR, the products were analysed by agarose gel 
electrophoresis (Figure 2.2.1.16) to determine that the fragment was at the 
expected size. The PCR products were subsequently purified using the 
Promega Wizard® DNA purification system (Section 2.2.1.6), digested with 
Sfi I and purified by phenol: chloroform extraction followed by ethanol 
precipitation. Purified PCR products were then sub-cloned between the Sfi I 
sites of pRTS-1.   Ligations of vector and insert DNA were carried out 
overnight at 16˚C (Section 2.2.1.7).  Following ligation, competent E. coli 
JM109 cells were transformed with the recombinant plasmid DNA. DNA mini-
preparations were prepared from cultures inoculated with single transformed 
colonies. Restriction digestion analysis was performed on the DNA to 
monitor the presence of hHey1 insert DNA. Although both Sfi I sites used for 
cloning were different in base-pair composition it was possible for the insert 
DNA to ligate into the vector in either the forward or reverse orientation as 
the overhangs produced are palindromes. To determine which orientation the 
insert DNA had ligated in, restriction analysis using Bst EII was performed 
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(Figure 6.8D). The correctly orientated clones were then purified using the 
Qiagen® Midi Kit (Section 2.2.1.12). 
 
 
Figure 6.8: Generation of pRTS-1 hHey1.  
(A) PCR product amplified from pSG5 FLAG Hey1, exhibiting a band at the 
expected size of approximately 955 bp. Lane 1 contains a 1 kb ladder. All DNA was 
analysed using 0.7-1% agarose-1X TAE gels and electrophoresis was carried out at 
100V for 1 hour in 1X TAE. (B) Restriction digestion of pRTS-1 with the expected Sfi 
I excised luc gene at 1652 bp in lane 1. The remaining linearised vector was 
phosphatase treated by CIP, to prevent re-circularisation. (C) Following ligation, 
recombinant vectors were analysed by Sfi I digestion followed by agarose gel 
electrophoresis. Lane 1 shows a 1 kb DNA ladder, the excised hHey 1 cDNA 
fragment from a positive recombinant clone is highlighted in red at the expected 
size, 955 bp. Lanes 2, 3, 6 and 8 comprised the pRTS-1 vector alone, whilst lanes 4 
and 7 contained undigested and digested pRTS-1 clones respectively, with the luc 
gene still present. (D) Restriction analysis of recombinant pRTS-1 hHey1 clones to 
determine correct insert orientation by digestion using Bst EII enzyme followed by 
agarose gel electrophoresis on a 0.7% agarose-1X TAE gel. In the correct 
orientation this would yield four fragments of 5597 bp, 4592 bp, 4964 bp, and 1957 
bp (highlighted in lane 2). However, incorrect orientation would produce four 
fragments of 6145 bp, 4964 bp, 4592 bp, and 1957 bp upon digestion, as seen in 
lane 3. A 1 kb ladder is seen in lane 1. 
 
To demonstrate that pRTS-1 hHey1 could be induced to express eGFP by 
tetracycline, DG75 cells were transfected with pRTS-1-hHey1. The 
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transfected cell pool was divided in two, half of the pool was cultured in 
tetracycline free supplemented RPMI medium, while the remaining half was 
cultured in the presence on tetracycline and the two cell pools were 
monitored by fluorescent microscopy after 48 hours. 
 
Figure 6.9: Induction of ectopic eGFP expression from pRTS-1 hHey 
(10x magnification).  
DG75-pRTS-1 hHEy1 cell pools were induced by addition of tetracycline to express 
Hey1 and GFP proteins. (A) The un-induced control cell pool (-Tet) displaying no 
GFP expression. (B) The induction of GFP protein expression by Tet (+Tet). The 
cell pools were examined 48 hours post-induction using an Olympus DP-50 
fluorescent microscope. 
 
The detection of Hey1 expression by Western blot analysis in this study 
proved unsuccessful. RT-qPCR was employed however to confirm inducible 
expression of hHey 1 mRNA from this vector. To estimate the relative levels 
of Hey1 mRNA expression from a transfected cell pool in which the pRTS-1-
hHey1 construct is induced, relative to an un-induced pool, the DG75 cell line 
was co-transfected with pRTS-1-hHey1. The transfected pool was divided 
and one portion was induced by the addition of 1µg/ml tetracycline to the 
culture medium. Subsequently, RNA samples were prepared from the un-
induced pool and the induced pool 48 hours after the addition of tetracycline 
and RT-qPCR was performed.  
BA 
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Figure 6.10: Induction of Hey1 mRNA from pRTS-1-hHey1.  
Hey1 expression was induced in DG75 cells transfected with pRTS-1 hHey1 by the 
addition of 1µg/ml tetracycline to the supplemented RPMI culture medium. However, 
increased Hey1 mRNA expression can be observed in the un-induced cell pool 
relative to the empty vector controls (pRTS-1 induced and un-induced). RNA 
samples were taken and RT-qPCR analysis was performed as described in the 
legend to figure 6.1. In this experiment, the control was designated as pRTS-1 (-
Tet); arbitrarily assigned a value of 1. (Data are Mean ±SD). 
 
The RT-qPCR analysis of DG75 cells transfected with pRTS-1-hHey1  
indicated that Hey1 mRNA was detectable in the absence of tetracycline. A 
38-fold increase in Hey1 mRNA levels can be seen due to un-induced pRTS-
1-hHey1, relative to the empty pRTS-1 vector. Tetracycline induction led to 
an 84-fold increase in the levels of Hey1 mRNA relative to the empty pRTS-1 
vector. However, relative to the un-induced construct, induction from the 
pRTS-1-hHey1 only increases the Hey1 expression levels 2-fold.  
 
To determine if the leaky expression from pRTS-1-hHey1 elicits a significant 
effect on a known Hey1 target, DG75 cells were co-transfected with pRTS-1-
hHey1 along with a luciferase reporter construct containing a Hey1 
responsive GATA4 promoter, pGL3-GATA4. GATA4 is a housekeeping gene 
that is repressed by Hey1. Once again the cell pool was divided in two, one 
half was induced by the addition of tetracycline to activate Hey1 expression, 
and the remaining half was left un-induced. DG75 was also co-transfected 
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with pGL3-GATA4 and pSG5 FLAG hHey1 as a positive control for Hey1 
mediated GATA4 repression. 
 
Figure 6.11: Ectopic Hey1 expression represses the GATA4 promoter.  
DG75 cells were co-transfected with 5 µg of pGL3-GATA4 reporter construct, 2 µg 
pCMVLacZ, to allow for normalisation, and either pSG5 FLAG hHey1 or pRTS-1-
hHey1. The total quantity of transfected plasmid was adjusted to 12 µg with the 
empty vector pSG5. Transfected cell pools were split into two and one portion was 
induced with tetracycline. Cells were harvested 48 hours after transfection and 
luciferase and β-gal assays were performed. Normalised luciferase values were 
expressed as fold-activation relative to the corresponding value obtained for the 
pGL3 GATA4 reporter construct when co-transfected with pSG5 FLAG hHey1; 
arbitrarily assigned a value of 1. (Data are Mean ±SD). 
 
It can be observed from figure 6.11, that GATA4 promoter activity is almost 
completely repressed by Hey1 expression, in agreement with published data 
(Fischer, et al. 2005). pSG5 FLAG Hey1 reduces the trans-activation of 
GATA4 over 2000-fold. In addition, induction of the pRTS-1-hHey1 construct 
by tetracycline down-regulated the GATA4 promoter to an equivalent degree. 
However, the leaky expression from the un-induced pRTS-1 hHey1 construct 
was sufficient to elicit a similar level of repression on the GATA4 promoter 
construct. It was clear at this point that regulatable expression of Hey1 from 
the pRTS-1 construct would not be achieved, it was decided not to proceed 
with this vector.  
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6.2.1.7 Determining the effect of EBNA2 on the Hey1 promoter in an 
EBV-negative BL 
 
Results previously obtained in two independent experiments indicated that 
an increase in Hey1 mRNA expression was found to coincide with increased 
EBNA2 protein expression (Section 6.2.1.1).  Thus EBNA2 was implicated as 
a trans-activator of Hey1 in a BL background. It was, therefore, of interest to 
determine if this up-regulation effect was elicited through the Hey1 promoter. 
The human Hey1 promoter-reporter construct used in this experiment was a 
gift from Dr. M Gessler (Zavadil, et al. 2004). 
 
 
Figure 6.12: Ectopic EBNA2 trans-activates the Hey1 promoter.  
DG75 cells were co-transfected with 2 µg of pGL3-Hey1 luciferase reporter 
construct, 2 µg pCMVLacZ, to allow for normalisation, and 5 µg pSG5-EBNA2. As 
negative controls DG75 was also transfected with (i) 2 µg of the empty pGL3-basic 
vector, (ii) 2 µg of the empty pGL3-basic vector along with 5 µg pSG5-EBNA2 and 
(iii) 2 µg of pGL3 Hey1. The total quantity of transfected plasmid was adjusted to 9 
µg with the empty vector pSG5. Transfected cells were harvested 48 hours later and 
luciferase and β-gal assays were performed. Normalised luciferase values were 
expressed as fold-activation relative to the corresponding value obtained for the 
empty pGL3 reporter construct; arbitrarily assigned a value of 1. (Data are Mean 
±SD).  
 
It initially appeared that EBNA2 was trans-activating the hey 1 promoter in 
pGL3 Hey1. However, co-transfection with both pGL3-basic and pSG5-
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EBNA2, resulted in a three-fold increase in luciferase activity, relative to 
transfection of DG75 with pGL3-basic alone. The luciferase expression levels 
were examined further and it was determined that luciferase production from 
pGL3-Hey1 increased three-fold upon co-transfection with pSG5-EBNA2. 
This pGL3 Hey1/ pSG5-EBNA2 trans-activating effect may not be due to a 
specific Hey1 target effect, but rather the up-regulation of luciferase 
production from the promoterless pGL3-basic host plasmid activity, due to 
EBNA2 expression. To investigate this further, DG75 cells were co-
transfected with increasing quantities of pSG5-EBNA2 and a constant 
quantity of pGL3-basic.  
 
In that experiment, a dose-dependent increase in pGL3-encoded luciferase 
activity can be observed in response to increasing quantities of pSG-EBNA2 
(Figure 6.13). EBNA2 may therefore be enhancing transcription of luc 
possibly from a cryptic promoter site on pGL3-basic. 
 
 
Figure 6.13: Ectopic EBNA2 induces luciferase activity from pGL3-
Basic. 
DG75 cells were co-transfected with 2 µg of pGL3-Basic luciferase reporter vector 
along with increasing quantities of pSG5-EBNA2 (1 µg, 3 µg and 7 µg). The total 
quantity of transfected plasmid was adjusted to 7 µg with the empty vector pSG5. 
The transfections were harvested 48 hours after transfection and luciferase and β-
gal assays were performed. Normalised luciferase values were expressed as fold-
activation relative to the corresponding value obtained for the EBNA2A (1µg) + 
pGL3-basic; arbitrarily assigned a value of 1. (Data are Mean ±SD). 
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6.2.2 Regulation of NR4A2 (Nurr1) by EBV 
 
NR4A2 is a transcription factor that forms part of the orphan receptor family 
(Park, et al. 2008). This family is a branch of the steroid-thyroid hormone 
receptor super family of the subfamily 4 group A, composed of NR4A1, also 
called Nur77, NR4A2, or Nurr1 and NR4A3 alternatively known as NOR1 
(Aherne, et al. 2009; Okabe, et al. 1995). These pleiotropic proteins have 
been implicated in steroidgenesis, neuronal development, atherogenesis and 
cell cycle regulation (Maxwell and Muscat 2006). The Nurr family member, 
Nur77, has been previously identified as a direct EBV target. EBNA2 has 
been shown to bind this pro-apoptotic Nur77 protein, sequestering it in the 
nucleus. This prevents Nur77 from eliciting its pro-apoptotic function which 
occurs via interactions with the mitochondria resulting in cytochrome c 
release. This indicates that there is precedent for modulation of this family by 
the activity of EBV. 
 
NR4A2, more commonly called Nurr1, was identified as a potential EBV 
cellular target gene from the RT Profiler PCR SuperArray presented in 
section 4.2.1. It was found that Nurr1 mRNA expression was down-regulated 
approximately 14-fold in naϊve B cells after infection by EBV. To determine 
the effect of the activation of the EBV growth programme on the expression 
levels of Nurr1 in an LCL cell culture model, ER/EB2.5 cells were cultured 
and RNA was prepared as described in section 4.2.3 
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Figure 6.14:  Induction of EBV driven proliferation in ER/EB2.5 leads to 
a decrease in the level of Nurr1 mRNA.  
RT-qPCR analysis was carried out to determine the levels of Nurr1 expression in 
resting B cells (ER/EB - est) relative to ER/EBNA2 activated cells (ER/EB + est). 
RNA samples were prepared at the time points indicated. (A) RT-qPCR analysis of 
Nurr1 mRNA levels in response to ER/EBNA2 activation. The post-induction time 
points are indicated on the graph. The RT-qPCR assay was performed as described 
in the legend to figure 6.1, results were normalised using the internal control, TBP, 
and were expressed as relative quantitation as a function of the control. In this 
experiment, the control for RT-Real time PCR was set as EBV cycling cells (EREB + 
est 24 hr): arbitrarily assigned a value of 1. (Data are Mean ±SD, *** P<0.001, 
**P<0.01). (B) The dissociation curve for the product of the Nurr1 assay was 
analysed to ensure a single specific peak, confirming accuracy of the experiment, 
as SYBR green does not give a gene-specific response. 
 
 
The results from this experiment showed that the steady state levels of Nurr1 
are down-regulated 16-fold in response to the EBV growth programme 
(Figure 6.14). This confirms the data from the RT Profiler PCR SuperArray, 
in which the expression levels of Nurr1 were shown to be reduced following 
B cell infection with EBV (Section 4.2.1). To confirm this, an estrogen 
withdrawal experiment was again performed using ER/EB2.5 (Figure 6.15). 
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Cells previously cycling in the presence of estrogen were washed as 
described in section 4.2.3. These cells were then seeded into T75 flasks at a 
density of 5 X 105 cells/ml (ER/EB2.5 – est 0 hr) and passaged every 48 
hours. Total mRNA samples were prepared at the time points indicated for 
the duration of time that the cells were cultured in β-estradiol free medium. 
 
 
 
Figure 6.15:  De-activation of ER/EBNA2 results in a significant 
increase in Nurr1 mRNA levels.  
(A) RT-qPCR was performed to determine the effect on Nurr1 mRNA levels in 
response to ER/EBNA2 de-activation (β-estradiol withdrawal). RNA samples were 
prepared at the post-withdrawal time points indicated on the graph. Assay and 
normalisation of results (relative to TBP) was performed as described in the legend 
to figure 6.1. In this experiment, the control was designated as ER/EB – est 0 hr; 
arbitrarily assigned a value of 1. (Data are Mean ±SD, ** P<0.01). (B) Western Blot 
showing de-activation of ER/EBNA2 in response to β-estradiol withdrawal. Protein 
harvested from cells cultured from β-estradiol medium (ER/EB2.5 –est 0 hr) exhibit 
the active 120 kDa ER/EBNA2 protein. After 24 hours, this band is detected at a 
lower molecular weight, indicative of inactive ER/EBNA2, due to the loss of β-
estradiol. All extracts were normalised to the loading control β-Actin. 
 
 
It can be seen from these results that as ER/EBNA2 is de-activated in 
ER/EB2.5, the Nurr1 mRNA levels increase significantly (Figure 6.15A). The 
de-activation of the ER/EBNA2 was verified by Western blotting (Figure 
6.15B). In this experiment a decrease in the level of chimeric EBNA2, over 
the duration of the time-course, was confirmed. 
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6.2.2.1 Nurr1 is repressed due to c-myc driven growth in the conditional 
LCL, P493-6 
 
P493-6, described previously in section 4.2.7, is a conditional LCL that has 
been engineered from the parental cell line ER/EB2.5. When starved of 
estrogen, P493.6 represents a resting B-cell that can be stimulated to 
proliferate either in response to (i) Myc in the combined absence of 
tetracycline and estrogen or (ii) EBNA2 in the presence of estrogen and 
tetracycline (Pajic, et al. 2000; Schuhmacher, et al. 2001). Total mRNA 
samples were prepared from a time course that was performed in section 
4.2.7 in which the P493.6 cell line was cultured on the EBV growth 
programme (+ β-estradiol, + Tet) or C-Myc (- β-estradiol, - Tet). RT-qPCR 
analysis was employed to determine if Nurr1 was differentially regulated in 
LCLs cycling due to EBV, compared to those cycling due to C-Myc.  
 
 
Figure 6.16: Down-regulation of Nurr1 by Myc driven proliferation in the 
conditional LCL, P493-6.  
The steady state levels of Nurr1 mRNA was significantly higher in P493-6 cells 
proliferating due to EBNA2 compared to the same cell background cycling due to 
Myc. Cells from the ER/EB2.5 sub-clone, P493-6, were divided and separately 
cultured to permit cycling on the EBV growth programme (+ β-estradiol, + Tet) or 
Myc programme (- β-estradiol, - Tet).  Total RNA samples were taken during each 
growth programme. At the cycling programme indicated, RT-qPCR was performed 
as previously described in figure legend 4.11. Results were normalised using the 
internal control, TBP, and were expressed as relative quantitation as a function of 
the control. In this experiment the control set at P493-6 Myc cells; arbitrarily 
assigned a value of 1. (Data are Mean ±SD, ** P<0.01).  
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It was determined from the RT-qPCR analysis that the steady state level of 
Nurr1 mRNA was significantly lower in cells proliferating due to C-Myc (- β-
estradiol, - Tet) in contrast to the cells proliferating due to EBV (+ β-estradiol, 
+ Tet)  (see Figure 6.16). P493-6 cells proliferating due to ER/EBNA2 
activation are reminiscent of the parental cell line ER/EB2.5. Therefore 
previous results indicate that the activation of ER/EBNA2 leads to the down-
regulation of Nurr1 in this cell background (Section 6.2.2). However, from this 
examination of the P493-6 cell line it can be observed that activation of the c-
Myc programme in the same cell background leads to even more potent 
down-regulation of Nurr1 at the transcriptional level. EBNA2 positively trans-
activates endogenous c-myc, and therefore C-Myc is expressed in both cell 
lines but to somewhat varying degrees. From the results obtained in this 
study, it could be speculated that the down-regulation of Nurr1 activity during 
infection of a resting B cell may be due to EBV induction of c-myc, 
consequently Nurr1 may be a negative target of c-myc, and as such, an 
indirect target of EBV infection.  
 
6.2.2.2 Relative Nurr1 expression is down-regulated in EBV-negative B 
cell lines. 
 
As described previously, phenotypically diverse B cell lines were employed in 
this study. Relative Nurr1 mRNA levels were next examined in a B cell panel 
comprising of several different B lymphocyte backgrounds: EBV-negative 
BLs, an EBV negative lymphoma cell line, an EBV-positive BL, and an LCL.  
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Figure 6.17: Comparative Nurr1 mRNA levels in B cell lines.  
RT-qPCR was used to monitor Nurr1 mRNA levels in a range of B cell lines 
including the EBV-negative B cell lines DG75, BJAB and Akata4E3, the EBV-
positive AG876 (group-III BL cell line), and the EBV-immortalised LCL IB4. RNA 
samples were prepared from each cell line in the same time frame, and RT-qPCR 
analysis of Nurr1 mRNA levels was performed as described in the legend to figure 
6.1. Results were normalised using the internal control, TBP, and were expressed 
as relative quantitation as a function of the control. In this experiment DG75 cells 
were set as control cells, arbitrarily assigned a value of 1. (Data are Mean ±SD). 
 
The results obtained showed that the steady state levels of Nurr1 mRNA 
were consistently lower in BL-derived EBV-negative cell lines (Figure 6.17). 
Taking into consideration the previous data presented in this study, indicating 
that Nurr1 is down-regulated in response to c-Myc expression, it was not 
surprising to observe basal Nurr1 expression levels at a lower level in these 
cell lines which have high c-Myc expression. However, although AG876 is a 
BL, and as such contains the characteristic BL translocation that results in 
the over-expression of c-Myc, it does not exhibit reduced Nurr1 mRNA 
transcription. The increased level of Nurr1 mRNA in AG876 is consistent with 
it being a C-myc-responsive gene. EBNA2 in fact represses C-myc 
expression from the translocated IgMu enhancer in BLs, and so EBV-positive 
(Type III) express BLs less C-myc than their EBV-negative counterparts 
(Jochner, et al. 1996). 
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6.2.3 Regulation of STIL by EBV 
 
STIL was identified as a candidate for EBV regulation from the results 
obtained from the RT Profiler PCR SuperArray, in section 4.2.1. As a gene 
included in the Notch signaling pathway array, STIL was analysed and found 
to be up-regulated 129-fold following infection of naïve B cells with EBV. 
STIL (SCL/TAL1 interrupting Locus), also known as SCL-interrupting protein 
(SIL), is a 143kDa cytoplasmic protein that is highly conserved in 
vertebrates. STIL is composed of 18 exons and has been mapped to the 
chromosomal location 1q32. STIL has been found to be ubiquitously 
expressed in cells during early embryonic development and in proliferating 
cells. During metaphase, STIL localizes to the mitotic spindle poles to co-
ordinate spindle organization (Reviewed in Kumar, et al. 2009).  
 
As described in chapter 4, the conditional LCL, ER/EB2.5 was used to 
corroborate results from the RT Profiler PCR SuperArray. The ER/EB2.5 cell 
line was prepared for an ER/EBNA2 activation time course as described in 
section 4.2.3. RNA samples were harvested from ER/EB2.5 cells (i) without 
the presence of β-estradiol and (ii) cycling on the EBV programme due to β-
estradiol activation of ER/EBNA2. STIL mRNA levels were examined using 
RT-qPCR. 
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Figure 6.18:  Induction of EBV driven proliferation in ER/EB2.5 leads to 
an increase in the level of STIL mRNA.  
RT-qPCR analysis was carried out to determine the levels of STIL expression in the 
cell culture model of resting B cells (ER/EB - est) relative to ER/EBNA2 activated 
cells (ER/EB + est). RNA samples were prepared at the time points indicated. (A) 
RT-qPCR analysis of STIL mRNA levels in response to ER/EBNA2 activation. The 
post-induction time points are indicated on the graph. The RT-qPCR assay was 
performed as described in the legend to figure 6.1, results were normalised using 
the internal control, TBP, and were expressed as relative quantitation as a function 
of the control. In this experiment, the control for RT-Real time PCR was set as EBV 
cycling cells (ER/EB + est 24 hr): arbitrarily assigned a value of 1. (Data are Mean 
±SD, ** P<0.01). (B) The dissociation curve for the product of the STIL assay was 
analysed to ensure a single specific peak, confirming accuracy of the experiment, 
as SYBR green does not give a gene specific response. 
 
It can be seen that STIL mRNA levels increased 3-fold after the activation of 
the EBV growth programme. In a second experiment, STIL mRNA levels 
were again monitored at various time points in ER/EB2.5 cells (i) as estrogen 
was withdrawn from ER/EB2.5 cells previously cycling on activated 
ER/EBNA2 and (ii) while the cell line was once again induced to proliferate 
due to EBV through β-estradiol induction (Figure 6.18).  
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Figure 6.19:  Modulation of the EBV growth programme in ER/EB2.5 
correlates with changes in STIL mRNA levels.  
To examine the modulated effect of STIL mRNA levels in response to activation and 
de-activation of EBV driven proliferation, an expanded time course of ER/EB2.5 
cycling cells was performed. This experiment was described in the legend to the 
figure 4.6. RNA samples were monitored and normalised using TBP as described in 
the legend to figure 6.1. In this experiment, the control was designated as ER/EB 
cycling on estrogen; arbitrarily assigned a value of 1. (Data are Mean ±SD, * 
P<0.05). 
 
Interestingly, the de-activation of ER/EBNA2 led to a transient increase in 
STIL mRNA levels; however, this was followed by a significant reduction by 
48 hours (Figure 6.19). Re-activation of ER/EBNA2 re-induced STIL, 
restoring the expression levels observed in cells cycling due to EBV. Thus 
these results show that STIL expression positively correlates with EBV latent 
gene expression in ER/EB2.5.  
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6.2.3.1 Relative STIL mRNA levels are similar in P493-6 cells cycling 
due to either C-myc or EBV 
 
STIL mRNA levels were then examined as before in P493.6 cells cycling on 
either the EBV growth programme (+ β-estradiol, + Tet) or C-MYC 
programme (- β-estradiol, - Tet).  
 
 
Figure 6.20: STIL mRNA levels are similar in P493-6 cells cycling due to 
either C-myc or EBV.  
The steady state levels of STIL mRNA were similar in P493-6 cells proliferating due 
to EBNA2 compared to the same cell background cycling due to Myc. Cells from the 
ER/EB2.5 sub-clone, P493-6, were divided and separately cultured to permit cycling 
on the EBV growth programme (+ β-estradiol, + Tet) or Myc programme (- β-
estradiol, - Tet).  Total RNA samples were taken during each growth programme. At 
the cycling programme indicated, RT-qPCR was performed as previously described 
in figure legend 4.11. Results were normalised using the internal control, TBP, and 
were expressed as relative quantitation as a function of the control. In this 
experiment the control set at P493-6 EBNA2 cells; arbitrarily assigned a value of 1. 
(Data are Mean ±SD).  
 
The results obtained in this experiment indicate that modulation of P493-6 
driven growth between c-Myc driven growth and EBV-driven growth does not 
differentially modulate STIL transcriptional activity in an LCL (Figure 6.20).  
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6.2.3.2 Comparative STIL mRNA levels in a panel of B cell lines. 
 
Relative STIL mRNA levels were examined as before in a panel of B cell 
lines -EBV-negative BLs including Akata4E3, DG75, and Ramos, an EBV 
negative lymphoma cell line, BJAB, an EBV-positive BL, AG876, and an 
EBV-positive LCL, IB4. 
 
 
 
Figure 6.21: Comparative STIL mRNA levels in B cell lines.  
RT-qPCR was used to monitor STIL mRNA levels in a range of B cell lines including 
the EBV-negative B cell lines DG75, BJAB and Akata4E3, the EBV-positive AG876 
(group-III BL cell line), and the EBV-immortalised LCL IB4. RNA samples were 
prepared from each cell line in the same time frame, and RT-qPCR analysis of STIL 
mRNA levels was performed as described in the legend to figure 6.1. Results were 
normalised using the internal control, TBP, and were expressed as relative 
quantitation as a function of the control. In this experiment BJAB cells were set as 
control cells, arbitrarily assigned a value of 1. (Data are Mean ±SD). 
 
The results obtained in this experiment indicate that STIL mRNA levels were 
similar across all cell lines examined (Figure 6.21). All of these results are in 
agreement with published data concluding that STIL expression is ubiquitous 
in proliferating cells. 
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6.2.3.3 No STIL regulation observed in response to EBNA2 expression 
in an EBV-negative BL. 
 
STIL mRNA levels were examined in response to EBNA2 expression in the 
EBV-negative BL-derived cells lines DG75-tTA-EBNA2 and BL41-K3. It can 
be seen that EBNA2 did not modulate STIL mRNA levels in either case 
(Figures 6.22 and 6.23).   
 
 
 
Figure 6.22: EBNA2 induction did not significantly regulate STIL in 
DG75-tTA-EBNA2.  
EBNA2 expression was induced in DG75-tTA-EBNA2 by the removal of tetracycline 
from the supplemented RPMI medium. RT-qPCR analysis of STIL mRNA levels in 
DG75-tTA-EBNA2 in response to EBNA2 induction. RNA samples were prepared at 
the time points indicated post-induction. RT-qPCR analysis was performed as 
described in the legend to figure 6.1, results were normalised using the internal 
control, TBP, and were expressed as relative quantitation as a function of the 
control. In this experiment, the control was designated as DG75-tTA-EBNA2 0 hr, 
arbitrarily assigned a value of 1. (Data are Mean ±SD). 
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Figure 6.23: ER/EBNA2 does not regulate STIL mRNA in BL41-K3.  
ER/EBNA2 was activated in BL41-K3 as described in the legend to figure 4.7. RT-
qPCR analysis was used to determine STIL mRNA levels in response to ER/EBNA2 
activation. The post-induction time points are indicated on the graph. The RT-qPCR 
assay was performed as described in the legend to figure 6.1, results were 
normalised using the internal control, TBP, and were expressed as relative 
quantitation as a function of the control. In this experiment, the control was 
designated as BL41-K3 0 hr, arbitrarily assigned a value of 1. (Data are Mean ±SD). 
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6.2.4 Up-regulation of CyclinE1 by EBV in ER/EB2.5 cells. 
 
Cyclin E1 is a 45kDa nuclear protein of the Cyclin family. Cyclins are positive 
regulators of cell cycle progression. Cyclin E1 is not detectable in resting 
peripheral B cells; however, upon stimulation of cell proliferation Cyclin E1 
expression is up-regulated (Hollyoake, et al. 1995, Ko, et al. 2009). Cyclin E1 
expression has been found to be induced in the late G1 phase but 
undergoes degradation upon entry into the S phase (Datta, et al. 2000). The 
role of Cyclin E1 in promoting cell cycle transition involves regulating cyclin-
dependent protein kinases (Cdks). In addition a role for Cyclin E1 in 
regulating cell cycle arrest in response to DNA damage has recently 
emerged (Lu, et al. 2009).  
 
From the RT Profiler PCR SuperArray data presented previously in Chapter 
4 (Section 4.2.1), it was observed that CyclinE1 mRNA levels increased 
approximately 286-fold after EBV infection of a naϊve B cell population. Here, 
this observation was corroborated using the ER/EB2.5 model, in which 
activation of the EBV growth programme coincided with a 4.5-fold up-
regulation in Cyclin E1 mRNA levels.  
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Figure 6.24:  Induction of EBV driven proliferation in ER/EB2.5 leads to 
an increase in the level of Cyclin E1 mRNA.  
RT-qPCR analysis was carried out to determine the levels of Cyclin E1 expression 
in resting B cells (ER/EB - est) relative to ER/EBNA2 activated cells (ER/EB + est). 
RNA samples were prepared at the time points indicated. (A) RT-qPCR analysis of 
Cyclin E1 mRNA levels in response to ER/EBNA2 activation. The post-induction 
time points are indicated on the graph. The RT-qPCR assay was performed as 
described in the legend to figure 6.1, results were normalised using the internal 
control, TBP, and were expressed as relative quantitation as a function of the 
control. In this experiment, the control for RT-qPCR was set as EBV cycling cells 
(EREB + est 0 hr): arbitrarily assigned a value of 1. (Data are Mean ±SD, *** 
P<0.001). (B) The dissociation curve for the product of the Cyclin E1 assay was 
analysed to ensure a single specific peak, confirming accuracy of the experiment, 
as SYBR green does not give a gene-specific response. 
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6.2.4.1 Relative CyclinE1 expression is similar in a panel of B cell lines. 
 
An examination of a panel of B cell lines revealed that relative Cyclin E1 
mRNA levels were similar in all cases (Figure 6.25). 
 
 
 
Figure 6.25: Comparative CyclinE1 mRNA levels in B cell lines.  
RT-qPCR was used to monitor Cyclin E1 mRNA levels in a range of B cell lines 
including the EBV-negative B cell lines DG75, BJAB and Akata4E3, the EBV-
positive AG876 (group-III BL cell line), and the EBV-immortalised LCL IB4. RNA 
samples were prepared from each cell line in the same time frame, and RT-qPCR 
analysis of Cyclin E1 mRNA levels was performed as described in the legend to 
figure 6.1. Results were normalised using the internal control, TBP, and were 
expressed as relative quantitation as a function of the control. In this experiment 
AG876 cells were set as control cells, arbitrarily assigned a value of 1. (Data are 
Mean ±SD). 
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6.2.5 Activation of the EBV growth programme in ER/EB2.5 has no 
significant effect on the expression of LRP5 
 
Low-density-lipoprotein (LDL) receptor-related protein 5 (LRP5) is a single-
pass transmembrane protein composed of 1615 amino acid residues. LRP5 
acts as a Wnt co-receptor critical for signaling in the canonical Wnt pathway 
(He, et al. 2004). LRP5 is classified as a member of a subfamily of the LDL 
family which also encompasses LRP6, another critical Wnt associated 
receptor (Pinson, et al. 2000; Tamai, et al. 2000).  
 
 
 
Figure 6.26:  Activation of the EBV growth programme in ER/EB2.5 
does not regulate LRP5.  
An experiment was carried out using ER/EB2.5 to assess the effect of ER/EBNA2 
activation on the mRNA levels of LRP5. RNA samples were taken during β-estradiol 
induction at the time points indicated. (A) RT-qPCR analysis was performed as 
described in the legend to figure 6.1, results were normalised using the internal 
control, TBP, and were expressed as relative quantitation as a function of the 
control. In this experiment, the control was set as ER/EB2.5 -est; arbitrarily assigned 
a value of 1. (Data are Mean ±SD, * P<0.05). (B) The dissociation curve for the 
product of the LRP5 assay was analysed to ensure a single specific peak, 
confirming that one specific PCR product was present. 
0.0
0.5
1.0
1.5
ER/EB2.5 -est ER/EB2.5 +est 
Re
la
tiv
e 
Qu
an
tit
at
io
n
Time (hr)
Activation of the EBV growth 
programme in ER/EB2.5 does not 
regulate LRP5
B 
A 
284 
 
LRP5 primers were present in two cell signaling gene panels, Notch and 
Wnt, displaying a 57-fold and 18-fold up-regulation respectively for LRP5 
expression post-EBV infection (Section 4.2.1).  In ER/EB2.5, there appears 
to be no significant effect on LRP5 gene expression due to the activation of 
ER-EBNA2 (Figure 6.26). Thus, the results obtained in this experiment do 
not corroborate the RT Profiler PCR SuperArray data obtained previously.  
 
6.2.6 Activation of the EBV growth programme in ER/EB2.5 leads to 
down-regulation of CIDEB mRNA levels 
 
The cell death-inducing DFFA45-like effector (CIDE) family consists of three 
members CIDEA, CIDEB and CIDEC/FSP27. These are conserved proteins 
named for the homology they share in the N terminal domain with the DNA 
fragmentation factor (DFF) (Inohara, et al. 1998; Da, et al. 2003). The CIDE 
family proteins have a number of essential responsibilities in various cellular 
processes including (i) metabolism regulation through lipid storage and 
droplet formation (Gong, et al. 2009), and (ii) as pro-apoptotic factors (Chen, 
et al. 2000).  
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Figure 6.27: Activation of the EBV growth programme in ER/EB2.5 
negatively regulates CIDEB.  
A β-estradiol induction experiment was carried out using ER/EB2.5 to assess the 
effect of ER/EBNA2 activation on the mRNA levels of CIDEB. RNA samples were 
taken during β-estradiol induction at the time points indicated. (A) RT-qPCR 
analysis was performed as described in the legend to figure 6.1, results were 
normalised using the internal control, TBP, and were expressed as relative 
quantitation as a function of the control. In this experiment, the control was 
designated ER/EB2.5 -est: arbitrarily assigned a value of 1 (Data are Mean ±SD, ** 
P<0.01). (B) The dissociation curve for the product of the CIDEB assay was 
analysed to ensure a single specific peak, confirming that one specific PCR product 
was present.  
 
The apoptosis RT Profiler PCR SuperArray indicated that CIDEB expression 
increased by 502930-fold after EBV infection of naϊve B cells (Section 4.2.1). 
Although this was highly likely to be erroneous, CIDEB expression was 
nonetheless investigated in ER/EB2.5. Significant CIDEB down-regulation 
was observed in response to the activation of ER/EBNA2, and therefore no 
conclusion can be drawn with respect to the regulation of CIDEB by EBV. 
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6.2.7 Activation of the EBV growth programme in ER/EB2.5, has no 
significant effect on the expression of c-Fos 
 
c-Fos is a member of the Fos family of transcription factors that forms part of 
the variable transcription factor complex, AP-1. The Fos family is composed 
of four proteins c-Fos, FosB and the splice varients Fra-1 and Fra-2 (Milde-
Langosch 2005). All four contain a basic leucine-zipper region required for 
dimerisation; however, only the two full length members c-Fos and FosB, 
harbour a trans-activation domain at their C terminus (Wisdom and Verma 
1993). 
 
 
 
Figure 6.28:  Activation of EBV driven proliferation in ER/EB2.5 does 
not modulate the level of c-Fos mRNA.  
RT-qPCR analysis was carried out to determine the levels of c-Fos expression in 
resting B cells (ER/EB - est) relative to ER/EBNA2 activated cells (ER/EB + est). 
RNA samples were prepared at the time points indicated. (A) RT-qPCR analysis of 
c-Fos mRNA levels in response to ER/EBNA2 activation. The post-induction time 
points are indicated on the graph. The RT-qPCR assay was performed as described 
in the legend to figure 6.1, results were normalised using the internal control, TBP, 
and were expressed as relative quantitation as a function of the control. In this 
experiment, the control was set as ER/EB2.5 -est; arbitrarily assigned a value of 1. 
(Data are Mean ±SD). (B) The dissociation curve for the product of the c-Fos assay 
was analysed to ensure a single specific peak, confirming that one specific PCR 
product was present. 
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The results from this experiment correlated with the data obtained from the 
EBV-naϊve B cell infection experiment in which c-Fos levels were repressed 
648-fold following EBV infection (Section 4.2.1). However, the steady state 
levels of c-Fos within the ER/EB2.5 cell line did not change due to the 
activation of ER/EBNA2 (Figure 6.28). Thus, the results obtained in the two 
experiments are not in agreement, and no conclusion can be made on the 
findings available. Published data indicate that c-Fos is a positively regulated 
target of EBV, resulting in elevated phosphorylated c-Fos (Vaysberg, et al. 
2008). However, EBV modulation at the transcriptional level has not been 
demonstrated to date.  
 
6.2.8 Activation of the EBV growth programme in the conditional LCL, 
ER/EB2.5, negatively regulates c-Jun mRNA expression 
 
The Jun family consists of three members c-Jun, JunB and JunD. These 
proteins can homodimerise (Jochum, et al. 2001) and heterodimerise with a 
range of transcription factors such as those from the Fos (Angel and Karin 
1991) and ATF (Hai and Hartman 2001) families and the basic leucine-zipper 
proteins CBP, MyoD, NFat and c-rel (Herdegen and Leah 1998). The c-Jun 
protein is composed of an N-terminal domain with binding and 
phosphorylation sites for c-Jun N-terminal kinases (JNK), followed by a 
trans-activation domain, a hinge region, a basic positively charged domain 
and the leucine zipper region before reaching the C terminus (Raivich 2008). 
Published data have revealed that c-Jun plays a pivotal role in EBV infected 
cells. It is a required co-factor for EBNA2-initiated LMP1 expression 
(Sjoblom, et al. 1998). It has been shown that c-Jun functions in B cells to 
potently inhibit differentiation (Prochownik, et al. 1990; Su, et al. 1991) and 
promote proliferation (Chen, et al. 2002). 
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Figure 6.29: Activation of the EBV growth programme in ER/EB2.5 
negatively regulates c-Jun.  
An experiment was carried out using ER/EB2.5 to assess the effect of 
ER/EBNA2 activation on the mRNA levels of c-Jun. RNA samples were 
taken during induction at the time points indicated. (A) RT-qPCR analysis 
was performed as described in the legend to figure 6.1, results were 
normalised using the internal control, TBP, and were expressed as relative 
quantitation as a function of the control. In this experiment, the control was 
set as ER/EB2.5 -est; arbitrarily assigned a value of 1. (Data are Mean ±SD, 
** P<0.01).  (B) The dissociation curve for the product of the c-Jun assay 
was analysed to ensure a single specific peak, confirming that one specific 
PCR product was present. 
 
The results from the activation of ER/EBNA2 in ER/EB2.5 indicate that the 
steady state levels of c-Jun are down-regulated 8-fold in response to EBV 
driven growth (Figure 6.29). These data confirm the preliminary data from the 
Wnt RT Profiler PCR SuperArray, in which the expression levels of c-Jun 
were shown to be reduced 200-fold by EBV-mediated B cell infection 
(Section 4.2.1). Although the two results were in agreement, they were 
surprising, as studies indicate that the levels of c-Jun are elevated in EBV 
infected cells due to LMP2A post-translational modifications of the protein 
(Chen, et al. 2002). 
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6.2.9 Activation of the EBV growth programme in ER/EB2.5, had no 
significant effect on the expression of TNFSF7 
 
Tumour necrosis factor superfamily member 7 (TNFSF7), also referred to as 
CD70 or CD27L, is part of a family of ligands required for modulation of the 
tumour necrosis factor (TNF) receptor superfamily. TNFSF7 can be detected 
in T and B cells along with monocytes at the mRNA level, and up-regulation 
of the protein can be detected in activated T and B lymphocytes (Cosman 
1994). Although TNFSF7 is the designated ligand for CD27, it also displays 
independent signaling activity, activating the PI3K and MAP kinase cascades 
(Borst, et al. 2005; Arens, et al. 2004; Garcia, et al. 2004).  
 
 
Figure 6.30: Activation of EBV driven proliferation in ER/EB2.5 does not 
modulate the level of TNFSF7 mRNA  
RT-qPCR analysis was carried out to determine the levels of TNFSF7 expression in 
resting B cells (ER/EB - est) relative to ER/EBNA2 activated cells (ER/EB + est). 
RNA samples were prepared at the time points indicated. (A) RT-qPCR analysis of 
TNFSF7 mRNA levels in response to ER/EBNA2 activation. The post-induction time 
points are indicated on the graph. The RT-qPCR assay was performed as described 
in the legend to figure 6.1, results were normalised using the internal control, TBP, 
and were expressed as relative quantitation as a function of the control. In this 
experiment, the control was set as ER/EB2.5 -est; arbitrarily assigned a value of 1. 
Data are Mean ±SD). (B) The dissociation curve for the product of the TNFSF7 
assay was analysed to ensure a single specific peak, confirming that one specific 
PCR product was present. 
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Activation of the EBV growth programme did not modulate the relative 
TNFSF7 mRNA levels when compared to β-estradiol starved cells (Figure 
6.30). This result is not in agreement with the data from the Apoptotic RT 
Profiler PCR SuperArray, which indicated that TNFSF7 was transcriptionally 
up-regulated 625-fold following EBV infection of naϊve B cells. (Section 
4.2.1). 
 
6.2.10 Activation of the EBV growth programme in ER/EB2.5, does not 
regulate MMP7 mRNA levels  
 
Matrix metalloproteinase 7 (MMP7) is the smallest protein from a family of 
zinc-dependent enzymes called the matrix metalloproteinases (MMPs). 
MMPs display association with a wide spectrum of malignancies and 
chemotherapeutic resistance (Almendro, et al. 2009; Kioi, et al. 2003; 
Mitsiades, et al. 2001). They confer this resistance and promote metastasis 
through a variety of mechanisms such as modulation of angiogenesis and 
innate immunity, along with degradation of extracellular matrix (ECM) 
proteins (Kioi, et al. 2003; Chambers and Matrisian 1997).  
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Figure 6.31: Activation of ER/EBNA2 in ER/EB2.5 does not regulate 
MMP7.  
An experiment was carried out using ER/EB2.5 to assess the effect of ER/EBNA2 
activation on the mRNA levels of MMP7. RNA samples were taken during β-
estradiol induction at the time points indicated. (A) RT-qPCR analysis was 
performed as described in the legend to figure 6.1, results were normalised using 
the internal control, TBP, and were expressed as relative quantitation as a function 
of the control. In this experiment, the control was set as ER/EB2.5 -est; arbitrarily 
assigned a value of 1. (Data are Mean ±SD). (B) The dissociation curve for the 
product of the MMP7 assay was analysed to ensure a single specific peak, 
confirming that one specific PCR product was present. 
 
The Notch RT Profiler PCR SuperArray data presented previously in Chapter 
4 indicated that MMP7 was transcriptionally up-regulated 317-fold by the 
EBV-infection of naϊve B cells (Section 4.2.1). However, this was not 
corroborated by the experiments performed in the ER/EB2.5 system. 
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6.2.11 Activation of the EBV growth programme in ER/EB2.5, drives the 
expression of TRAF4 
 
Tumour necrosis factor receptor (TNFR) associated factor (TRAF) 4 is one of 
seven known constituents of the TRAF family, which, with the exception of 
TRAF1, is ubiquitously expressed (Guo, et al. 2009). This group of adaptor 
proteins form stable trimer complexes to elicit a range of responses involving 
NF-κB, JNK and receptor-interacting kinase (RIP) (Guo, et al. 2009). 
 
 
Figure 6.32:  Activation of EBV driven proliferation in ER/EB2.5 trans-
activates TRAF4.  
RT-qPCR analysis was carried out to determine the levels of TRAF4 expression in 
resting B cells (ER/EB - est) relative to ER/EBNA2 activated cells (ER/EB + est). 
RNA samples were prepared at the time points indicated. (A) RT-qPCR analysis of 
TRAF4 mRNA levels in response to ER/EBNA2 activation. The post-induction time 
points are indicated on the graph. The RT-qPCR assay was performed as described 
in the legend to figure 6.1, results were normalised using the internal control, TBP, 
and were expressed as relative quantitation as a function of the control. In this 
experiment, the control was set as ER/EB2.5 -est; arbitrarily assigned a value of 1. 
(Data are Mean ±SD, * P<0.05). (B) The dissociation curve for the product of the 
TRAF4 assay was analysed to ensure a single specific peak, confirming that one 
specific PCR product was present. 
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The apoptosis RT Profiler PCR SuperArray indicated that TRAF4 gene 
expression increased 133-fold after the EBV infection of naϊve B cells 
(Section 4.2.1). TRAF4 transcriptional activity was then examined in 
ER/EB2.5 and the activation of ER/EBNA2 resulted in a marginal 1.5-fold up-
regulation of TRAF4 (Figure 6.32), corroborating the observation made in the 
EBV infection experiment.  
 
6.2.12 Activation of the EBV growth programme in ER/EB2.5, induces 
Fas expression. 
 
Fas (CD95/APO-1) is a 48kDa pro-apoptotic membrane protein of a 
subgroup of the TNFR family. These proteins contain an 80 aa cytoplasmic 
tail designated the intracellular “death domain” which is responsible for 
stimulation of caspase dependent apoptosis. Fas activity is crucial for healthy 
maintenance of the immune system through eradication of pathogen-
infected, obsolete and auto-reactive cells, along with lymphocytes presenting 
with aberrant growth patterns (Reviewed in Strasser, et al. 2009).  
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Figure 6.33: Activation of the EBV growth programme positively 
regulates Fas.  
An experiment was carried out using ER/EB2.5 to assess the effect of ER/EBNA2 
activation on the mRNA levels of Fas. RNA samples were taken during β-estradiol 
induction at the time points indicated. (A) RT-qPCR analysis was performed as 
described in the legend to figure 6.1, results were normalised using the internal 
control, TBP, and were expressed as relative quantitation as a function of the 
control. In this experiment, the control was set as ER/EB2.5 -est; arbitrarily assigned 
a value of 1. (Data are Mean ±SD, * P<0.05). (B) The dissociation curve for the 
product of the Fas assay was analysed to ensure a single specific peak, confirming 
that one specific PCR product was present. 
 
Fas transcriptional activity was then examined in ER/EB2.5 and the 
activation of ER/EBNA2 also resulted in a marginal 1.8-fold up-regulation of 
TRAF4 (Figure 7.8), corroborating the observation made in the EBV infection 
experiment. 
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6.3 Discussion 
 
The findings of the RT Profiler PCR SuperArray were corroborated by the 
cell culture infection model ER/EB2.5 in many instances. However, not all the 
genes modulated in the naϊve B cell pool, due to EBV infection, were found 
to be modulated in ER/EB2.5 in this study (Table 6.1). This may have been 
due to a combination of factors such as; (i) irreversible changes occurring in 
the naϊve B cell pool after contact with the virus or; (ii) the shortcomings of an 
inducible cell line like ER/EB2.5, due to the presence of a potent hormone 
such as estrogen.  
Gene Array Name 
Modulation due to EBV 
Infection 
RT Profiler 
PCR 
SuperArray 
Cell Culture 
Model 
(EREB2.5) 
CCNE1  Notch  286 4.5 
CIDEB  Apoptosis  502931 2 
FAS  Apoptosis  605 1.8 
Fos  Notch  648 2 
Jun  Wnt 201 8 
LRP5  Notch  57 - 
Wnt  19 - 
MMP7  Notch  317 - 
TNFSF7  Apoptosis  626 - 
TRAF4  Apoptosis  133 1.5 
NR4A2 Notch  14 16 
STIL  Notch  129 3 
Hey1  Notch  121 8 
TLE1  Wnt  43 5 
Notch  44 
 
Table 6.1: Comparative gene expression results from the RT Profiler 
PCR SuperArray and the ER/EB2.5 cell pre- and post-EBV infection.  
Comparison of the fold change in mRNA expression levels from; (i) samples taken 
from negatively purified naïve B cells against cells taken 3 days post-infection with 
GFP-tagged EBV from the RT Profiler PCR SuperArray and (ii) the mRNA 
expression levels in ER/EB2.5 after the activation of the EBV growth programme. 
Fold changes highlighted in blue indicate down-regulated genes, red indicate up-
regulated genes while entries denoted in yellow signify genes unaffected after EBV 
infection. Genes that have two results are present in more than one cell signaling 
gene panel.  
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Of the thirteen novel targets analysed in this study, nine targets were found 
to be modulated similarly after the infection of a naϊve B cell pool by GFP-
tagged EBV, and due to the activation of the EBV growth programme in the 
ER/EB2.5 cell line. This corroborating data lends support to their potential as 
EBV target genes, making these nine genes interesting targets for future 
study. Three of the genes found to be modulated due to EBV infection of the 
naϊve B cell pool; LRP5, MMP7 and TNFSF7 were not found to be regulated 
in the cell culture model after activation of the EBV growth programme. 
Although the results between the two experiments were not in agreement, 
these three genes still merit further study as they may still play a role in an 
EBV infected cell. The shortcomings of the cell culture model may have 
limited the scope of study with respect to these target genes, particularly 
LRP5, which was found to be modulated in two RT Profiler PCR SuperArray 
panels. Only the results of the CIDEB study gave conflicting results between 
the two infection methods, however it is worth noting that the fold up-
regulation for CIDEB in the RT Profiler PCR SuperArray was unrealistically 
high.  
 
In this study, Hey1, Nurr1, STIL and CyclinE1 were investigated further using 
ER/EB2.5 and several additional B cell lines in an attempt to define the 
relationship between these genes and EBV.  
 
Hey1 
 
Findings from this study indicate that Hey1 is a cellular target of EBV in a B 
cell. In particular, EBNA2 has been implicated here as an EBV latent protein 
capable of trans-activating Hey1. Activating or inducing EBNA2 expression 
correlated with an increase in Hey1 expression in two independent 
conditional BLs although these results could not be confirmed at the protein 
level (Section 6.2.1.1). Whether this EBNA2-mediated trans-activation of 
Hey1 was elicited at the promoter level by EBNA2 was not clarified in this 
study, as it was discovered that EBNA2 has the ability to trans-activate the 
empty luciferase reporter vector, pGL3-Basic. Whether this EBNA2-mediated 
trans-activation of Hey1 was elicited at the promoter level by EBNA2 was not 
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elucidated in this study, as it was discovered that EBNA2 affected luciferase 
expression from the empty vector, pGL3-Basic. A future possible step would 
be to sub-clone the Hey1 promoter region into a different luciferase reporter 
vector, such as pGL2-basic, known to be unaffected by EBNA2 activity. This 
could clarify the potential role of EBNA2 on the Hey1 promoter.  
 
Due to simultaneous characterisation of the Hey family in a variety of 
laboratories the Hey proteins have an array of additional names including; 
HRT (Hairy-related transcription factor) (Nakagawa, et al. 1999), Hesr 
(Hairy/Enhancer of split related protein) (Kokubo, et al. 1999), Herp (Hes-
related repressor protein) (Iso, et al. 2001), and CHF (Cardiovascular helix-
loop-helix factor) (Chin, et al. 2000). As these names suggest, Hey proteins 
present a strong likeness to the Hes family. Hey proteins are highly 
conserved throughout evolution and have been shown to regulate a variety 
of cellular decisions in different processes, such as cardiac development 
(Fischer and Gessler 2003), angiogenesis (Fischer, et al. 2004), 
neurogenesis (Sakamoto, et al. 2003) and segmentation. Dys-regulation of 
the bHLH family has also been implicated in an oncogenic role (Sun, Ghaffari 
and Taneja 2007).  
 
The Hey family displays a dynamic expression profile throughout the body 
and expression has been observed in a wide range of species; however, it is 
notably absent from Caenorhabditis elegans (Fischer, et al. 2002). Hey 
expression is only partially overlapping, implying that each family member 
has unique functions and that they are differentially regulated (Maier and 
Gessler 2000). The Hey family members share similar domain organisation 
to other bHLH family members, most notably another key downstream 
effector of notch, the Hes family. The Hey family consists of conserved 
regions; a bHLH domain is followed by an Orange domain, a motif unique to 
bHLH factors. Proline rich regions are comparable between the members; 
however, the carboxy-terminal motif displays amino acid variation. Hey 
proteins exhibit an YRPW motif that is distinct from the highly conserved 
bHLH associated WRPW motif (Steidl, et al. 2000).  
298 
 
 
 
Figure 6.34: Schematic comparing the structure of Hey family members 
with their fellow bHLH-O family members, Hes.  
The proteins have a highly similar structure as far as the bHLH and Orange 
domains, the proline rich regions do not differ much; however the Hes family have a 
WRPW motif that is involved with its interaction with the repressor protein TLE1, 
whilst the Hey family have a YRPW motif that to date shows no evidence of 
recruiting TLE1 (Sun, et al. 2007). 
 
Generally, Hairy and Hes proteins recruit TLE to elicit the characteristic 
negative regulation exerted by the bHLH family. This recruitment is facilitated 
by the highly conserved WRPW carboxy terminal (Fisher, et al 1996; Sun, et 
al. 2001). Indeed, the runt (Runx) family of proteins possess a similarly 
conserved VWRPY motif that also interacts with TLE (Aronson, et al. 1997). 
Surprisingly, Hey, although displaying a conserved carboxy region, YRPW, 
similar to that of Hes, hairy and Runx, exhibits negligible association with 
TLE proteins. Mutational analysis substituting the Y residue with a W enables 
Hey1 to associate with TLE. This indicates that the lack of TLE binding 
capability by Hey1 is attributable to the deviated motif at the W residue 
(Fischer, et al. 2002). A number of differences in functionality and regulation 
have been found due to this deviated YRPW motif; however, deletion of the 
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YRPW motif in Hey1 does not inhibit its transcriptional repression activity, 
thus suggesting different roles for the YRPW motif of Hey1 and WRPW motif 
of Hes1 (Sun, et al. 2001). The WRPW motif in Hes recruits TLE, and is 
crucial for repressor activity. However there is no evidence to indicate that 
the YRPW motif presented by the Hey proteins recruits the TLE co-
repressor. In addition, although Hey proteins do not recruit TLE as a co-
repressor, the bHLH domain and Orange domain can recruit the HDAC co-
repressor complex associated with TLE function to repress transcription of 
target genes (Nakagawa, et al. 2000; Iso, et al. 2001).  
 
Hey proteins are capable of homo and heterodimerisation through the HLH 
domain (Fischer, et al. 2002). The HLH region also facilitates association 
with related proteins such as the Hes family (Sun, et al. 2001). This HLH led 
binding effect is potentiated by the presence of the orange domain (Fischer, 
et al. 2002). Hey proteins elicit transcriptional repression through two known 
mechanisms; (i) directly binding target genes displaying a specific cognate 
sequence, via the basic domain. A highly specific consensus site for Hey 
family members has been identified. This characteristic hexamer recognition 
site had the core binding sequence ‘CACGTG’, and was found to be an E-
box motif (Fischer, et al. 2002). Once bound to the target, repressor proteins 
are recruited via the YRPW or orange domain (Huang, et al. 2004a) or (ii) by 
heterodimerising with, and sequestering bHLH activator proteins. Once 
bound in these non-functional dimers, repression of the activator protein 
target gene occurs (Huang, et al. 2004a). Hey promoters lack TATA boxes; 
on the other hand, they contain other initiator elements such as GC rich 
regions and Sp1/Sp3 binding sites (Maier and Gessler 2000). The Hey family 
are recognised components of the Notch signaling pathway. Notch signaling 
stimulates the transcription factor CBF1/RBP-Jκ which in turn activates notch 
target genes via a distinct recognition sequence (Reviewed in Miele 2006). 
Several potential CBF1/RBP-Jκ, cognate sequences have been identified in 
the Hey promoters (Fischer, et al. 2002). Maier and Gessler have shown 
using promoter constructs for each family member, that (i) the Hey genes are 
Notch activated and (ii) that this activation requires the CBF1/RBP-Jκ 
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recognition motifs in the promoter regions. The Hey1 promoter contains five 
potential CBF1/RBP-Jκ sites; however, only two have been shown to be 
functional (Maier and Gessler 2000). 
 
The Hey family are known transcriptional repressors that act as key 
participants in cardiac and vascular development during embryogenesis. At 
the initial stages of growth, all Hey genes are expressed in distinct 
compartments of the cardiac and vascular precursor cells (Fischer, et al. 
2002). Evidence suggests that although Hey1 has a central task in the vital 
notch signaling cascade, it appears to be a non-essential gene in this 
context. Studies have revealed that Hey1 possess a redundant function, as 
Hey1 knockout mice are viable and generally healthy animals inferring that 
other family members or cellular genes can sufficiently compensate for Hey1 
function (Fischer, et al. 2002). Combined Hey1 and Hey2 knockout mice die 
in utero due to developmental failure in blood vessel development and 
arterial-venous differentiation (Fischer, et al. 2004). Hey family members 
have been shown to repress the cardiac activators GATA4 and 6, this 
inhibition is due to direct binding of Hey proteins to GATA4 and GATA6, 
preventing transcriptional up-regulation of the genes (Fischer, et al. 2005). 
 
Besides its role in physiological developmental processes, Hey1 has been 
found to up-regulate the tumour suppressor gene p53. p53 is a negative 
regulator of cell proliferation and an inducer of apoptosis (Huang, et al. 
2004a). Unexpectedly, when it is considered that p53 exerts a repressional 
effect on cell proliferation, p53 is also found to be up-regulated in EBV 
infected cells (Rickinson and Kieff 2001; Cannell, et al. 1998). One key 
regulator of p53 activity is the human double minute 2 (HDM2) protein. This 
regulatory factor directs ubiquitin-led degradation of p53. Evidence has 
revealed that Hey1 enhances p53 activity indirectly by transcriptional 
repression of HDM2 (Huang, et al. 2004a). Thus, in this context, Hey1 plays 
the role of a tumour suppressor. To maintain a latent infection within the 
host, EBV generally subverts cellular features that promote cell growth and 
survival whilst eliciting a minimal chance of discovery by the immune 
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surveillance. However, unexpectedly, evidence demonstrates that EBV 
stimulates the expression of the pro-apoptotic p53 gene (Rickinson and Kieff 
2001; Cannell, et al. 1998). p53 is a crucial tumour suppressor gene that 
supports cell cycle arrest, senescence and apoptosis in response to stimuli 
such as damaged DNA, UV light and oncogene activation. In addition, as a 
precautionary measure, the host will attempt to eliminate any cells presenting 
irregularities in p53 function (Vogelstein, et al. 2000; Balint and Vousden 
2001). The role of p53 regulation in oncogenesis is well established. Indeed, 
it has been shown that p53 mutation is a causative factor in approximately 
50% of all human malignancies (Hainaut and Hollstein 2000). In addition, in 
some forms of cancer in which the p53 gene is intact, evasion and resistance 
to the p53 signaling cascade is a factor in oncogenic establishment (Huang, 
et al. 2004a, Vogelstein, Lane and Levine 2000). Thus, ineffective responses 
to p53 are detrimental to healthy maintenance of cells; however, a fine 
balance of p53 activity must be maintained to sustain cell survival. It is most 
likely that EBV increases p53 expression so as not to flag the cell for 
destruction but only to such a level that it cannot exceed the threshold for 
apoptosis. Although EBV has been shown to promote p53 expression, the 
mechanism by which this effect is exerted has not been fully elucidated. In 
this study, it has been shown that EBV infection of B cells stimulates Hey1 
expression. Hey1 is a known inducer of p53 (Huang, et al. 2004a) and thus it 
may be the case that EBV mediated Hey1 expression links EBV signaling 
and p53 up-regulation.  
 
A body of evidence is beginning to associate bHLH family members with 
oncogenesis. Expression profiling of non-small cell lung cancer (NSCLC) 
cells illustrated increased expression levels for Hey1 and HeyL (Collins, et al. 
2004). In prostate cells Hey1 expression can be detected in both the nucleus 
and cytoplasm. However, it has been shown that in malignant prostate cells, 
Hey1 is expelled exclusively into the cytoplasm, thus preventing Hey1 led 
regulation. This implicates a potential step involving modulated Hey1 
expression and prostate cancer development (Belandia, et al. 2005). 
Although evidence is providing a connection between bHLH family and 
oncogenesis, no defined role has been elucidated for any of the Hey family.  
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Nurr1 
 
Significant down-regulation of Nurr1 transcription was observed just 24 hours 
after the activation of ER/EBNA2 in ER/EB2.5 (Section 6.2.2). De-activation 
of ER/EBNA2 in the same cell line restored Nurr1 transcriptional expression. 
These findings indicate that Nurr1 is negatively regulated by EBV in an LCL. 
However, in an isogenic LCL, P493-6, in which proliferation can be 
conditionally regulated to be driven due to EBV latent genes or c-Myc 
expression, it was found that c-Myc had a more significant negative effect on 
Nurr1 in comparison to EBV driven proliferation. As EBV up-regulates c-myc 
expression upon transformation of a B cell, the down-regulation of Nurr1 
observed in the ER/EB2.5 cell line may possibly be due to up-regulation of c-
Myc. This suggests that Nurr1 may be a direct target of c-myc activity and 
not of the EBV latent proteins. The results acquired from the examination of 
a B cell panel corroborate this theory as Nurr1 expression was found to be 
down-regulated in B cell lines with elevated c-Myc expression. Many of the 
cellular changes at the expression level in EBV infected cells are secondary 
effects of EBV-mediated c-Myc up-regulation, rather than direct modulation 
by EBV products. The c-Myc-mediated regulation within the EBV infected cell 
plays a significant role in the maintenance of EBV-led B cell immortalisation. 
Thus the unexplored role of Nurr1 in B cells, and the demonstrated 
regulation of Nurr1 by EBV in the same cell background, makes this an 
interesting target for future study. 
 
Nurr proteins act as constitutively active ligand independent receptors that 
are tightly regulated (i) at the transcriptional level, (ii) by sub-cellular 
localisation and (iii) by post-translational modification (Reviewed in Aherne, 
et al. 2009). Nurr1 has been identified as a key pan-neurological transcription 
factor. The Nurr1 transcription factor has been found to associate with NFκB 
(Wan and Lenardo 2009), and this co-regulation by the two factors in 
microglia and astrocytes results in inhibition of pro-inflammatory genes 
(Saijo, et al. 2009). This function of Nurr1 has been implicated as a key 
factor in familial Parkinson’s disease, as cells found in sufferers of 
303 
 
Parkinson’s demonstrate mutations of the Nurr1 (Le, et al. 2003). In contrast 
to this anti-inflammatory role, over-expression of Nurr1 has been found to be 
a consistent factor for pro-inflammatory response in multiple sclerosis (Doi, 
et al. 2008). Little is known of the role of Nurr1 in the immune system; 
however, some studies indicate that (i) that over-expression of Nurr1 by T 
cells is found predominantly in MS suffers in contrast to healthy subjects and 
(ii) that Nurr1 over-expression in T cells stimulates the release of the pro-
inflammatory cytokines, IL-17 and IFN-γ (Reviewed in Doi, et al. 2008). 
Current published data indicate that Nurr1 functions in a context-dependent 
manner and that any dys-regulation can play a role in debilitating diseases 
such as MS (Doi, et al. 2008) and Parkinson’s disease (Le, et al. 2008).  
 
Much of the work published on Nurr1 focuses on the development and 
maintenance of midbrain dopaminergic neurons and the pro-inflammatory 
role of Nurr1 in autoimmune diseases such as MS and rheumatoid arthritis 
(RA) (Davies, et al. 2005). The function of Nurr1 appears to be very much 
context-dependent with Nurr1 presenting conflicting roles in different cell 
types, such as its anti-inflammatory role in microglia relative to its pro-
inflammatory role in T lymphocytes (Saijo, et al. 2009). This makes it difficult 
to determine a reason for Nurr1 down-regulation in an EBV infected cell, as 
little is known of the role of Nurr1 in the B cell setting. An observation that 
may be relevant to this study, however, is that there is a direct association 
between Nurr1 and the chemotherapeutic drug, 6-mercaptopurine (6-MP). 
Expression of Nurr1 has been shown to be up-regulated by 6-MP. 6-MP is an 
anti-proliferative and cytotoxic drug used to treat both autoimmune diseases 
and various types of leukaemia. The positive regulation of Nurr1 by 6-MP 
may imply that (in the context of a T-lymphocyte), Nurr1 is a potential 
mediator of the anti-proliferative and cytotoxic effect of 6-MP. Furthermore, 
the expression of Nurr1 correlates with the spectrum of cell types that 
respond to 6-MP chemotherapy.  
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STIL 
STIL was first discovered due to its association with T-cell acute 
lymphoblastic leukemia (T-ALL), in which a specific deletion fusing the 
promoter of STIL to the coding region of T-Cell acute lymphocytic leukaemia 
1 (TAL1 also called SCL) occurs, inducing abnormal expression of TAL1 
(Aplan, et al. 1991). Dys-regulation of TAL1 expression has been found in 
25% of patients suffering from T-ALL (Hsu, et al. 1994). The STIL gene is 
normally expressed in T cells; however, SCL/TAL1 is not. This translocation 
event results in inappropriate expression of the SCL/TAL1 gene and 
contributes to the development of leukaemia (Aplan, et al. 1991). STIL bears 
no homology to other known proteins and little is known of the function of 
STIL, although its requirement for mitotic entry has been confirmed. STIL has 
been shown to be an immediate early gene that peaks during mitosis but 
degrades soon after (Reviewed in Erez, et al. 2007). Structural studies of the 
STIL protein have not identified a DNA-binding motif, a transmembrane 
domain or a secretion signal (Colaizzo-Anas and Aplan 2003); however, a 
putative nuclear localisation signal has been documented (Karkera, et al. 
2002). Preliminary studies of the STIL promoter have revealed that the 
promoter contains three consensus CCAAT boxes but no evident TATA box. 
It also contains putative binding sites for SP1, ESF and GATA-1 (Colaizzo-
Anas and Aplan 2003). Recent investigations have revealed that STIL can be 
regulated by the E2F transcription factor family. Studies involving siRNA 
knockdown of E2F family members led to a decrease in STIL expression and 
this coincided with a delayed entry into mitosis (Erez, et al. 2008). Studies of 
cancer expression profiles have revealed that an increase in STIL levels 
facilitated amplified mitotic activity, and that knockdown of STIL using 
shRNAs and siRNAs in a number of cancer cell lines (including those of 
colon cancer, breast adenocarcinoma, pancreatic carcinoma, prostate 
adenocarcinoma and non-small cell lung carcinoma), caused growth arrest of 
the malignant cells by preventing mitotic entry (Erez, et al. 2007). 
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The results obtained in this study regarding STIL might be explained by the 
growth activation properties of EBV in a B cell background. Numerous 
studies have indicated that cells cannot progress through mitosis without 
facilitation by STIL activity. Therefore, any increased proliferative activity, 
such as that seen due to oncogenesis, requires an increase in STIL 
expression. In this study, naive B cells were driven to proliferate following 
EBV infection (Section 4.2.1). It is possible, therefore, that activation of 
proliferation per se instigates an increase in STIL expression. Up-regulation 
of STIL was also observed using the ER/EB2.5 cell culture model; however, 
this is much the same situation in that activation of the EBV growth 
programme drives proliferation (Section 6.2.3). Whether EBV directly targets 
STIL or if STIL up-regulation is an indirect effect of transformation is unclear. 
Increased STIL activity is beginning to appear as a constant feature of 
aberrant cell growth (Erez, et al. 2007). Consistent with this, similar STIL 
mRNA levels were seen to occur here in all B cell lines examined, 
irrespective of the presence of EBV latent proteins (Section 6.2.3.2). 
 
Cyclin E1 
 
In this study it was observed that Cyclin E1 was transcriptionally up-
regulated after EBV infection of naive B cells (Section 4.2.1) and by the 
activation of the EBV growth programme in ER/EB2.5 (Section 6.2.4). EBV 
mediated up-regulation of CyclinE1 was previously noted elsewhere and 
found to be due to the activation of proliferation in the EBV infected cells 
(Hollyoake, et al. 1995; Möröy and Geisen 2004). Cyclin D has also been 
shown to be an EBV-responsive gene, up-regulated upon infection of the B 
lymphocyte. Furthermore, CyclinE1 activation has more recently been found 
to be dependent on Cyclin D expression (Möröy and Geisen 2004). 
 
Elevated Cyclin E1 expression has been associated with a diverse spectrum 
of malignancies, and in numerous studies, signifies a poor patient prognosis. 
Indeed, amplified Cyclin E1 expression has repeatedly been shown to be a 
feature of advanced stage carcinoma (Ko, et al. 2009). The development of 
all tumours involves similar events to facilitate tumour progression. In early 
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stages, key factors in malignant establishment include angiogenesis and 
cellular adhesion, as the tumour progresses activity moves more towards 
driving cellular proliferation. Cyclin E1 expression in later stages of 
carcinoma facilitates cellular proliferation. It has been demonstrated that 
increased Cyclin E1 mRNA levels are present in advanced nasopharyngeal 
carcinoma (NPC) tumours (Ko, et al. 2009). Several studies have reported 
similar findings, confirming elevated Cyclin E1 expression levels in later 
clinical stage tumours such as non-small cell lung cancer (Fukuse, et al. 
2000), papillary thyroid cancer (Brzezinski, et al. 2004), testicular germ cell 
cancer (Datta, et al. 2000), gastric cancer (Bani-Hani, et al. 2005) and breast 
cancer (Peters, et al. 2004). A direct correlation has been demonstrated 
between high Cyclin E1 expression and reduced survival rates in NPC (Ko, 
et al. 2009), breast cancer (Peters, et al. 2004) and non-small cell lung 
cancer (Müller-Tidow, et al. 2001). This evidence, when taken together, 
brings to light the value of Cyclin E1 as a potential prognostic factor for some 
tumours. 
 
Remaining candidate genes 
 
The results obtained in this chapter for the remaining genes identified as 
candidate EBV cellular targets, indicated that: (i) although TNFSF7, LRP5 
and MMP7 were transcriptionally up-regulated following EBV/naïve B cell 
infection (by RT Profiler PCR SuperArray), no significant changes to their 
mRNA levels were seen upon activation of the EBV growth programme in 
ER/EB2.5; (ii) CIDEB, shown to be up-regulated following EBV infection, was 
seen to be down-regulated in the ER/EB2.5 model, (iii) the expression of c-
Fos, found to be down-regulated following EBV infection, was not seen to 
change in the ER/EB2.5 system; (iv) c-Jun was down-regulated following 
both EBV/B cell infection and activation of the EBV growth programme in 
ER/EB2.5, (v) both TRAF4 and FAS were up-regulated following EBV/B cell 
infection and activation of the EBV growth programme in ER/EB2.5. 
 
Although no conclusion could be drawn for MMP7 regulation in this study 
with the results available, evidence has been reported in agreement with the 
307 
 
RT Profiler PCR SuperArray results. Data have been published linking 
elevated MMP7 expression with EBV stimulated infection. Hertle and 
colleagues compiled a genome wide expression panel of EBNA3A target 
genes using an Affymetrix gene array. Among the 167 up-regulated targets 
identified in the study, MMP7 was found to be up-regulated 49-fold in 
comparison to EBNA3A knockout LCLs (Hertle, et al. 2009). 
 
In vivo studies have shown that transition from a naϊve B cell to an activated 
blast involves a significant phenotypic shift. One feature of the phenotype 
change involves the induction of Fas expression in the centroblast (Spender 
and Inman 2009). It may be argued that the Fas up-regulation is due to 
cellular activation rather than direct EBV modulation; however, a number of 
studies have demonstrated Fas modulation by the EBV latent protein LMP1 
in both BLs (Henriquez, et al. 1999) and LCLs (Le Clorennec, et al. 2006; 
Falk, et al. 1992). Thus implicating Fas as an EBV target therefore not a 
novel cellular gene to pursue for this investigation. 
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Chapter 7: Overall Conclusions 
 
 
 
  
309 
 
In this investigation a panel of potential novel EBV target genes was 
compiled from the data obtained from a naϊve B cell infection study. Genes 
that were significantly modulated in the RT Profiler PCR SuperArray 
experiment were assessed with respect to their novelty and potential for a 
role in an EBV infected cell. This entailed cross referencing the published 
data available for each gene and identifying the various role/s for each gene 
(Table 7.1). The development and maintenance of latent EBV infection in B 
cells is a balance of immune evasion and propagation. EBV subverts cellular 
pathways that control differentiation, proliferation, and apoptosis so as to 
ensure the long-term survival of the infected cell (Cader, et al. 2010). The 
genes selected for further study have a function in many of the cellular 
processes frequently targeted by EBV activity (Table 7.1). 
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Gene Regulation (SuperArray) 
Cell 
Signaling 
Array Panel 
Role/s 
CCNE1           
(Cyclin E1) Up Notch Cell cycle 
CIDEB Up Apoptosis Activates Apoptosis 
FAS Up Apoptosis Activates Apoptosis and NF-kB 
signaling 
Fos Down Notch Positive Proliferative effect, Associated with Transformation 
Jun Down Wnt Positive Proliferative effect, Associated with Transformation. 
LRP5 Up Notch Component of Wnt signaling Wnt 
MMP7 Up Notch Proliferation, Migration and Apoptosis 
TNFSF7 Up Apoptosis Proliferation, and B cell 
activation 
TRAF4 Up Apoptosis Activates NF-kB and JNK Signaling. Role in apoptosis. 
NR4A2           
(Nurr1) Down Notch Cell cycle (implicated) 
STIL Up Notch Cell cycle and Proliferation 
Hey1 Up Notch Notch responsive transcriptional 
repressor 
TLE1 Down 
Wnt Represses NF-kB and Wnt 
signaling. Potential role in cell 
cycle. Notch 
Table 7.1: Summary of the known role/s for selected target genes, and 
the signaling pathways involved.  
Summary of the role of each studied gene, and the RT Profiler PCR SuperArray 
panel in which they were analysed. The modulation observed in response to EBV 
infection of the naive B cell pool can be found in second column on the left 
 
One important mechanism contributing to survival of the EBV-infected cell is 
the dysregulation of certain Bcl-2 family members, and of particular interest 
in this study was the modulation of anti-apoptotic member bfl-1 by the LMP1 
and EBNA2. The Bcl-2 family maintain a tight equilibrium of pro- and anti-
apoptotic members in a healthy cell (Kuroda and Taniwaki 2009), and EBV 
can distort this balance in favour of inappropriate cell survival (Le Clorennec, 
et al. 2008). The EBV-mediated transcriptional regulation of bfl-1 in B 
lymphocytes was examined in this study. It was determined that two 
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transcription factor recognition sites in the bfl-1 promoter, from two different 
pathways, Notch and NF-κB, are vital for EBV-mediated up-regulation of bfl-
1 (Section 3.2.4). In addition, the presence of one of these functional binding 
sites can compensate for the loss of the other; thus, the inhibition of both 
LMP1 and EBNA2 is required to prevent bfl-1 modulation by EBV.  
 
Several novel EBV regulated cellular target genes were identified in this 
investigation including (i) TLE1, (ii) Hey1, (iii) STIL, (iv) NR4A2, and Cyclin 
E1. TLE1 was demonstrated to be a negative transcriptional target of EBV in 
naϊve B cells and an LCL (Section 4.2.2 and 4.2.3). TLE1 expression levels 
were found to be more potently down-regulated in BLs than LCLs (4.2.8). 
The lower levels of TLE1 in the BL-derived cell lines was in agreement with 
recently published findings that implicate TLE1 as a negative regulator of 
haematological cell fate (Fraga, et al. 2008). Ectopic TLE1 in an LCL led to a 
reduced rate of proliferation of that cell line (Section 5.2.4) and expression of 
the exogenous protein was lost over time. These findings indicated that 
elevated TLE1 conferred a negative growth advantage in this cell setting, 
giving a rationale for its negative regulation by EBV. Examination of 
expression of selected genes indicated that ectopic TLE1 down-regulated 
key genes such as Cyclin D1 (Section 5.2.6.1) and Runx3 (Section 5.2.6.4), 
which are required for proliferation in B lymphocytes. In addition to this, 
ectopic TLE1 also led to increased levels of the EBV latent protein EBNA2 
(5.2.5). The level of EBNA2 expression is tightly maintained within an EBV 
infected cell and excessive expression of EBNA2 is known to have a 
negative impact on cell survival (Floettmann, et al. 1996). 
  
To further understand the role of TLE1 in an LCL, shRNA expressing vectors 
were used to knockdown TLE1. Due to the low transfection efficiency 
obtained in these cells, a new protocol was established to permit the isolation 
of an enriched pool of viable transfected cells (Section 5.2.7). The use of a 
combined purification method involving Ficoll and positive selection with the 
lectin Con A, facilitated the analysis of transfected cell pools with reduced 
background from dead or dying cells. Phenotypic analysis demonstrated an 
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increased proliferative capacity in the TLE1 shRNA knockdown cell pools, 
relative to a cell pool encompassing a scrambled shRNA vector (Section 
5.2.11). This corroborated previous results indicating that ectopic TLE1 
reduced the proliferative capacity of an LCL (Section 5.2.4). The growth 
advantage conferred by the knockdown of TLE1 may be due, at least in part, 
to the modulation of Cyclin D1, which showed significant up-regulation in 
response to TLE1 knockdown (Section 5.2.8.2) 
 
Although designated primarily a virus of the B cell compartment, other cell 
types such as epithelial cells and a number of T and NK cell lines can also 
be infected by EBV. Growth transformation does not occur in these cells 
however, and infection is often cytotoxic. A restricted EBV gene expression 
pattern can be found that relates to those found in corresponding EBV-
associated tumours of epithelial, T or NK cell origin (Reviewed in Tierney, et 
al. 2007). The latency III growth programme of EBV is unique to cells of the 
B cell lineage. As previously described, EBV latency can arise from three 
viral promoters: the Qp, the Wp or the Cp. Cp stimulation leads to the 
transcription of a single alternatively spliced and alternatively polyadenylated 
transcripts that give rise to EBNA-LP, EBNA2,  EBNA1, EBNA3A, -B, or –C. 
This transcription of the full panel of EBV latent genes is initially directed by 
the Wp, with a subsequent switch to Cp, and this form of latency occurs only 
in B lymphocytes (Rickinson and Kieff 2007). Tierney and colleagues 
determined that the B lymphotrophism of EBV is due to the recruitment of the 
B cell specific Pax5 (Tierney, et al. 2007). Upon initial B cell infection by 
EBV, EBNA2 and EBNA-LP are the first viral latent proteins expressed 
originating from the Wp (Kieff and Rickinson 2007). Tierney’s research 
laboratory identified two Pax5 binding sites in the Wp and mutational/deletion 
analyses demonstrated that in the absence Pax5 binding, viral infection of B 
lymphocytes did not succeed (Tierney, et al. 2007). Moreover, the infection 
of epithelial cells with these recombinant viruses led to latency I and II states 
as efficiently as was the case with wild-type EBV (Tierney, et al. 2007). It 
was concluded that the EBV latency III growth programme requires the B cell 
specific Pax5. In the present study, Pax5 was identified as a negative target 
of TLE1 in an LCL, making EBV-mediated repression of TLE1 a logical 
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interaction from the standpoint of this B cell immortalising virus. Pax5 is 
expressed endogenously in B cells and is consequently present when EBV 
infection occurs, facilitating Wp activation. The down-regulation of TLE1 
upon EBV infection of B lymphocytes may have the advantage of relieving 
TLE1-mediated Pax5 repression, thus potentiating Pax5 driven Wp activity, 
permitting EBV to express its EBNAs. 
 
The transfected IB4 cell pool preferentially lost ectopic TLE1 over time, thus 
the cell pool did not appear to be stable in the long term. RT-qPCR analysis 
of potential TLE1-regulated genes showed that E2A and Pax5 were both 
down-regulated at the mRNA level at earlier times in the cell pool expressing 
ectopic TLE1 (Section 5.2.6.2 and section 5.2.6.3). Pax5 is a downstream 
E2A-regulated gene, and as such, it cannot be discerned whether Pax5 
repression was due to E2A down-regulation or directly due to TLE1. Down-
regulation of E2A would have an impact on the stability of a B cell population; 
however, as E2A trans-activates the key B lymphocyte transcription factor, 
Ebf1 (Smith, et al. 2002). Ebf1 is the intermediary activator to Pax5 driven 
expression (Roessler, et al. 2007). Ebf1 also has a second promoter; 
however, that is driven by Pax5, thus enabling continued Pax5 and Ebf1 
activation with a positive feedback loop between the two promoters. 
Nevertheless it might be the case that the loss of ectopic TLE1-expressing 
cells over time could be in part due to the down-regulation of these key B cell 
regulators E2A and Pax5.  
 
In this study it was not possible to establish whether TLE1 down-regulation 
was due to EBNA2. In BL41-K3, EBNA2 appeared to positively regulate 
TLE1, however this was not confirmed in a second BL cell line in which 
EBNA2 was also expressed as sole EBV protein ((DG75 tTA-EBNA2);  
Section 4.2.6). In the pcDNA3-TLE1-transfected IB4 cell pool, significant 
down-regulation of CD23 can be observed (Figure 5.2.6.5). EBNA2 has 
already been shown to trans-activate CD23. TLE1-down-regulation might 
potentiate this pro-survival interaction; however, EBNA2 targets CBF1-
binding sites in the CD23a promoter. In addition, the presence of two 
putative Pax5-binding sites was also confirmed in the CD23 promoter 
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(Hubmann, et al. 2002). Results presented in this thesis indicate that Pax5 is 
a negative target of TLE1. The CBF-1 binding sites allow EBNA2 to induce 
CD23a expression, likewise the presence of Pax5 motifs are evidence of a 
possible indirect route for TLE1 to down-regulate this gene. The down-
regulation of both Pax5 and CD23 would be a disadvantage to the EBV-
infected cell, thus giving a clear rationale for EBV-mediated TLE1 repression.  
 
Considering the Pax5 down-regulation observed due to ectopic TLE1, and 
taking account of a positive role for Pax5 in the induction of Wp activity, the 
expression of EBNA1 and EBNA2 was therefore next examined. 
Surprisingly, EBNA2 mRNA levels were up-regulated in comparison to the 
control cell pool (Figure 5.7, Section 5.2.5). However, in the same 
experiment EBNA1 mRNA levels remained unchanged between cell pools 
(Figure 5.8 Section 5.2.5). Bearing this in mind, and the fact that the IB4 cell 
line does not possess a functioning Cp, regulation of EBV latent gene 
expression by TLE1 in this cell line is likely to occur through the Wp. 
Transcription from the Wp is regulated by several transcription factors 
including the YY1, RFX, Pax5 and CREB (Tierney, et al. 2000; Kirby, 
Rickinson and Bell 2000). Furthermore, it has been demonstrated that 
methylation of the Pax5- and CREB-binding sites in the Wp can prevent 
binding by their cognate transcription factors (Tierney, et al. 2000). Of the 
three EBNA promoters on the EBV episome only Wp has been shown to 
display a methylated state (Park, et al. 2007). Park and colleagues quantified 
the methylation status of Wp regulatory region and discovered that in every 
case the CREB-binding site was subject to a greater degree of 
hypermethylation that the Pax5-binding site (Park, et al. 2007). This group 
then demonstrated a correlation between LCL passage number and 
increased Wp methylation. Moreover this enhancement of Wp 
hypermethylation coincided with a decrease in EBNA2 expression in three 
different established LCLs (Park, et al. 2007). TLE1 may regulate the Wp via 
Pax5 down-regulation. Considering this, however, one would have expected 
to observe EBNA2 down-regulation due to ectopic TLE1, which was not the 
case. Considering that TLE proteins have been shown elsewhere to regulate 
315 
 
the Cp (Almqvist 2005), a central role for TLE proteins in setting the level of 
EBV latent gene expression is emerging and warrants further investigation.  
 
In addition to down-regulating TLE1, another negative target of EBV was 
identified in this study, Nurr1 (Section 6.2.2). However, due to the fact that 
Nurr1 expression was found to be significantly more potently down-regulated 
in an LCL driven to proliferate due to C-Myc, in comparison to the same cell 
line cycling due to the EBV-growth programme, it was speculated that Nurr1 
may be a negative target of C-Myc (Section 6.2.2.1). This then implied that 
the EBV-mediated increase in C-MYC expression in an LCL resulted in the 
down-regulation of Nurr1, thus making Nurr1 an indirect target of EBV 
activity. This was confirmed somewhat by the analysis of a panel of B cell 
lines, in which cell lines encompassing C-MYC over-expression 
demonstrated more potent down-regulation of Nurr1 in contrast to two EBV 
positive cell lines (Section 6.2.2.2). 
 
The Notch associated transcription factor, Hey1, was identified as a positive 
EBV target following EBV infection of naϊve B cells, and after the activation of 
the EBV-driven growth programme in a conditional LCL (Section 4.2.1 and 
6.2.1). Hey1 was shown to repress the activity of both a Notch and NF-κB 
responsive promoters in an EBV-negative BL (Sections 6.2.1.3 and 6.2.1.4). 
Further evidence indicated that EBNA2 was responsible for the induction of 
Hey1 expression (Section 6.2.1.1). It has been shown elsewhere that Hey1 
mediates the activation of p53, an occurrence that is coincident with EBV 
infection (Huang, et al. 2004a). 
 
Central to B-cell immortalisation by EBV is the modulation of host cellular 
gene expression by viral gene products.  In this study, potential EBV-host 
interactions were identified that may positively contribute to the survival of 
the virus-infected cell. Further characterisation of these may shed light on the 
mechanisms that drive cell transformation, the establishment of life-long 
latency and potentially the development of EBV-associated B cell 
malignancies.  A better understanding of the EBV B cell immortalisation 
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process may present therapeutic targets of relevance to EBV associated and 
non-associated B cell diseases. 
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Solutions for DNA Manipulation 
 
Storage of DNA 
0.5 M EDTA (pH 8.0) 
 
186.1 g   EDTA 
800 ml   dH2O 
6 g    NaOH pellets 
 
The pH was adjusted to 8.0 by addition of 5 M NaOH and the volume 
adjusted to 1 L with dH2O.  The solution was sterilised by autoclaving and 
stored at room temperature. 
 
TE buffer (pH 8.0) 
 
10 mM   Tris-Cl (pH 8.0) 
1 mM    EDTA  (pH 8.0) 
 
 
Solution for Bacterial Growth Media  
 
Ampicillin stock solution 
 
A stock solution of ampicillin was made up to a concentration of 100 mg/ml in 
dH2O. 
The stock solution was filter sterilised and stored at -20˚C. 
 
 
  
c 
 
LB broth 
 
5g    Tryptone 
2.5g    Yeast extract 
5g    NaCl 
 
The volume was adjusted to 500ml, followed by autoclaving for 20 minutes at 
15 lb/sq. and storage at 4˚C. 
 
LB broth with ampicllin  
 
Ampicillin was added to autoclaved LB broth to a final concentration of 100 
µg/ml and stored at 4˚C. 
 
NZY+ Broth 
 
10g    NZ amine (casein hydrolysate) 
5g    Yeast extract 
5g    NaCl 
 
The Volume was adjusted to 1lt with dH2O, the pH was adjusted to pH7.5 
using NaOH followed by autoclaving. Add the following filter sterilised 
supplements prior to use; 
 
12.5ml    MgCL2 (1M) 
12.5ml   MgSO4 (1M) 
20ml     Glucose (20% w/v) or 10ml Glucose (2M) 
 
  
d 
 
LB agar 
 
5 g    Tryptone 
2.5 g    Yeast extract 
5 g    NaCl 
7.5 g    Agar 
 
The volume was adjusted to 500 ml with dH20, followed by autoclaving and 
agar plates were stored at 4˚C. 
 
LB agar with antibiotics 
 
Antibiotics were added to autoclaved LB broth to a final concentration of 
100µg/ml (Ampicillin), after cooling the LB agar to ~50˚C.  Plates were stored 
at 4˚C. 
 
SOB medium 
 
10g    Tryptone 
2.5g    Yeast extract 
0.025g   NaCl 
5ml    KCl (250 mM) 
 
The pH was adjusted to 7.0 with 5M NaOH.   
The volume was adjusted to 500ml with dH20 and the medium autoclaved.   
2.5ml of 2M MgCl2 was added after cooling the broth to 5˚C and the medium 
was stored at 4˚C.   
 
  
e 
 
SOC medium 
 
98ml    SOB medium 
2ml    1M glucose (filter sterilised) 
Stored at 4˚C.  
 
Solutions for Preparation of Competent Cells 
 
1M MgSO4 
 
24.65g    MgSO4.7H20 
100ml    dH20 
 
Sterilised by filtering and stored at room temperature. 
 
TFB1 
 
30mM    Potassium acetate 
10mM    CaCl2 
50mM    MnCl2 
100mM   RbCl 
15%    Glycerol 
 
The pH was adjusted to 5.8 with 1M acetic acid, and the solution filter 
sterilised and stored at room temperature. 
 
  
f 
 
TFB2 
 
100mM   MOPS (pH 6.5) 
75mM    CaCl2 
10mM    RbCl 
15%     Glycerol 
 
The pH was adjusted to 6.5 with 1M KOH, and the solution filter sterilised 
and stored at room temperature. 
 
Solutions for DNA preparations 
   
Buffer P1 (Re-suspension buffer) 
 
50mM    Tris-Cl (pH 8.0) 
10mM    EDTA (pH8.0) 
100µg/ml    RNase A 
 
Stored at 4˚C following addition of RNase A. 
 
DNase-free RNase 
 
RNase A (1mg/ml) in upH2O. 
Heated to 100˚C for 30 minutes.   
Cooled slowly and stored at -20˚C. 
 
Buffer P2 (Lysis buffer) 
 
200 mM   NaOH 
1 % (w/v)   SDS 
 
Stored at room temperature.  
 
g 
 
Buffer P3 (Neutralisation buffer; (3 M potassium acetate)) 
 
29.6g    Potassium acetate 
50ml     dH2O 
11.5ml   Glacial acetic acid 
 
Adjust volume to 100ml with dH2O. 
The resulting solution is 3 M with respect to potassium and 5M with respect 
to acetate. 
Stored at room temperature. 
 
Buffer QBT (Equilibration buffer) 
 
750mM   NaCl 
50mM    MOPS (pH 7.0) 
15% (v/v)   Isopropanol 
0.15% (v/v)   Triton-X 100 
 
Stored at room temperature. 
 
Buffer QC (Wash buffer) 
 
1M    NaCl 
50mM    MOPS (pH 7.0) 
15% (v/v)   Isopropanol 
 
Stored at room temperature. 
 
  
h 
 
Buffer QF (Elution buffer) 
 
1.25M    NaCl 
50mM    Tris-Cl (pH 8.5) 
15%    Isopropanol 
 
Stored at room temperature. 
 
50 % (v/v) Glycerol 
 
25ml   glycerol 
25ml   dH2O 
 
The solution was autoclaved and stored at room temperature. 
 
Annealing buffer 
 
100mM   Potassium acetate  
30mM    Hepes-KOH, pH 7.4  
2mM    Magnesium acetate 
 
Stored at 4 – 8 ˚C. 
 
Solutions for Agarose Gel Electrophoresis 
 
50X TAE (Tris-acetate/EDTA electrophoresis buffer) 
 
242g    Tris base 
57.1ml   Glacial acetic acid 
100ml    0.5M EDTA (pH 8.0) 
 
The volume was adjusted to 1L with dH2O and the buffer was stored at room 
temperature. 
 
i 
 
1X TAE (Working solution) 
 
20ml    50X TAE 
980ml    dH2O 
 
Stored at room temperature. 
 
Agarose gel loading dye 
 
40% (w/v)   Sucrose 
0.25% (w/v)   Bromophenol blue 
 
Stored at room temperature. 
 
Ethidium bromide 
 
10mg    Ethidium bromide 
1ml    dH2O 
 
The solution was stored in the dark at 4ºC. 100 µl of stock solution was 
added to 1L of dH2O for TAE gel staining.  
 
  
j 
 
Solutions for Cell Culture  
 
Media and Supplements 
 
Supplemented RPMI 1640 (200 ml) 
 
176ml    RPMI 1640  
20ml Foetal bovine serum (de-complemented at 50˚C 
for 30 mins) 
2ml    200mM L-glutamine 
2ml    Penicillin/streptomycin (10 mg/ml) 
 
Estrogen (β-Estradiol) 
 
A 20 mM solution was prepared in 100% ethanol and stored at -20˚C. 
 
Tetracycline 
 
A 5 mg/ml stock was prepared in 100% ethanol and stored at -20˚C.   
 
Geneticin (G418) 
 
A 50 mg/ml stock was prepared in cell culture medium and stored at -20˚C 
 
Puromycin 
 
A 25 mg/ml stock was prepared in distilled water and stored at -20˚C.   
 
Phosphate buffered saline (PBS) 
 
5 tablets were dissolved in 500 ml dH2O to give a 1X working concentration 
of PBS, and the solution was sterilised by autoclaving.   
 
k 
 
Solutions for DEAE-Dextran Tranfections Protocol 
 
Tris buffered saline (TBS)      
 
25mM    Tris-Cl (pH 7.4)    
137mM   NaCl 
5mM    KCL 
0.7mM   CaCl2 
0.5mM   MgCl2 
0.6mM   Na2HPO4 
 
To make 200ml TBS: 
5ml    1M Tris-Cl (pH 7.4) 
5.48ml   5M NaCl 
0.5ml    2M KCl 
1.4ml    100mM CaCl2 
0.1ml    1M MgCl2 
0.2ml    0.6M Na2HPO4 
187.32ml   upH2O 
 
TBS was prepared from autoclaved stocks, aliquoted and filter sterilised 
before use.   
 
DEAE dextran 
 
DEAE dextran was prepared at a concentration of 1mg/ml in TBS on the day 
of use and filter sterilised. 
 
  
l 
 
β-Galactosidase Assay 
 
100X Mg solution 
 
0.1M    MgCl2 
4.5M    2- β-mercaptoethanol 
 
Stored at -20˚C. 
 
0.1M sodium phosphate buffer 
 
41ml    0.2M Na2HPO4.2H2O 
9ml    0,2M NaH2PO4.2H2O 
50ml    dH2O 
 
1X ONPG substrate 
 
ONPG was prepared at a concentration of 4 mg/ml in 0.1 M sodium 
phosphate buffer (pH 7.5) and stored at -20˚C.   
 
1M sodium carbonate 
 
10.59g   
100ml    dH2O 
 
Stored at room temperature. 
 
EDAC 
 
EDAC was prepared at a concentration of 75mg/ml in PBS on the day of use. 
 
  
m 
 
Con A 
 
Con A  was prepared at a concentration of 1mg/ml in ultra pure water and 
stored at -20˚C. 
 
Working solutions were prepared on the day of use at a concentration of 100 
µg/ml in PBS. 
 
 
Solutions for RNA Analysis 
 
DEPC-treated H2O 
 
1ml    DEPC 
1000ml   dH2O 
 
The mixture was left in a fume cupboard overnight, followed by autoclaving.   
 
RNA loading buffer 
50%     Glycerol 
1mM    EDTA (pH 8.0) 
0.25%    Bromophenol blue 
0.25%    Xylene cyanol FF 
1µg/ul    Ethidium bromide 
 
  
n 
 
Solutions for Protein Analysis 
 
Solutions for Protein Isolation 
 
Suspension buffer 
 
0.1M    NaCl 
0.01M    Tris-Cl (pH 7.6) 
0.001M   EDTA (pH 8.0) 
1µg/ml   leupeptin 
1µg/ml   Aprotinin 
100µg/ml   PMSF 
 
Stored at 4˚C 
 
Leupeptin 
 
A stock solution of leupeptin was made to a concentration 2 mg/ml in dH2O 
and stored at –20˚C. 
 
Aprotinin 
 
0.1  M stock solution of aprotinin was made up in dH2O and stored at -20˚C. 
 
PMSF 
 
A stock solution of PMSF was made up in isopropanol and stored at -20˚C in 
the dark.  
 
  
o 
 
2X SDS loading buffer 
 
100mM   Tris-Cl (pH 7.6) 
4% (w/v)    SDS 
20% (w/v)   Glycerol 
10% (v/v)   2-mercaptoethanol 
0.2%    Bromophenol blue 
 
Stored at room temperature. 
 
Solutions for SDS-PAGE/ Western Blotting 
 
Table  A: 10% (v/v) resolving gels and 5 % (v/v) stacking polyacrlyamide 
gels 
Component 10 % Resolving Gel 
(ml) 
5 % Stacking Gel 
(ml) 
Acrylagel  3.33 0.42 
Bis-Acrylagel 1.35 0.168 
1.5M Tris (pH 8.8) 2.5 0 
1M Tris (pH 6.8) 0 0.312 
dH2O  2.61 1.5475 
10% (v/v) SDS 0.10 0.025 
10% (v/v) APS 0.10 0.025 
TEMED 0.01 0.0025 
Total 10 ml 2.5 ml 
 
5X Tris-glycine running buffer 
 
15.1g    Tris base 
95.4g    Glycine (pH 8.3) 
50ml    10 % (w/v) SDS 
 
Made up to 1 L with dH2O and stored at room temperature. 
p 
 
1X Tris-glycine running buffer  
 
200ml    5X Tris-glycine running buffer 
800ml    dH2O 
 
Transfer buffer 
 
750ml    dH2O 
2.9g    Glycine 
5.8g    Tris base 
3.7ml    10 % (w/v) SDS 
200ml    Methanol 
 
Adjusted volume to 1 L with dH2O and stored at 4˚C. 
 
1X Tris buffered saline (TBS) 
 
6.1g    Tris base 
8.8g     NaCl 
800ml    dH2O 
 
The pH was adjusted to 7.5 with HCl and the volume adjusted to 1 L.  Stored 
at room temperature. 
 
TBS-T 
 
1L    1X TBS 
1ml    Tween 20 
 
Stored at room temperature. 
 
  
q 
 
Blocking Buffer 
 
5g    non fat dry milk powder 
100ml    TBS-T 
 
Stored at 4˚C. 
 
  
 
 
 
 
 
 
 
 
The goal of science and engineering is to build 
better mousetraps. The goal of nature is to build 
better mice. 
 
